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This thesis examines several aspects of the debate on the choice of best first- 
line treatment for infantile spasms. The first part of the thesis describes, analy­
ses and interprets outcomes from the United Kingdom Infantile Spasms Study 
(UKISS), a multicentre randomised controlled trial that compares treatment 
with prednisolone or tetracosactide (hormonal treatments) against vigabatrin. 
This study was coordinated from the Bath Unit for Research in Paediatrics 
at the Royal United Hospital, Bath, and showed that the early primary clini­
cal response, cessation of spasms, was significantly more likely in infants who 
were allocated hormonal treatments. However, the overall proportions with 
relapse-free response at the end of the study period, when the child reached 
the age of 12 to 14 months, were similar in all three treatment groups. In a 
group of infants of a priori interest who had no identified underlying aetiol­
ogy, neurodevelopmental outcomes were significantly better in children who 
had been allocated hormonal treatments, although this finding was not robust 
within a sensitivity analysis.
The second part of the thesis examines problems with case definitions and 
outcome measures in epidemiological and interventional studies of infantile 
spasms, and describes the development of West Delphi, a consensus elicitation 
process that has produced published proposals for standardised case defini­
tions and outcome measures for such studies. Its most novel proposals were: 
(1) that the primary clinical outcome cessation of spasms should be defined by 
the absence of observed spasms for at least 28 days from the time of the last 
observed spasms, with the last spasms being observed within 14 days of treat­
ment allocation; and (2) that there should be a standardised primary electro- 
clinical response that studies should also report as a primary outcome.
2Declaration
I declare that the work presented in this Ph.D. thesis consists of my origi­
nal work. It was performed with help from investigators participating in the 
United Kingdom Infantile Spasms Study, and with help from contributors to 
the West Delphi Group. Lists of contributors appear in appendix A. Details 
of contributions to the United Kingdom Infantile Spasms Study are stated in 
chapter 2, and in particular section 2.1.1; and contributions to the West Del­
phi consensus statement are stated in chapter 5. The initial study design for 
the United Kingdom Infantile Spasms Study was formulated before I joined 
the study team, but I contributed to the design of instruments for data collec­
tion, including the UKISS trial folders and patients' diaries; and I designed and 
constructed the initial UKISS study electronic database. Work relating to the 
submission of applications for ethical and management approval was shared 
primarily with Dr Stuart W. Edwards, as was work relating to data collection 
and recording. The BMJ paper on response times of ethics committees was my 
original idea, and I was jointly responsible for the study design with Prof. John 
P. Osborne and Dr Edwards. The drafting of the Lancet and Lancet Neurology 
papers was shared with Prof. Osborne and other members of the UKISS trial 
steering committee, and data analysis was performed by me and Dr Anthony 
L. Johnson, who was the official statistician to the study. The idea behind the 
West Delphi consensus status was originally suggested by me and took shape 
in discussions with Prof. Osborne. Members of the West Delphi Group were 
jointly responsible for the consensus statement that appeared in Epilepsia. I 
acted as facilitator and drafted the paper for publication, incorporating and 
seeking consensus on any amendments.
Acknowledgements
3
I wish to express my gratitude to Professor John P. Osborne, my supervi­
sor in this project, chair of the United Kingdom Infantile Spasms Study, and co­
guarantor of West Delphi, without whom this thesis would not have been con­
ceived, and whose support and encouragement have been constant. I wish to 
thank Dr Stuart W. Edwards, Research Fellow at the Bath Unit for Research 
in Paediatrics, and the UKISS Study Administrator, for his diligent and sys­
tematic approach to ensuring that UKISS was successful. Further thanks are 
due to Dr Finbar J.K. O'Callaghan, a third member of the UKISS steering com­
mittee whose advice I value greatly. I wish to thank Mrs Karen Giles, whose 
keen skills in information technology have been of great benefit to the study. 
Further thanks are due to Mrs Heather Hill, who provided proficient technical 
support, especially in the administration of West Delphi.
The studies reported here required the participation of several hundred 
paediatricians and paediatric neurologists -  throughout the UK in the 150 cen­
tres that were eligible to enroll participants for UKISS, and internationally in 
the 15 countries participating in West Delphi. The names of these doctors, who 
gave generously of their time and enthusiasm, appear in appendix A. Par­
ticular thanks are due to the members of the UKISS steering committee and 
the data monitoring and ethics committee, and especially to Dr Ellie Hancock, 
whose steadfast work during the early part of the study laid extremely strong 
foundations for what followed. Special thanks are also due to Dr Tony John­
son, the study statistician, who performed several of the analyses presented in 
the thesis.
Funding for part of these studies was generously provided by the Bath Unit 
for Research in Paediatrics (BURP) and by Cow & Gate Limited. I also ac­
knowledge a travel grant kindly given by Hoechst Marion Roussel.
4I could not have completed this work without learning about biostatistics, 
child neurology, and clinical neurophysiology, and I would like to thank the 
members of institutions in Bristol, London, and St. Louis that have inspired 
and guided me in these areas. My formal training in epidemiology and bio­
statistics was from Professor Stuart J. Pocock and other members of the Med­
ical Statistics Unit in the Department of Epidemiology and Population Health 
at the London School of Hygiene & Tropical Medicine. My training in child 
neurology and clinical epilepsy was provided by Professor P.M. "Mick" Leary 
and Drs Philip E. Jardine, Jayesh S. Patel, and Peta M. Sharpies in the Depart­
ment of Paediatric Neurology at Bristol Royal Hospital for Children and at 
Frenchay Hospital, Bristol. And I learned clinical neurophysiology and paedi­
atric epilepsy from Drs Susan T. Arnold, W. Edwin Dodson, Kevin Ess, Frank 
Gilliam, Christina Gumett, K. Liu Lin Thio, N. Edwin Trevathan, Michael 
Wong, Kelvin Yamada, and John M. Zempel at Washington University School 
of Medicine; and with help from Barb Smith and the EEG Laboratory Staff at 
St. Louis Children's Hospital, St. Louis, Missouri, USA.
In the course of this research, I have had the great privilege of meeting 
the inspirational paediatric neurologist, Professor Yukio Fukuyama of Tokyo 
Women's Medical University. He was publishing in this research area when I 
was myself an infant. I am very grateful to him for his interest in this current 
work and for his generous support.
Finally, the main cost of undertaking such a product is paid in time that 
should have been spent with my family doing things that are properly consid­
ered more exciting. I appreciate the support and encouragement of my wife, 
Prisca, and the welcome distractions provided by Eric and Emma; and I hope 





List of figures 12
List of tables 13
1 Introduction 15
1.1 Historical b ack g ro u n d ...................................................................  15
1.2 Content and scope of this th es is .....................................................  17
1.3 General reviews of infantile spasms ............................................  18
1.4 Definition of infantile sp a sm s ........................................................  18
1.4.1 Necessary and sufficient features...................................... 20
1.4.2 Aetiological subgroups: symptomatic, cryptogenic, and 
idiopathic..............................................................................  22
1.4.3 Associated conditions and distinguishing features . . . .  24
1.5 Clinical features of infantile spasms ............................................  26
1.5.1 Distinct forms of infantile s p a s m s ...................................  27
1.5.2 Other features of spasm s....................................................  28
1.5.3 Factors that precipitate sp a sm s ......................................... 29
4
CONTENTS 5
1.5.4 The timing and duration of ictal e v e n ts .......................... 29
1.5.5 Relationship to other seizures...........................................  30
1.5.6 Differential diagnosis of infantile s p a s m s ....................... 31
1.6 Electroencephalographic features of infantile s p a s m s ............... 32
1.6.1 H ypsarrhy thm ia...............................................................  32
1.6.2 Atypical and modified hypsarrhythm ia.......................... 33
1.6.3 Ictal EEG features...............................................................  36
1.7 Epidemiology of infantile spasm s.................................................  36
1.7.1 Incidence and prevalence of infantile sp asm s.................  36
1.7.2 Sex distribution of infantile spasms ...............................  38
1.7.3 Family history of ep ilepsy .................................................  38
1.7.4 Age at onset of infantile spasms .....................................  38
1.7.5 Natural history of infantile spasm s..................................  40
1.7.6 Underlying disorders and ae tio lo g y ................................ 40
1.7.7 Prognosis in infantile sp a sm s...........................................  44
1.8 Treatment of Infantile S pasm s.......................................................  47
1.8.1 Brief review of treatments for infantile sp a sm s ..............  48
1.8.2 An overview of hormonal tre a tm e n ts ............................. 54
1.8.3 Steroid treatments other than prednisolone....................  55
1.8.4 Rationale for hormonal treatments in infantile spasms . 56
1.9 ACTH and tetracosactide ............................................................. 56
1.9.1 Effectiveness of ACTH and tetracosactide.......................  58
1.9.2 Safety of ACTH and tetracosactide................................... 59
1.9.3 ACTH and tetracosactide regimens ................................ 61
1.10 Prednisolone and p red n iso n e .......................................................  62
1.10.1 Effectiveness of prednisolone and p re d n iso n e ..............  62
1.10.2 Safety of prednisolone and p re d n is o n e .......................... 63
1.11 V igabatrin .......................................................................................  63
CONTENTS 6
1.11.1 Effectiveness of vigabatrin................................................. 64
1.11.2 Visual field losses associated with v igabatrin ................. 64
1.12 Studies comparing ACTH, corticosteroids, or vigabatrin . . . .  66
1.12.1 Studies comparing ACTH with corticosteroids.............. 66
1.12.2 Studies comparing hormonal treatments against 
v ig ab a trin ...........................................................................  67
1.12.3 Hormonal and vigabatrin combination th e r a p y   69
1.13 Aims of this thesis...........................................................................  69
2 UKISS Study Design 71
2.1 Early development of UKISS ........................................................  71
2.1.1 Origins of the s t u d y .........................................................  71
2.1.2 Rationale for the s tu d y ......................................................  72
2.1.3 General form of the s tu d y ................................................. 73
2.2 Classification of infantile spasms used in U K IS S ........................  74
2.3 Issues relating to the UKISS study p ro to c o l................................. 75
2.3.1 Eligibility c rite ria ...............................................................  75
2.3.2 Exclusion of cases with tuberous sclerosis......................  76
2.3.3 O u tcom es........................................................................... 76
2.3.4 Patient D ia r y .....................................................................  79
2.3.5 Classification and reporting of adverse e v e n ts .............. 80
2.3.6 Definition of treatment d ays..............................................  83
2.3.7 Timing of the follow-up E E G ...........................................  83
2.4 Study tre a tm e n ts ............................................................................  84
2.4.1 Prednesol®; prednisolone................................................. 84
2.4.2 Synacthen® Depot; te tracosactide ..................................  84
2.4.3 Sabril® Sachets; v ig a b a tr in .............................................. 84
2.4.4 Treatment a llocation .........................................................  85
CONTENTS 7
2.4.5 Concomitant therapy........................................................... 85
2.4.6 Permitted modifications and protocol v io la tions............  85
2.4.7 Consent procedures ........................................................... 86
2.4.8 M ask ing ...............................................................................  86
2.4.9 Conduct of study after assessment of primary clinical
o u tco m e ..............................................................................  87
2.4.10 Developmental a ssessm en t...............................................  88
2.5 Data and safety m o n ito rin g .......................................................... 89
2.6 Safety, licensing, and ethical is s u e s ............................................... 90
2.6.1 Licensing provisions for treatments used in UKISS . . .  90
2.6.2 Withdrawal of licence for A C T H ......................................  91
2.6.3 Visual field losses associated with v igabatrin ..................  91
2.6.4 Tetracosactide and benzyl a lc o h o l .................................... 92
2.6.5 Tetracosactide and anaphylactic reactions........................  95
2.6.6 Indemnity arrangements.....................................................  96
2.7 Statistical m e th o d s ........................................................................  96
2.7.1 Summary and test statistics for main outcom es...............  96
2.7.2 Planned multiple tests and subgroup an a ly ses ...............  97
2.7.3 Stratification at randomisation to control for potential
prognostic factors................................................................  97
3 UKISS Early Outcomes 99
3.1 Administration and progress of the S tu d y ..................................  100
3.2 Sample size requirements and estimates of accrual r a t e  103
3.2.1 Study of local research ethics committee response times 105
3.2.2 Protocol am en d m en ts ........................................................  108
3.2.3 Effects of need for NHS trust management approval. . . 109
3.2.4 Problems with accrual of p a rtic ip an ts .............................. 110
CONTENTS 8
3.3 Patient characteristics...................................................................112
3.3.1 Ineligible patients............................................................ 113
3.3.2 Baseline classification of underlying a e tio lo g y ........... 117
3.3.3 Final classification of underlying ae tio lo g y .................117
3.3.4 Features of cases from the non-randomised study . . . .  119
3.3.5 Compliance with treatment pro tocol............................ 122
3.3.6 Completion of study d iaries........................................... 123
3.4 Primary clinical response: cessation of spasms ................................. 123
3.4.1 Proportions with cessation of spasms ................................... 123
3.4.2 Time to cessation of sp a sm s ..............................................125
3.4.3 Factors potentially biasing cessation of spasms outcome . . 125
3.4.4 Cessation of spasms and stratified randomisation
variables........................................................................... 128
3.5 Other early outcom es..........................................................................131
3.5.1 Electroencephalographic changes by study day 19 . . .  . 131
3.5.2 Adverse events at study day 1 4 ..................................... 132
3.6 Summary of UKISS early outcom es...................................................138
4 UKISS Later Outcomes 139
4.1 Conduct of the later part of the study ................................................139
4.1.1 Ages and duration in study at follow-up assessments . . 140
4.1.2 Conduct of neurodevelopmental assessments ..................143
4.2 Neurodevelopmental outcom es........................................................ 143
4.2.1 Investigation of potential bias in timing of Vineland
assessm ents..................................................................... 147
4.2.2 Vineland domain sc o re s .................................................148
4.3 Analysis of potential prognostic factors for neurodevelopment . 149
CONTENTS 9
4.3.1 Neurodevelopmental outcome and underlying
aetiology..................................................................................149
4.3.2 Lead-time to treatment as a potential predictor of
neurodevelopmental outcome ............................................ 151
4.4 Secondary outcomes of the randomised
controlled t r ia l .....................................................................................160
4.4.1 Relapse and relapse-free re sp o n se ........................................160
4.4.2 Progression to other seizure t y p e s ........................................161
4.5 Adverse events after study day 1 4 ..................................................163
4.5.1 Deaths occurring after study day 1 4 .....................................163
4.5.2 Non-fatal adverse events reported after study day 14 . . 164
4.6 Summary of later outcomes from UKISS.........................................166
5 West Delphi 167
5.1 Overview of West Delphi................................................................... 167
5.2 Methods and conduct of West Delphi...............................................169
5.3 West Delphi round 1 .........................................................................172
5.3.1 Round 1 responses to multiple-choice q u estio n s 173
5.3.2 Round 1 responses to open q u e s tio n s ..................................176
5.4 West Delphi round 2 .........................................................................177
5.4.1 Round 2 qualitative responses ............................................. 178
5.4.2 Round 2 responses to multiple-choice q u estio n s  187
5.5 West Delphi round 3 .........................................................................188
5.6 West Delphi round 4 .........................................................................192
5.7 West Delphi rounds 5 and 6 .............................................................196
6 Discussion 200
6.1 Summary of main findings in this th e s is .........................................200
6.2 Discussion of U K IS S ........................................................................ 201
CONTENTS 10
6.2.1 Comparison of UKISS findings with other studies of
hormonal treatments against v igabatrin .......................203
6.2.2 Comparison of UKISS findings with other studies of
v ig ab a trin ........................................................................204
6.2.3 Comparison of UKISS findings with other studies of
prednisolone against te tracosactide ............................ 207
6.2.4 Neurodevelopmental outcomes.....................................209
6.2.5 Effects of delayed treatment upon neurodevelopmental
o u tco m e ...........................................................................211
6.2.6 Value of pre-randomisation stratification variables . . . .  213
6.2.7 Administrative d e la y s ................................................... 213
6.2.8 Discussion of response times of local research ethics
committees ............................................................................ 214
6.2.9 Adverse e v e n ts ...............................................................215
6.2.10 Potential roles of chance and bias in UKISS................ 216
6.2.11 Validity and generalisability of findings from UKISS . . 219
6.2.12 Methodological and procedural insights from UKISS . . 219
6.2.13 Impact of findings of UKISS.......................................... 221
6.3 Discussion of West D e lp h i................................................................221
6.3.1 West Delphi proposed case definitions.................................223
6.3.2 West Delphi proposed outcome m easures...........................228
6.3.3 Methodological and procedural problems with
West D e lp h i..................................................................... 230
6.3.4 Summary of West D e lp h i ............................................. 230
6.4 Considerations for future s tu d ie s .................................................... 231
6.5 Conclusions of this thesis ................................................................232
A Study contributors 234
CONTENTS 11
A.l Members of the UKISS Trial Steering
Com m ittee...........................................................................................234
A .l  Members of the UKISS Data Monitoring and Ethics Committee 236
A.3 Centres and local investigators approved to enroll cases 237
A.4 Members of the West Delphi Group .............................................. 243
B The UKISS Study Protocol 244
B.l Protocol approved by Multicentre Research Ethics Committee . 244
B.2 Study protocol amendment 11 May 2000 ..................................... 252
B.3 Study protocol amendment 30 April 2001 ..................................  254
C Data from West Delphi 255
C.l Round 1 in v ita tio n ........................................................................... 255
C.2 West Delphi round 1 q u e s tio n s .......................................................255
C.3 West Delphi round 2 q u e s tio n s .......................................................256
C.4 West Delphi round 3 q u e s tio n s .......................................................260
C.5 West Delphi Round 4 questions.......................................................266
D West Delphi Consensus Statement 274
E Abbreviations 287
F Thesis publications 289
F.1 Original a rtic le s .................................................................................289
F.2 Review articles .................................................................................290
F.3 L e t te r s ............................................................................................... 290




3.1 UKISS early outcomes trial flow d ia g ra m ..................................  114
4.1 UKISS later outcomes trial flow diagram .........................................141
4.2 Vineland ABC scores by treatment g r o u p ...................................... 145
4.3 Vineland ABC score by dichotomised aetiology............................. 149
4.4 Vineland ABC score by primary clinical response.......................... 150
4.5 Vineland ABC scores by treatment box-whisker............................. 152
4.6 Vineland ABC score by treatment where no identified aetiology 153
4.7 Time to last reported spasm with 95% C I s .......................................154
4.8 Time to last reported spasm for dichotomised treatments . . . .  155
4.9 Time to last reported spasm for all three tre a tm e n ts ..................... 156
4.10 Time to reported spasms with 95% C Is ............................................ 157
4.11 Time to reported spasms for dichotomised treatm ents.................. 158
4.12 Time to reported spasms for all three trea tm en ts ........................... 159
5.1 West Delphi round 3 classification flow d ia g ra m ...........................189
5.2 West Delphi round 3 hypsarrhythmia classification........................ 190
A.l UKISS contributors (part 1) ..............................................................241
A.2 UKISS contributors (part 2) ............................................................. 242
D.l West Delphi consensus classification flow d iagram ........................277
D.2 West Delphi consensus hypsarrhythmia classification.................. 278
12
List of Tables
1.1 Features of atypical and modified hypsarrhythm ia......................  34
3.1 Centres eligible to enroll participants.............................................. 100
3.2 Accrual of participants 1999-2000 inclusive.......................................101
3.3 Accrual of participants 2001-2002 inclusive.......................................102
3.4 Power calculations given different assumptions ..........................105
3.5 LREC response t im e s ........................................................................ 106
3.6 Documents required and time to LREC d e c is io n ..........................107
3.7 Trial participant baseline characteristics ( 1 ) .................................... 115
3.8 Trial participant baseline characteristics ( 2 ) .................................... 116
3.9 Final classification of underlying a e tio lo g y .................................... 118
3.10 Classification of aetiology in non-randomised c a s e s ..................... 121
3.11 Cessation of spasms by treatment and dichotomised aetiology . . 124
3.12 Cessation of spasms by age at onset of spasms ...............................127
3.13 Cessation of spasms by final aetiological category...................... 129
3.14 Cessation of spasms by stratified randomisation sex category . . . 129
3.15 Cessation of spasms by stratified randomisation age category . . . 130
3.16 Cessation of spasms by composite stratified category................ 131
3.17 Classification of baseline and follow-up E E G ................................133
3.18 EEGs by treatment and primary clinical response..........................134
3.19 Numbers with early adverse events .............................................. 136
3.20 Types of early adverse e v en t.............................................................137
13
LIST OF TABLES 14
4.1 Ages at follow-up assessm en ts........................................................ 142
4.2 Vineland ABC score by treatm ent.................................................... 144
4.3 Vineland ABC scores by aetiology ................................................. 146
4.4 Vineland ABC score by treatment and a e tio lo g y .......................... 146
4.5 Vineland domain scores by tr e a tm e n t .............................................148
4.6 Vineland ABC score by ae tio logy .................................................... 150
4.7 Vineland ABC score by primary clinical response.......................... 150
4.8 Outcomes by lead-time and dichotomised aetio logy ..................... 151
4.9 Vineland ABC score by lead-time and aetiology .......................... 152
4.10 Epilepsy o u tc o m e s ............................................................................ 162
5.1 Contributors to West Delphi and responses to each round . . . .  170
5.2 West Delphi round 1 resonses...........................................................172
5.3 West Delphi round 2 re sp o n ses ........................................................ 180
5.4 Round 2, question 2(a) responses.....................................................181
5.5 Round 2, question 2(b) responses.................................................... 182
5.6 Round 2, question 2(c) resp o n ses.....................................................184
5.7 Round 2, question 2(d) responses.....................................................184
5.8 Round 2, question 2(e) responses.....................................................185
5.9 Round 2, question 2(f) re sp o n se s .....................................................185
5.10 Round 2, question 2(g) responses.....................................................185
5.11 Round 2, question 25 responses........................................................186
5.12 West Delphi round 3 re sp o n ses ........................................................ 191
5.13 Areas covered in West Delphi round 4 ............................................ 193
5.14 Areas covered in West Delphi round 5 ............................................ 197




The first written description of what is now known as infantile spasms ap­
peared in 1841 [1]. William James West, a general practitioner in Tonbridge, 
Kent described, in a letter to the Lancet, episodes of repeated head nodding in 
his son, James Edwin West [2,3]. A contemporary of West, William Newnham, 
had seen a case a year earlier. After reading West's account, Newnham com­
piled details of four cases, including the one that he had treated and that of 
James Edwin West [4].
Little therapeutic progress occurred during the century after West's de­
scription, though the names by which the disorder was known proliferated 
[5]. However, there was a breakthrough in the early 1950s, with published 
reports of the disorder being associated with characteristic EEG findings. In 
1949, Vasquez and Turner described ten cases to the Sociedad Argentina de Pedi- 
atrta, with electroencephalographic findings in eight cases that they described 
as a diffuse, paroxysmal cerebral dysrhythmia* that was of high voltage, dif­
fusely disorganised, and irregular* [6].
.. urn difusa disritmia cerebral paroxistica. .."
*"... de gran voltaje, difusamente desorganizada e irregular. .."
15
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In 1952, Gastaut and Remond described what appears to be the same con­
dition, distinguishing a form of bilateral myoclonus that they called myoclonies 
type B. They described an ictal spike-and-slow-wave complex* that tended to 
repeat in a more or less periodic fashion5 [7]. And that same year, Gibbs and 
Gibbs provided an influential description in English in their Atlas of Electroen­
cephalography [8]:
... random high voltage slow waves and spikes. These spikes vary from 
moment to moment, both in duration and location. At times they appear 
to be focal, and a few seconds later they seem to originate from multiple 
foci. Occasionally, the spike discharge becomes generalized, but it never 
appears as a rhythmically repetitive and highly organized pattern that 
could be confused with a discharge of the petit mal variant type. The 
abnormality is almost continuous.
Gibbs and Gibbs called the characteristic EEG pattern hypsarrhythmia, a term 
derived from the Greek xv^eXo^ (high) and aggu'dpoq (non-rhythmic) [9].
In the late 1950s, investigators used this new clinical and electroencephalo- 
graphic information to study the effects of potential treatments. There were 
soon reports from Belgium [10], France [11], Japan [12], Switzerland [13], and 
the United States [14,15] on the treatment effects of adrenocorticotrophic hor­
mone (ACTH) and corticosteroids. These became the mainstays of treatment 
for the condition that became known best as infantile spasms or West syndrome.
Although several new antiepileptic drugs became available during the next 
three decades, none was more effective than hormonal treatments. However, 
vigabatrin, which was first licensed for therapeutic use in 1989, proved to be an 
effective treatment of infantile spasms and came to be considered as a valid al­
ternative first-line treatment for infantile spasms. One small randomised trial
.. le complexe « pointe-onde lent "
§"... tendent parfois A se repeter, de fagon plus ou moins periodique..."
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suggested that it is a particularly good treatment for infantile spasms when 
the underlying cause is tuberous sclerosis (TSC) [16]. Since it is administered 
orally and it was believed to have only minor adverse effects, vigabatrin be­
came a popular choice as first-line treatment of infantile spasms.
1.2 Content and scope of this thesis
This thesis examines the relative effectiveness and safety of hormonal and vi­
gabatrin treatment of infantile spasms, and reports the results of a multicentre 
randomised trial. This introduction discusses definitions, classification and 
clinical features of infantile spasms. It summarises the basic epidemiologi­
cal features, the frequency and underlying disorders associated with infantile 
spasms. And it discusses previous studies of treatments for infantile spasms 
with a particular focus on randomised trials that include hormonal treatments 
or vigabatrin.
Chapter 2 outlines the design of the United Kingdom Infantile Spasms Study 
(UKISS). It describes how the study protocol was developed after initial ap­
proval was granted; some aspects of the administration of the study; and is­
sues relating to safety, licensing, and ethics. Chapter 3 reports early outcomes 
from the UKISS randomised trial, involving the period up to study day 14; and 
chapter 4 reports outcomes from the later part of the study, including relapse 
of spasms in primary clinical responders, progression to other seizures types, 
and neurodevelopmental outcomes.
Chapter 5 reports the administration and results of West Delphi, a consensus 
elicitation process that I developed with Professor John Osborne in response 
to problems that became apparent when we critically appraised the design of 
UKISS and other studies of infantile spasms.
Chapter 6 discusses, in the context of earlier and recent research, the find­
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ings of UKISS and the results of West Delphi, and how these two initiatives 
might influence future investigations and the treatment of infantile spasms.
1.3 General reviews of infantile spasms
This thesis dtes many important published articles in the field of infantile 
spasms, particularly those relating to case definition and treatment. To get a 
general overview of infantile spasms, good resources are the reviews given in 
the short monographs by Jeavons and Bower [17], and by Lacy and Penry [18]; 
and collected information in the books edited by Gastaut, Roger, Soulayrol and 
Pinsard [19], Dulac, Chugani and Dalla Bemardina [20] and by Schwartzkroin 
and Rho [21]. The proceedings of a 1985 symposium on infantile spasms is 
published in volume 9 of Brain & Development [22]. Recent reviews that appear 
as chapters in major textbooks of epilepsy include those by Dulac, Plouin and 
Schlumberger [23] and that by Holmes and Vigevano [24].
1.4 Definition of infantile spasms
The term infantile spasms was not established as the standard term for this 
epilepsy condition until the early 1960s. Gastaut and Poirier, in their report 
of a symposium held in Marseilles in 1960, listed fifty-five synonyms for this 
disorder: 21 English; 9 German; and 25 French or latinate in origin [5]. Many 
of the names describe the nature of the movement: for example, jackknife con­
vulsions; Komplimentierkrampfe; and spasmes salutoires. Other names suggest the 
suddenness or severity of the movements: for example, lightning major seizures; 
Blitz-Nick-und-Salaamkrampfe; and propulsions epileptiques. A further synonym, 
Vencephalopathie myoclonique infantile avec hypsarrhythmie (EMIH) (infantile my- 
oclonique epilepsy with hypsarrhythmia), was coined as a result of the Mar-
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settles symposium, but this term has not stood the test of time.
In tribute to the doctor who gave the first written description of the dis­
order, Gastaut and others attending the symposium suggested the term West 
syndrome, at that time recommending that this term be used to describe histori­
cal aspects of the disorder [5]. Since then, however, the term West syndrome has 
been used in wider and inconsistent contexts, sometimes referring to the triad 
of spasms, hypsarrhythmia, and developmental delay [18]; sometimes refer­
ring to the former two features without requiring the third [25]; and at other 
times referring to any two of the three features. For many physicians, the term 
West syndrome is simply a synonym for infantile spasms [26].
The term infantile spasms ("Spasms, Infantile") was introduced as a Med­
ical Subject Heading (MeSH) term at the (United States) National Library of 
Medicine in 1977 [27]. It gives the definition: "An epileptic syndrome char­
acterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psy­
chomotor development at seizure onset." The triad thus defined does require 
developmental delay from the time of onset of spasms. The MeSH definition 
distinguishes two forms: symptomatic and cryptogenic, with the latter term be­
ing considered to be synonymous with the term idiopathic.
Other terms, epileptic spasms and, more simply, spasms, have been used to 
describe this seizure type occurring in clusters [28]. These terms disregard any 
limits of age and include the so-called periodic spasms that were first described 
by Gobbi et al [29]. It has been suggested that the term epileptic spasms may 
become preferred to infantile spasms [28].
Periodic spasms are clusters of spasms that occur in older childhood, and 
which do not have an EEG pattern of hypsarrhythmia. They often start with a 
focal seizure or EEG discharge followed by spasms that are often asymmetric 
or even unilateral. The EEG then typically shows slow waves time-locked to 
the clinical spasms, with superimposed low-amplitude fast activity.
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There is substantial disagreement about the classification and definition 
of infantile spasms in three areas. First, which features are necessary and 
which sufficient to define the infantile spasms. Second, how infantile spasms 
should be divided into the aetiological categories that are variously described 
as symptomatic, idiopathic, and cryptogenic. And third, which spectrum of 
epileptic disorders infantile spasms falls within, and how to distinguish infan­
tile spasms from other members of such spectra.
1.4.1 Necessary and sufficient features
There is no consensus on what constitute necessary and sufficient features to 
define infantile spasms. Most investigators would agree that spasms involving 
axial muscles and an associated abnormal EEG would be necessary features, 
but some investigators have suggested that relatively subtle movements asso­
ciated with a hypsarrhythmic EEG are sufficient to define a case. Thus, even 
axial spasms are not considered by all investigators to be a necessary feature. 
Some investigators have suggested that features such as non-focal onset, on­
set before one year of age, the occurrence of spasms in temporal clusters, and 
left-right symmetry of spasms are necessary features.
It is recognised that a hypsarrhythmic EEG pattern can occur in the absence 
of spasms, and so this cannot be considered to be a sufficient feature. Neither is 
hypsarrhythmia a necessary feature, since it is known that other EEG patterns 
are found early and late in the evolution of infantile spasms, and that any EEG 
pattern may be modified by treatment. Despite this, the term hypsarrhythmia 
was used during the 1950s and 1960s as a synonym for infantile spasms, and 
hypsarrhythmia may well have been portrayed by some investigators as being 
both a necessary and sufficient condition for the diagnosis of infantile spasms 
[30].
The range of ideas and disagreement about what are necessary and suffi­
CHAPTER 1. INTRODUCTION 21
cient features of infantile spasms are illustrated by published reports of com­
missions and workshops sponsored by the International League Against Epile­
psy (ILAE). The ILAE International Classification of Epileptic Seizures of 1970, 
inspired by Gastaut, recommended that infantile spasms be classified as a type 
of generalised seizure [31, 32]. This classification implies bilateral symmetry 
and a non-focal onset. The classification also stated that infantile spasms: (1) 
is a seizure disorder of infants; (2) has an underlying substrate and cause that 
is unknown; (3) is associated with an interictal EEG that shows hypsarrhyth­
mia; and (4) shows varied ictal EEG changes: usually flattening, but sometimes 
more prominent spikes and slow waves.
A proposal for revised clinical and electroencephalographic classification of 
epileptic seizures in 1981 did not mention infantile spasms [33], but a proposal 
for classification of epilepsies and epileptic syndromes published in 1985 did 
include infantile spasms and stated that its onset had to occur within the first 
year of life [34]. A further proposed revision of this classification of epilepsies 
and epileptic syndromes, published in 1989, based its definition of infantile 
spasms on the triad of spasms, hypsarrhythmia, and developmental delay, but 
conceded that one element of the three may be missing [35]. It required that 
onset, "always occurs before the age of one year," and added that the age of 
onset peaks between 4 and 7 months of age. The proposal added further epi­
demiological and therapeutic observations, suggesting that the mixed form of 
spasms is commonest, and that adrenocorticotropic hormone or corticosteroid 
treatments influence neurodevelopmental outcome.
This 1989 ILAE proposal defined and distinguished symptomatic and cryp­
togenic infantile spasms. Children would be classified as having symptomatic 
infantile spasms if they had neurological, developmental, or radiological signs 
of brain damage preceding the onset of spasms; if they had a known underly­
ing cause; or if there were preceding seizures of another type. Children with­
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out these features, which it suggested is a smaller group, would be classified 
as having cryptogenic infantile spasms.
The Commission on Pediatric Epilepsy of the ILAE held a workshop on in­
fantile spasms in 1991 [28]. This workshop recommended that infantile spasms 
should not be confined to the International Classification of Epileptic Syn­
dromes, but should be included also in the broader International Classifica­
tion of Epileptic Seizures. The definition of infantile spasms that was recom­
mended by this commission is generally more permissive than earlier defini­
tions, and is markedly different from that of the 1989 commission. In partic­
ular: (1) onset is not confined to the first year of life; (2) the spasms are often 
associated with hypsarrhythmia during infancy, but this is modified by age, 
underlying brain lesions, and sleep-wake state; and (3) the definition of West 
syndrome is determined by the association of the spasms with hypsarrhyth­
mia. The workshop recognised that West syndrome is often associated with 
developmental delay, but suggested that developmental delay ought not to be 
required to make a diagnosis of West syndrome.
The workshop made three other important recommendations. First, that 
the term infantile spasms be dropped in favour of the term spasms. Second, that 
the term modified hypsarrhythmia should be discarded in favour of describing 
the specific modifying features in each case. And third, that the term idiopathic 
infantile spasms be reserved for cases with more specific features.
1.4.2 Aetiological subgroups: symptomatic, cryptogenic, and 
idiopathic
The terms symptomatic, cryptogenic and idiopathic have been used in different 
senses by different investigators. In general, the term symptomatic has been 
used to describe a child who has a known cause for the infantile spasms.
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This cause may be: (1) described in the medical history, as with neonatal en­
cephalopathy with seizures; (2) anatomical, such as a major brain malforma­
tion proven by neuroimaging; (3) biochemical, such as phenylketonuria; or (4) 
a genetic syndrome, such as tuberous sclerosis. However, the term symptomatic 
is often used in cases where no specific underlying aetiology is identified but 
where it is inferred, probably because there is substantial developmental de­
lay, that a significant underlying aetiology must be present. Dulac and Plouin 
listed eight definitions of non-symptomatic infantile spasms that have been 
used by other authors, five of which required there to be normal development 
before onset of spasms [36].
The terms cryptogenic and idiopathic have tended to be used as synonyms 
for any non-symptomatic case. However, these terms have etymologies that 
suggest a distinction. The term cryptogenic, from the Greek Kgvirroq (hidden) 
and 7evo<; (origin), suggests that an underlying cause is suspected but cannot 
be found. The term idiopathic, from the Greek tSioq (self) and nai?oc (disease), 
suggests a disorder produced by itself and with no underlying cause.
The 1991 workshop on infantile spasms made use of this distinction to 
describe the clinical and electrophysiological features of a group of children 
whom they define as having idiopathic infantile spasms. It suggested that this 
idiopathic form is distinguished by the following features: (1) normal devel­
opment before the onset of spasms; (2) no preceding seizures of any type; (3) 
normal clinical examination (4) normal computed tomography (CT) and mag­
netic resonance (MR) imaging; (5) hypsarrhythmia occurring between spasms 
within a cluster of spasms; and (6) no evidence of a focal lesion on either ictal 
or interictal EEG.
One problem with this definition of an idiopathic group as suggested by 
Dulac et al is that it requires, as part of its definition, normal final developmen­
tal outcome [36]. It thus includes information that is not known at the time of
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diagnosis and can only be determined retrospectively. Also, the final develop­
mental status might be influenced by factors that are entirely unrelated to and 
independent of the infantile spasms. The electroencephalographic features of 
this group, hypsarrhythmia recurring between spasms within a cluster, are not 
specific to idiopathic cases but are also found in infants with Down syndrome 
[37].
1.4.3 Associated conditions and distinguishing features
Infantile spasms may also be defined by their relationships to other forms of 
epilepsy. On the basis of EEG features, Lennox and Davis considered infantile 
spasms to be related to generalised absence epilepsy, including it as a member 
of a petit mal quadrette [42]. Livingston et al suggested that infantile spasms was 
part of a group of conditions called minor motor epilepsy and which included 
akinetic seizures and head nodding episodes [43]. Gastaut considered infantile 
spasms to be related to myoclonic epilepsy, hence referring to it as one of the 
myoclonies B [7].
Ohtahara has suggested that infantile spasms are part of a spectrum of age- 
dependent epileptic encephalopathies consisting of early infantile epileptic en­
cephalopathy (EIEE; Ohtahara syndrome), infantile spasms (West syndrome), 
and Lennox-Gastaut syndrome [44,45,46]. This idea is based on the observa­
tion that the clinical and EEG patterns occur at certain ages and during critical 
stages of development. Features common to the age-dependent epileptic en­
cephalopathies include characteristic EEG features, heterogenous underlying 
disorders, frequent developmental delay or learning disability, and often in­
tractability to treatment [44].
Many children progress from Ohtahara syndrome to West syndrome or 
infantile spasms, or from infantile spasms to Lennox-Gastaut syndrome, or 
both. In a series of children with age-dependent encephalopathies described
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by Ohtahara, 9/14 children who had Ohtahara syndrome developed infantile 
spasms, and 17/88 children with infantile spasms developed Lennox-Gastaut 
syndrome. Some children progress through all three conditions. This concept 
of age-dependent epileptic encephalopathies is currently popular.
Aicardi and Chevrie proposed a classification that distinguishes infantile 
spasms, which would always have a hypsarrhythmic EEG pattern, from my­
oclonic epilepsies of childhood, which would have spike-wave or polyspike- 
wave EEG abnormalities without evidence of the more chaotic hypsarrhyth­
mia [30]. Myoclonic episodes tend to be shorter than the episodes associ­
ated with infantile spasms, and the duration of muscle contraction associ­
ated with each episode can be measured by electromyography (EMG). Tonic 
seizures tend to last longer than the spasm movements associated with infan­
tile spasms. However, it is arguable whether infantile spasms can be reliably 
distinguished from myoclonic epilepsies of childhood by episode duration. 
Some authors have described lightning spasms, a form of infantile spasms with 
spasms of shorter duration. However, they have not justified this classification 
as a separate form by suggesting features that would otherwise distinguish 
these cases from other cases of infantile spasms [17,47].
Ohtahara syndrome consists of tonic spasms occurring during the first few 
weeks of life associated with an EEG showing a burst-suppression pattern dur­
ing both wakefulness and sleep. It is often associated with structural lesions, 
severe neurodevelopmental delay, and progression to other seizure types in 
later life. Some investigators suggest that Ohtahara syndrome is an early form 
of infantile spasms [48]. In the same age group, a burst-suppression EEG pat­
tern with erratic myoclonus but no evidence of tonic seizures is consistent with 
the diagnosis of early myoclonic encephalopathy, which is more frequently as­
sociated metabolic disorders. There is continued debate about whether these 
syndromes are reliably distinguishable [49,50].
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Lennox-Gastaut syndrome usually has an onset between the ages of 1 and 
7 years, but so-called early-onset cases may occur during the first year of life 
[48]. It may be difficult to distinguish early-onset cases of Lennox-Gastaut 
syndrome from later-onset cases of infantile spasms, particularly since cases of 
infantile spasms with late onset and cases of Lennox-Gastaut syndrome with 
early onset less often show typical EEG changes. The diagnosis of Lennox- 
Gastaut syndrome is considered to be clear once atonic and absence seizures 
become evident, but it may be impossible to decide whether the earlier features 
were due to Lennox-Gastaut syndrome or infantile spasms.
1.5 Clinical features of infantile spasms
The clinical features of infantile spasms are described excellently in the mono­
graph by Lacy and Penry [18], and information in this section is taken from 
that source unless stated otherwise.
There is a general consensus that infantile spasms is a type of seizure dis­
order, and there is agreement about its fundamental forms. However, there 
is disagreement about whether subtler movements should be regarded as be­
ing infantile spasms. The spasms may be flexor, extensor, or mixed; and the 
most characteristic movement is a sudden onset of contraction of the muscles 
involved, this usually occurring with bilateral symmetry and synchrony
Flexor spasms involve sudden, simultaneous flexion of the neck and trunk; 
bilateral, symmetrical flexion, abduction, or adduction of the upper limbs; and 
flexion and adduction of the lower limbs. At the end of a spasm, the upper 
limbs may be either strongly abducted, resembling a Moro reflex, or adducted 
across the child's front and resembling a self-embrace. Extensor spasms involve 
sudden extension of the neck and trunk; bilateral, symmetrical extension and 
abduction of the upper limbs; and extension at the hips and knees. They par­
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tially resembles a Moro reflex, and have been described as a cheerleader spasms. 
There can also be mixed spasms, which consist of either flexion or extension 
of the neck and trunk with the limb movements being opposed to the truncal 
posture. The spasms usually occur in batches or clusters, and the term mixed 
spasms can be used in an alternative sense to indicate that some clusters con­
sist of predominantly flexion movements of limbs and trunk, and other clus­
ters consist predominantly of extension movements. In some children, single 
spasms occur on some occasions and clusters at other times. Rarely, a child 
has single spasms on all occasions. Between cases, there are wide ranges in 
the number of clusters occurring during one day and in the number of spasms 
occurring within a cluster. As the disorder progresses, there may also be sub­
stantial variation in these features within any one case.
1.5.1 Distinct forms of infantile spasms
There is controversy about whether the other forms of infantile spasms de­
scribed by some investigators are infantile spasms or another type of seizure. 
One controversial form is the head nodding spasm, which seems to precede or 
remain after the more classical forms of infantile spasms. Some investigators 
think it is a distinct type of seizure that is associated with infantile spasms, and 
others suggest that it is a distinct form of infantile spasms.
Another form of spasm that has been regarded as an associated but separate 
type of seizure by some researchers is the tonic spasm. In this form, the child 
has a rigid posture and a fine tremor of the outstretched limbs. Briefer spasms 
that resemble myoclonus have been described as lightning spasms, as discussed 
in section 1.4.3.
More arguable forms are those that are described as partial or fragmented 
infantile spasms. These include: unilateral spasms; those involving only up­
per or lower limbs; those involving only part of one set of limbs, such as the
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shoulders alone; and those involving flexion of either the neck or the trunk, 
but not both. Some investigators state that infantile spasms are, by definition, 
bilateral, symmetrical, and generalised. However, it is generally accepted that 
some degree of asymmetry and lateralisation, such as turning of the head or 
rolling of the head to one side, may occur in infantile spasms. In the study 
of Fusco and Vigevano, asymmetrical spasms occurred only in children with 
symptomatic infantile spasms, and were noted in 8/20 (40%) of such cases [51]. 
The cases classified as symptomatic in that study included five with "spasms of 
unknown prenatal etiology."
1.5.2 Other features of spasms
It is difficult to assess whether consciousness is lost during spasms, or merely 
impaired. The scream or cry that often accompanies the spasms may be a 
sign of distress associated with spasms, or it may be part of the seizure. Such 
screams are more likely to occur at the end of a cluster of spasms, rather than 
before or during the cluster. Other features that may occur during a cluster 
of spasms include: laughter or smiling; a frightened or confused facial expres­
sion; flushing, pallor, cyanosis, or sweating; dilated pupils or fluttering eyelids; 
staring, rolling or lateral movements of the eyes; nystagmus; the production of 
tears; hiccups or respiratory arrest; tremulousness; or incontinence of urine or 
faeces.
Several features have been described during the period between clusters 
of spasms, the commonest of which are tremulousness, irritability, and rigid 
posturing, often with arching of the back. These interictal features are thought 
to be more common in children who suffer more frequent spasms. Drowsiness 
has been described at the end of a cluster of spasms, and seems to be associated 
with clusters of longer duration.
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1.5.3 Factors that precipitate spasms
Several factors have been described that might, in a predisposed child, trigger 
spasms. The states of consciousness between sleeping and waking or between 
waking and sleeping -  the so-called twilight states -  have been described as a 
triggering factor in many studies. Other putative factors include: handling; 
feeding; hunger; startle or fright; excitement or anger; urination or defaecation; 
fever; excessive environmental heat. Twilight states are more likely to occur 
in the morning and evening, especially in older children. However, no studies 
have described a tendency for spasms to occur at a particular time of day.
1.5.4 The timing and duration of ictal events
There is no standard definition of the ictal event associated with infantile spasms, 
Some investigators suggest that a single spasm might constitute an ictal event, 
but others suggest that the cluster of spasms is the more appropriate mea­
sure. Since single spasms can occur, the duration of an ictal event might be 
as short as a few seconds. Some series have been described in which "several 
thousands" of spasms have occurred, and an ictal event might last longer than 
twenty minutes. It seems that spasms are less frequent when they are first no­
ticed, peak in frequency and duration when the disorder is well established, 
and then diminish in frequency and duration as the disorder resolves.
Fusco and Vigevano reported the mean duration of spasms as recorded by 
EMG of the deltoid muscle as being 1.25 seconds and 1.56 seconds in cryp­
togenic and symptomatic groups respectively [51]. The study did not report 
full ranges or an overall median or mean, but no spasms were longer than
2.4 seconds.
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1.5.5 Relationship to other seizures
Antecedent seizures are relatively common. Many children with infantile sp­
asms have had neonatal encephalopathy with seizures. Infantile spasms may 
be the next seizure disorder to develop, or there may be other seizure types 
during the interim. Infantile spasms may be preceded by generalised or fo­
cal epileptic seizures, the latter especially in infants who have focal neurolog­
ical lesions. Some investigators have also described myoclonic and akinetic 
seizures preceding the onset of infantile spasms. Estimates of the proportion 
of children with infantile spasms who had antecedent seizures are influenced 
by the classification of seizures such as head nodding, which some investiga­
tors regard as being early signs of infantile spasms. Finally, the tonic seizures 
of early infantile epileptic encephalopathy (Ohtahara syndrome) evolve rela­
tively commonly into infantile spasms.
Concurrent seizures, particulary focal seizures, are common with infantile 
spasms. Druckman and Chao described concurrent seizures in 26/73 (36%) 
of children, and Jeavons and Bower described them in 30/112 (27%) of chil­
dren [17, 52]. Most of these were considered to be generalised seizures, but 
some were described as focal, akinetic or mixed types. Ohtsuka et al have de­
scribed partial seizures occurring in 40% of children with West syndrome [53]. 
Concurrent partial seizures are recognised to be particularly common in tuber­
ous sclerosis, and EEG-video monitoring has shown that partial seizures can 
have a complex sequence of close temporal association with the clinical spasms 
[54, 55]. Plouin et al performed EEG-video monitoring on 74 infants and re­
ported partial seizures in half of cases classified as symptomatic and one-third 
of cases classified as cryptogenic [56]. They reported that this finding was as­
sociated with poorer response to treatment with corticosteroids.
Subsequent seizures are also known to be common. Early studies by Jeav-
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ons and colleagues showed that about half of the children who became spasm- 
free developed, either before or after the spasms had ceased, other types of 
seizure [57, 58]. Subsequent seizures may be generalised, focal, or akinetic, 
and Lennox-Gastaut syndrome occurs relatively frequently. However, studies 
have shown substantial variation in the proportion of children with infantile 
spasms who later develop focal seizures [18].
1.5.6 Differential diagnosis of infantile spasms
The most likely differential diagnoses of infantile spasms are conditions that 
generally present during the first year of life. They may be divided into two 
groups: disorders or symptoms that are paroxysmal or episodic and which 
are not associated with epileptic EEG patterns; and other forms of epileptic 
seizures or syndromes [48]. Non-epileptic disorders that might be mistaken 
for infantile spasms include: abdominal pain (colic); benign neonatal sleep my­
oclonus; benign paroxysmal tonic upward gaze; hyperekplexia; Sandifer syn­
drome; early breath-holding spells and syncopal episodes; adverse reactions 
to exogenous agents; paroxysmal dystonia or choreoathetosis; increased Moro 
reflex with episodes of opisthotonus; episodes of self-gratification or infantile 
masturbation; and shuddering attacks. Spasms associated with a normal EEG 
have been termed benign myoclonus of early infancy (BMEI) by Lombroso 
and Fejerman [59], and benign nonepileptic infantile spasms by Dravet et al 
[60]. BMEI resembles non-symptomatic infantile spasms in several ways. The 
age at onset is 4 to 9 months, and the spasms occur in series of myoclonic or 
brief tonic contractions of the neck, shoulders and upper limbs. However, the 
spasms associated with BMEI rarely occur during sleep; the awake and sleep 
EEG patterns are normal; and developmental prognosis is normal.
Epilepsy conditions that might be mistakenly diagnosed as infantile spasms 
include: early myoclonic encephalopathy; early infantile epileptic encephalopa-
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thy (Ohtahara syndrome); benign myoclonic epilepsy of infancy; myoclonic- 
atonic-astatic epilepsies; and early-onset Lennox-Gastaut syndrome. In addi­
tion, partial seizures may mimic infantile spasms that are asymmetrical. The 
differential diagnosis in older children includes Lennox-Gastaut syndrome and 
periodic spasms [29].
1.6 Electroencephalographic features of infantile 
spasms
The use of video EEG in the study of infantile spasms was first described by 
Frost et al in 1978 [61]. The system included monitoring of EEG, electromyo­
gram (EMG), electrocardiogram (ECG), electro-oculogram (EOG), respiration 
rate, galvanic skin responses, and measurement of acceleration of body parts 
in three axes. These were linked to a synchronous video recording.
1.6.1 Hypsarrhythmia
The classical EEG pattern associated with infantile spasms is hypsarrhyth- 
mia, which generally occurs during the interictal period between clusters of 
spasms. (In some early works, hypsarrhythmia was spelt hypsarhythmia, with 
a single r, but Jeavons and Bower standardised the English spelling to have 
a double r in keeping with the Greek rule that a word beginning with the 
letter g, (rho) takes a double g when prefixed [17].) A hypsarrhythmic EEG 
pattern is neither a necessary nor a sufficient feature of infantile spasms. How­
ever, the two are strongly associated, and hypsarrhythmia has been used as a 
synonym of infantile spasms. One early paper described approximately two- 
thirds (51/80) of children with hypsarrhythmia as having seizure disorders 
other than infantile spasms [62].
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The classical EEG pattern of hypsarrhythmia described by Gibbs and Gibbs 
is generally thought to occur in immature and developing nervous systems. 
The most characteristic feature seems to be that the focal spikes-and-sharp 
waves are positioned inconstantly, shifting from moment to moment [9]. The 
pathophysiological mechanism that produces this EEG pattern is not known, 
but it is likely that it involves both cerebral cortex and subcortex [63]. The hyp- 
sarrhythmic pattern may be interrupted by fast waves, high voltage spikes, 
polyspikes, slow waves, or sudden suppression of electrical activity. The am­
plitude of the spike-and-sharp waves is often greater over the posterior head 
regions, a feature that is said to distinguish hypsarrhythmia from the EEG of 
early-onset Lennox-Gastaut syndrome [9].
Although hypsarrhythmia is generally described as an interictal EEG pat­
tern, it has been said to occur between single spasms within a cluster in the 
group described as idiopathic by the 1991 ILAE workshop. One early study 
suggested that hypsarrhythmia can occur at any time between the first few 
days of life and 3 years of age, but that it most commonly occurs between the 
ages of 3 and 6 months [15].
Hypsarrhythmia is often present during both wakefulness and sleep, but 
in some cases it is found only during sleep [17]. In fact, despite the original 
assertion by Gibbs and Gibbs that hypsarrhythmia is "almost continuous, and 
in most cases [evident] as clearly in the waking as in the sleeping record," 
later studies have shown hypsarrhythmmia to be state-dependent and more 
common in sleep [64].
1.6.2 Atypical and modified hypsarrhythmia
The terms atypical, first introduced by Gastaut, and modified, first used by Gibbs 
and Gibbs, are used to describe EEG patterns that are often regarded as being 
"decidedly abnormal but not truly hypsarrhythmic" [8,18, 65, 66]. Such EEG
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Table 1.1: Features described as atypical and modified by Gastaut and Hrachovy 
et al, respectively.
Feature Description Atypical Modified
Amplitude High amplitude activity Yes Yes
Asymmetry Asymmetry of wave amplitude af­
fecting a part or whole of one cere­
bral cortex: at its most extreme, 
hemihypsarrhythmia
Yes Yes
Attenuation Episodes of generalised, regional, 
or localised voltage attenuation, 
usually lasting from 2 to 10 seconds
No Yes
Focality Evidence of spikes and spike- 
waves associated consistently with 
an irritative focus
Yes Yes
Fragmentation Temporal variation in EEG patterm Yes No
Slow wave Excessive slow wave activity Yes Yes
Synchrony Increased synchronisation between 
hemispheres, also known as period­
icity
No Yes
patterns show a degree of organisation that is described as synchrony or peri­
odicity and which is said to be distinct from the totally chaotic EEG pattern of 
typical or classical hypsarrhythmia.
Gastaut et al described five features that defined hypsarythmies atypiques (ta­
ble 1.1) [65]. The first feature was temporal fragmentation during wakefulness, 
rather than during sleep. They noted that such fragmentation tends to occur 
prior to resolution of hypsarrhythmia. A second feature was excessive slow 
wave activity. The third feature contrasted the second: high amplitude fast ac­
tivity. A fourth feature was an asymmetry of wave amplitude affecting a part 
or whole of one cerebral cortex. And the fifth feature was spikes and spike- 
waves associated with an irritative focus.
Hrachovy et al also described variations in the EEG pattern, preferring the 
term modified to atypical, and noting that rapid eye movement sleep (REM) in 
particular is associated with marked improvement in the hypsarrhythmic pat­
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tern [67]. They suggested that high voltage, asynchrony, seizure type and ictal 
EEG patterns are features that are maintained. The modifying features they 
described are: (1) increased interhemispheric synchronisation; (2) asymmetry, 
at its most extreme, hemihypsarrhythmia; (3) a consistent focus of abnormal 
discharge; (4) episodes of generalised, regional, or localised voltage attenua­
tion, usually lasting from 2 to 10 seconds; and (5) a pattern that is predomi­
nantly high-voltage bilaterally asynchronous slow activity. They described a 
periodic appearance consisting of grouping of spike, sharp wave and slow wave 
discharges during NREM sleep, and disappearance of hypsarrhythmia during 
REM sleep. A reduction or disappearance of hypsarrhythmia, lasting for sev­
eral seconds to minutes and called relative normalisation, was noticed during 
arousal from NREM or REM sleep.
Modifying features included in Gastaut's atypical hypsarrhythmia classifi­
cation: interhemispheric asymmetry, high amplitude slow activity with little 
sharp wave or spike activity, and signs of a focal irritative lesion. In addition, 
they described increased interhemispheric synchronisation and episodes of at­
tenuation. Synchrony has also been termed periodicity, and has been shown to 
occur in some cases before the development of typical hypsarrhythmia [63,68]. 
It has been suggested that this synchrony is the essential defining feature of 
modified hypsarrhythmia [18].
These features are described in qualitative rather than quantitative terms, 
and it is likely that there would be substantial inter-rater, and possibly intra­
rater variation, in classifications based upon these criteria. Also, the under­
lying mechanisms that produce these features may have different structural, 
functional or prognostic significance, and the collective terms atypical hypsar­
rhythmia and modified hypsarrhythmia may not be useful. The 1991ILAE work­
shop on infantile spasms recommended that these terms are no longer used, 
and that the specific features are described separately [28]. Hypsarrhythmia
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that persists during a cluster of spasms was described by Fusco and Vigevano 
as a feature that is associated with better prognosis [51]. This has been de­
scribed by the 1991 Workshop as one of the features that define the idiopathic 
form of infantile spasms. However, it has also been reported as a feature found 
in children with infantile spasms and Down syndrome [37].
1.6.3 Ictal EEG features
Fusco and Vigevano described three EEG patterns during clusters of clinical 
spasms: (1) a medium or high amplitude slow wave that was positive over the 
vertex and central regions, and often accompanied by very low amplitude fast 
activity; (2) a spindle-like activity of medium amplitude at 14-16 Hz; and (3) 
a pattern of diffuse flattening, which is commonly called an electrodecremental 
pattern.
1.7 Epidemiology of infantile spasms
The epidemiology of infantile spasms has been reviewed by Cowan and Hud­
son, and by Hurst [69,70].
1.7.1 Incidence and prevalence of infantile spasms
The main measure of disease frequency for infantile spasms is the number of 
cases occurring per number of live births. This is an incidence proportion, or 
incidence rate. Some studies have looked at cumulative incidence or period 
prevalence by following children through the first two years of life, or longer. 
These estimates are affected by deaths occurring during the period of study. 
All such studies of infantile spasms are rendered difficult to interpret by vari­
ations in case definition [70].
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Melchior reported 113 cases identified in a Danish survey between 1970 and 
1975. In order to study any effect of pertussis immunisation, they compared 
the distribution of age at onset with cases reported in the period 1957-67 [71]. 
Melchior did not state the population denominator, but it was later estimated 
to be between 0.25 and 0.35 per 1000 live births [72]. Riikonen and Donner 
studied 107 children bom in the county of Uusimaa, Finland and from these 
estimate the incidence in the three periods 1960-66,1967-71, and 1972-76 to be 
0.42, 0.38, and 0.42 per 1000 live births respectively [72]. There was temporal 
variation in underlying aetiology, suggesting that the small variation in the 
three estimates is partly due to chance. Eeg-Olofsson and Sidenvall studied 
incidence in the Uppsala region of Sweden and found an incidence of 1.4 per 
1000 live births in one county in the north-east of this region [73] and suggested 
that this cluster of very high incidence was related to the release of material 
from the nuclear power generator at Chernobyl. However, a later report stated 
an incidence range in these counties of 0.17 to 0.76 per 1000 live births [74].
A large study of the incidence of seizures in the United States by Ellenberg 
et al failed to distinguish infantile spasms from other "minor motor seizures," 
including tonic, myoclonic, akinetic and asymmetrical seizures [75]. Trevathan 
et al performed a population-based study in Atlanta, Georgia between 1975 
and 1977, ascertaining cases from reports provided by 21 EEG laboratories and 
by history from children involved in a cross-sectional survey [76]. They esti­
mated cumulative incidence at 2 years of age to be 0.29 per 1000 live births, 
and age-specific prevalence at 10 years of age to be 0.20 per 1000. Since not 
all cases of infantile spasms will have hypsarrhythmia, this is likely to be an 
underestimate of true incidence. With some standardisation of population de­
nominators and exclusion of 10/269 children with onset of spasms after 1 year, 
Hurst estimated a prevalence for infantile spasms from the United Kingdom 
National Childhood Encephalopathy Study (NCES) to be 0.13 per 1000 chil­
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dren aged between 2 months and 3 years [70,77].
1.7.2 Sex distribution of infantile spasms
Some early studies suggested that males were more likely to be diagnosed with 
infantile spasms than females. One early study found a male to female ratio 
of approximately 2.25:1 (104 males and 46 females) [58]. However, a review 
of 444 cases from 8 earlier studies, showed an appreciably lower maleifemale 
ratio of 1.35:1 (255 males and 189 females) [18] and one recent series of infants 
with infantile spasms had 60 males and 56 females, a ratio of approximately 
1:1 [78]. It appears that males are more likely to develop infantile spasms, but 
the size of this increased risk may be small.
1.7.3 Family history of epilepsy
It has been suggested that the incidence of epilepsy is lower in relatives of per­
sons who have had infantile spasms than in relatives of persons with other 
forms of epilepsy [18]. Some underlying causes, such as tuberous sclerosis, 
are inherited and associated with other seizure types. In such cases, a family 
history of infantile spasms might be expected, but would depend upon the 
probability of an affected person having children, and people with learning 
difficulties tend to have lower fertility rates. There have been reports of infan­
tile spasms occurring in twins, and in siblings in a family with X-linked mental 
retardation (section 1.7.6) [79,80,81].
1.7.4 Age at onset of infantile spasms
There is often a significant period between onset of spasms and diagnosis, and 
it may be difficult to distinguish antecedent developmental delay or regression 
from apparently antecedent developmental problems that are actually due to
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this period during which clinical spasms are not recognised. In addition, it is 
likely that many cases have electroencephalographic abnormalities earlier still. 
In this thesis, I use the term apparent lead-time to diagnosis to indicate an elapsed 
period between onset of observed spasms and diagnosis. The term lead-time 
to diagnosis without further qualification indicates an elapsed period between 
actual biological onset of spasms or the electrographic equivalent, whether ob­
served or unobserved.
The distribution of ages at onset of spasms is difficult to determine for sev­
eral reasons. First, there is often substantial uncertainty about the apparent 
lead-time to diagnosis. Second, some investigators and ILAE commissions 
have defined upper age limits for onset of infantile spasms so that are differ­
ences due to case definition between different periods of study. Typical upper 
age limits are 1 year and 2 years, despite the fact that early reports included 
children with onset at older ages [17,18,34,35,82]. Melchior used cumulative 
distributions of age at onset in two time periods to investigate the potential 
effect of pertussis immunisation and found 6% to have onset before 2 months 
and 3% to have onset between 12 and 17 months [71].
Differences in case definition result in some studies having right-censored 
ages of onset. A recent series of 116 cases reported by Fejerman et al, for exam­
ple, reported a median age for onset of spasms of 5.6 months and a range of 2 
to 10 months. However, despite these variations in classification and eligibil­
ity for study, it seems that the median and mode months of onset of infantile 
spasms are in the middle of the first year of life. Few cases occur in the first two 
months of life, and even though reporting practices may cause bias, it seems 
that few cases occur after 12 months of age [78].
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1.7.5 Natural history of infantile spasms
It is necessary to refer to earlier studies to make inferences about the natural 
history of duration and age at cessation of spasms. Without specific treatment 
interventions, infantile spasms may cease several weeks after onset, or may 
continue for several years. Jeavons and colleagues reported on 116 children, 
having excluded 34 children who had died while still suffering from infantile 
spasms or for whom there was incomplete follow-up data [58]. All of these 
children were followed beyond 3 years old, and some had been treated with 
ACTH or steroids. Spasms ceased before one year of age in 32 (28%); before 2 
years of age in 57 (49%); before 3 years of age in 75 (65%); in 86 (74%) by 4 years 
of age; and in 98 (85%) before 5 years of age. The proportions with continued 
spasms would be smaller today, since there are more effective first-line and 
second-line treatments. Prognosis is discussed more fully in Section 1.7.7.
1.7.6 Underlying disorders and aetiology
Issues relating to the classification of cases of infantile spasms into aetiological 
subgroups are discussed in section 1.4.2. Since there has been variable usage 
of the terms cryptogenic and idiopathic, in this section I will refer to the terms 
collectively as non-symptomatic unless a more specific usage is appropriate.
In case series described before cryptogenic and idiopathic forms of infantile 
spasms were distinguished, the reported proportions with non-symptomatic 
infantile spasms ranged from 15% to 56% [40, 41]. Lacy and Penry reviewed 
ten large studies performed before 1973, and found that the mean proportion 
with non-symptomatic spasms was 40% [18]. A review of studies reported be­
tween 1973 and 1982 reported the proportion of cases with non-symptomatic 
infantile spasms to range between 15% and 53%. The population-based study 
by Trevathan et al reported infants notified by EEG departments in the Atlanta
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area. It found that half of identified cases were classified as non-symptomatic. 
Variably defined favourable outcomes in children classified as having non- 
symptomatic infantile spasms have been reported in proportions ranging from 
approximately one-fifth (21%) to more than half of cases (58%) [36].
It is almost certain that, as neuroimaging and genetic diagnostic techniques 
become more sensitive, a higher proportion of cases will be classified as symp­
tomatic at the time of diagnosis of infantile spasms. The development of mag­
netic resonance imaging, for example, has led to the recognition of previously 
undetectable cerebral cortical dysplasias, and the development of more sen­
sitive imaging protocols performed by machines with higher magnetic field 
strength further increases the detection of even more subtle lesions.
Proportions of cases with specific underlying causes
Cases with specific underlying aetiologies are reviewed by Dalla Bemardina 
and Dulac [38], with further categorisation of symptomatic cases into groups 
relating to timing of the aetiological agent's action: prenatal, perinatal, or 
postnatal causes; and, independently, into groups described as clastic, de­
generative (or metabolic), malformative, and cryptogenic. They discuss the 
issue of competing potential underlying causes, and also a specific problem 
relating misclassification of cases considered to have a postnatal cause due 
to immunisation. Since the report of findings from the National Childhood 
Encephalopathy Study performed in the United Kingdom between 1976 and 
1979, the causal link between immunisation and infantile spasms is considered 
to be weak and the apparent association to be confounded by the often coinci­
dent timing of immunisation schedules and the age-dependent propensity to 
develop infantile spasms [77,39].
A neuropathological review of 50 cases from Vienna, Austria combined 
with 214 other reported cases suggested that one-third (30-34%) of cases of
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infantile spasms with early fatal outcomes were due to cerebral malformations 
but, like other studies to date looking at underlying conditions, this was not 
a population-based study [83]. Also, there is an obvious selection bias associ­
ated with including only cases subject to postmortem examinations. This same 
study reported that 36 to 40% of cases were associated with perinatal brain 
damage, and that 17% were associated with underlying metabolic disorders.
Tuberous sclerosis is known to be a common underlying cause of infantile 
spasms, but estimates of its relative frequency also vary greatly. A review by 
Curatolo reported that tuberous sclerosis was identified as being the underly­
ing cause in between 7% and 25% of symptomatic cases, and a study he per­
formed with colleagues reported a prevalence of 11% in a series of 164 infants 
undergoing CT scanning [84,85].
Specific underlying causes
There are many disorders that are found to coexist with infantile spasms and 
that might be considered to cause the spasms and the associated developmen­
tal delay. The combination of the epileptiform EEG with delayed or regressing 
development is often described as a epileptic encephalopathy. Thus, a number 
of putative causal mechanisms are invoked to describe events surrounding 
infantile spasms. Underlying conditions, genetic predisposition, or acquired 
diseases cause an epilepsy condition, and those underlying or acquired fac­
tors might cause developmental delay or regression, but so might the epilepsy 
itself. This thesis often uses the term underlying condition to describe the un­
derlying disorder, genetic predisposition, or acquired disease, rather than any 
term that has causal connotations, such as aetiology or underlying cause.
Some of these conditions may coexist with infantile spasms by chance. His- 
tidinemia, for example, is a relatively common metabolic disorder, and has 
only once been described in association with infantile spasms [86, 87]. The
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following underlying conditions have been described in association with in­
fantile spasms and may have a causal role. A broad outline of these conditions 
and citations are given by Aicardi, and by Dalla Bemardina and Dulac [26,38]. 
The list below is not exhaustive, but gives an idea of the range of conditions 
with which infantile spasms have been described. References are given for 
underlying conditions that are not described in the above reviews.
Brain neoplasms: benign and malignant tumours; hypothalamic hamartoma.
Endocrine, metabolic, and toxic: histidinemia [86]; histidinuria; hyperor­
nithinemia, hyperammonemia and homocitruUinemia (HHH syndrome); lead 
toxicity; Leigh disease; lithium toxicity; neonatal adrenoleukodystrophy; non­
ketotic hyperglycinemia; progressive encephalopathy with edema, hypsarr­
hythmia, and optic atrophy (PEHO syndrome); phenylketonuria; pyridoxine 
dependency; pyruvate carboxylase deficiency; sudanophilic leukodystrophy.
Nervous system infections: bacterial meningitis (meningococcus, pneumo­
coccus); pertussis [88]; prenatal infections (cytomegalovirus, rubella, syphilis; 
toxoplasmosis) viral encephalitis (adenovirus, enterovirus, herpesvirus) [88].
Cerebrovascular: acute dehydration; cardiac arrest; cardiac surgery; cerebro­
vascular infarction; intraventricular haemorrhage; subarachnoid haemorrhage.
Perinatal: abruptio placentae; brainstem gliosis; hydranencephaly; hypoxic- 
ischemic encephalopathy; intrauterine growth retardation; leukomalacia; ma­
ternal diabetes mellitus; maternal pre-eclamptic toxemia; multicystic encephalo- 
malacia; porencephaly; ulegyria.
Congenital: agenesis of corpus callosum; Aicardi syndrome; cortical dyspla­
sia, megalencephaly; cortical sublaminar heterotopia; costo-oculo-facial syn-
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drome (COFS); Down syndrome [37]; hemimegalencephaly; holoprosenceph- 
aly; incontinentia pigmenti; linear nevus syndrome; lissencephaly (Miller-Die- 
ker syndrome, isolated lissencephaly sequence, and X-linked lissencephaly); 
neurofibromatosis type 1 (NF1); Rett syndrome; schizencephaly; tuberous scle­
rosis (TS); Sturge-Weber syndrome; and X-linked disruption of the serine/thr­
eonine kinase 9 gene [89]; X-linked mutation of the Aristaless-related homeo- 
box gene (ARX) [90].
External injury: accidental injury; drowning injury [91]; non-accidental in­
jury; subdural haemorrhage.
Reiter et al have reported infantile spasms occurring in siblings in 2 families. 
In one family the infantile spasms occurred in monozygotic twins. [80] One of 
the four cases had later delayed development. A contentious issue has been 
whether pertussis immunisation causes infantile spasms and other forms of 
encephalopathy in infancy [71, 92]. Hrachovy et al reported HLA types in 29 
children with infantile spasms with those of 218 healthy controls and found 
a higher prevalence of the Class II antigen, HLA-DRw52, though the statisti­
cal analysis did not involve any adjustment for multiple testing. An earlier 
study on 21 children with infantile spasms by Howitz and Platz showed no 
association of infantile spasms with Class I HLA antigens.
1.7.7 Prognosis in infantile spasms
There can be little doubt that outcomes in infantile spasms are strongly related 
to underlying conditions. In general, it is suggested that cases classified as 
symptomatic have poorer outcomes, but there is variation in this classification 
used between studies, and any symptomatic group will consist of a variety 
of conditions with potentially different prognoses. Convulsive seizures pre­
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ceding the onset of spasms, or other convulsive seizures occurring during the 
same period as the spasms, are thought to be associated with a higher chance 
of seizures in later life. Similarly, preceding developmental delay is thought to 
be associated with poorer later development.
Matsumoto et al sought follow-up information about development at the 
age of 6 years on 262 children treated between 1963 and 1972 in Nagoya, Japan 
[40]. Information was available for 162 (62%) cases. Forty-eight (18%) had 
died, 32 (12%) before the age of 6 years. They received replies from 60/116 
(52%) families whose children had been lost to follow-up. Of the 162 cases 
successfully followed-up, they classified 18 (11%) as cryptogenic by criteria that 
many would be more appropriate for classification as idiopathic. Ninety-eight 
(60%) were classified as symptomatic and 46 (28%) as doubtful. They suggested 
that later development was poorer if there was a prenatal or perinatal aetiol­
ogy, or structural damage evident on pneumoencephalography. The magni­
tude of these effects are difficult to quantify.
Matsumoto et al also suggested that a longer lead-time to treatment was 
associated with poorer prognosis for development in cases they had classi­
fied as cryptogenic, though this may be affected by biases related to incomplete 
information and misclassification. The argument that longer lead-time to di­
agnosis modifies prognosis is not proven, and some authors have cited the ab­
sence of evidence in defence of study designs that involve delays in treatment 
[93,94,95].
Dalla Bemardina and Dulac have proposed four broad categories of aeti­
ology -  clastic, degenerative, malformation, and cryptogenic idiopathic -  and that, 
by classifying cases into one of these four groups or as idiopathic, it is possi­
ble to identify five patterns of prognosis [38]. First, extensive malformation 
or destruction of the brain are likely to produce protracted infantile spasms. 
Second, cortical lesions, such as those found in tuberous sclerosis or hypoxic-
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ischaemic encephalopathy, are associated with multifocal epilepsy. Third, a 
single focus, such as might be found with porencephaly, cortical dysplasia, or 
some cases of tuberous sclerosis, will cause focal epilepsy. Fourth, they suggest 
that Lennox-Gastaut is a likely outcome in cases with cryptogenic forms of in­
fantile spasms. And fifth, they suggest that cessation of seizures and normal 
subsequent development occurs with idiopathic infantile spasms.
Survival and mortality
As with prognosis for development and convulsive seizures, death rates are 
strongly related to underlying disorders. One early study of 7 children re­
ported reported that all seven children had died by 3 years of age [96]. One 
cohort of 150 children was followed by Jeavons et al to the age of 12 years, 
by which time 33 (22%) had died [58]. And an early study by Gibbs et al re­
ported death in 11 of 103 children [41]. The commonest stated cause of death 
was aspiration pneumonia, though this is likely to be causally related more 
to underlying neurodevelopmental problems than to the spasms themselves. 
It is possible that the risk of death due to infective causes was modified by 
treatment with ACTH.
Neurodevelopmental outcomes
The neurodevelopmental outcomes of 64 infants treated with ACTH or pred­
nisone were reported Glaze et al [97]. The average age at follow-up was 50 
months. Three (5%) had died, and 41 (64%) had significant neurodevelop­
mental problems, with an IQ of less than 50. Of 8 children with no identified 
underlying cause, 3 had normal development or minimal neurodevelopmental 
problems at follow-up. Other seizures occurred in 34 (53%).
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1.8 Treatment of Infantile Spasms
There is scepticism about the quality of evidence informing the choice of first- 
line treatment for infantile spasms. This scepticism was expressed amusingly 
in 1995 by the Archivist of Archives of Disease in Childhood, who ironically im­
plies that inappropriate subgroup analyses, combination treatments, and anec­
dotal opinion are all too common [98].
Infantile spasms should be treated with nitrazepam and a month of corti- 
cotrophin followed by two months of prednisolone unless the year ends 
with an odd number and your grandmother was bom on a Wednesday, 
when sodium valproate and prednisolone for six weeks are de rigeur, al­
though you could make do with vigabatrine [sic] and three weeks of hy­
drocortisone if your favourite colour is blue and Jupiter is about to collide 
with Mars.
In the United Kingdom in the latter half of the 1990s, the most common first 
choice treatments for infantile spasms were hormonal treatments, such as oral 
prednisolone or ACTH, and vigabatrin. Sodium valproate or valproic add 
are still occasionally used as a first-line treatment. Pyridoxal phosphate (or 
pyridoxine; vitamin B6) has been used in several studies, and is popular in 
Japan, where it is often combined with sodium valproate or low-dose ACTH. 
Surgical procedures are considered if medical treatments are ineffective and 
there is a focal lesion that is thought to trigger the seizures. Newer drugs, such 
as topiramate and zonisamide, have been investigated as add-on treatments, 
but reports have not suggested them to be superior to hormonal treatments or 
vigabatrin. These treatments are discussed in more detail in section 1.8.1.
Efficacy criteria between studies of infantile spasms may vary markedly, 
and some studies do not state explicit definitions for even the main outcome 
measure. For example, the measurement may be made after several weeks or
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several months, or no time limit at all may be stated. Also, some definitions 
of outcome measure include other requirements, such as resolution of hypsar- 
rhythmia. Outcomes such as mean reduction in number of spasms are likely to 
be less valuable than cessation of spasms, since any continual spasms indicate 
continuation of an underlying disease process that is likely to interfere with 
development.
The collective term generally used for hormonal treatments is steroids. How­
ever, ACTH and its synthetic derivatives do not have a steroid structure and, 
although the scientific principal of parsimony would support the idea that 
ACTH acts primarily via an effect upon increased adrenal production of en­
dogenous corticosteroids, this is not certain and this assumption has been chal­
lenged [99]. For these reasons, in this thesis the term hormonal treatment is used 
as a collective term for treatment with ACTH, derivatives of ACTH, or corti­
costeroids. Although thyrotrophin-releasing hormone (TRH; thyrotropin (US)) 
has been used to treat infantile spasms, no reference to this is intended when 
referring to hormonal treatment [100].
1.8.1 Brief review of treatments for infantile spasms
ACTH moieties: Pentella et al treated 5 cases of infantile spasms with an 
ACTH4_9 analogue and found no evidence of any treatment effect. [101] Willig 
and Lagenstein treated 7 cases with ACTH4_i0, again without any evident 
treatment effect [102]. The ACTHi_24 analogue tetractosactide (cosyntropin) 
is one of the drugs studied in UKISS and is discussed in section 1.9 [103].
Barbiturates: Riikonen et al reported use of brief thiopentone anaesthesia, 
using an intravenous dose of 30 m g/kg, in five cases of infantile spasms. Three 
patients had EEG changes of burst-suppression, but spasms relapsed and the 
treatment was not considered to be very effective [104].
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Benzodiazepines: These were a popular treatment in the 1960s, with nitraz­
epam finding particular popularity. The series of Volzke et al reported cessa­
tion of spasms after treatment for one week in 11/24 (46%) of cases [105]. De 
Negri et al found a poor response to high-dose rectal diazepam in 10 children 
with hypsarrhythmia, in contrast to good EEG responses in children with elec­
trical status epilepticus in sleep (ESES) [106].
Corticotrophin-releasing factor antagonists: This has been studied in a phase 
II trial by Baram, but its effect was not convincing [107]. This lack of effect is 
possibly due to failure of the drug to cross the blood-brain barrier.
Dexamethasone: Treatment with depot dexamethasone is discussed in sec­
tion 1.8.3 [108].
Felbamate: This is recognised as a treatment of a range of generalised and fo­
cal onset seizures, though its use is limited because of risks of aplastic anaemia 
and hepatotoxidty. A study by Hosain et al suggested that felbamate as add-on 
therapy might reduce frequency of spasms, but the study did not include any 
controls or report a reliable outcome related to cessation of spasms [109].
Ganaxolone: There has been one phase II trial of the neuroactive steroid, 
ganaxolone, which included children with infantile spasms [110]. Ganaxolone 
binds to the GABA receptor complex but has no steroid hormonal activity. It 
had some effect on the frequency of spasms in children who had not responded 
to other treatments, but had no significant effect on cessation of spasms.
Immunoglobulins: One study looked at 7 patients with Lennox-Gastaut syn­
drome, some of whom had had infantile spasms [111]. Another study reported 
11 children with infantile spasms, 6 of which were classified as cryptogenic
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[112], and one study reported findings in 15 children, 3 of whom had infantile 
spasms [113].
Lamotrigine: A study reported by Veggiotti et al showed little effect of lamot- 
rigine upon infantile spasms in 30 patients, all of whom had already received 
combinations of steroids (n = 21), vigabatrin (n = 23), sodium valproate (n = 29), 
and benzodiazepines (n = 26) [114]. After 3 months of lamotrigine treatment, 
spasms were reported to have stopped in 5/30 (17%), and to have continued 
with no substantial change in frequency in 19/30 (63%).
Methysergide and a-methylparatyrosine: Methysergide is a serotonin (5HT) 
receptor blocker, and a-methylparatyrosine is a competitive blocker of tyro­
sine hydroxylase and hence of catecholamine synthesis. Methysergide has 
been used to treat myoclonic conditions such as dyssynergia cerebellaris my- 
oclonica (Ramsey Hunt syndrome), paramyoclonus multiplex, and L-dopa in­
duced myoclonus [115]. Hrachovy et al believed infantile spasms to be due in 
part to increased brainstem adrenergic or serotonergic activity [94]. They stud­
ied 24 children, 23 of whom were classified as symptomatic, and defined their 
primary outcome as cessation of spasms and resolution of hypsarrhythmia af­
ter three weeks of treatment. As first-line treatment, 12 were given methy­
sergide and 12 were given a-methylparatyrosine. Only 3/24 had a primary 
response, 2 of whom had received a-methylparatyrosine, and one had an early 
relapse of spasms. They considered this to be an ineffective treatment.
Naloxone: Nalin et al found no substantial effect of naloxone on infantile 
spasms in 5 chidren [116].
Nitrazepam: There has been one study of nitrazepam versus ACTH, though 
the results are difficult to interpret because of co-administration of other anti­
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epileptic drugs, including valproic acid [117]. Response was defined as a 75- 
100% reduction in spasms.
Pyridoxine (vitamin B6): The term vitamin B6 is used to describe pyridox- 
ine, pyridoxal, and pyridoxamine, but the Coimcil on Pharmacy and Chem­
istry has assigned the name pyridoxine to the vitamin [118]. Pyridoxine is the 
primary alcohol, with pyridoxal having an aldehyde group at the 4-position 
of the pyridine nucleus, and pyridoxamine having an aminoethyl group at 
this position. Studies by Ohtsuka et al have suggested that infantile spasms 
might respond to treatment with pyridoxine. In their initial study, they found 
that 15/118 (13%) of cases responded to treatment with cessation of spasms, 
though they did not state how soon after administration of pyridoxal phos­
phate the cessation occurred [119]. They used a tryptophan load test to iden­
tify whether any of the children had a deficiency of vitamin B6, and found 
that there was a slightly increased excretion of xanthurenic acid in only one 
case. Cumulatively, they treated 216 infants with pyridoxine between 1969 
and 1998, and found that 30 (14%) responded with cessation of spasms for a 
period of 1 month or longer [120]. In some cases, the pyridoxine was added 
to treatments that had been ineffective. With such a low response rate and ill- 
defined time-to-response, it is difficult to determine what proportion of these 
responses might be spontaneous improvement. As well as a potential treat­
ment effect in any case of infantile spasms, pyridoxine has a specific effect in 
children with pyridoxine-dependent seizures [121,122].
Sulthiame: This is a sulphonamide derivative and an inhibitor of carbonic 
anhydrase. A non-randomised add-on study of pyridoxine and sulthiame re­
ported cessation of spasms within 7 days in 7/12 males with newly diagnosed 
infantile spasms [123].
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Tetrabenazine: This inhibits the reuptake and storage of monoamines, and is 
sometimes used to treat severe tardive dyskinesia [124]. Hrachovy et al investi­
gated its effects in infantile spasms, again exploring the hypothesis that an im­
portant factor is an imbalance of brainstem neurotransmitters [125]. They stud­
ied 12 children, 5 of whom had previously received ACTH and prednisone, but 
none showed any benefit.
Thyrotrophin-releasing hormone (TRH): A study by Matsumoto et al used 
a non-randomised design and compared cessation of spasms after 16 days of 
treatment with TRH and ACTH. The TRH group had 7/13 (54%) responses 
compared with 15/20 (75%) in the ACTH group [100]. These were not con­
temporaneous groups: the TRH-treated group was studied during a later pe­
riod than the ACTH-treated group. Four children in the TRH had recurrence 
of spasms within 3 months.
Hagabine: A small study has reported the use of tiagabine in infantile spasms 
but it has shown little treatment effect [126].
Topiramate: Glauser et al studied the effects of topiramate as treatment in 
11 children who had not responded to treatment with two established drugs, 
though the established drugs did not include vigabatrin [127]. The initial treat­
ment was tapered and stopped over one week unless it was a benzodiazepine 
or phenobarbital, in which case it was continued. Five children met the pri­
mary response criteria of cessation of spasms and absence of hypsarrhythmia 
on 24-hour video EEG. Two of these responded within 14 days after starting 
treatment with topiramate, but the other 3 responded between 1 and 3 months.
Typhoid vaccine: Garcia de Alba et al studied the effects of fever after giv­
ing a vaccine to typhoid and paratyphoid (TBA) on 4 children with infantile
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spasms that had not responded to treatment with ACTH, prednisolone, ni­
trazepam and other treatments. They reported improvement and resolution of 
hypsarrhythmia [128].
Valproic acid and sodium valproate: This is available as a sodium salt or 
acid (sodium valproate (sodium dipropylacetic acid) or valproic acid (n-di- 
propylacetic acid)). It was a popular choice in the late 1980s and early 1990s, 
and remains a common choice as second- or third-line treatment today. Pavone 
et al reported cessation of spasms at 20 days in 4/18 infants treated with val­
proate 20m g/kg/day [129]. There is an association with idiosyncratic liver 
dysfunction that can be fatal, and this has reduced enthusiasm for using it. One 
non-randomised study of 42 children treated with doses of valproate around 
10 times that conventionally used for the treatment of epilepsy, with a range of 
100 to 300mg/kg/day, reported that 33 (79%) had resolution of hypsarrhyth­
mia by 21 days, with 8 (19%) later relapsing [130]. One group reported good 
responses to a combination of sodium valproate and oral hydrocortisone [131].
Zonisamide: Suzuki et al used zonisamide as add-on therapy for 11 cases 
of infantile spasms that had not responded to treatment with pyridoxine. By 
5 days of treatment, 4/11 had cessation of spasms and resolution of hypsar­
rhythmia, but 2/4 relapsed within 6 weeks [132]. Yanai et al studied the effects 
of zonisamide add-on or monotherapy in 27 children, with cessation of spasms 
in 9/27 (33%) [133]. Mean time to cessation of spasms was 5 days, and relapse 
occurred in 4 /9  cases.
Ketogenic Diet: The ketogenic diet has been used with some success in in­
fants, including some with infantile spasms [134],
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Surgical treatment* Surgical treatment has become popular for older infants 
and children who have focal lesions and who have not responded to treatment 
with more conventional drugs. The results of studies vary widely, probably 
because of differences in selection criteria and the age at which surgery was 
performed. Since surgical treatment is only considered when several medical 
treatments have failed, this area is not explored in this thesis.
1.8.2 An overview of hormonal treatments
The term steroid refers to chemicals that have a particular four-ring structure 
that includes 21 carbon atoms. The term corticosteroid refers to chemicals with 
steroid structures that are produced by the adrenal cortex, and to analogues 
of these chemicals. There are two subgroups of corticosteroids: mineralo- 
corticoids, which have relatively more potent effects upon electrolyte balance 
within the body; and glucocorticoids, which have structural characteristics 
that seem to confer greater anti-inflammatory effects. Glucocorticoids gener­
ally have a A-4,3-keto-ll/3,17a,21-trihydroxysteroid structure. Subtle modifi­
cations of this structure affect anti-inflammatory and other activity.
Cortisol, which is produced in the adrenal cortex, has a single bonded hy­
droxyl group at the 11th carbon. Cortisone is identical to cortisol but has a dou­
ble bonded oxygen molecule in place of the hydroxyl group on the 11th carbon. 
Hydrocortisone is structurally identical to cortisol, but is a term reserved for 
the synthetic preparation that may be administered as a drug. Prednisolone is 
identical to cortisol apart from the presence of an extra double bond. This mi­
nor structural difference makes prednisolone more active than cortisol. Pred­
nisone is, similarly, a structural analogue of cortisone. Other glucocorticoids 
include dexamethasone, which has an alpha-methyl group on carbon 16, and 
betamethasone, which has a beta-methyl group on carbon 16.
Glucocorticoids are commonly used to suppress inflammatory reactions.
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They work in part by an effect upon white blood cells, generally causing a 
fall in the peripheral lymphocyte count and a rise in the neutrophil count 
[103]. However, the exact mechanisms of their effects are not fully known. 
Potential mechanisms of effect include: impairing opsonisation of antigens; 
inhibiting superoxide production by neutrophils; impairing the production of 
leukotrienes and prostaglandins; interrupting cell-to-cell communication by 
altering the release of cytokines; and altering inflammatory cell adhesion to 
and migration through the vascular endothelium.
The hypothalamo-pituitary-cortical axis is the system of hormones and hor­
monal transport mechanisms that regulate the levels of steroids in the body. 
The hypothalamus produces corticotrophin-releasing hormone (CRH). CRH 
travels to the anterior pituitary gland and stimulates production of adrenocor- 
ticotrophin (ACTH). Corticotrophin is the synthetic analogue of ACTH that 
may be given as a drug, but this is often referred to without confusion as 
ACTH. ACTH regulates the production of glucocorticoids by the adrenal cor­
tex. Both CRH and ACTH are polypeptides [103].
1.8.3 Steroid treatments other than prednisolone
Prednisolone and prednisone are the most commonly used steroid treatments 
of infantile spasms, but dexamethasone and hydrocortisone have also been 
used.
Dexamethasone
Yamamoto et al treated 5 cases of infantile spasms with dexamethasone palmi- 
tate (liposteroid) depot preparation using a regimen of 7 injections over a pe­
riod of 3 months [108]. They compared this treatment with 5 children treated 
with ACTH 25 micrograms per kilogram per day given for 6 weeks. In all
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cases, spasms stopped and hypsairhythmia resolved within 6 to 8 weeks, th­
ough relapses or partial seizures were later noted in 3 patients in each group.
Hydrocortisone
Hydrocortisone is structurally equivalent to endogenously produced corticos­
terone, but the term hydrocortisone is reserved for the administered drug. It 
has been used in studies in France. For example, it was used in the trial of 
Chiron et al that compared the effects of hydrocortisone and vigabatrin in chil­
dren with infantile spasms and tuberous sclerosis [16]. Since hydrocortisone is 
identical to endogenously produced corticosterone, it might be argued that any 
ACTH-induced effect mediated via adrenal steroid production is most closely 
mimicked by administration of hydrocortisone. However, it has generally not 
been used to treat infantile spasms in the UK or the US.
1.8.4 Rationale for hormonal treatments in infantile spasms
The use of hormonal treatments is largely empirical, though was in part sug­
gested by early observations that they are effective in some forms of epilepsy
[135]. Robinson suggested in 1985 that this empiricism was likely to persist for 
a long time [115]. He also suggested that early treatment of cryptogenic cases 
of infantile spasms resulted in improved developmental outcome.
1.9 ACTH and tetracosactide
Adrenocorticotrophic hormone (ACTH), which is also known as corticotro- 
phin and corticotropin, is a polypeptide chain of 39 amino acids produced 
by the basophilic cells of the anterior pituitary in response to stimulation by 
corticotrophin-releasing hormone (CRH), which is also known as corticotropin- 
releasing factor (CRF). The biological activity of ACTH resides in the 24 amino
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acids at the N-terminal end of the polypeptide chain, and these 24 amino acids 
are the same in humans, sheep, cows and horses.
ACTH stimulates production of steroids in the adrenal glands by a mech­
anism that involves 3,5-adenosine monophosphate (cyclic AMP; cAMP) and 
which regulates the rate-limiting step of steroid production from cholesterol. 
The main products of this stimulation are cortisol, which when administered 
as a drug is called hydrocortisone, and corticosterone. In addition, ACTH stim­
ulates the production of small amounts of several androgenic steroids and al­
dosterone.
The potency of ACTH and its synthetic analogues have traditionally been 
determined by an assay of adrenal ascorbic acid depletion in rats whose pi­
tuitary glands have been removed. However, the validity of such assays has 
been questioned and there are few comparisons of ACTH analogue potency
[136].
Tetracosactide is the polypeptide chain containing the 24 biologically active 
N-terminal amino acids of corticotrophin. The former British Approved Name 
(BAN) was tetracosactrin. The new BAN is now the same as the Recommended 
International Non-proprietary Name (rINN): tetracosactide. Two other generic 
names, cosyntropin and tetracosapeptide, appear in North American texts [137, 
138]. The actions of tetracosactide are similar to that of endogenous or admin­
istered ACTH, but it is thought to have less potential for causing immunolog­
ical reactions and greater potential antigenic action residing in the C-terminal 
amino acids, 22-39.
The potency of tetracosactide is said to be such that 0.25 mg is equivalent to 
25IU of corticotrophin. In its standard formulation, it is rapidly absorbed after 
being given intramuscularly, and larger doses are associated with longer du­
ration of stimulated steroid levels. Thus, alternate day dose frequency seems 
to be effective. It is rapidly removed from the plasma by several tissues, but
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little is known about its distribution and metabolism. A depot formulation is 
also available. One regimen for depot tetracosactide was suggested by Ler- 
man and Kivity: 1 mg IM alternate days for 2 weeks; then 1 mg twice a week 
for 2 weeks; then 1 mg weekly for 4 to 6 weeks; then 0.5 mg weekly for 2 weeks 
[139]. With this regimen, the total duration of tetracosactide treatment is 10 to 
12 weeks. However, this was only Stage I of their suggested regimen for the 
treatment of infantile spasms. Stage II required "prednisone by mouth for at 
least six months," 10 m g/day for the first month and then tapering.
1.9.1 Effectiveness of ACTH and tetracosactide
Reports in the 1940s and 1950s about the use of oral corticosteroids and ACTH 
in seizure conditions disagreed about whether the seizures improved or wors­
ened. In 1950, Klein and Livingston reported that seizures improved in 4 of 6 
children who had not responded to any of the standard treatments available 
at that time [135]. At the end of that decade, several reports appeared of suc­
cessful treatment with ACTH [10-15] and with oral corticosteroids [13, 14]. 
These studies were case series rather than controlled trials with well-specified 
outcomes. The mechanism of this therapeutic effect of ACTH has not been 
determined.
There are no large studies of treatment of infantile spasms that have aimed 
specifically to assess the efficacy of tetracosactide, although studies of cases 
that have been treated with animal-derived and synthetic forms of ACTH have 
looked at aspects of safety of synthetic preparations that have included tetra­
cosactide.
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1.9.2 Safety of ACTH and tetracosactide
There are many potential adverse effects associated with treatment with ACTH 
[140,141]. Suppression of the immune system predisposes to infection, and 
clinical signs may be masked because of suppressed inflammatory responses, 
a combination that may be rapidly fatal [142]. Reported infections include 
pneumonia and subcutaneous abscess [100]. Adrenal suppression may occur 
during treatment of children with infantile spasms, [143,144,145] and there 
are risks of hypertension and glucose intolerance, though these might not 
be associated with any long-term morbidity. Other problems reported dur­
ing treatment of infantile spasms with corticotrophin or synthetic ACTH in­
clude cardiac hypertrophy and enlargement of a cardiac rhabdomyoma [146, 
147, 148]. Investigators have also reported metabolic disturbances such as 
hypokalaemia, hypocalcaemia, hypophosphataemia and hypomagnesaemia 
[149,150,151]. Zeharia et al reported hyperkalaemia in two children after stop­
ping treatment with depot tetracosactide [152]. Their treatment regimen was a 
modified form of that described by Lerman and Kivity, the planned duration 
of depot tetracosactide treatment being 8 weeks [139]. In one case, treatment 
had stopped after 2 weeks because of gastroenteritis. Another recognised com­
plication is cataract [100]. Glaze et al reported evidence of brain shrinkage after 
two weeks of treatment with ACTH or prednisone in two-thirds of children, 
though this is not known to be associated with any long-term adverse effect 
[153].
Early reports suggested high incidences of adverse effects in children treated 
for infantile spasms with corticotrophin and, though numbers were too small 
for firm inferences to be made, these tended to be higher with synthetic ACTH 
preparations such as zinc tetracosactrin (Synacthen® Depot and S-Cortrophin® 
Depot) [140,154,155]. The duration of ACTH treatment at that time was often
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several months, and the risks associated with synthetic ACTH preparations 
are likely to be smaller now that shorter duration and alternate day regimens 
are preferred.
Bovine-derived ACTH was withdrawn from the UK market in 1998 and the 
ACTH preparation now commonly used to treat infantile spasms is a depot 
tetracosactide. No formal statement was made of reasons for its withdrawal, 
but this may have been because of its higher antigenicity or because of poten­
tial risks of transmission of new variant Creutzfeld-Jakob disease (nv-CJD).
Riikonen and Donner reviewed 162 children who had been treated for in­
fantile spasms treated with ACTH preparations between 1960 and 1972 [140]. 
The Helsinki hospitals participating in this study used long-acting ACTH pre­
parations and two synthetic forms of zinc tetracosactide (Synacthen® Depot 
and S-Cortrophin® Depot). Until 1969, the treatment regimens used 40 units 
for 3 weeks, 20 units for 2 weeks, and then a one-week taper. After 1969, most 
children received higher doses: initially 120 to 160 units for 3 weeks, then 60 
to 80 units for 2 weeks, and then a one-week taper.
The study reported adverse effects in 60 (37%) of children; and serious ad­
verse effects in 24 (15%), of which 8 (5%) were fatal. Six of the eight fatal 
deaths occurred approximately 6 weeks after treatment started. Six of the chil­
dren died of pneumonia, four of whom had identified causes: Staphylococcus 
aureus, Klebsiella pneumoniae, Escherichia coli, and Pneumocystis carinii. There 
were also reported non-fatal cases of pneumonia due to Staphylococcus aureus 
and Pneumocystis carinii. The presence of these organisms strongly suggests 
immunosuppression, the most likely cause of which was hormonal treatment.
Plasma cortisol levels were measured in only 4 children, and the reasons 
for selecting these 4 children for this investigation are not stated. The mea­
surements were timed to occur 2 days before the hormonal treatment was due 
to stop, and 3 of the 4 children had low or unrecordable levels of cortisol.
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Infections occurred in 35/139 (25%) of children treated with ACTH prepa­
rations, and in 10/23 (45%) of children treated with synthetic ACTH. These 
differences are not statistically significant (x ,^) = 3.29; P = 0.08), but the num­
ber of children treated with synthetic forms of ACTH was small. Infections oc­
curred in 22/97 (23%) of children treated with lower doses, and in 21/54 (39%) 
of children treated with higher doses. These proportions are significantly dif­
ferent (xfi) — 4.47; P = 0.034). Unfortunately, the data presented in table 2 of 
that paper do not indicate whether the 11 children who were given a combi­
nation of ACTH and dexamethasone received higher or lower doses of ACTH, 
so this re-analysis is incomplete. Also, the data do not allow an analysis of 
possible effect-modification of any effect of higher dose by the type of ACTH 
used.
Adverse effects associated with treatment with tetracosactide are similar to 
those associated with treatment with animal-derived ACTH [140, 149]. An 
apparently worse safety profile may be due to using relatively high doses 
[154,155]. One study specifically reported impairment of polymorphonuclear 
neutrophil function in children with infantile spasms treated with synthetic 
ACTH [156]. Brombacher et al reported allergic reactions to Synacthen Depot 
but not to the /?1—24 moiety alone, suggesting that combination with the zinc 
complex contributes to allergenicity [157].
1.9.3 ACTH and tetracosactide regimens
Dosage regimens for corticotrophin have ranged widely in both dose and du­
ration. Hrachovy et al used 20 IU /day for 2 weeks followed by a one-week ta­
pered reduction in dose in one study [93], but had earlier used up to 40IU /day 
for six weeks [158]. A more aggressive regimen, reported by Riikonen and 
Donner, is up to 160 IU /day for 3 weeks, then up to 80 IU /day for a further 2 
weeks, and a 1-week taper [140]. Lerman and Kivity report a starting dose of
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up to 100 IU /day that is reduced after spasms stopped and is continued for up 
to 6 months [139].
One study suggested that infections were commoner in children treated 
with higher compared with lower doses [140]. A retrospective study of the 
same children suggested that a higher dose of 120 IU /day was no more effec­
tive than a lower dose of 20 to 40 IU /day [159]. A randomised trial comparing 
higher dose, longer duration of treatment with lower dose, shorter duration 
reported no significant differences in efficacy, but a significant difference in the 
proportions with reported adverse effects [160]. Because of the study design, 
we cannot infer whether the higher proportion of adverse events are associated 
with the higher dose or the longer duration of treatment.
1.10 Prednisolone and prednisone
1.10.1 Effectiveness of prednisolone and prednisone
It is thought that frequent administration of oral corticosteroids is required to 
maintain levels similar to those that would be produced by the administration 
of ACTH or its derivatives [161]. One non-randomised study of treatment of 
infantile spasms suggested that ACTH has a better treatment effect than pred­
nisone [141]. Studies that compare these treatments using randomly allocated 
treatments are discussed below.
In children, drug doses are often calculated by body weight or body surface 
area, the latter being calculated from information about weight and height. 
However, some investigators have argued that higher doses of oral steroids are 
relatively safer in children, and that such doses are required in the treatment 
of infantile spasms in order to obtain a therapeutic effect equivalent to that of 
ACTH preparations [162].
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1.10.2 Safety of prednisolone and prednisone
The main adverse effects reported in children are related to fluid and elec­
trolyte imbalance, and infection. Infectious and immune complications include 
increased susceptibility to infection, an increased risk of infection with op­
portunistic organisms, and a suppressed inflammatory response to infections 
that masks clinical signs. Fluid and electrolyte disturbances include: fluid and 
sodium retention; hypertension; potassium loss; and hypokalaemic alkalosis. 
The risks of adverse effects attributable to prednisolone are likely to be re­
lated to dose and duration of treatment. In adults, prednisolone doses of less 
than 40 m g/day for less than three weeks are thought not to confer an im­
portant risk of suppression of the hypothalamic-pituitary-adrenal (HPA) axis. 
However, suppression of adrenal responses has been shown to occur in adults 
after short-term, high-dose treatment with glucocorticoids [163]. HPA axis 
suppression can lead to acute adrenal insufficiency, hypotension, and death. 
Other endocrine and metabolic adverse effects include cushingoid appearance, 
weight gain, increased appetite, impaired carbohydrate tolerance, and a nega­
tive body balance of calcium and protein.
Anaphylactic reactions due to treatment with prednisolone have been re­
ported, but are rare.
1.11 Vigabatrin
Vigabatrin is an irreversible inhibitor of the enzyme gamma-aminobutyric acid 
transaminase [164]. This enzyme degrades gamma-aminobutyric acid (GABA), 
which is a major inhibitory neurotransmitter within the human central ner­
vous system. The design and development of vigabatrin was motivated by 
a desire to make GABA more available in the central nervous system. Since 
most earlier antiepileptic pharmaceutical preparations arguably owed more to
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serendipity than focus on a specific mechanism and structure, vigabatrin has 
been described as the world's first designer antiepileptic drug [165]. The in­
ternational birth date (IBD) of vigabatrin was 22 September 1989, and the first 
country to approve its marketing was the United Kingdom.
1.11.1 Effectiveness of vigabatrin
Several early studies of vigabatrin treatment of children with epilepsy sug­
gested that it had best effect in partial seizures and infantile spasms [166]. Two 
randomised studies have compared vigabatrin with hormonal treatment of in­
fantile spasms, and there have many series and non-randomised studies. A ret­
rospective study of 192 children with infantile spasms treated with vigabatrin 
showed that over two-thirds stopped having spasms during the initial phase 
of treatment [167,168]. The proportions responding were higher in the lowest 
age group and in infants with tuberous sclerosis. Of those who responded, 
approximately one-fifth had relapse of spasms and one-fifth developed other 
seizure types.
Chiron et al studied 70 children who had failed to respond to various other 
treatments of infantile spasms and reported the effects of treatment with vi­
gabatrin [169]. Of these 70 children, 47 (67%) were less than a year old and 
43 (61%) had previously been treated with corticosteroids. Spasms ceased in 
29/68 (43%) of children, and reduction of greater than 50% in spasm frequency 
was reported in 46/68 (68%) of children.
1.11.2 Visual field losses associated with vigabatrin
Since it was thought to be the safer drug, there was an argument for choosing 
vigabatrin as first-line treatment of infantile spasms and reserving hormonal 
treatment for children who did not respond to vigabatrin, even if vigabatrin
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was rather less effective in stopping spasms. Adverse effects reported in earlier 
studies were restricted to non-serious effects such as drowsiness, irritability, 
and hypotonia.
In 1997, investigators reported several cases of visual field loss in adults 
treated with vigabatrin [170] and we now know that there is a substantial 
risk of such visual field losses. Although there may be important sampling 
biases that make risk estimates high, studies of adults treated with vigaba­
trin suggest that visual field losses may develop in one-third to one-half of 
cases [171,172,173]. Vigabatrin seems also to affect colour vision and visual 
acuity [172]. Some electrophysiological measurements, such as the electro- 
oculographic Arden index, are abnormal during treatment, but do not predict 
visual field losses [173].
Visual field losses due to vigabatrin are persistent and probably irreversible. 
A few case reports of apparent recovery are hard to interpret, since it is hard 
to exclude the possibility of unreliable earlier visual field assessments or the 
subjects learning better to perform the tests [174,175]. Onset of symptoms has 
been described to occur from one month to several years after start of treat­
ment [176,177]. In many cases, there is a distinctive pattern of concentric vi­
sual field loss, with relative sparing of the temporal fields and more marked 
involvement of the nasal fields [171]. This pattern means that even relatively 
severe concentric losses may be asymptomatic. However, such visual losses 
have important effects upon lifestyle, the most obvious of which is eligibility 
for a driving licence.
Cases of visual field loss attributable to vigabatrin have been described in 
children [178,179,180]. These visual losses are particularly evident with static 
perimetry, but are thought not to be reliably assessable in children whose de­
velopmental age is less than nine years [181]. Thus, there is much uncertainty 
about risks of visual field loss in children treated for infantile spasms.
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1.12 Studies comparing ACTH, corticosteroids, or 
vigabatrin
Placebo controlled trial designs are unusual in treatment studies of epilepsy. 
It is more common for comparisons to be made between treatments. This sec­
tion summarises significant studies that compared any two of the treatments 
studied in UKISS.
1.12.1 Studies comparing ACTH with corticosteroids
Baram et al compared treatment with ACTH 150IU/m2/day  and prednisone 
2m g/kg/day  in a randomised trail that enrolled 29/34 eligible infants and 
recorded response after 14 days of treatment [182]. Hrachovy et al reported 
prospective, open studies of treatment with ACTH and with prednisone, and 
a randomised, double-blind, placebo-controlled trial. The open studies sug­
gested that cessation of spasms is more likely with ACTH. The Hrachovy group 
also performed a randomised trial using either ACTH 20 to 30 IU /day or pred­
nisone 2 m g/kg/day, but did not show any significant differences is main out­
come [93]. However, the study included only 24 participants. Snead et al re­
ported a study comparing treatment of infantile spasms and other childhood 
seizure disorders with ACTH or prednisone [183,184]. This study did not have 
randomly allocated treatments or blinding, and the seizure control outcome was 
not clearly defined. It compared ACTH gel against prednisone with the fol­
lowing regimens. ACTH was given as 150 IU /m 2/day  in 2 divided doses for 1 
week, followed by 75 IU /m 2/day  for 1 week then alternate days for 2 weeks, 
then a tapering dose over 8 weeks. Prednisone was given as 3 m g/kg /day  in 2 
divided doses for 4 weeks, then 3 m g/kg/day  alternate days for 4 weeks, and 
was then tapered over a period of 8 weeks. Although these studies influenced
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the design of UKISS, the findings of these studies are discussed in more detail 
in section 6.2.3.
1.12.2 Studies comparing hormonal treatments against 
vigabatrin
One study has compared hydrocortisone with vigabatrin as first-line treatment 
of infantile spasms in children whose underlying cause was tuberous sclero­
sis [16]. Twenty-two participants were randomly allocated treatment, eleven 
each to hydrocortisone and vigabatrin. The main outcome measure was ces­
sation of spasms during the first month of treatment combined with absence 
of evidence of spasms on a standard EEG. Absence of hypsarrhythmia was 
not required to define a primary outcome. Nine (41%) of the children had ev­
idence of hypsarrhythmia on the initial EEG. Only one child was reported to 
have hypsarrhythmia on an EEG performed at two months after study entry. 
That child had been treated with both hydrocortisone and vigabatrin, and had 
not had hypsarrhythmia on the initial EEG.
Information about spasm frequency was obtained from a diary completed 
by the child's carers, but the paper does not report the minimum period of 
spasm-freedom that was required in order to define a primary response. All 
eleven children who were treated initially with vigabatrin were spasm-free at 
one month, with a reported mean time to cessation of spasms of 3.5 days. 
Of the 11 children in the group treated initially with hydrocortisone, 5 were 
spasm-free at one month, with a reported mean time to cessation of spasms of 
13 days. The six children who did not respond, and one child that did respond 
but who had developed an adverse effect, were later treated with vigabatrin, 
and all of these were reported to be spasm-free at the end of two months. 
Adverse effects were described in 9/11 participants initially treated with hy­
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drocortisone, and in 3/11 of those initially treated with vigabatrin. Some ad­
verse events were classified as "severe", but no distinction was made between 
serious and non-serious adverse events. One or more adverse effects were 
reported more commonly in the group allocated hydrocortisone (two-sided 
Fisher exact test P = 0.03). The abstract of the paper quotes an inappropriate 
P value for the difference in proportions of cases with one or more reported 
adverse effects. An appropriate statistical test for this difference is the two- 
sided Fisher exact test.
Only one randomised trial to date has directly compared treatment of in­
fantile spasms with either ACTFI or vigabatrin [185,186,187]. Forty-two par­
ticipants were randomly allocated treatment with either 10 IU /day (100 /zg per 
day) of an ACTH depot preparation or vigabatrin 100 to 150 mg/day. If there 
was an inadequate response to the randomly allocated treatment after 20 days, 
the alternative treatment was given. The proportion of children whose spasms 
had stopped before 20 days was 14/19 (74%) in the ACTH-treated group and 
11/23 (48%) in the vigabatrin-treated group. The difference in treatment ef­
fect, analysed by intention-to-treat, was 26%, with a 95% confidence interval 
for that difference from -3% to 54% [188]. Data from this study suggest that, 
for the outcome measure cessation of spasms, vigabatrin is unlikely to be a better 
treatment than low-dose ACTH.
Adverse effects were reported more frequently in the group treated initially 
with ACTH 7/19 (37%) than in the group treated initially with vigabatrin 3/13 
(13%). Typical adverse effects attributed to vigabatrin were drowsiness, irri­
tability and hypotonia; and, for ACTH, hypertension. However, it is difficult 
to interpret the adverse effects attributed to ACTH because hypertension is not 
defined in the paper. None of the adverse effects were classified as serious. The 
authors concluded that vigabatrin is a reasonable first-choice treatment for in­
fantile spasms, the assumption being that it has a lower risk of adverse events
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than hormonal treatments.
1.12.3 Hormonal and vigabatrin combination therapy
Zafeiriou et al reported combination treatment of 9 infants with infantile spa­
sms, hypsarrhythmia and developmental delay, and who were later found to 
have cerebral palsy ("static encephalopathy") [189]. The treatment regimen 
was ACTH 4 IU /kg/day with tapering after 2 weeks and duration of treatment 
4 to 6 weeks, and vigabatrin 80-120 m g/kg/day  during that same period and 
continued after ACTH was stopped. Spasms stopped within 7 days in all 9 
infants. One child had generalised tonic-clonic seizures 9 months later, and 
the other 8 were seizure-free after a mean duration of follow-up of 19 months.
Studies such as that of Vigevano and Cilio, and UKISS, in which the al­
ternative treatment is given if the initial treatment is unsuccessful, might be 
regarded to involve combination treatments rather than crossover treatments, 
since there is no effective washout period between administration of the ini­
tial and subsequent drugs. However, statistical analysis and interpretation of 
the 'crossover' component of these trials is difficult. For example, only non­
responders are given the second treatment, and their outcomes in the second 
phase of the study cannot be properly regarded as independent of outcomes in 
the first phase. On the other hand, even though children who fail to respond to 
the initial treatment may have spasms that are harder to control, there is a nat­
ural reduction in time to cessation of spasms that may be modelled as survival 
time data.
1.13 Aims of this thesis
From the late 1950s until the 1990s, the most popular first-line treatments for 
infantile spasms were hormonal treatments such as corticotrophin and pred­
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nisolone. During the 1990s, vigabatrin became an increasingly popular first- 
line treatment. However, studies of potential adverse visual field losses, the 
first cases of which were reported in 1997, suggest that this is a substantial 
risk, and better estimates of effectiveness and risks associated with these treat­
ments are now essential.
The initial aims of this thesis were to provide epidemiological information 
about the incidence of infantile spasms in the United Kingdom, and to report 
the results of a randomised controlled trial of three treatments for this seri­
ous condition. The main instrument for meeting these aims was the United 
Kingdom Infantile Spasms Study (UKISS). Slow accrual of cases and emerging 
issues about potential designs for studies of infantile spasms led to a change in 
emphasis and aims for this thesis. It was evident that there is a need for stan­
dardisation for case definitions and outcome measures in studies of infantile 
spasms, and presentation of provisional ideas on this theme led to a consensus 
elicitation process called West Delphi.
Chapter 2
The United Kingdom Infantile 
Spasm Study Design and Protocol
2.1 Early development of UKISS
2.1.1 Origins of the study
The United Kingdom Infantile Spasm study originated in discussions in 1995 
between Professor John P. Osborne, Dr Eleanor Hancock and Dr Finbar J.K. 
O'Callaghan. At that time vigabatrin was becoming increasingly popular as 
a first-line treatment for infantile spasms, but these discussants were not con­
vinced that vigabatrin had proven itself to be better than hormonal treatments. 
Professor Osborne had experienced success in treating infantile spasms with 
doses of oral steroids that are higher than those usually used. A retrospective 
study of cases of infantile spasms that had been treated with prednisolone, 
an oral corticosteroid, at the Royal United Hospital, Bath showed that pred­
nisolone had a good treatment effect and that few important adverse effects 
were observed [162].
These investigators suggested two questions. First, are hormonal treat­
ments or vigabatrin significantly better first-line treatments of infantile spasms
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than the other? And second, is the apparently better treatment effect of ACTH 
that has been reported in some studies due to an insufficient dose or duration 
of oral corticosteroids? These questions were discussed with paediatric neurol­
ogists in Cambridge, Liverpool, London, Manchester, and Southampton, and 
a statistician at the Medical Research Council Biostatistics Unit in Cambridge. 
These formed a core group that later developed into the UKISS trial steering 
committee (appendix A).
Applications for funding for the study were made first to the Medical Re­
search Council (MRC), with an initial proposal submitted in June 1996. The 
response to this proposal was made in November 1996 and stated that the 
study was potentially competitive. A full proposal was submitted in February 
1997, but the final decision was that the study would not receive MRC fund­
ing. A proposal for funding was then made to the Bath Unit for Research in 
Paediatrics (BURP), which agreed to fund the application with a grant to be 
held at the University of Bath.
2.1.2 Rationale for the study
The rationale of the United Kingdom Infantile Spasm Study was to obtain re­
liable estimates of treatment and adverse effects of hormonal and vigabatrin 
treatments of infantile spasms in order to decide if any one of them can be 
regarded as the best first-line treatment. It was considered important that 
prednisolone and tetracosactide were administered with regimens that were 
similar in duration and potency. Part of the rationale for the study was to use 
reliable neurodevelopmental outcome measures, since these are arguably more 
important outcome measures than cessation of spasms and resolution of EEG 
features.
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2.1.3 General form of the study
A major aim of the study was to place these effect measures in the context 
of the public health importance of infantile spasms. Though small in num­
ber and influenced by underlying causes, there is a substantial cost burden for 
morbidity due to infantile spasms. Thus, the study aimed to get reliable esti­
mates of incidence rates and, even though the absolute numbers are relatively 
small, the study was intended to be in the form of an effectiveness study rather 
than that of an efficacy study. The analysis of data from participants who were 
prospectively and contemporaneously enrolled in the non-randomised study 
is broadly consistent with the approach of an effectiveness study. The findings 
from this element of the study are not presented in this thesis.
Efficacy studies aim to measure treatment and adverse effects due to treat­
ments or other interventions, making measurements that attempt to control 
for extraneous occurrences such as non-compliance with treatment and mis- 
classification of either diagnosis or outcome. In general, such studies are used 
to make inferences about biological effects. They tend to be small studies with 
relatively homogeneous participants [190].
Effectiveness studies aim to look at the effects of interventions applied on 
a large scale. Such studies are used to assess the impact of an intervention 
or treatment on larger populations, employing simple methods of assessment 
and data capture. They address the question of what effect the intervention 
would have on a population where non-compliance, heterogeneity and mis- 
classification will occur and might be common. Synonyms include effectiveness 
trials, public health trials, large-scale and large simple (LS) trials.
Effectiveness trials have several advantages. Treatments based on sound 
biological principles may be less effective when used outside the setting of a 
homogeneous population in a highly controlled trial. Effectiveness trials have
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greater external validity and are likely to have a faster impact on clinical prac­
tice. However, in most therapeutic areas, effectiveness trials would enroll large 
numbers of participants, and possibly tens of thousands.
2.2 Classification of infantile spasms used in UKISS
The most inclusive definition of infantile spasms requires the characteristic 
clinical feature, the spasms, but does not require any specific age limit or the 
presence of any particular EEG feature [28]. Earlier classifications of infan­
tile spasms into symptomatic and, variously defined, cryptogenic or idiopathic, 
groups has been followed by the definition of a more specific idiopathic group. 
However, the distinctiveness of this idiopathic form of infantile spasms has not 
been generally accepted, and some investigators have suggested that this clas­
sification also will change in the future [36].
In keeping with the pragmatic criteria of an effectiveness study, the study 
protocol of the United Kingdom Infantile Spasm Study used the clinical diag­
nosis of the local investigator to define a diagnosis of infantile spasms, and did 
not state highly specific clinical and electroencephalographic criteria (appen­
dix B.l). The study used cessation of seizures as measured by the carers and 
local investigators as measures of outcome. As such, it measures the effects 
of treatment of infantile spasms as diagnosed and assessed using criteria that 
were in common practice in the UK at the time of study design.
In UKISS, we used the term symptomatic as outlined in earlier definitions, 
and we include neurodevelopmental delay identified before onset of spasms 
as a risk factor for symptomatic onset. We consider the cryptogenic and idio­
pathic forms of infantile spasms to be distinct, although not necessarily distin­
guishable, and we refer to these forms collectively as non-symptomatic. These 
definitions allow inclusion of children who have the clinical features of in­
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fantile spasms, irrespective of whether the EEG shows features described as 
hypsarrhythmia. It was expected that local investigators would perform sleep 
or video EEGs if standard EEGs are normal, since these more sensitively de­
tect abnormal EEG patterns. Children with normal awake and sleep EEGs are 
considered to have a form of benign myoclonus, since a normal EEG pattern is 
considered to be incompatible with a diagnosis of infantile spasms.
At the time of study enrolment, cases were classified as being at risk of hav­
ing symptomatic infantile spasms, or as being likely to have non-symptomatic 
infantile spasms. Unless otherwise stated in this thesis, this classification -  
made at the time of diagnosis of infantile spasms -  rather them any classifica­
tion made later and after further investigation, is used for subgroup analyses 
based on aetiology. Subgroup analyses of outcomes based upon this initial 
aetiological classification will best inform initial treatment decisions. Where 
analyses are based on classifications based on later or final diagnoses, we clearly 
state that a secondary classification is being used.
2.3 Issues relating to the UKISS study protocol
The protocol of the United Kingdom Infantile Spasm Study is reproduced in 
appendix B.l. Some elements of the study protocol required further definition 
and development, as discussed in the following sections.
2.3.1 Eligibility criteria
Section four of the study protocol suggests that an EEG should be performed 
soon after a clinical diagnosis so that treatment should not be delayed for more 
them 72 hours. The trial steering committee considered it important, for ethical 
reasons, that treatment decisions should not be delayed for longer than this 
period. One scenario that was not considered in the study protocol is that in
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which a local investigator considers infantile spasms as part of a differential 
diagnosis but wishes to defer treatment until an EEG has been performed and 
supports the diagnosis. In such cases, there is not any issue of treatment de­
lay attributable to participation in the study, since the delay is attributable to 
working practices in that district. We considered this scenario in the context of 
the study aims and decided that such cases should be eligible to enroll if the 
treatment was decided within 72 hours of the local investigator interpreting 
the EEG and diagnosing infantile spasms.
2.3.2 Exclusion of cases with tuberous sclerosis
The UKISS trial steering committee considered at the early design stage of 
UKISS that there was a strong, though not unanimous, opinion amongst pae­
diatricians and paediatric neurologists in the United Kingdom that infantile 
spasms occurring in infants who have tuberous sclerosis respond particularly 
well to treatment with vigabatrin. It was thought that, since most treating 
physicians were likely to prefer vigabatrin over hormonal treatments in such 
cases, there would be relatively small numbers of cases with tuberous sclerosis 
allocated to each of the randomisation strata. It was felt that this would make 
the interpretation of outcomes in the tuberous sclerosis group difficult, and 
that it would be better to exclude these infants from the randomised controlled 
trial (section B.l on page 245). However, it was intended that they would be 
included in the non-randomised element of the study. This is discussed further 
in section 6.2.12.
2.3.3 Outcomes
Issues relating to outcome are detailed in sections 14-19, 21, 25, and 26 of the 
study protocol (appendix B.l, pages 249 to 251). The structure of data used to
CHAPTER 2. UKISS STUDY DESIGN 77
measure outcomes was not fully defined by the study protocol and was devel­
oped further as the the main tools for obtaining these data were developed. 
These tools were the patient's diary and the trial folder.
Response and relapse: Definitions for these are given in section 14 of study 
protocol (page 249). The study protocol states that a responder is a child "in 
whom there is total cessation of spasms for at least 48 hours up to and includ­
ing the end of the fourteenth day of treatment." This definition, taken alone, 
is ambiguous. One interpretation requires that cessation occurs before the end 
of the 12th day, and a spasm-free period of at least 48 hours, but would per­
mit relapse to occur before the end of the 14th day. A second interpretation 
requires that the spasm-free period include the end of the 14th day, and would 
not permit relapse to occur before that time. The UKISS Trial Steering Commit­
tee agreed that the primary outcome would be determined using the definition 
that required cessation of spasms to include the end of Day 14 after allocation 
of randomised treatment, and Professor Osborne confirmed that this was his 
initial intention behind the definition.
Relapse: A relapse is defined as a single spasm in a responder. Two observa­
tions are pertinent. First, the intended definition would be more precise if it 
read one or more spasms, since there would be no plausible reason to require 
a spasm to be single rather than part of a cluster in order for it to constitute 
a relapse. Second, it could be argued that relapse presupposes response and 
that, since the third paragraph of section 14 discusses the scenario in which a 
child relapses before the end of the fourteenth day, we may deduce that both 
relapse and response may occur before the end of the fourteenth day. How­
ever, the trial steering committee discussed this issue and confirmed that the 
term relapse was used in the looser sense of "recurrence of spasms" rather than
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indicating "recurrence of spasms after a primary clinical outcome". Hence, the 
first interpretation stated in the above section remains appropriate and was 
the definition intended by the trial steering committee. In other words, for the 
primary outcome to be considered positive, cessation of spasms had to occur 
before the end of study day 12, with no reported spasms throughout study 
days 13 and 14.
Main outcome: The definition of the primary outcome measure given in sec­
tion 25 of the protocol (page 251) is ambiguous in the same way as the defi­
nition of a responder. However, it is clear from the above discussion that its 
intended definition is as discussed in the two sections above. The actual main 
measures of effect are proportions derived from the numbers responding to 
each allocated trial treatment.
Secondary outcomes
Some of the secondary outcome measures stated in Section 26 of the study 
protocol (page 251) required further details for clear definition.
Time to cessation of spasms: The time taken to cessation of spasms (subsec­
tion 26.1) is that period between allocation of randomised treatment (Day 0) 
and the first spasm-free day that heralded a period of 48 hours or more of 
freedom from spasms.
Resolution of hypsarrhythmia at Day 14: Resolution ofhypsarrhythmia at Day 
14 (subsection 26.5) is only measured in children who had hypsarrhythmia at 
enrolment and whose spasms have ceased, consistent with a primary clinical 
response.
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Normalisation of EEG pattern: This is another potential outcome measure 
used in children who are primary responders, and refers to finding an EEG 
pattern that is within normal limits in cases where there was any EEG abnor­
mality, either hypsarrhythmic or non-hypsarrhythmic, at the start of the study. 
However, this outcome is less useful than resolution of hypsarrhythmia because it 
is more strongly influenced by underlying disorders and would not necessar­
ily be expected to occur even if the infantile spasms were successfully treated.
Partial response: The reduction in number of spasms required to define a 
partial response (section 26.2) is to 50% or less of the original number of clus­
ters of spasms.
Relapse rates: The relapse outcome of most interest is the proportion of in­
fants responding and relapsing by the end of the study. This can be represented 
as the proportion of randomised participants responding and relapsing, or as 
the proportion of respondents that later relapse. The former representation is 
preferable because it presents the data with the randomised unit as the denom­
inator.
2.3.4 Patient Diary
The development of the diary was an important extension of the study proto­
col. Its structure and content had to balance several competing demands. First, 
the questions asked had to give information relevant to the outcomes sought 
by the study. Second, the diary had to be simple enough for use by carers with 
modest reading ages and who were not familiar with medical terms. Third, 
it required a balance between seeking quantitative data and not encouraging 
carers to report with spurious accuracy.
We required that treatment of infantile spasms not be delayed by the ad-
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ministration of the trial. For this reason, it was not possible to have a prospec­
tive period of data collection before treatment started. The ranges for counts 
of spasms during the week before treatment started were as follows. For the 
number of clusters per day: 5 or fewer; 6 to 10; 11 to 20; 21 to 40; more than 40. 
For the number of spasms in a cluster: 5 or fewer; 6 to 10; 11 to 20; 21 to 40; 41 to 
80; more than 80. However, it was later considered, particularly in the light of 
comments from participants in West Delphi, that the partial response outcome 
discussed above is of little value and it was later decided not to analyse these 
data.
2.3.5 Classification and reporting of adverse events 
Classification of adverse events
Section 18 of the study protocol (page 250) stated that the trial centre should be 
informed and treatment should be stopped if there were unacceptable adverse 
effects. This section was considered by the data monitoring and ethics com­
mittee not to define adequately serious adverse events. This was reviewed by 
the trial steering committee. There were several issues.
First, it might be desirable to continue treatment with prednisolone or tetra- 
cosactide if an adverse event was caused by adrenocortical insufficiency. Such 
insufficiency might be due to inhibition of central stimulation of the adrenal 
cortex and would be best treated by continuing or increasing the dose of pred­
nisolone or tetracosactide. Thus, it was inappropriate to recommend that the 
treatment should be stopped in all cases where there had been a reported ad­
verse event, and it was inappropriate to use the need to stop treatment as the 
sole criterion of seriousness.
There was a second issue relating to stopping treatment as the sole criterion 
of seriousness. Even though the duration of treatment with vigabatrin is left to
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the discretion of the local investigator, the duration of exposure to vigabatrin 
is likely to be longer than that of exposure to prednisolone or tetracosactide. 
In addition, adverse events due to prednisolone or tetracosactide might occur 
after treatment had stopped. Thus, there might be an important bias such that, 
using the stopping of treatment criterion, serious adverse events would have a 
greater chance of being recorded in participants receiving vigabatrin since the 
duration of treatment with that drug is longer.
A third issue was that of classifying any adverse events. The steering com­
mittee considered developing the protocol to code adverse events according to 
the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA is a stan­
dard medical terminology for drug regulation that has its origins development 
of standard terms for the Adverse Drug Reactions On-line Information and Track­
ing (ADROIT) database of the UK Medicines Control Agency (MCA) [191]. This 
terminology was adopted by the International Conference on Harmonisation 
(ICH) in October 1994, under the name Medical Dictionary for Drug Regulatory 
Affairs (MEDDRA). MedDRA is an "implementable version" of MEDDRA, and 
was adopted by the ICH in July 1997. However, it was decided that, although 
we wished UKISS to conform to ICH recommendations and standards as much 
as possible, the cost and complexity of MedDRA was inappropriate for a study 
with the budget and resources of UKISS.
Duration of monitoring
Information about adverse events was sought from both the local investiga­
tor and the carer throughout the study, from the diary, day 14 report form, 
forms submitted at 3-monthly periods after enrolment, and at the time of final 
follow-up. Serious adverse events were reported to the local and multicentre 
research ethics committees (LREC and MREC) and the data monitoring and 
ethics committee (DMEC) during the course of the study. Using agreed cri­
CHAPTER 2. UKISS STUDY DESIGN 82
teria, we reported any deaths in study participants during the study period, 
admissions to hospital that were potentially attributable to an adverse effect of 
medication, withdrawal of medication due to a treatment adverse effect, and 
cases where extra treatments were required because of medication.
Reporting of adverse events
It was considered important to obtain complete information about potential 
adverse reactions. The questions about adverse events were left open-ended 
and invited responses about unusual reactions, other illnesses and other treat­
ments. They did not require the local investigator to consider the event to be 
directly attributable to the treatment (that is, an adverse reaction) but encourage 
reporting of any adverse event. This wide range of questions was chosen to 
increase the sensitivity and completeness of reporting, and provided informa­
tion that would allow later consideration of whether the treatment was directly 
related to the adverse event. Closed questions about specific, expected drug 
reactions were not asked, since we thought that they would be suggestive and 
prompt responses.
The table in the patient's diary that seeks information about continuing 
seizures asks about seizures during the week after the participant's first birth­
day. This was chosen because it was memorable and would be measured at a 
standard age. The table provides information that can be compared with the 
local investigator's reporting of continuing seizures at the time of the final as­
sessment. Participants enrolled at less than 9 months of age would have a final 
assessment at 12 months of age. However, those enrolled at nine months of 
age or greater could have a final assessment up to the age of 14 months, and 
reporting of continuing seizures by the local investigator and in the patient's 
diary, since they refer to different ages, might be different.
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2.3.6 Definition of treatment days
The timing of follow-up consultations and investigations was stated in the 
study protocol (section 14, page 249) but the definition of study days was not 
explicitly stated. We decided to classify the day on which a treatment decision 
was made as Day 0. This was likely to be the same day as the day of notifica­
tion and, for participants enrolled in the randomised trial, the day on which 
randomised treatment was allocated. All subsequent days start at midnight 
because a fixed time for increments to occur is simpler than one that varies be­
tween participants. Also, this is consistent with the timing of reported spasms 
obtained from the patient's diary. Thus, Day 0 was of variable length and it is 
possible, where treatment was allocated late in day, that the first dose of treat­
ment would be given on Day 1, even though in fact given within several hours 
of treatment allocation.
2.3.7 Timing of the follow-up EEG
An important consideration was the timing of the follow-up EEG. The protocol 
requested that this be performed soon after day 14 of treatment but not before 
that day (section 26.5 of study protocol). There were two issues with this re­
quirement. First, local investigators might request an EEG at a time that would 
make it available for review by them at the day 14 visit. We thought that this 
would be convenient for the participant and carers and ought not to be con­
sidered as a protocol violation. Second, a primary outcome would require the 
last seizure to have occurred before the end of day 12, and resolution of EEG 
abnormalities is an outcome of interest only in participants who have become 
spasm-free. For these reasons, EEGs measured between day 12 and day 14 are 
likely to provide important information and ought not to be classified as pro­
tocol violations. In order to allow follow-up EEGs to be performed later than
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14 days without serious bias occurring, we decided that EEGs performed after 
day 14 but before day 20 would be included as valid outcome investigations. 
Thus, the timing of valid follow-up EEGs was any time during a full week 
from the time cessation of spasms had to have occurred to five days after the 
timing of the follow-up assessment.
2.4 Study treatments
2.4.1 Prednesol®; prednisolone
Glaxo Wellcome, Stockley Park West, Middlesex, UB111BT. Small tablets; 
pink; engraved Prednesol Glaxo on one side and scored on the reverse. Each 
tablet contains 5 mg of prednisolone as the sodium phosphate ester. After a 
change of licence, most centres used prednisolone soluble tablets, Sovereign 
Medical, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, UK.
2.4.2 Synacthen® Depot; tetracosactide
The former BAN for this drug was tetracosactrin and the rINN is tetracos­
actide. Alliance Pharmaceuticals UK Ltd, Avonbridge House, 2 Bath Road, 
Chippenham, Wiltshire, SN15 2BB. A sterile, white suspension that settles on 
standing. Contains 1 mg of Synacthen per ml and 10 mg of benzyl alcohol per 
ml. The preparation is available in 1 ml ampoules, which also contain zinc, 
sodium phosphate, sodium chloride, sodium hydroxide, and water.
2.4.3 Sabril® Sachets; vigabatrin
Hoechst Marion Roussel Ltd, Broadwater Park, Denham, Uxbridge, Middle­
sex, UB9 5HP. From March 2000, when there was a merger and reorganisation, 
the manufacturer of Sabril was Aventis Pharma Ltd, Aventis House, 50 Kings
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Hill Avenue, West Mailing, Kent, ME19 4AH. Sachet of powder containing 
500 mg of vigabatrin.
2.4.4 Treatment allocation
Randomised treatment was allocated by opening sealed envelopes that had 
been prepared by Dr Peter Lewis, a biostatistician in the Department of Med­
ical Sciences of the University of Bath. Sixteen randomisation blocks were used 
to reduce the chances of important differences in potential prognostic factors 
between randomised groups. These factors were: sex; symptomatic or non- 
symptomatic status at onset; and four age categories. These are outlined in the 
study protocol.
2.4.5 Concomitant therapy
Concomitant treatments were allowed. In particular, participants who were 
being treated with antiepileptic drugs at the time of enrolment were allowed 
to continue such treatments if that was the local investigator's preference. The 
study protocol allowed but discouraged starting pyridoxine during the first 28 
days of the study.
2.4.6 Permitted modifications and protocol violations
The study protocol did not define limits outside of which an action would be 
considered to be a violation of the protocol. For more important features of 
the study, such as the timing of valid follow-up EEGs and tolerance limits for 
the timing and dosing of trial treatments, such limits were defined and applied 
prior to data analysis.
The treatment schedule is described in the section 8 of the study protocol 
(page 246) and compliance is discussed in section 21 (page 250). These did not
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specify explicit criteria defining compliance with treatment intervention, but 
such criteria were defined by the trial steering committee before data analy­
sis. Rounding doses of vigabatrin, which was dependent upon the weight of 
the child, was permitted. Treatments were considered non-compliant if any 
changes in dose or schedule occurred outside a 24-hour limit of that stated in 
the study protocol, and any treatment dose was considered non-compliant if it 
fell outside a 10% limit of the dose stated in the protocol.
2.4.7 Consent procedures
Informed consent was obtained from the carer after counselling by a local in­
vestigator and completion of a consent checklist. The checklist ensured that 
essential information and rights were communicated to the carer. A copy of 
the signed consent form was given to the carer for future reference. Comments 
from LRECs and new information about the risks of visual field loss associ­
ated with vigabatrin were incorporated into two new information sheets that 
were given to parents or guardians before consent was sought. These Extra 
information sheets for parents or guardians were approved by the MREC and con­
stituted protocol amendments dated 11 May 2000 and 30 April 2001. Relevant 
information from these information sheets is shown on pages 252 and 254.
2.4.8 Masking
No masking, or blinding, was employed for several reasons. First, providing 
placebo preparations of injectable drugs would almost certainly have been re­
garded as unethical and would have discouraged participation in the study. 
Second, there would have been added costs in obtaining and distributing pla­
cebo medications. Third, the role of the local pharmacy would have been more 
important, and this would also have added substantially to the cost and ad­
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ministrative demands of the study. Finally, it would have been difficult to 
maintain an effective blinding if there were prominent identifiable adverse ef­
fects of one of the treatments, such as increased appetite and weight gain with 
hormonal treatments.
2.4.9 Conduct of study after assessment of primary clinical 
outcome
Following the assessment on study day 14 of the study, the infants were re­
viewed by the local investigator as often as was deemed necessary. The pro­
tocol requested 3-monthly reports that included information on any spasms 
since the last assessment, any other epileptic seizures, changes to treatment, 
adverse events, and details of further investigations. A final clinical assess­
ment was made by the local investigator when the enrolled infant was approx­
imately 12 months old.
After reporting the early outcomes, the parents or guardians were asked 
to complete a diary daily between study days 15 and 28, and thereafter to 
complete these details weekly. Diary information included the occurrence and 
number of any spasms, and adverse events. In addition, on a daily basis dur­
ing the last week before their final assessment, the parents were asked to record 
any spasms or epileptic seizures.
Infants who had not responded to their allocated treatment by day 14 were 
given treatment determined by their local investigator. The protocol requested, 
but did not require, that the local investigator offer the alternative trial treat­
ment (vigabatrin after hormonal treatment and vice versa) at the trial dosage. 
If an infant who had responded to vigabatrin then relapsed, we suggested that 
the local investigator increase the dose to around 150 m g/kg. In the case of 
relapse in an infant who had responded to a hormonal treatment, the protocol
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suggested repeating the course of hormonal treatment once before offering the 
alternate treatment.
The three monthly reports, final report, diaries and any other informa­
tion sent such as copy clinic letters, were scrutinised by two members of the 
trial steering committee, Professor John P. Osborne and Dr Stuart W. Edwards. 
They independently looked for any evidence of relapse, defined as any episode 
of recurrent spasms, including even a single reported spasm. Later clinical re­
sponse was defined, as for the primary clinical response, as a period of 48 
hours with no reported spasms. In addition, these reports recorded any pe­
riod of greater than one month in which there was absence of clinical evidence 
of spasms.
2.4.10 Developmental assessment
Developmental assessments were made around the age of 14 months using 
Vineland Adaptive Behavior Scales: Interview Edition, Survey Form (VABS) [192]. 
This is similar in content to the original Vineland and provides a general over­
view of adaptive behavior using 297 items. There is also an Interview Edition, 
Expanded Form with 577 items that include the 297 items from the survey form. 
The expanded form is suitable for assessment of individual treatment pro­
grammes and specific educational needs, but the survey form is suitable for 
comparisons of groups.
The Vineland scales cover a range of adaptive behaviours in four domains, 
each of which have two or three subdomains (shown in parentheses): commu­
nication (receptive, expressive, and written); daily living skills (personal, do­
mestic, and community); socialization (interpersonal relationships; play and 
leisure time; and coping skills); and motor skills (gross and fine). An adaptive 
behaviour composite score is derived by summing the scores from these do­
mains and applying an adjustment for age at time of assessment. This score
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was used as the primary neurodevelopmental outcome for UKISS and is here* 
after referred to as the Vineland ABC score.
The Vineland test has been standardized on a sample of 3000 children form­
ing a representative national sample matched to United States census data. 
The sample was stratified by age, race, gender, region, parental education, 
and community size, and additional interpretative data were obtained from 
supplementary norm groups of children with disabilities. It has been been 
used in the United Kingdom for other developmental follow-up studies, and in 
the United States for developmental studies on children with infantile spasms 
[193,194]. The age adjustments are applied by monthly age periods, and the 
standardised score has a population mean of 100 points and a standard devia­
tion of 15 points.
Vineland assessments were made by the author, who acted as the sole as­
sessor, performing a telephone interview of one parent or guardian. The as­
sessor refrained from examining the records of each child before making the 
telephone call and asked the parent or guardian not to make any specific com­
ments about treatments until after the Vineland assessment was complete, but 
he was not blind to allocated treatment. No estimate of sample size was un­
dertaken for this part of the study since there were no reliable prior data on 
which to estimate effect size.
2.5 Data and safety monitoring
A data monitoring and ethics committee was invited to review the study. The 
members of this committee are listed in Appendix A. There was no set date 
for trial termination other than recruitment of 250 trial participants. It became 
evident after only six months of the study that enrolling 250 trial participants 
would take far longer than had been anticipated.
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Any decision to recommend early termination of the study was at the dis­
cretion of the Data Monitoring and Ethics Committee. The priority was the 
safety of the enrolled infants. However, there was no predetermined number 
or proportion of adverse events of any kind that would be considered suffi­
ciently important to recommend trial termination. In addition, since outcomes 
determined at 12 to 14 months of age were at least as important as earlier out­
comes and would be relatively statistically underpowered if the study were 
terminated early, a significant difference in the earlier outcomes would not 
necessarily lead to a recommendation that the trial be terminated early.
2.6 Safety, licensing, and ethical issues
2.6.1 Licensing provisions for treatments used in UKISS
Synacthen Depot is not licensed for marketing as a treatment of infantile sp­
asms. Local investigators using Synacthen Depot on participants of UKISS 
were exempted from the need to have a clinical trial certificate (CTX) under the 
Doctors' and Dentists' Exemption Scheme (DDX) outlined in The Medicines 
(Exemption from Licences)(Special Cases and Miscellaneous Provisions) Order 
1972. The MCA makes such exemptions when it has not positively assessed 
the product for safety, quality or efficacy. The DDX approval for Synacthen® 
Depot was effective from 10 September 1998. The MCA also granted a DDX 
approval for the use of Prednesol®, which also had no licence for specific use 
as a treatment for infantile spasms.
For vigabatrin (Sabril®), the summary of product characteristics states that 
monotherapy of infantile spasms is a specific indication for use, and so no spe­
cial licensing arrangements were required. This specific indication remained 
after the extensive review by the European Committee on Proprietary Medicinal
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Products.
2.6.2 Withdrawal of licence for ACTH
The first UKISS study design was intended to compare vigabatrin with pred­
nisolone and ACTH. However, there had been increasing concern and uncer­
tainty at that time about the risks associated with using bovine products be­
cause of uncertainty about risks of new variant Creutzfeld-Jakob disease (nv- 
CJD), and the trial steering committee had already considered suitable alterna­
tive products. ACTH was withdrawn from the UK market in 1997 but is in fact 
derived from porcine brains. Synthetic forms of ACTH have been used since 
the 1960s, and these are a natural choice as an alternative to bovine-derived 
ACTH.
2.6.3 Visual field losses associated with vigabatrin
The first reports of visual field losses in patients being treated with vigabatrin 
appeared in 1997. A causal link was considered, but the problem was not 
thought to be important. First, the risk was thought to be low. Second, the 
drug had been marketed for seven years before these first cases were reported. 
And third, the adult cases that were first reported had been asymptomatic and 
the visual field losses had not interfered with their lifestyle until the diagnosis 
was made.
The potential risk to visual fields due to treatment with vigabatrin was noti­
fied to the MREC in May 1998. At this time, Hoechst Marion Roussel regarded 
the small number of reports as important and undertook to provide the study 
with periodic safety update reports (PSURs).
As a result of prospective studies, it is thought that there occurs a specific 
form of visual field loss, known as vigabatrin-attributable visual field loss (V-
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AVFL). This is typically concentric and more marked in the nasal quadrant of 
the visual field. The severity of these visual field losses can be classified accord­
ing to a guideline that uses kinetic perimetry with a 14e isopter reference and 
angles subtended in the temporal, superior, nasal, and inferior visual fields. 
Severe losses are defined as those associated with angles of vision less than 30 
degrees in all quadrants, and less than 20 degrees in the superior and nasal 
quadrants. Moderate losses are associated with angles less than 50 degrees in 
all quadrants, and less than 35 degrees in the superior and nasal quadrants. 
Mild losses are associated with angles less than: 70 degrees in the temporal 
quadrant; 50 degrees in the inferior quadrant; 45 degrees in the nasal quad­
rant; and 40 degrees in the superior quadrant.
Although patients who have these visual field losses generally have no re­
lated symptoms, the losses are sufficient to require that a driving licence be 
withdrawn. In the light of these new risks, there was a major review of vi­
gabatrin by the European Committee for Proprietary Medicinal Products (CPMP). 
New prescribing information was issued by Hoechst Marion Roussel in August 
1999, and monotherapy of infantile spasms remained a specific indication for 
use. At that time, visual field losses had not been reported in children.
2.6.4 Tetracosactide and benzyl alcohol
On 12 June 1997, the Pharmaceutical Committee of the European Commission Dir­
ectorate-General III, Industry, Industrial Affairs III (DGIII/E/3) issued a guideline 
that acts as an annex to the European Union Council Directive 75/318/EEC. 
This Guideline on the Excipients in the Label and Package Leaflet of Medicinal Prod­
ucts for Human Use is now included in The Rules Governing Medicinal Products 
in the European Community Volume IIIB: Guidelines. It states that the label of 
products intended for parenteral use and which contain benzyl alcohol as an 
excipient should state: Contraindicated in infants or young children; up to 3 years
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old. Samples of the outer and immediate packaging and of the package leaflet 
have to be submitted to the competent authority before the product may be 
used commercially. Package leaflets were formerly known as datasheets, but 
were subsequently referred to as a Summaries of Product Characteristics (SmPCs).
On 3 March 1999, the Medicines Control Agency endorsed the new SmPC 
for Synacthen® Depot, and this included the statement that the product is not 
recommended for use in children under 3 years old, The Medical Assessor 
at the Clinical Trials Unit of the MCA was unable to establish or obtain the 
pertinent data used to justify the guideline. A request for this information was 
also made to the Head of Unit at DGIII/E/3, but we did not receive a response. 
A review of published papers about benzyl alcohol suggested a small number 
of papers which might have influenced the EU guideline. We summarised the 
findings of these papers and submitted the summary and original papers to 
the MREC.
Gershanik et al reported a syndrome of respiratory distress, convulsions, 
metabolic acidosis, and sometimes death, in children associated with adminis­
tration of benzyl alcohol with estimated doses of 99 to 234 m g/kg/day. All of 
these infants had birth weights less than 2.5 kg [195].
Anderson et al reported the case of a 3.35 kg, 35-week gestation neonate that 
had high levels of benzoic acid, a liver metabolite of benzyl alcohol, and of hip- 
puric acid, the glycine conjugate of benzoic acid [196]. They estimated that she 
had received between 32 and 105 m g/kg of benzyl alcohol during the first 7 
days of life, the source being a sodium chloride vascular flush that contained 
benzyl alcohol at a concentration of 9 mg/m l. They suggest that the cause of 
elevated benzoic acid levels are immature hepatic conjugation and renal excre­
tion, and that the infant they reported was at risk because her liver function 
was impaired by hydrops fetalis. They were not certain that her respiratory 
symptoms were attributable to benzyl alcohol.
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Hiller et al reviewed 198 infants with birth weights less than 1.25 kg in Port­
land, Oregon [197]. The earlier cohort of 103 infants had received vascular 
flush solutions containing benzyl alcohol, and the later cohort of 95 infants had 
received solutions without benzyl alcohol. The later cohort had a lower mor­
tality rate: 35/95 (37%) compared with 64/103 (62%) (x^) =  12.6, P < 0.001). 
An associated study reported that the earlier cohort also had a higher rate of 
cerebral palsy [198]. Even though a bias due to period effects is likely and sur­
vival might be expected to be better in a later cohort, this appears to be good 
evidence that benzyl alcohol increases mortality and morbidity in preterm in­
fants.
Jardine & Rogers reported outcomes on 450 infants admitted to neonatal 
intensive care units in Pittsburgh, Pennsylvania, USA [199]. An earlier cohort 
of 218 infants had received benzyl alcohol, but a later cohort of 232 infants had 
not. The earlier cohort had an increased risk of intraventricular haemorrhage 
of grade II or higher and there was evidence of an inverse dose-response ef­
fect for this risk: relative risk was higher in neonates who received less than 
30 m l/kg of flush solution than in those who had received more than 30 ml/kg. 
This apparent inverse dose-response effect is hard to interpret. Kemicterus, 
yellow staining of the basal ganglia of the brain due to infiltration by bilirubin, 
was found at postmortem examination in 15/49 (31%) of infants who had re­
ceived benzyl alcohol during the earlier period, and in none of 22 infants who 
were examined in the later period and who had not received benzyl alcohol.
In addition to reviewing published data, we asked the United Kingdom 
Medicines Control Agency Pharmacovigilance Group to perform an ADROIT Data­
base search on benzyl alcohol. The database search result was reported on 7 
April 2000 and showed no reported cases of metabolic acidosis, kemicterus or 
intraventricular haemorrhage associated with the use of benzyl alcohol in the 
UK in children outside the immediate neonatal period.
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The UKISS trial steering committee informed the MREC of the change in 
the Summary of Product Characteristics and stated its interpretation that there 
were minimal risks associated with the administration, outside the immedi­
ate neonatal period, of the very small amount of benzyl alcohol contained in 
Synacthen® Depot. The MREC approved the continued use of Synacthen® 
Depot and no further action was required.
2.6.5 Tetracosactide and anaphylactic reactions
The study protocol was reviewed by the MREC after ACTH was replaced by 
Synacthen® Depot. The MREC wished to know more about risks of anaphy­
lactic reactions caused by Synacthen® Depot. The UKISS steering committee 
requested a search of the Medicines Control Agency ADROIT database for se­
rious adverse effects associated with tetracosactide. This search revealed 12 
reported cases of fatal or serious reactions in children aged 17 years or under. 
The youngest of these cases was 2 years old, and this was the sole report in a 
child under 5 years of age. Two of the reactions were fatal. These occurred in 
children aged 14 and 15 years of age, and were not necessarily attributable to 
tetracosactide.
Even though the number of children given tetracosactide during that pe­
riod is not known, and many cases of adverse effects are not reported to the 
MCA, the interpretation of the UKISS Steering Committee was that this search 
suggested a low risk of serious adverse effects due to Synacthen® Depot in in­
fants aged less than 1 year. In general, anaphylactic reactions are rare in young 
children, and the UKISS steering committee thought that the risk any such re­
action during the study was low. The MREC was informed about the results of 
the ADROIT Database search, and it agreed that tetracosactide could be used 
in the study.
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2.6.6 Indemnity arrangements
Any study sponsored by a member of the Association of British Pharmaceuti­
cal Industries (ABPI) requires indemnity arrangements that include payment of 
no-fault compensation. Such arrangements are not required of studies, such 
as UKISS, that are not sponsored by pharmaceutical companies. The UKISS 
steering committee considered obtaining such indemnity, and Professor John 
Osborne told the MREC about these explorations on 6 March 1998. How­
ever, arrangements for no-fault compensation payments were not completed 
because they would have been too expensive.
The National Health Service Litigation Authority (NHSLA) confirmed that it 
undertakes to provide indemnity for NHS personnel participating, as part of 
their NHS duties, in studies that have appropriate approval from research 
ethics committees and NHS trusts. However, this indemnity would not ex­
tend to members of the UKISS Steering Committee for actions relating to study 
design and conduct that would not be considered to be part of normal NHS 
duties.
2.7 Statistical methods
Statistical analyses were made using Stata Release 8.0 [200]. The unit of analy­
sis was the individual participant in the study. All analyses of trial data were 
made by intention to treat and according to the recommendations of the re­
vised CONSORT statement (Consolidated Standards of Reporting Trials) [201].
2.7.1 Summary and test statistics for main outcomes
The intended primary outcomes for UKISS were the proportions with cessa­
tion of spasms for a period of at least 48 hours, and including study days 13
CHAPTER 2. UKISS STUDY DESIGN 97
and 14, after allocation of randomised treatment. The intended primary analy­
ses were of hormonal treatments versus vigabatrin, and of prednisolone ver­
sus tetracosactide, as described in the UKISS study protocol (appendix B.l). 
Differences in proportions are compared using Pearson chi-square tests (ab­
breviated as x\d) where d indicates the number of degrees of freedom) often 
with reporting of effect estimates and 95% confidence intervals (CIs). Neu- 
rodevelopmental outcomes and other continuous variable data are compared 
by means of unpaired f-tests. A two-way analysis of variance (ANOVA) model 
is used to investigate the relative contributions upon neurodevelopmental out­
comes of randomised treatment, presence or absence of identified underlying 
aetiology, and presence or absence of primary clinical response. The compar­
ison of contrasts from the ANOVA model is made using the least significant 
difference (LSD) test [202]. Kaplan-Meier estimates are used to graphically 
represent time to reported spasms after study day 14 [203].
2.7.2 Planned multiple tests and subgroup analyses
Subgroup analyses were not clearly defined in the UKISS study protocol, but 
with respect to neurodevelopmental outcomes there was a priori interest in any 
differences in the subgroup with no identified underlying cause. This was the 
only subgroup analysis approved a priori by the trial steering committee.
2.7.3 Stratification at randomisation to control for potential 
prognostic factors
With such an uncommon condition and the relatively small sample size, there 
is a limited number of prognostic factors that can be controlled. Randomi­
sation occurred in groups stratified by sex and by age; and by a composite 
variable defined by whether there was a diagnosed underlying cause at time
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of randomisation or developmental delay that preceded the onset of spasms, 
or both. These randomisation strata were intended to reduce the chance of 
significant imbalance between treatment groups, but we were aware that the 
small numbers would severely limit any formal tests for heterogeneity of effect 
across strata and formal analysis of prognostic factors. Probably the strongest 
prognostic factor for response to treatment with vigabatrin, a diagnosis of 
tuberous sclerosis (TSC), was controlled by making children with this diag­
nosis ineligible for randomised treatment. However, up to 70% of children 
with TSC have new mutations and will not be identified by family history, and 
diagnosis may not occur at the time of allocation of randomised treatment.
Chapter 3 
Study Conduct and Early Outcomes 
from the United Kingdom Infantile 
Spasms Study
This chapter presents analyses of UKISS data. Section 3.1 describes the progress 
of the study and shows that the accrual of participants was substantially slower 
than had been predicted by the trial steering committee. Section 3.2.1 describes 
a study of response times by local research ethics committees, the results of 
which were published in the BMJ [204]. Section 3.3 describes baseline charac­
teristics of study participants, in particular underlying aetiology, and informa­
tion relating to compliance. Section 3.4 describes findings relating to the pri­
mary clinical response, cessation of spasms, which were reported in the Lancet 
[205]. And section 3.5 describes EEG and adverse event related outcomes for 
the early part of the study.
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Table 3.1: Incremental (cumulative) number of centres eligible to enroll and 
notify cases to UKISS by month of study.
Number of centres
Year 1999 2000 2001
Month





June 1 (1) 9 (123)
July 17 (18) 11 (134)
August 15 (33) 4 (138)
September 22 (55) 1 (139) 1 (150)
October 18 (73) 6 (145)
November 8 (81)
December 1 (146)
3.1 Administration and progress of the Study
The United Kingdom Infantile Spasm Study was first approved by the South 
& West Multicentre Research Ethics Committee on 15 April 1998. However, 
it was necessary to inform the MREC about several issues and to request a 
number of protocol amendments before the protocol dated September 1998 
was approved on 9 October 1998. The protocol was referred to as Version 2, 
MREC approved. These issues are discussed more fully in the section on safety, 
licensing, and ethical issues on page 90.
The first participant was enrolled on 30 June 1999. The incremental and cu­
mulative numbers of centres eligible to recruit study participants each month 
is shown in table 3.1 and the accrual of study participants by month of enrol­
ment is shown in tables 3.2 and 3.3 on pages 101 and 102.
The conduct of the study was impeded by delays in recruiting centres, and 
by a lower rate of notification of cases than had been predicted. The delays in 
recruitment of centres were attributed to three sources: (1) competing demands
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June 1 0 0 1
July 0 0 0 0
August 0 0 0 0
September 0 0 0 0
October 3 2 3 8
November 2 0 3 5
December 1 1 0 2
Cumulative 7 3 6 16
2000
January 4 2 0 6
February 3 1 1 5
March 3 2 1 6
April 2 0 1 3
May 3 2 6 11
June 6 1 1 8
July 4 4 0 8
August 4 2 4 10
September 1 2 3 6
October 3 1 3 7
November 2 0 0 2
December 2 3 1 5
Cumulative 44 23 27 94
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January 3 2 3 8
February 0 6 2 8
March 5 3 1 9
April 2 2 1 5
May 4 4 2 10
June 5 4 3 12
July 1 5 0 6
August 4 4 0 8
September 4 1 0 5
October 4 4 0 8
November 5 4 0 9
December 1 1 1 3
Cumulative 82 63 40 185
2002
January 1 2 1 4
February 2 3 1 6
March 4 1 0 5
April 2 2 1 5
May 3 3 0 6
June 4 3 0 7
July 3 4 1 8
August 3 3 1 7
September 1 5 2 8
October 1 7 0 8
November 0 4 1 5
December 1 0 1 2
Cumulative 107 100 571 264
1 Eight notified only cases had no recorded notification date.
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upon local investigators; (2) delays in approval being granted by local research 
ethics committees; and (3) delays in approval being granted by the responsible 
members of NHS trust management. We investigated these sources of delay 
and attempted to reduce the delays by amending the administration of the 
study.
3.2 Sample size requirements and estimates of 
accrual rate
The estimated accrual rate of between 130 and 340 new cases per year was 
probably high for several reasons. The estimated incidence rate of infantile 
spasms and the associated sample size calculation are outlined in sections 20 
and 27 of the study protocol. The estimate of the UK birth rate of 800 000 per 
year is high. The number of live births in the UK in 1997 was 726 000; and that 
in England & Wales was 642 000. The trend in number of live births has been 
downward since 1990 and the annual average UK births for the 5-year period 
1996-2000 was 630959 [206]. Second, the estimated enrolment rate assumed 
that nearly all districts in the UK would be recruited to the study. Third, it 
assumed that nearly all cases that were eligible would be invited to participate. 
And fourth, it assumed that nearly all carers who were invited to participate 
would agree, whereas the proportion of cases accepting participation in a trial 
is usually less than half [190].
The steering committee thought that a difference in treatment effects as 
great as 20% would be clinically important. The main outcome measure is 
a binary response of spasms continuing or having stopped for 48 hours before 
14 days of completed treatment. The steering committee thought that 70% and 
50% were likely values for the proportions responding to better and poorer 
treatments.
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The protocol used these estimates for clinically important differences in 
treatment effect; a two-sided a  value of 0.05 for the type I error associated with 
the hypothesis test; and a sample size of 250 participants randomly allocated 
treatments in the ratio 2:1:1. The power (1 - (3) to detect a difference as great or 
greater than that considered clinically important between groups given either 
hormonal treatments or vigabatrin was 88%. The power to detect the same 
difference between the groups given either prednisolone or tetracosactide was 
55%.
This sample size calculation was performed before some important infor­
mation became available. First, the publication of the randomised trial per­
formed by Vigevano and Cilio [187]. And second, the finding of a lower than 
expected notification rate for UKISS. The section on problems with accrual pro­
vides details of sample size calculations that used scenarios suggested by this 
new information.
The sample size requirements were recalculated using different assump­
tions about differences in effect in order to estimate the power associated with 
smaller sample sizes. These results are shown in table 3.4. The comparison 
that assumes a 70% response to the better treatment and 50% response to the 
poorer treatment was that used in the original UKISS power calculation. The 
76% vs 48% comparison and sample size of 42 represents the study of Vigevano 
& Cilio, which had a 33% power to detect the reported difference [187]. The 
difference they found was 8% greater than that assumed for the original UKISS 
calculation. The 75% vs 50% comparisons with different sample sizes assume a 
difference in treatment effect closer to that of the study of Vigevano and Cilio.
These power calculations suggest that, if the difference in treatment effect 
is greater by a 5% difference than that of the original UKISS power calculation, 
the power would be nearly as great with a sample size of 150 participants 
rather than 250 participants.
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Table 3.4: Power calculations given different assumptions about 
proportions responding in each main treatment group.
Differences in effect Total number Power (%)







76% vs 48%2 42 33
75% vs 50%3 150 86
100 66
80 55
1 Difference used for the original UKISS sample size calculation.
2 Difference detected by Vigevano and Cilio [187].
3 Difference assumed in order to reassess UKISS sample size requirements.
3.2.1 Study of local research ethics committee response times
As well as qualitative problems with LREC roles, there were appreciable de­
lays in approving the study. Studies with approval from multicentre research 
ethics committees (MRECs) are, according to guidelines issued by the Depart­
ment of Health in 1998, supposed to be approved by LRECs within 21 days 
of submission [207]. The reason for submission is to ensure that there are no 
specific ethical issues that pertain to that locality and there is the possibility, of 
course, that there might be some compelling reason not to grant approval lo­
cally. We studied prospectively the time taken for such approval to be granted 
and published a short paper describing our findings [204]. These data are 
shown in tables 3.5 and 3.6 on pages 106 and 107.
Table 3.5: Response times of 99 local research ethic committees for submission made between September 1998 and September 1999.
Median (5th-95th centile) 
response time in days
Number (%) of committees 
responding within 21 days
Time of submission1
Earlier (n = 48) 26 (6-57) 15 (31)
Later (n = 51) 28 (3-98) 18 (35)
Type of committee2
Fast track (n = 44) 30 (4-85) 14 (32)
Standard (n = 55) 25 (7-64) 19 (35)
Total (n = 99) 28 (4^73) 33 (33)
Earlier submissions were those received before April 1999.













Table 3.6: Numbers of documents required and first decisions of 99 local research ethic committees.
Median (5th-95th centile) number 
of document copies required
Number (%) of submissions 
approved after first review
Time of submission
Earlier (n = 48) 4 (1-15) 39 (81)
Later (n = 51) 4 (1-15) 43 (84)
Type of committee
Fast track (n = 44) 3 (2-13) 35 (80)
Standard (n = 55) 11 (1-15) 47 (85)
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Earlier submissions were those received before April 1999. LRECs classi­
fied as fast-track were those that had stated an intention to use executive sub­
committees in order to speed the processing of MREC-approved studies. Only 
one third of LRECs approved the study within the 21 days recommended by 
the NHS Executive. Committees that used an executive subcommittee in or­
der to expedite approval of MREC-approved studies did not make quicker 
decisions. However, such committees did require significantly fewer copies of 
MREC correspondence and protocols.
3.2.2 Protocol amendments
In response to comments from LRECs, two protocol amendments were devel­
oped, approved by the UKISS steering committee, approved by the MREC, 
and distributed to LRECs and local investigators. These were approved by the 
MREC on 11 May 2000 and 30 April 2001.
An extra information sheet for parents or guardians was submitted to the 
MREC for approval on 11 May 2000, and was approved on 12 June 2000. It 
addressed most of the criticisms that had been made by LRECs during the 
first 11 months of the study by providing an explanation for carers. This ex­
tra information became a protocol amendment and is included in appendix 
B.2. This amendment provided information relating to the potential risks of 
visual field loss with vigabatrin; it clarified that the dose of prednisolone be­
ing used in the study is higher than typically used in clinical practice for most 
conditions; it made an explanation the prednisolone is structurally slightly dif­
ferent from corticosteroids that are produced in vivo; and it provided informa­
tion about the appropriate timing of immunisations after the administration of 
prednisolone or tetracosactide.
A further protocol amendment was formally approved on 30 April 2001 
and the relevant changes are shown in appendix B.3. In addition to the pre­
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vious information, this amendment provided extra safety information relating 
to the risks of intercurrent infection while being treated with prednisolone or 
tetracosactide.
3.2.3 Effects of need for NHS trust management approval
Approval of the study by responsible members of the local NHS trust was re­
quired for three reasons. First, such approval is required for any study that 
is not sponsored by a member of the ABPI in order for the NHS indemnity 
arrangements to apply. These indemnity arrangements are regulated by the 
NHS Litigation Authority (NHSLA). Second, there is a requirement to reg­
ister research and development programs that are being performed within 
the NHS. Most NHS trusts have a research and development department that 
takes responsibility for this. And third, the NHS trust needs to consider any 
effects new research projects might have upon the use of human and material 
resources. This third consideration includes external or internal funding, and 
is often monitored by the research and development department of the trust.
While recruiting in the earlier part of the study, the lead local investiga­
tor was asked for the name of the person thought to be responsible for han­
dling the NHS trust approval of new research projects. It soon became clear, 
however, that the most appropriate person to whom to make a submission for 
NHS trust management approval was the chief executive of the trust. Tasks 
tended to be delegated more quickly by chief executives than by other man­
agers, though we did not formally record response times to requests for man­
agement approval. Trusts managed the approval of UKISS in a variety of ways, 
and the study did not have a protocol for obtaining such approval. A letter 
from an appropriate member of the trust management, such as the chief ex­
ecutive or the medical director, was regarded as being sufficient evidence of 
approval.
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3.2.4 Problems with accrual of participants
Enrolment of participants was slower than expected for several reasons. First, 
the estimates of accrual rate were over-optimistic since it made no allowance 
for the proportion of families approached who were likely to decline the offer 
to participate in the study. A personal communication from the UKISS trial 
steering committee statistician, Dr Anthony L. Johnson, indicated that the pro­
portion of potential participants finally enrolling in studies with which he had 
been involved was around 50%. Second, there were delays due to changes in 
licences for study drugs. Third, there were delays in LREC and in NHS trust 
management approval of the study in each district, as discussed above. And 
fourth, some districts appeared not to notify cases that were eligible for inclu­
sion in the study.
Cumulative recruitment of districts is shown in table 3.1 on page 100. When 
the first case was enrolled, on 31 June 1999, there were 18 districts approved 
to notify cases. Six months later, 81 centres were approved. By the end of June 
2000, this number had risen to 119.
By the end of one year from the enrolment of the first participant, 52 par­
ticipants had been notified. Of these, 27 were enrolled in the randomised trial, 
10 were enrolled in the epidemiology study, and 14 were merely notified. The 
monthly accrual and cumulative accrual of cases is shown in tables 3.2 and 3.3 
on pages 101 and 102. Of the 52 notified cases, 22 were reported from a district 
notifying one case only, 12 were from districts that had notified 2 cases, 6 were 
from districts that had notified 3 cases, and 12 were from centres that had re­
ported 6 cases. Thus, 58% of cases were from districts notifying more than one 
case. However, of the 32 districts that had notified any cases, 69% had reported 
only one case.
CHAPTER 3. UKISS EARLY OUTCOMES 111
Survey of number of potential participants
A brief survey was made of lead local investigators in the last week of June 
2000. The questionnaire asked about potential study participants not notified, 
and whether they had declined invitation or not been invited to participate. 
It was sent to lead local investigators in districts that were approved to enrol 
participants at that time.
An informal analysis of notified cases suggested that potential participants 
were not being notified from some districts, and that there were important 
variations in reporting from region to region. In particular, at the end of the 
first year, there were fewer than expected reports from North and South Tham­
es regions, and from the Trent region. We thought that the most likely expla­
nation for the poor notification rate was likely to be that investigators had not 
been reminded sufficiently frequently. Because of this, we increased the fre­
quency of newsletters, and circulated them to all local investigators. Also, we 
sent newsletters designed for EEG departments. Other interventions aimed 
at increasing and maintaining awareness of the study were: a poster adver­
tisement in the mail sent to 6,200 members of the of the Royal College of Pae­
diatrics and Child Health with its quarterly newsletter, and a short article in 
the BACCH Newsletter, the newsletter of the British Association of Commu­
nity Child Health. As can be seen from tables 3.2 and 3.3, the response to 
these interventions was not associated with a marked increase in enrolment 
and notification. However, it is likely that the interventions helped to sustain 
awareness and interest in the study.
Review of sample size requirements
At this stage of the study, where it was evident that the rate of accrual was 
substantially lower than had been predicted, a review of sample size require­
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ments. There were two main motivations for this review. First, the randomised 
trial reported by Vigevano and Cilio showed a larger difference in treatment 
effects than was assumed during the calculation of sample sizes for UKISS. 
Second, the notification of cases to the UKISS trial centre was lower than had 
been expected, and we wished to review the time it was likely to take to recruit 
a number of participants sufficient to provide useful information. The details 
of these revised power calculations are given in section 3.2 and table 3.4.
These sample size calculations showed that the study by Vigevano and 
Cilio had a low statistical power (33%) to detect a difference as great as the 
one it actually found, and that UKISS would need 140 participants in order to 
detect the same difference as that found by Vigevano and Cilio with a power 
of 90%. This information was considered valuable and was thought likely to 
influence decisions on stopping the study before the planned accrual of 250 
randomised participants.
The trial steering committee estimated that funding for the study would 
not extend beyond December 2002. It considered that aiming for accrual of 
120 participants, with an 80% power to detect the 20% difference in effect for 
the primary comparison of hormonal treatments against vigabatrin, was a rea­
sonable approach.
3.3 Patient characteristics
By December 2002, the study had enrolled participants over a 31-month pe­
riod from June 1999. Of 208 infants whose eligibility for enrolment in the ran­
domised trial was assessed, 107 were allocated randomised treatment (figure 
3.1). Of the 107 participants in the RCT, 64 (60%) were male. The baseline char­
acteristics of study participants are shown in table 3.7 on page 115. Data for 
the variables age at onset of spasms and duration of spasms at time of randomisa-
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turn were collected from local investigators to the nearest whole month. The 
median duration of spasms was unknown for 6 infants (2 infants allocated 
prednisolone, 1 infant allocated tetracosactide, and 3 infants allocated vigaba- 
trin).
The risk factors for neurodevelopmental delay were used as criteria for 
stratified randomisation. Some infants had more than one of these risk fac­
tors (table 3.8 on page 116). There were no striking imbalances in baseline 
characteristics between the three treatment groups. An analysis of the value of 
the variables used for stratified randomisation is shown in section 3.4.4.
3.3.1 Ineligible patients
Information about ineligible patients is available for infants who were excluded 
from the randomised controlled trial and included in the non-randomised study. 
However, information is not available for infants who were solely notified to 
the UKISS trial centre. Approximately two-thirds of infants excluded from the 
randomised trial were ineligible because the parents or guardians preferred 
a non-randomised treatment to be administered (figure 3.1). Approximately 
one-third (29 infants) were excluded because they met one or more of the ran­
domised trial exclusion criteria. Tuberous sclerosis, either diagnosed defini­
tively or highly suspected (probably because of a family history of tuberous 
sclerosis) was the reason for exclusion in approximately half (14/29) of these 
cases. In one case it was considered that the parents were not able to assess 
the presence or frequency of spasms reliably, and in another case the local in­
vestigator had a strong preference for one of the trial drugs, even though the 
parents were apparently agreeable to the idea of giving a treatment allocated 
randomly. In 6 cases, randomisation was precluded by delays and adminis­
trative problems related to verifying ethical and management approval of the 
study.
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Figure 3.1: Flow diagram showing disposition of participants assessed for in­
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Vigabatrin given
71 = 51 
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Administrative: 71 = 6 
Parental ability: 71 =  1
Clinician preference: n = 1
Protocol exclusion: 71 = 29
Tuberous sclerosis: n = 14 
Age > 1 year: 71 = 7
Age < 2 months: n = 2 
Previous treatment: 71 = 3 
Contraindication: n = 2
Table 3.7: Baseline characteristics of UKISS randomised trial participants (1).
Hormonal Treatments Vigabatrin
Prednisolone Tetracosactide Combined
Number allocated randomised treatment 30 25 55 52
Male 18 14 32 32
Female 12 11 23 20
Median (range) age in months at onset of spasms 5(0-10) 5(0-10) 5(0-10) 5(0-10)
Age at randomisation
60 to 119 days 1 2 3 3
120 to 179 days 11 8 19 17
180 to 239 days 7 8 15 13
240 days and older 11 7 18 19
Median age (range) in months at randomisation 6(3-10) 6(3-11) 6(3-11) 6 (2-11)
Median duration (range) in months of spasms at 
randomisation1 0 (0-8) 1(0-4) 1 (0-8) 1 (0-6)












Table 3.8: Baseline characteristics of UKISS randomised trial participants (2),
Hormonal Treatments Vigabatrin
Prednisolone Tetracosactide Combined
Higher risk of neurodevelopmental delay1 15 12 27 22
Chromosomal abnormality 2 0 2 2
Syndrome 3 2 5 2
Neonatal encephalopathy with seizures 4 5 9 8
Cerebral palsy before onset of spasms 8 4 12 10
Delayed development before spasms 13 12 25 19
Underlying aetiology
Prenatal 8 6 14 15
Perinatal 5 3 8 9
Postnatal 2 1 3 0
Uncertain classification 2 2 4 6
No cause found 13 12 25 21
Not known2 0 1 1 1
1 Some of these infants had more than one risk factor for neurodevelopmental delay.
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3.3.2 Baseline classification of underlying aetiology
The study protocol did not specify details of aetiological categories to be used 
in analysis of data, but it stated that such analysis would include diagnostic 
subgroups such as cerebral dysgenesis, chromosomal anomalies, and metabolic 
diseases (section 23 of ukiss study protocol). The pre-randomisation stratifica­
tion variable used to dichotomise infants with higher from lower risk of poor 
developmental outcomes was a composite of known or highly suspected un­
derlying aetiology and known developmental delay. In order to standardise 
this process, we later decided to use the Paediatric Adaptation oflCD-10 (The In­
ternational Statistical Classification of Diseases and Related Health Problems, Tenth 
Revision, 1992), which was published by the Royal College of Paediatrics and Child 
Health in 1996. At the time of randomisation, study participants were classified 
by time of onset of the underlying condition into one of three groups: prenatal, 
perinatal, or postnatal. Study participants were placed in specific aetiological 
groups using all information available at the end of the study, rather than at 
the time of diagnosis alone, thus effectively giving a final diagnosis. The re­
sults of these early and final aetiological classifications are shown in tables 3.8 
and 3.13 respectively.
3.3.3 Final classification of underlying aetiology
The final classification of cases by underlying aetiology is shown in table 3.9. 
Underlying aetiology was classified using the paediatric adaptation of the ICD- 
10. We required cranial imaging, CT or MRI, and scrutiny of history and clini­
cal examination before determining that no underlying cause could be identi­
fied. Most infants had additional investigations, in particular ophthalmic ex­
amination and urinary metabolic screen.
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Table 3.9: Final classification of underlying aetiology in cases allocated random 
treatments.
Aetiology Number
Cerebrovascular: infarct or stroke 14
Chromosomal (n = 4)
Down syndrome 2
Deletion chromosome lq36 and terminal short arm 1
Deletion chromosome lp36 1







Focal cortical dysplasia 1
Signs & symptoms, not otherwise specified (n = 6)
Dysmorphic features 1
Abnormal basal ganglia 1
Cerebral atrophy 1
Intracerebral calcification 1
Optic nerve hypoplasia 1
Focal arachnoid cyst 1
Hypoxic-ischaemic encephalopathy (n = 10)
Perinatal 9
Prenatal 1
Periventricular haemorrhage/leukomalacia (perinatal) 5
Metabolic or endocrine (n = 3)
Transient neonatal hypoglycaemia 1
Pyridoxine dependency 1
Enzyme deficiency 1




Other: perinatal -  maternal drug abuse 2
Total 59
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3.3.4 Features of cases from the non-randomised study
It was initially intended that there would be substantial and complete informa­
tion relating to the incidence of infantile spasms and the proportions of cases 
with specific underlying causes; and that this information would allow an as­
sessment of the validity and generalisability of information obtained from the 
randomised controlled trial. This element of the study was smaller and less 
useful than was originally intended.
Overall, 265 infants were notified to the UKISS trial centre during the course 
of the study. Of these, no further information was available on 58 cases, and 
107 cases were enrolled in the randomised controlled trial and are reported in 
detail elsewhere in this thesis. One hundred cases were enrolled in the non- 
randomised study.
These non-randomised cases consisted of 59 male and 41 female infants. 
Underlying cause was not known in 11 cases because information about in­
vestigations and results was incomplete. In 22 cases, there had been extensive 
investigation and no cause was found. Specific causes were reported in 67 
cases, as shown in table 3.10 on page 121.
The treatments allocated to the non-randomised cases were: vigabatrin 
(n = 61), prednisolone (n = 28), tetracosactide (n = 10), and sodium valproate 
(rt = 1). Of the 15 cases classified as having tuberous sclerosis, 11 were treated 
with vigabatrin, 3 with prednisolone, and 1 with sodium valproate. Informa­
tion relating to the cessation of spasms outcome variable was available for 88 
(88%) of the 100 non-randomised cases. Of these cases, the proportion with 
cessation of spasms was 45/88 (51%) and the proportion with non-cessation of 
spasms was 43/88 (49%). Cessation of spasms was reported in 20/34 (59%) of 
those given hormonal treatments and in 25/53 (47%) of those given vigaba­
trin. This difference is not statistically significant (x^) = 1.13; P  = 0.29).
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There were 87 cases in which underlying aetiology was reliably classified 
and the cessation of spasms outcome was reported. One case with missing in­
formation relating to investigations was classified as a non-responder. In the 
other 12 cases, aetiological and outcome information were both unavailable. 
Of those with an identified underlying aetiology, 33/65 (51%) had cessation of 
spasms; and of those without an identified underlying aetiology after extensive 
investigation, cessation of spasms was reported in 12/22 (55%). There was no 
significant difference in proportions responding by presence or absence of an 
identified underlying aetiology = 0.09; P  = 0.76).
Cases with tuberous sclerosis are of particular interest since they were ex­
cluded from the randomised trial element of the study. Of the 15 cases with 
tuberous sclerosis, the cessation of spasms outcome was known in 14 cases. 
Of these 14 cases, 10 (71%) had cessation of spasms and 4 (29%) were non­
responders. Cessation of spasms was reported in 8/10 cases given vigabatrin 
(with outcome being unknown in another single case) and in 2/3 cases given 
prednisolone. The case treated with sodium valproate was a non-responder.
One of the initial aims of UKISS was to obtain reliable epidemiological data 
on a large population-based sample of cases from the United Kingdom. How­
ever, accrual of cases was slower than planned, and notification and reporting 
of non-randomised cases was substantially lower than the estimate of incident 
cases in the UK during the study period. Also, neurodevelopmental assess­
ments were not made on cases who were not randomly allocated treatments. 
These issues are discussed further in sections 2.3.2, 6.2.10, and 6.2.12. Only 
very limited inferences can be made from these data, and no further data about 
non-randomised cases are reported in this thesis. Further information in this 
chapter and chapter 4 relate to information from the randomised trial compo­
nent of the study.
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Table 3.10: Final classification of underlying aetiology in non-randomised 
cases.
Aetiology Number
Cerebrovascular: infarct or stroke 2
Chromosomal (n = 31)
Tuberous sclerosis 15
Down syndrome 9
Deletion chromosome 17pl3.3 1




Neurofibromatosis type 1 1
PEHO syndrome 1
Malformations (n -  6)
Focal cortical dysplasia 2
Lissencephaly 2
Schizencephaly 1
Agenesis of the corpus callosum 1




Hyperintense basal ganglia on MRI 1
Parenchymal heterotopias 1
Hypoxic-ischaemic encephalopathy (n = 10)
Perinatal 7
Prenatal 3
Periventricular haemorrhage/leukomalacia (perinatal) 6
Metabolic or endocrine (n = 1)
Transient neonatal hypoglycaemia 1
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3.3.5 Compliance with treatment protocol
Although tolerance limits for compliance were not stated in the study protocol, 
we later decided that we would consider any child to have complied fully 
with the treatment protocol if drug doses were within 10% of those stated in 
the study protocol, if the frequency of administration was appropriate, and 
if any changes to the regimen were made within 24 hours of that stated in 
the study protocol [205]. Although the study protocol was not explicit that 
the day of randomisation was considered to be study day 0 and some local 
investigators might have made changes based on the assumption that this was 
study day 1, we felt that a 24-hour tolerance limit was appropriate and not over­
conservative.
The dose was reported as given in full compliance with the protocol in 
21/30 (70%) infants allocated prednisolone, 16/25 (64%) of those allocated 
tetracosactide, and 29/52 (56%) of those allocated vigabatrin. In 18 infants 
(5/30 (17%) of those allocated prednisolone, 4/25 (16%) allocated tetracosac­
tide, and 9/52 (17%) allocated vigabatrin) the regimen given was appropri­
ate given that adverse events were reported and justified amendment of the 
treatment regimen. In 11 infants (1 allocated prednisolone, 5 allocated tetra­
cosactide, and 5 allocated vigabatrin) we were unable to verify that the reg­
imen accorded fully with the study protocol, and in 12 infants (3 allocated 
prednisolone, and 9 allocated vigabatrin) we were certain that there had been 
deviation from the study protocol.
An alternative or additional treatment for spasms was administered after 
allocation of randomised treatment and before study day 14 in the case of 6 in­
fants: 2 infants allocated prednisolone received vigabatrin; 3 infants allocated 
vigabatrin received prednisolone; and 1 infant allocated vigabatrin received 
lorazepam. Prior treatment for seizures other than infantile spasms was con­
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tinued during study days 0 to 14 in 32 infants (9 allocated prednisolone, 9 
allocated tetracosactide, and 14 allocated vigabatrin). Four infants received 
pyridoxine (1 allocated prednisolone and 3 allocated vigabatrin). In one in­
fant there appeared to be response to pyridoxine, relapse of seizures after later 
withdrawal of the pyridoxine, and secondary response after pyridoxine was 
reintroduced. This case met criteria for the diagnosis of pyridoxine dependent 
seizures.
3.3.6 Completion of study diaries
Diaries containing information about spasms and treatment during study days 
0 to 14 were returned to the study centre in 91/107 (85%) of cases (24/30 (80%) 
allocated prednisolone, 21/25 (84%) allocated tetracosactide, and 46/52 (88%) 
allocated vigabatrin).
3.4 Primary clinical response: cessation of spasms
3.4.1 Proportions with cessation of spasms
The primary outcome of cessation of spasms, defined as absence of observed 
or reported spasms for at least 48 consecutive hours and for a period that in­
cluded study days 13 and 14, was reported in a significantly higher propor­
tion of infants allocated hormonal treatments than infants allocated vigabatrin: 
40/55 (73%) vs 28/52 (54%) (difference 19% (95% Cl 1% to 37%); x\i) =4.11; 
P  = 0.04). The cessation of spasms outcome, stratified by underlying aetiolog- 
ical category, is shown in table 3.11. There were no significant differences 
in the proportions with cessation of spasms between the two hormonal treat­
ment groups: 19/25 (76%) in those allocated tetracosactide and 21/30 (70%) 
in those allocated prednisolone. Two infants allocated tetracosactide were in
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Prenatal 6/8 5/6 11/14 7/15
Perinatal 3/5 3/3 6/8 5/9
Postnatal 1/2 1/1 2/3 0
Other 2/2 0/2 2/4 3/6
Undetermined 9/13 10/13 19/26 13/22
All categories 21/30 19/25 40/55 28/52
fact given prednisolone as the first-line treatment, and both of these infants 
were reported to have cessation of spasms. The reason for these infants being 
given prednisolone rather than tetracosactide was that the parents expressed a 
wish to avoid intramuscular injection. They were permitted into the study be­
cause it was considered at the time of randomisation that their inclusion (with 
an agreement to administer prednisolone in place of tetracosactide if neces­
sary) would not alter the primary comparison of hormonal treatments against 
vigabatrin. In addition, one infant allocated vigabatrin was in fact given pred­
nisolone as first-line treatment, again because of parental preference stated af­
ter allocation of randomised treatment, and this infant was also reported to 
have cessation of spasms. If an analysis were to be made by initial treatment ad­
ministered rather than by intention to treat, there would be a marginally larger 
difference in responses between hormonal treatments and vigabatrin (41/56 
(73%) vs 27/51 (53%)) and a marginally smaller difference between tetracosac­
tide and prednisolone (17/23 (74%) vs 23/32 (72%)).
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3.4.2 Time to cessation of spasms
Since time to cessation of spasms is conditional upon a response at study day 
14, the variable time to cessation of spasms was reported as the number of con­
secutive days known to be spasm-free at the end of study day 14. In the case 
of 7 infants who did not have cessation of spasms (4 allocated hormonal treat­
ments and 3 allocated vigabatrin) the reported information did not indicate 
whether spasms were present on both days 13 and 14 or on only one of these 
days. Their number of consecutive days free of spasms was not known and 
was set to zero. One infant allocated a hormonal treatment was known to be 
free of spasms on days 13 and 14 but the day of response was uncertain. This 
infant's number of consecutive days free of spasms was set at two days. The 
median (25th, 75th) number of consecutive days spasm-free at the end of study 
day 14 was 9 (1,12) for those allocated hormonal treatments and 2.5 (0,12) for 
those allocated vigabatrin (Wilcoxon rank-sum test P = 0.04). This analysis was 
performed by Dr Anthony L. Johnson, the study statistician.
3.4.3 Factors potentially biasing cessation of spasms outcome 
Cessation o f spasms and age at onset of spasms
There was no obvious trend in proportions responding according to age at 
onset of spasms (table 3.12).
Cessation o f spasms and lead-time to treatment
Since delays in treatment might be associated with poorer outcomes, we in­
vestigated the effect of lead-time to treatment’, that is, duration of spasms before 
treatment intervention. Precise dates identified by history as being the date of 
onset of clinical spasms were reported in 44/107 (41%) of enrolled infants. The 
range of reported durations between onset of clinical spasms and date of ran­
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domisation in these 44 infants was 2 to 102 days. For 96/107 (90%) of infants, 
the duration of spasms could be reliably classified into one of two groups: less 
than or equal to one month (one month taken as being 30 days) and one month 
or longer. The duration of spasms could not be reliably classified in 11 cases. 
Of those that were categorised, 61/96 (64%) had spasms for one month or less, 
and 35/96 (35%) for longer than one month.
Lead-time to treatment did not significantly predict cessation of spasms, which 
was reported in 41/61 (67%) of infants with a lead-time of less than 1 month 
and in 21/35 (60%) of those with lead-time of greater than 1 month (difference 
7% (95% Cl -13% to +27%); X2{1) = 0.51; P = 0.48).
Cessation o f spasms and underlying aetiology
Cases classified by underlying aetiological categories are shown in table 3.13. 
As can be seen from this table , there were relatively sparse data for any one 
specific underlying aetiology, but the outcome variable cessation of spasms did 
not vary substantially between underlying aetiological groups. The propor­
tions of infants with cessation of spasms were similar in the groups of infants di­
chotomised as having or not having an identified underlying aetiology: (36/59 
(61%) vs 31/46 (67%), difference -6%  (95% Cl -25%  to +12%); *^=0.45; 
P  -  0.50). Two infants were not classified into aetiology known or not known 
groups because they had not had neuroimaging studies and classification could 
not be made reliably.
Table 3.12: Cessation of spasms by age at onset of spasms.
Age in months
1 2 3 4 5 6 7 8 9 10 Total
Cessation of spasms 1/1 4/7 6/9 11/21 12/19 14/15 10/12 4 /7 3/4 2/6 67/101
Percentage 100% 57% 67% 52% 63% 93% 83% 57% 75% 33% 66%
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Cessation o f spasms and baseline EEG features
Cessation of spasms did not differ significantly between groups with or with­
out reported hypsarrhythmia in the baseline EEG. Of 83 infants with baseline 
EEGs reported as hypsarrhythmic, 53 (64%) had cessation of spasms, compared 
with 15/24 (63%) of those whose baseline EEG was not reported as hypsar­
rhythmic. The respective proportions by treatment group were 30/39 (77%) 
and 10/16 (63%) for infants allocated hormonal treatments, and 23/44 (52%) 
and 5/8  (63%) for infants allocated vigabatrin. More detailed analysis of base­
line EEG characteristics by modifying features is not practicable because the 
form and content of reporting was not standardised.
3.4.4 Cessation of spasms and stratified randomisation 
variables
Stratified randomisation was used to reduce the risk of any significant imbal­
ance in important prognostic factors between treatment groups. The variables 
used for this stratified randomisation were sex, age category at randomisa­
tion, and aetiological categorisation at randomisation. These are described in 
more detail in section 5 of the UKISS study protocol (page 246). Their value 
was assessed by examining any associations they might have with the variable 
cessation of spasms.
The relationship between cessation of spasms and sex is shown in table 
3.14. Cessation of spasms occurred in 43/64 (67%) of males and 25/43 (58%) 
of females, a difference that is not statistically significant (9% (95% Cl —10% 
to +28%); X(i) =0.91; P = 0.34). Stratified randomisation age category also had 
no significant association with cessation of spasms (Pearson X(3) =4.60; P = 0.21) 
and no evident trend. Three cases were allocated to wrong age categories at 
randomisation. An infant with cessation of spasms aged 179 days at enrolment
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Table 3.13: Cessation of spasms by final aetiological category.
Aetiology n
Cessation o f spasms 
Number (%)
Cerebrovascular 14 10 (71%)
Chromosomal 4 2 (50%)
Malformation 9 4 (44%)
Signs and symptoms NOS 6 3 (50%)
Hypoxic-ischaemic encephalopathy 10 5 (50%)
PVH/PVL 5 5 (100%)
Metabolic or endocrine 3 1 (33%)
Nervous system 6 4 (66%)
Other 2 2 (100%)
Known cause 59 36 (61%)
No cause found 46 31 (67%)
Not known 2 1 (50%)
Total 107 68 (64%)
Table 3.14: Cessation of spasms by stratified randomisation sex category.
Cessation o f spasms
Sex Yes No Total
Male 43 21 64
Female 25 18 43
Total 68 39 107
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Table 3.15: Cessation of spasms by stratified randomisation age category.
Cessation o f spasms Total
Age category Yes No
60-119 days 4 2 6
120-179 days 19 17 36
189-239 days 23 7 30
240 days and older 22 13 35
Total 68 39 107
was allocated treatment from the 180-239 days old age randomisation stratum; 
an infant with cessation of spasms aged 265 days at enrolment was allocated 
treatment from the 120-179 days old age randomisation stratum; and an infant 
who was a primary clinical non-responder aged 211 days at enrolment was 
allocated treatment from the 240 days and older age randomisation stratum. Af­
ter adjustment for this misclassification, the values for the chi-square test are 
not substantially different (X(3) = 4.06; P = 0.26). Table 3.15 shows these propor­
tions after adjustment for misclassification at the time of randomisation. Table 
3.16 shows the numbers with cessation of spasms by the stratified randomisa­
tion composite aetiological categories. Although cessation of spasms was com­
moner in infants who had normal development preceding diagnosis of spasms 
and no identified underlying aetiology at the time of enrolment, the differ­
ences between the two aetiological categories was not significant (28/49 (57%) 
vs 40/58 (69%), difference -12% (95% Cl -30% to +6%); X(i} = 1*60; P = 0.21).
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Table 3.16: Cessation of spasms by stratified randomisation composite aetiology 
category.
Cessation o f spasms Total
Stratified category Yes No
Delayed development or known aetiology 28 21 49
Normal development and no known aetiology 40 18 58
Total 68 39 107
3.5 Other early outcomes
3.5.1 Electroencephalographic changes by study day 19
The patterns of reported EEG findings at baseline and during study days 12 to 
19 are shown in tables 3.17 and 3.18. Two infants had follow-up EEGs reported 
as normal despite being classified as non-responders with respect to the pri­
mary clinical outcome, cessation of spasms. One of these infants had an EEG on 
study day 18 and the diary reported that the last witnessed spasm was seen on 
study day 17. The other infant was reported as having a single, non-clustered 
spasm on each of five days prior to no further spasms being witnessed, and 
the follow-up EEG was performed on one of these final 5 days.
Six infants had cessation of spasms but EEGs that were reported as showing 
hypsarrhythmia. Using the outcome that is suggested in chapter 5 as consti­
tuting a primary electroclinical outcome -  that is, cessation of clinical spasms 
and resolution of hypsarrhythmia -  electroclinical response was confirmed in 
38/55 infants allocated hormonal treatments and 24/52 infants allocated viga­
batrin. These differences are statistically significant (23% (95% Cl 5% to 41%); 
X(X) = 5.77, P = 0.02) but are subject to potential bias since EEG outcomes were 
not recorded within the set time limits for 10 infants allocated hormonal treat­
ments and 9 infants allocated vigabatrin. Performing a sensitivity analysis that
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assumes all unrecorded vigabatrin cases had resolution of hypsarrhythmia 
and all unrecorded hormonal treatment cases had continuing hypsarrhythmia 
gives a non-significant result (difference 6% (95% Cl —12 to +24%); X(p = 0.38, 
P = 0.54).
3.5.2 Adverse events at study day 14
No infants died during the period up to study day 14, but treatment was 
stopped due to reported adverse events in two infants. In the case of one infant 
allocated prednisolone, treatment was stopped due to reported vomiting and 
hypertension, though the Day 14 report gave no indication of significant sys­
temic hypertension and the local investigator was noted to have commented 
that he would have preferred the treatment randomisation process to have 
resulted in allocation of vigabatrin and that he had concerns about the risks 
of adverse events with prednisolone. One infant allocated tetracosactide re­
sponded with cessation of spasms but was withdrawn from treatment after 
developing a rash.
Adverse events were reported in 30/55 (55%) of infants allocated hormonal 
treatments (19/30 (63%) prednisolone and 11/25 (44%) tetracosactide) and 
28/52 (54%) allocated vigabatrin (table 3.19). Four infants had a reduction in 
treatment doses without complete cessation of treatment, and 12 infants con­
tinued treatment but with deferred increases in the treatment regimen. With 
respect to these outcomes, there were no significant differences between treat­
ment groups.




hypsarrhythmic 16/30 (53%) 23/25 (92%)
39/55 (71%) 44/52 (85%)
Follow-up EEG 
Performed
23/30(77%) 20/25 (80%) 43/55 (78%) 46/52 (88%)
Follow-up EEG1
Normal 5/23 (22%)2 1/20 (5%)3 6/43 (14%) 6/46 (13%)4
Abnormal but 
non-hypsarrhythmic 14/23 (61%) 17/20 (85%) 31/43 (72%)
20/46 (43%)
Hypsarrhythmic 4/23 (17%)5 2/20 (10%)5 6/43 (14%) 20/46 (43%)6
1 Valid follow-up EEGs were those performed between study days 12 and 19.
2 Baseline EEG was hypsarrhythmic in 4/5.
3 Baseline EEG was hypsarrhythmic.
4 Baseline EEG was hypsarrhythmic in 5/6.
5 One infant with hypsarrhythmic follow-up EEG had cessation of spasms.
6 Four infants with hypsarrhythmic follow-up EEG had cessation of spasms.
Table 3.18: EEGs at baseline and follow-up by allocated treatment and primary clinical response, stratified by presence or absence of 
hypsarrhythmia in baseline EEG.
Hormonal Treatment Vigabatrin
Prednisolone Tetracosactide Combined
Baseline hypsarrhythmia Present Absent Present Absent Present Absent Present Absent
Follow-up EEG
Hypsarrhythmia 4 1 2 0 6 1 16 1
Responder 1 0 1 0 2 0 4 0
Not hypsarrhythmia 10 10 16 2 26 12 20 6
Normal EEG 4 1 1 0 5 1 4 1
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Irritability was reported commonly in those allocated hormonal treatments, 
and significantly more often than with vigabatrin (19/55 (35%) vs 2/52 (4%); 
X(i, = 16-0, P < 0.001)(table 3.20). The most commonly reported symptom with 
vigabatrin was drowsiness, which was significantly less common with hor­
monal treatments (14/52 (27%) vs 6/55 (11%); xfi) =4.51, P = 0.034). Increased 
appetite was more commonly reported with hormonal treatments, but the num­
bers were relatively small and the difference was not statistically significant 
(7/55 (13%) vs 1/52 (2%); two-sided Fisher exact test P = 0.06).
Systemic blood pressures in those allocated hormonal treatments were re­
corded, on one or more occasions, to be above 110/80 mmHg in 11/55 (20%) of 
infants and above 120/90 mmHg in 8/55 (15%) of infants, with the respective 
proportions being 7/30 (23%) and 4/30 (13% for those allocated prednisolone, 
and 4/25 (16%) for both systemic blood pressure levels in those allocated tetra­
cosactide. Two infants allocated prednisolone were given diuretics as an inter­
vention to reduce what was considered by the local investigator to be clin­
ically significant systemic hypertension. Glycosuria was recorded in only 1 
infant, which had been allocated tetracosactide, but no infants developed di­
abetes mellitus and none were treated specifically for hyperglycaemia. There 
were no reported adverse events for the 3 infants who received prednisolone 
but had been randomly allocated tetracosactide or vigabatrin, although one 
was reported to have at least one systemic blood pressure measurement over 
120/90 mmHg without any specific intervention.
Table 3.19: Number of adverse events reported during study days 1-14 by intention-to-treat.
Hormonal Treatments Vigabatrin
Prednisolone Tetracosactide Combined
Allocated treatment 30 25 55 52
Adverse events 19 11 30 28
Treatment stopped 1 1 2 0
Treatment reduced 1 1 2 2
Increase avoided1 3 2 5 7
Treatment not altered 14 8 22 19













Table 3.20: Types of adverse events reported during study days 1-14 by intention-to-treat.
Hormonal Treatments Vigabatrin
Prednisolone Tetracosactide Combined
Gastrointestinal 7 5 12 11
Irritability 12 7 19 2
Drowsiness 5 1 6 14
Infection 3 0 3 5
Increased appetite 4 3 7 1
Dermatological 1 3 4 2
Fluid/electrolyte/BP1 3 2 5 0
Neuropsychiatric2 1 0 1 4
Hypertonia 0 2 2 0
Varicella exposure3 1 1 2 0
Other 3 4 7 5
1 Includes hypertension and any disturbance of fluids or electrolytes.
2 Most commonly sleep disturbance.
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3.6 Summary of UKISS early outcomes
The most striking finding from the early part of UKISS was that the primary 
clinical outcome, cessation of spasms, was reported significantly more frequently 
in infants allocated hormonal treatments, with a difference in proportions re­
sponding that was similar to the clinically important difference of 20% that 
was used for the original power calculation for this study. The effect estimates 
for the groups allocated prednisolone and tetracosactide were similar. These 
findings are discussed further in chapter 6.
Chapter 4 
Later Outcomes from the United 
Kingdom Infantile Spasms Study
This chapter reports and analyses later outcomes from the United Kingdom 
Infantile Spasms Study. The protocol provided for these outcomes to be as­
sessed when the study participant reached the age of 12 to 14 months. Section
4.1 describes the conduct of the later part of the study. Sections 4.2 and 4.3 
describe neurodevelopmental outcomes and potential factors that might act as 
prognostic factors or biases for these outcomes. Section 4.4 reports secondary 
outcomes from the later part of the study particularly relapse of spasms and 
progression to other seizure types; and section 4.5 describes adverse events, 
including deaths, occurring during the study period.
4.1 Conduct of the later part of the study
A final clinical assessment was made on 106 of the 107 enrolled children since 
one case (study death 1 in section 4.5) died before any routine follow-up assess­
ment was made. The follow-up data after the study day 14 was obtained pri­
marily from forms completed at 3-monthly intervals (UKISS trial folder forms
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6a, 6b, and 6c) and from form 7. Form 7 was intended to be completed at the 
time of final clinical assessment, and only infants who were enrolled before the 
age of 3 months would have required completion of all forms 6. However, in 
some cases one of the forms 6 was completed closer to the planned final clinical 
assessment age of 12-14 months than was form 7, and therefore final clinical 
assessment information was sometimes taken from one of the forms 6. Final 
clinical assessment data were taken exclusively from form 7 in 96 cases; from 
forms 6a, 6b, and 6c in i ,  3, and 2 cases respectively; and from a combination 
of form 7 with form 6a, 6b, or 6c in 2,2, and 1 cases respectively.
4.1.1 Ages and duration in study at follow-up assessments
The median age at time of first 3-rri6rithly assessment was 10.4 months (IQR 
8.3-12.4; range 6.2-16.6). The median duration of enrolment at the time of com­
pletion of the first 3-monthly assessment form was 3.2 months (IQR 2.9-3.7; 
range 1.7-9.5). The mean (SD) age at time of final clinical assessment (n = 106) 
was 418 (43) days or 13.7 (1.4) months. The range of ages was 352 to 622 days 
(11.6 to 20.4 months) with a median of 416 days (13.7 months) and interquar­
tile range 386 to 441 days (12.7 to 14.5 months). The median duration of en­
rolment at the time of final clinical assessment was 6.6 months (IQR 5.1-8.7; 
range 1.7-12.7). The median age at completion of Vineland Adaptive Behavior 
Scales was 14.7 months (IQR 14.3-15.1; range 13.8-19.6). The median duration 
of study enrolment at the time of Vineland assessment was 8.3 months (IQR 
6.2-10.0; range 3.1-14.4). These ages and durations, stratified by randomised 
treatment, are shown in table 4.1. There is no evidence of any significant dif­
ferences in these ages and durations between treatment groups that might bias 
the analysis of outcomes.
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Figure 4.1: Flow diagram showing disposition of participants in randomised 




























Median age (IQR) 1 9.9 (8.2-12.4) 10.3 (8.8-12.0) 10.1 (8.3-12.4) 10.8 (8.2-16.0)
Median study duration (IQR) 3.1 (2.8-3.5) 3.2 (3.0-4.1) 3.2 (2.9-3.7) 3.1 (2.7-3.7)
Final clinical assessment
Median age (IQR) 13.9 (12.7-14.6) 13.2 (12.6-14.5) 13.4 (12.6-14.6) 13.7 (12.8-14.5)
Median study duration (IQR) 6.8 (5.5—8.6) 7.8 (5.6—8.7) 7.3 (5.5-8.7) 6.4 (4.5-8.9)
Vineland assessment
Median age (IQR) 14.7 (14.3-15.0) 14.7 (14.3-15.2) 14.7 (14.3-15.1) 14.8 (14.3-15.1)
Median study duration (IQR) 7.7 (6.0-10.1) 8.7 (6.6-10.0) 8.4 (6.3-10.0) 8.0 (6.0-9.7)
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Diary entries for the final week of the study were returned in only 19/106 
(18%) of cases. The range of ages for the first day of completion of these diaries 
during the final week was 365 to 426 days, with a median of 366 days and 
interquartile range 365 to 370 days.
4.1.2 Conduct of neurodevelopmental assessments
Neurodevelopment was assessed by means of Vineland Adaptive Behavior 
Scales, as described in section 2.4.10 on page 88. Vineland assessments were 
made in 101 of the 107 randomised study participants. Five children died be­
fore the follow-assessment was made (2 infants allocated prednisolone and 3 
infants allocated vigabatrin) and one infant was withdrawn from the study. 
This last case was withdrawn because of confusion over classification on the 
part of the local investigator. He informed the trial centre that the child had 
withdrawn from the study and it was assumed at the trial coordinating cen­
tre that the reason for this was withdrawal of parental consent. However, the 
local investigator later informed the trial centre, when asked to state if there 
was any stated reason for withdrawal of parental consent, that the intended 
message was merely that the child was a non-responder with respect to the 
primary outcome cessation of spasms. The local investigator had assumed that 
primary clinical non-response removed any need for further follow-up. Thus, 
Vineland assessments were made in 52 children allocated hormonal treatments 
(27 allocated prednisolone and all 25 allocated tetracosactide) and 49 children 
allocated vigabatrin.
4.2 Neurodevelopmental outcomes
Descriptive statistics for the Vineland ABC scores by treatment group are shown 
in table 4.2, and the full distribution of these scores are shown in figure 4.2. The
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Table 4.2: Vineland Adaptive Behavior Scales composite scores at age 14 
months by treatment group.
Hormonal Treatments Vigabatrin
Prednisolone Tetracosactide Combined
Randomised 30 25 55 52
Died 2 0 2 3
Test not done 1 0 1 0
Score available 27 (90%) 25 (100%) 52 (95%) 49 (94%)
Mean 78.0 78.8 78.4 77.5
SD 15.8 17.8 16.6 12.7
SEM 3.0 3.6 2.3 1.8
Median 74 81 74.5 77
Range 60-114 50-107 50-114 51-107
Interquartile range 65-87 65-97 65-92.5 70-86
overall mean (SD) Vineland ABC score for the 101 children assessed was 78.0 
(14.9) with a range of 50 to 114. The overall median Vineland ABC score was 76 
and the interquartile range was 67 to 89. Most children enrolled in the UKISS 
trial had Vineland ABC scores below the population average of 100. Approx­
imately one-third of cases had scores below 2 standard deviations from the 
mean (n = 31 (31%)) and two-thirds had scores at least one standard deviation 
below the mean (n = 68 (67%)). One-third had a Vineland ABC score within 
one standard deviation of the mean (n = 33 (33%)) and 8 of these had scores 
above the population mean.
Developmental scores for specific aetiological categories are shown in table 
4.3. Overall, there were no significant differences in mean (SD) Vineland scores 
by treatment group (hormonal treatment 78.6 (16.8) vs vigabatrin 77.5 (12.7)).
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Figure 4.2: Distribution of Vineland ABC scores by treatment group.
There were no significant differences in Vineland ABC score by sex (mean (SD) 
79.3 (15.6) for males and 76.4 (13.9) for females).
The subgroup of infants with no identified underlying aetiology was of a 
priori interest. These were investigated by means of an analysis of variance 
(ANOVA) model with differences for the specific comparison of interest being 
made by a least significant difference test. The results of this ANOVA model 
are reported in table 4.4, where the number of observations is 99 and the overall 
number of degrees of freedom is 95. This ANOVA model shows that the pres­
ence of an identified underlying aetiology was associated with significantly 
lower Vineland ABC scores (£1,95 = 13.80; P < 0.001).
In infants with no identified underlying aetiology, there was a significant 
difference between treatment groups in mean Vineland ABC score, with scores 
being higher in those allocated hormonal treatment 88.2 (17.3) compared with 
those allocated vigabatrin 78.9 (14.3) (least significant difference test f(95) = 2.28; 
P = 0.03; difference 9.3; 95% Cl for the difference +1.2 to +17.3). This analysis
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Table 4.3: Vineland ABC scores by category of underlying aetiology.
Aetiological category n Mean SD Range
Cerebrovascular 14 79.4 10.0 54-95
Chromosomal 4 74.5 7.5 65-83
Malformations 9 70.4 15.2 51-94
Signs & symptoms NOS 5 71.8 21.3 50-106
HIE 10 69.1 6.6 60-81
PVH/PVL 5 74.2 8.0 65-87
Metabolic /  Endocrine 2 76.0 4.2 73-79
Nervous system NOS 4 70.3 6.2 61-74
Other 1 62.0 - -
Table 4.4: Analysis of variance of Vineland ABC score by randomised treat­
ment and presence or absence of identified underlying aetiology.
Source of variation d.f. Mean square F P
Treatment group 1 109.27 0.59 0.44
Aetiology 1 2548.70 13.80 < 0.001
Treatment x Aetiology 1 1251.59 6.78 0.011
Residual error 95 184.70
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included 45 infants (24 allocated hormonal treatments and 21 allocated vigaba- 
trin). A sensitivity analysis was performed by including the two children who 
were not reliably classified as having or not having an identified underlying 
aetiology because they had not had any neuroimaging studies. The sensitivity 
analysis included these infants in such as way as to reduce the difference found 
to a minimum. The first of these was a male infant had been allocated vigaba- 
trin and had cessation of spasms with a subsequent Vineland ABC score of 93. 
He was included in the sensitivity analysis as having no identified underlying 
aetiology. The other case was a female infant that had been allocated tetracos- 
actide, had not had cessation of spasms, and had a Vineland ABC score of 57. 
She was also included in the sensitivity analysis with classification as having 
no identified underlying aetiology. In this sensitivity analysis, the respective 
mean (SD) Vineland ABC scores were 86.9 (18.1) and 79.5 (14.3) (f(97) = 1.82, 
P = 0.07; difference 7.4; 95% Cl -0.7 to +15.4).
The mean Vineland ABC score in the group of 54 children with an identified 
underlying aetiology was higher in those allocated vigabatrin, but the differ­
ence in scores was not significant (75.9 (11.3) vs 70.8 (11.1); f(95) = 1.36; P = 0.18; 
difference 5.0 (95% Cl -2.3 to +12.4)). This analysis was not of a priori interest, 
but is warranted by the significant interaction term in the ANOVA model.
4.2.1 Investigation of potential bias in timing of Vineland 
assessments
There is a possibility that differences in Vineland ABC score are due to bias 
in the timing of these assessments. Since the scores are age standardised by 
whole months of age, the age standardisation process is relatively more gener­
ous to infants who are assessed later in the month of age than to those who are 
assessed earlier. To investigate whether there were any large differences in the
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Communication 79.4 (10.5) 82.2 (13.3) 80.8 (11.9) 78.9 (9.4)
Living skills 85.0 (11.4) 84.6 (15.4) 84.8 (13.4) 84.7 (9.5)
Socialization 86.6 (16.9) 86.3 (19.5) 86.4 (18.1) 88.1 (16.2)
Motor 77.6 (18.5) 77.9 (20.1) 77.7 (19.1) 76.5 (15.1)
timing of Vineland assessments by treatment group, cases were dichotomised 
into those whose assessment was performed earlier in the month of age (that 
is, before the mid-point of the month of age) and those whose assessment was 
performed later in the month of age. This analysis showed that there was 
no significant difference in the proportions assessed later in the month of age 
(hormonal treatment group 20/52 (38%) vs vigabatrin group 23/49 (47%); dif­
ference - 8% (95% Cl -28% to +11%); x\i) = 0.74, P = 0.39).
4.2.2 Vineland domain scores
Outcomes for the separate Vineland domain scores are shown in table 4.5. 
Since we had no a priori hypothesis about how these domain scores might 
be affected by treatments, we did not perform separate statistical tests on these 
results. There were no striking differences in the domain scores between treat­
ments, but for all three treatments mean scores were lower for the motor do­
main than for other domains.
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Figure 4.3: Box-whisker plot of Vineland ABC scores by presence or absence of 
identified underlying aetiology.
4.3 Analysis of potential prognostic factors for 
neurodevelopment
4.3.1 Neurodevelopmental outcome and underlying 
aetiology
Mean (SD) Vineland ABC scores were significantly lower in infants with a 
known underlying aetiology than in infants for whom no underlying cause 
was found (73.3 (11.4) vs 83.8 (16.5), difference 10.5 (95% Cl 4.9 to 16.1); t {97) = 
3.70, P < 0.001) (figure 4.3 and table 4.6). Mean (SD) Vineland ABC scores 
were significantly higher in infants who were primary clinical responders (80.9 
(15.0) vs 72.7 (13.4), difference 8.2 (95% Cl 2.2 to 14.2); tm  = 2.68, P = 0.009) (fig­
ure 4.4 and table 4.7). These findings invite the question whether the effect of 
primary clinical response might be on a causal pathway that is initiated by the 
allocated treatment.
CHAPTER 4. UKISS LATER OUTCOMES 150
Table 4.6: Vineland ABC score by presence or absence of identified underlying 
aetiology
Known aetiology No cause found
Number (%) tested 54(92) 45 (98)
Mean (SD) 73.3 (11.4) 83.8 (16.5)














Cessation of spasms Non-cessation of spasms
Figure 4.4: Box-whisker plot of Vineland ABC scores by primary clinical re­
sponse.
Table 4.7: Vineland ABC score by primary clinical response
Responder Non-responder
Number (%) tested 66(97) 35 (90)
Mean (SD) 80.9 (15.0) 72.7 (13.4)
Median (IQR) 78.5 (70-93) 71 (62-86)
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Table 4.8: Effects of lead-time to treatment upon main outcomes stratified by 
presence or absence of identified underlying aetiology.
Aetiology Lead-time Cessation of spasms Vineland ABC score 
Mean (SD)


















1 Cessation of spasms: xfi) = 1-52; P = 0.22.
2Cessation of spasms: xfi) = 0*08; P = 0.78.
3Cessation of spasms: xfi) = 0.51; P = 0.48.
4Includes 2 cases with aetiological category undetermined.
4.3.2 Lead-time to treatment as a potential predictor of 
neurodevelopmental outcome
Mean (SD) VABS composite scores were not significantly different in those 
with lead-time to treatment of less than 1 month compared with those with lead- 
time to treatment of 1 month or greater (80.3 (14.9) vs 76.1 (15.1), difference 4.3 
(95% Cl —2.2 to +10.7; t89 = 1.32; P = 0.19). Analyses were also made of the 
subgroups with known aetiology and no identified underlying cause, with a 
priori interest focussed primarily on the group with no identified underlying 
cause. In neither group was there any significant association between lead-time 
to treatment and cessation of spasms or Vineland ABC score (table 4.8). Table 4.9 
shows the results of an ANOVA with Vineland ABC score with lead-time and 
dichotomised etiology and including an interaction term. The interaction term 
is not significant and lead-time does not independently predict Vineland ABC 
score.
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Table 4.9: Analysis of variance of Vineland ABC score by lead-time to treatment 
and presence or absence of identified underlying aetiology.
Source of variation d.f. Mean square F P
Lead-time 1 333.97 1.73 0.19
Aetiology 1 2720.61 14.1 < 0.001
Lead-time x Aetiology 1 46.66 0.24 0.62
Residual error 85 192.54
Hormonal treatment Vigabatrin




















Figure 4.6: Box-whisker plot of Vineland ABC scores by treatment group where 
no identified underlying aetology.
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Figure 4.9: Kaplan-Meier survival estimates of time to last reported spasm before study day 14 for all three treatment groups.
Kaplan-Meier survival estimate
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4.4 Secondary outcomes of the randomised 
controlled trial
Secondary outcomes are defined in section 26 of the UKISS trial protocol. Item 
6 of the stated secondary outcomes, developmental progress at age of 14 months, 
was later considered to be a main outcome measure, and has already been dis­
cussed above. Item 2, partial response defined as reduction in the number of 
spasms during the first two weeks of treatment, was later considered to be of 
little or no clinical interest, as is discussed in chapter 5. Item 1, time taken to 
complete cessation of spasms for a period of 48 hours, is presented below as 
analysed and presented in the Lancet early outcomes paper. Item 3, relapse 
rates, are discussed below and presented as relapse-free response, a variable that 
was favoured by members of the West Delphi group. Items 4 and 5, presence 
of other seizure types at age 14 months and resolution of hypsarrhythmia at 
day 14 of the study, are discussed below.
4.4.1 Relapse and relapse-free response
There was no significant difference between hormonal treatment and vigaba­
trin groups in the proportions with no reported spasms at final clinical as­
sessment (41/55 (75%) vs 39/51 (76%), difference -2%  (95% Cl -18  to +14%);
=0.05, P = 0.82); and no significant difference in the proportions reported 
to have relapse-free response (that is, cessation of spasms at study day 14 and no 
reported spasms thereafter) (22/55 (40%) vs 19/52 (37%), difference 3% (95% 
Cl —18% to +14%); xfi) =0.14, P = 0.71). Thus, although the primary clinical 
response, cessation of spasms, was commoner with hormonal treatments than 
with vigabatrin, relapse of spasms was commoner with hormonal treatments. 
The proportions with relapse-free response in the three treatment groups were
CHAPTER 4. UKISS LATER OUTCOMES 161
prednisolone 12/30 (40%), tetracosactide 10/25 (40%), and vigabatrin 19/52 
(37%). The relapse outcome could not be reliably determined initially in one 
infant allocated tetracosactide because the local investigator was unsure how 
to interpret reports of subtle head movements during one stage of follow-up, 
but the consensus at the UKISS trial centre was that this case was best classi­
fied as having relapse of clinical spasms. Of the 26 infants who were primary 
clinical responders but relapsed before the final clinical assessment, the earliest 
relapse occurred before 3 months from study enrolment in all but 2 infants (one 
infant allocated prednisolone and one allocated vigabatrin). In one infant allo­
cated tetracosactide, the first relapse of spasms occurred while the infant was 
living abroad and the timing of that relapse could not be reliably determined.
4.4.2 Progression to other seizure types
Seizures other than infantile spasms were reported in the follow-up period to 
age 12 months in 50 (47%) of infants, with missing data in one case treated 
with vigabatrin (table 4.10). There was no significant difference between hor­
monal treatment and vigabatrin groups in the frequency of seizures develop­
ing after treatment for infantile spasms (29/55 (53%) vs 21/51 (41%); x 2\) = 1-42, 
P = 0.23).
At final clinical assessment, 13/106 (12%) infants were reported as having 
both spasms and seizures, 13/106 (12%) had reported spasms but no seizures, 
20/106 (19%) had reported seizures but no spasms, and 60/106 (57%) had re­
ports of neither spasms nor seizures. Reported absence of both spasms and 
seizures at the final clinical assessment was commoner with vigabatrin than 
with hormonal treatments, but this difference was not statistically significant 
(32/51 (63%) vs 28/55 (51%); x 2{1) = 1.51, P = 0.22).
Table 4.10: Epilepsy outcomes (spasms and other seizure types) reported study day 14 by treatment group and stratified by presence 









Aetiology(+) 30 9 2 7
Hormonal treatment Cessation(+) 16 0 1 2
Cessation(-) 2 3* 1 1
Vigabatrin Cessation(+) 8 3* 0 2
Cessation(-) 4 3 0 2
Aetiology(-) 30 11 11 6
Hormonal treatment Cessation(+) 8 9 3 1
Cessation(-) 2 1 1 4
Vigabatrin Cessation(+) 13 1 1 0
Cessation(-) 7 0 6 1
Total 60 20 13 13
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4.5 Adverse events after study day 14
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4.5.1 Deaths occurring after study day 14
Of the five infants who died before the Vineland assessment was performed, 
three were randomly allocated vigabatrin at the start of the study, and two 
were allocated prednisolone. One infant (study death 1 below) was allocated 
vigabatrin, did not have cessation of spasms, and later died of an infection while 
being treated with prednisolone. It is probable that the treatment with pred­
nisolone contributed to this death by suppressing immune responses or mask­
ing clinical signs of sepsis, but this is conjectural.
Study death 1
This male infant was enrolled in the study aged 146 days (4.8 months) and 
was allocated treatment with vigabatrin. There was no cessation of spasms and 
treatment with prednisolone was started on study day 15. He died aged 178 
days (5.9 months), 32 days after enrolment in study. The certified cause of 
death was: la. Staphylococcus aureus septicaemia.
Study death 2
This male infant was enrolled in the study aged 151 days (almost 5 months) 
and was allocated treatment with prednisolone. There was cessation of spasms 
but later relapse of spasms, and treatment with vigabatrin and nitrazepam was 
added. He died at the age of 392 days (12.9 months), 241 days after study 
enrolment. The certified cause of death was: la. Leigh's encephalopathy.
Study death 3
This male infant was enrolled in the study aged 328 days (10.8 months) and 
was allocated treatment with vigabatrin. There was no cessation of spasms and
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he later received prednisolone. He died aged 403 days (13.3 months), 75 days 
after study enrolment. The certified cause of death was: la. Encephalopathy; 
lb. Primary cerebral atrophy.
Study death 4
This male infant was enrolled in the study aged 348 days (11.4 months), was 
allocated treatment with vigabatrin, and had cessation of spasms without any 
later relapse of spasms. He did not receive treatment with prednisolone or 
with any other antiepileptic drugs. He died aged 406 days (13.3 months), 58 
days after study enrolment. The certified cause of death was: la. Aspiration of 
vomitus; lb. Cerebral palsy.
Study death 5
This male infant was enrolled in the study aged 330 days (10.8 months) and 
allocated treatment with prednisolone. He did not have cessation of spasms and 
later received vigabatrin, carbamazepine, and clobazam. He died aged 471 
days (15.5 months), 141 days after study enrolment. The certified cause of 
death was: la: Bronchopneumonia; lb. Chronic lung disease; n. Microcephaly.
4.5.2 Non-fatal adverse events reported after study day 14
Treatment with randomly allocated medication was reported to be stopped af­
ter study day 14 because of adverse effects in 3 cases, all of which received 
treatment with vigabatrin. In two of these cases the infants were admitted to 
hospital and treatment was stopped during the hospital admission. The stated 
symptoms were: (1) Vomiting, weight loss and poor feeding, leading to hos­
pital admission; (2) Excessive drowsiness and continued seizures, leading to
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hospital admission; and (3) Irritability, excessive drowsiness, and vomiting. 
One infant had irritability early during treatment with vigabatrin and later de­
veloped excessive drowsiness. Treatment was reduced but continued. One 
infant in the hormonal treatment group was admitted to hospital on two oc­
casions because of systemic hypertension, and treatment was reduced. None 
of these infants were reported to have permanent problems as a result of these 
adverse effects.
Overall, 8 infants (2 allocated hormonal treatments and 6 allocated vigaba­
trin) were admitted to hospital because of infectious illnesses. One infant was 
admitted on two occasions because of uncontrolled hypertension. Another in­
fant was admitted to hospital because of a complication attributed to treatment 
with topiramate. Chickenpox was reported in three infants (2 allocated viga­
batrin and 1 allocated tetracosactide depot) during the study period, but none 
of these was given zoster immunoglobulin.
Seven infants were reported to require admission to hospital because of 
illnesses attributed to infection. Varicella-zoster infection (chickenpox) was 
reported in 3 infants (2 allocated vigabatrin and 1 allocated tetracosactide) and 
2 infants allocated hormonal treatments were given varicella immunoglobulin 
because of potential exposure to zoster during the period of likely vulnerability 
due to hormonal treatment.
Overall, during the period of follow-up to final clinical assessment, 25 study 
infants were reported to require admission to hospital for reasons that did not 
require reduction in medication or stopping of medication.
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4.6 Summary of later outcomes from UKISS
The most striking finding from the later part of UKISS was that children with 
no identified underlying cause, in whom we had a priori considered that a 
protective effect of early treatment would be most readily detected, had sig­
nificantly higher Vineland ABC scores if they had been allocated hormonal 
treatments rather than vigabatrin. These findings are discussed in chapter 6.
Chapter 5
West Delphi: An International 
Consensus on Case Definitions, 
Outcomes and Outcome Measures 
for Studies of Infantile Spasms
5.1 Overview of West Delphi
Reviewing the evidence for various treatments of infantile spasms led to the 
realization that there is substantial variation in how outcomes are defined and 
measured, and also variation in case definitions for children with infantile 
spasms. Professor John Osborne and I decided that an effective approach to 
this problem would be to propose a Delphi process aiming to provide an in­
ternational standard for case definitions and outcome measures for studies of 
infantile spasms. Our discussion led to the drafting of an initial proposal paper 
that was presented by Professor Osborne at an International Symposium on the 
West Syndrome and Other Infantile Epileptic Encephalopathies at Tokyo Women's 
Medical University, Tokyo, Japan: 9-11 February, 2001 [208]. The idea of such
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an international consensus was warmly received and several investigators in­
formally agreed to participate in the process. It was informally agreed that a 
process conducted by email would be efficient and acceptable.
In the discussion following this paper, it was determined that this consen­
sus process would attempt, among other things, to define limits for the EEG 
features of hypsarrhythmia, including modified or atypical hypsarrhythmia 
[8, 32, 67]. Many participants were enthusiastic about this proposal, though 
some thought that, in particular, it would be difficult to achieve a consensus on 
EEG characteristics. By allusion to William James West and the Delphi process 
used for consensus elicitation, we decided to refer to this process as West Del­
phi.
It was noted that several ILAE commissions and workshops have proposed 
definitions and classifications of infantile spasms, and some elements of these 
are not mutually consistent. For example, proposals from the ILAE Commis­
sions on Classification and Terminology in 1985 and 1989 suggested that cases 
of infantile spasms should always have onset of symptoms before 12 months of 
age, whereas a 1991 workshop of the ILAE Commission on Pediatric Epilepsy 
suggested that infantile spasms "transcends age groups and may occur in in­
fancy or childhood" [28,34,35]. Variation in age of onset as a defining criterion 
alters epidemiological characteristics such as median age at onset of illness, 
and affects estimates of age-dependent outcomes. In addition to differences in 
definitions and criteria proposed by the ILAE, there are many other variations 
in definition, classification, and outcome criteria between published studies.
West Delphi consisted of 6 rounds, though the last two rounds consisted 
mainly of approval of wording for both the consensus statement and the as­
sociated explanatory material that constituted a draft paper to be submitted 
for publication. There was general consensus within the West Delphi Group 
that the finally agreed draft should be submitted to the journal Epilepsia, and
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a version with minor amendments to the one submitted for publication was 
published in November 2004 [209].
5.2 Methods and conduct of West Delphi
West Delphi was based on the system known as a Delphi process, a method for 
eliciting expert consensus developed by the RAND Corporation in the early 
1950s [210]. In summary, a Delphi process involves isolated experts giving 
their judgments or opinions to a moderator or facilitator who makes those 
opinions anonymous and redistributes them to the full group of experts [211]. 
The process was administered by email and responses were collated by the au­
thor of this thesis, who acted as facilitator of the process. Professor Osborne 
acted as guarantor of the process, but was not aware of the identity of individ­
ual respondents and himself participated as a contributor and respondent to 
questions.
Invitations were sent by email to 133 persons who had published papers as 
primary authors on infantile spasms during the previous 10 years, or who were 
known to the author of this thesis or Professor John Osborne to have an inter­
est in infantile spasms. Criteria for selection included presentation at recent 
symposia on infantile spasms in Seattle, USA and Tokyo, Japan; and publica­
tion of a paper on infantile spasms in the previous ten years. Invitations were 
limited by the ability of the author to locate an email address for the potential 
participant. Invited persons were asked to forward the email to anyone who 
they thought would be interested in participating.
The first round included 10 questions with multiple choice format responses 
(MCQs) that acted as "ice-breaking" questions to stimulate debate and ex­
plored some controversial areas. These questions, and those of subsequent 
rounds, are reproduced in appendix C and responses are reported in this chap-
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Table 5.1: Contributors to West Delphi (parentheses indicating responses re­
ceived too late to be incorporated into feedback).
Rounds Authorship
Name 1 2 3 4 5
Giuliano Avanzini * * Yes
Tallie Baram * * * Yes
Rochelle Caplan * No
Roberto Caraballo * * * * Yes
Kevin Farrell * * * Yes
Tiziana Granata * * * * Yes
Eleanor Hancock * * Yes
Hideji Hattori * No
Masatoshi Ito * * * * * Yes
Masayuki Itoh * No
Osamu Kanazawa * No
Jun Kohyama * * * * Yes
Roshan Lai Koul * * * * * Yes
Lee Wei Ling * No
Liao Jianxiang * * * * Yes
Marissa Lukban * * * Yes
Tony Marson * * * Yes
Atsuko Matsuo * No
Brain Neville (*) * * * Yes
Harry Nomayo * * * * * Yes
Hirokazu Oguni * * * * * Yes
Shunsuke Ohtahara * * * * * Yes
Hian-Tat Ong * * * * * Yes
Marilyn Ortiz * * No
John Osborne * * * * * Yes
Desiderio Pozo Lauzan * * * Yes
Dietz Rating (*) * * * Yes
Aida Salonga * * * * Yes
Ingrid Scheffer * No
Bernhard Schmitt * * * * * Yes
Ulrich Stephani (*) * No
Yoshihiro Takeuchi * No
Malinee Thambyayah * * * * * Yes
Federico Vigevano * * * Yes
Anannit Visudtibhan * * * * Yes
William Whitehouse * * * * * Yes
Virginia Wong * * Yes
Hitoshi Yamamoto * No
Hideo Yamanouchi * * * * Yes
Chainllie Young * * * * Yes
Zhou Zhongshu * * Yes
Total 31 27 20 22 26 30
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ter.
In addition to responding to round 1 questions, those agreeing to partici­
pate were asked to formulate further questions as a unique contribution to the 
study. The process made provision for participants to enter after the first round 
since not all interested persons would necessarily have been contacted in time 
to respond to round 1. We suggested that, in order to be considered members 
of the West Delphi Group, participants would need to make contributions to 
other rounds and to agree the final draft of the proposal. We also suggested 
that minority and dissenting views would be clearly represented in the final 
draft, and that the views of contributors would not be censored.
The content and form of subsequent rounds was determined in part by the 
suggestions of contributors. There was a balance between eliciting quantita­
tive information about the strength of agreements, and eliciting qualitative and 
creative views on approaching problems of definition, classification, and mea­
surement. The process aimed to focus on aspects of definition and outcome, 
and to develop proposals that would clarify and simplify study design without 
introducing unnecessary constraints. Although some participants during the 
course of the process were keen to make statements relating to evidence for 
choosing particular first-line treatments, we had decided before the process 
that we would not attempt to summarise or appraise such information in West 
Delphi.
In this thesis, reference to questions and statements in the West Delphi 
rounds are referred to by abbreviations referring to the round and question 
number such that R1Q5, for example, refers to West Delphi round 1 question 
5; and R4S1 to refer to round 4 statement 1.
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Table 5.2: Responses to multiple-choice questions in West Delphi round 1.
Question number
1 2 3 4 5 6 7 8 9 10
Response (a) 3 11 2 5 2 2 9 2 3 2
Response (b) 14 8 10 14 10 8 12 1 10 3
Response (c) 7 0 5 4 3 4 6 3 9 5
Response (d) 6 7 11 5 12 15 3 6 7 13
Response (e) 1 5 3 3 4 2 0 12 2 7
Response (f) - 5 - 1
Response (g) - - - - - - - 2 - -
Total 31 31 31 31 31 31 30 31 31 31
Questions appear in appendix C.2 on page 255.
5.3 West Delphi round 1
Invitations to round 1 were sent on 16 January 2002 and the deadline for receipt 
of responses was 8 February 2002. The ten initial questions covered the fol­
lowing areas: clinical features; restrictions for age at onset; assessing develop­
mental delay; the usefulness of etiologic subgroups; the likelihood of reaching 
consensus on a definition of hypsarrhythmia; using aggregated data; defining 
developmental delay; and the interpretation of adverse effects. Round 1 ques­
tions are shown in appendix C.2 on page 255, and responses are shown in table 
5.2.
There were 31 responses, with contributors from the following countries: 
Australia, Canada, Germany, Hong Kong, Italy, Japan, Malaysia, Oman, Phillip- 
ines, Singapore, Switzerland, Thailand, the United Kingdom, and the United 
States. One-third of the responses were from Japan and 5 responses were from 
persons whose invitations were forwarded from other direct invitees. These 
responses were from Drs Lukban, Granata, Ortiz, Lee, and Stephani. One re­
sponse was received from four contributors who had discussed West Delphi 
round 1 questions in the context of a consensus document that they had pre-
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pared earlier. This was a German language document prepared by a group 
referring to itself as the Konigsteiner Kreis. These comments were treated as 
a single response in order to avoid undue influence of mutual contributors. 
One other response was a consensus of opinions from two contributors from 
one centre (Drs Avanzini and Granata) who were asked to respond individu­
ally to subsequent rounds. Three persons responded to Round 1 too late for 
their responses to be included in the analysis. These were Drs Neville, Caplan, 
and Liao. The full list of round 1 contributors is shown in table 5.1. This ta­
ble shows which contributors became final co-authors of the paper and which 
responses (in parentheses) were received too late to be incorporated into feed­
back to other contributors.
5.3.1 Round 1 responses to multiple-choice questions
More than half of the participants agreed that the clinical features of infantile 
spasms were well established (R1Q1) though some contributors included EEG 
features in their descriptions of what was intended to be restricted to clinical 
features. One contributor suggested the term epileptic spasms to describe the 
clinical features prior to any consideration of EEG features, and one suggested 
that clustering of spasms was a necessary feature for the syndrome of infantile 
spasms.
While a 1-year upper age limit was the most popular single choice for age 
at onset of spasms (R1Q2) there was relatively little agreement on this point. 
One third of contributors thought that infantile spasms should be diagnosed 
only if onset occurs before one year of age, and three fifths thought that a limit 
of either 1 or 2 years was appropriate. One sixth of contributors thought that 
there should not be any definitional upper age limit for onset of spasms. One 
contributor commented that 90% of cases have onset of symptoms by 1 year 
of age and that including cases with later onset might cause confusion with
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other conditions, and another suggested that there is little evidence that infan­
tile spasms occur after 2 years of age. One contributor suggested developing 
clearer guidelines about adjusting for gestational age, and one comment was 
that it would be useful to define subgroups for age at onset of spasms, with the 
terms: early (under 3 months of age), classic (3 to 12 months), and late (over 12 
months).
Overall, contributors tended to disagree with the statement (R1Q3) that de­
velopmental delay could be reliably timed and classified as preceding onset 
of spasms. Several participants suggested that age modifies the ability to as­
sess development, with particular difficulties below 3 months of age. Another 
comment was that the time of onset of spasms cannot be reliably determined, 
and that apparent developmental delay may in fact be due to unrecognised 
spasms.
Three fifths of contributors indicated (R1Q4) that they considered aetiolog- 
ical categorisation into the groups cryptogenic, idiopathic, and symptomatic, to 
be useful, though 1 in 10 disagreed strongly. Some participants commented 
that this classification is likely to depend upon the sensitivity of the investiga­
tive techniques used, suggesting that there would be a trend over successive 
periods towards a higher proportion being classified as symptomatic. One sug­
gestion was that symptomatic and cryptogenic groups should be collapsed into 
a single group and contrasted with non-symptomatic cases, since this might 
better reflect prognosis. One contributor advocated clarity in defining the tim­
ing of such classification by distinguishing a categorisation made at the time of 
diagnosis and initial treatment from categorisation made when the final diag­
nostic workup has been completed. One third of contributors agreed (R1Q5) 
that the distinction between cryptogenic and idiopathic cases can be made read­
ily and clearly, but few had strong responses to this statement and there was a 
tendency to disagreement with the statement.
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One third of contributors thought attempts to identify EEG features that 
are necessary and sufficient to define hypsarrhythmia (R1Q6) would be too 
ambitious, but over half thought that it was feasible. One suggestion was that, 
even if hypsarrhythmia cannot be reliably defined, specific features that are 
not those of hypsarrhythmia could be used to rule out West syndrome.
The question whether aggregated data from studies, such as meta-analyses, 
would be likely to help in making treatment decisions (R1Q7) was the only 
response for which there was greater than two-thirds agreement, and no con­
tributors disagreed strongly. This provided extra motivation for continuing 
with the attempts at consensus and standardisation since aggregating infor­
mation from different studies is greatly facilitated by standardised definitions 
and methodology.
Only one fifth of contributors thought that 7 or fewer days would be a suffi­
cient spasm-free period to define cessation of spasms (R1Q8). Two fifths thought 
that 1 month was an appropriate period, and one-sixth thought that the most 
appropriate period was two weeks. Fewer than half of contributors definitely 
agreed with the statement (R1Q9) that the presence of hypertension implies 
the occurrence of a serious adverse event.
Almost two thirds of contributors thought that developmental assessments 
(R1Q10) should take place at least as late as 5 years of age, and one-third of 
those preferred 12 years. Several contributors suggested that an assessment at 
age 12 years should include items that assess cognitive, social and school func­
tioning. Other contributors were interested in defining a neurodevelopmental, 
social and educational outcome based upon whether study participants are in 
mainstream or special schools at the age of 5 years.
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5.3.2 Round 1 responses to open questions
In addition to responses to these MCQs, there were many qualitative responses 
and suggestions that informed the design of questions in subsequent rounds. 
There were several requests for clearer definitions and consistent usage of the 
terms epileptic spasms, infantile spasms, and West syndrome, and for criteria to de­
fine what constitutes a clinical spasm. There were requests to define the ictal 
unit, and also to define the relationships between infantile spasms and other 
syndromes, such as early infantile epileptic encephalopathy (Ohtahara syn­
drome), Lennox-Gastaut syndrome, and partial epilepsy with periodic spasms 
(Gobbi syndrome). There were questions about classifying cases with hyp­
sarrhythmia but no clinical spasms, and about classifying cases with hypsar­
rhythmia and other seizure types. Several contributors asked about retaining 
or dropping the aetiological category cryptogenic. Others asked about retaining 
or dropping developmental delay at onset as a criterion for West syndrome. 
One suggestion was that developmental delay might be classified as autistic- 
type, impaired visual function, or motor.
Several contributors suggested exploring and summarising pathophysio­
logical hypotheses in the hope of formulating a succinct definition of infantile 
spasms. Other concerns relating to putative mechanisms were about the sig­
nificance of asymmetrical clinical spasms and of different clinical semiology 
(flexor, extensor, or mixed spasms). Several contributors were interested in 
defining a minimal set or an appropriate cascade of investigations for stud­
ies of infantile spasms, and ways to link these investigations with etiologic 
or prognostic classes of infantile spasms. One contributor suggested a mini­
mal set of investigations that would include ictal and interictal standard EEGs 
(with 12-hour EEG-video preferred) and MRI brain scan. One contributor was 
interested in prospectively measuring trunk, head and limb movements, and
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others were interested in the potential diagnostic role of EMG. One question 
related to appropriateness of different types of sleep EEG (sleep deprived, se­
dated, melatonin-induced) and several contributors wished to consider the 
prognostic value of EEG features.
One suggestion was that there should be 5 ordered categories of outcome, 
consisting of 3 levels of "success" and two levels of "failure". These suggested 
categories were: (1) seizure-free and normal EEG; (2) seizure-free, no hyp­
sarrhythmia, and no ictal EEG pattern; (3) no spasms, other seizure type(s) 
present, and no hypsarrhythmia; (4) seizure-free but persistent hypsarrhyth­
mia or continuous slow spike waves in sleep; and (5) persistent spasms. How­
ever, these classes mix clinical and electrographic outcomes and do not neces­
sarily follow a clear ordering. For example, is outcome (4) necessarily a better 
outcome than outcome (5), or would that depend upon the EEG pattern ac­
companying the clinical spasms?
Several contributors were interested in recommendations on treatment strate­
gies (specific first-line treatments; doses; add-on treatment; duration of treat­
ment; new AEDs; most appropriate treatments for developing countries). How­
ever, these ideas extended beyond those originally intended by the consensus 
process and were considered likely to considerably extend the time required 
for the process. One contributor wished to discuss the therapeutic role of pyri- 
doxine, and since pyridoxine has both therapeutic and diagnostic roles, this 
was considered an appropriate subject for address by West Delphi.
5.4 West Delphi round 2
In round 2, a specific request was made to recruit contributors from Africa, 
China and South America. However, we had few contacts in those regions 
and anticipated technical difficulties in delivering email. Also, we encouraged
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the participation of investigators from France which, from the time of Gastaut, 
has had a rich history of contribution to the study of infantile spasms. How­
ever, despite directly approaching one investigator and receiving a positive 
response, we ultimately failed to recruit any regular contributor from France.
Invitations to participate in round 2 of West Delphi were sent on 18 and 20 
February 2002, and the deadline for receipt of responses was 11 March 2002. 
The invitations were accompanied by feedback on responses to round 1. By 11 
March, 20 participants had responded. One of these, Dr Rating, did not pro­
vide full answers, but suggested that his responses would agree with those of 
Dr Schmitt. This response was not counted as an individual response, but Dr 
Rating was added to the respondent list. Three potential participants, one from 
each of France, the United Kingdom, and the United States, had expressed a 
keen intention to respond to this round, and two others had requested an ex­
tended deadline. On 14 March 2002, potential contributors were told that the 
deadline had been extended to 25 March 2002. Eight other responses were 
received, making a total of 27 responses to round 2. Six of these were con­
tributors who had not responded to round 1, one of whom sent a response 
to round 1 that was too late for analysis, and one other of which was Dr Rat­
ing's response (not counted as an independent response). A response from Dr 
Caraballo (Argentina) was received too late for inclusion in feedback.
5.4.1 Round 2 qualitative responses
The first section of round 2 sought qualitative comments and suggestions in 
several areas of study design (appendix C.3).
In response to R1Q1, the wording of the overview statement of infantile 
spasms, 10 contributors made no specific comments. Five said that they agreed 
with the statement without any amendments, and 6 suggested modifying or 
dropping the final sentence since they felt there is insufficient evidence that
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spasms originate from the subcortex. This area of the statement was the most 
contentious. One contributor suggested adding the statement: "Psychomotor 
arrest or retardation usually occur after onset of spasms." Another suggested 
changing "infantile spasms" to "West syndrome" and changing "epileptic spa­
sms" to "infantile spasms". One suggested that "two years old" should be 
changed to "one year old", and another suggested that onset should always 
be below two years of age. With respect to hypsarrhythmia, one respondent 
suggested qualifying the statement by adding the phrase, "which is usually 
found between attacks of IS," and also suggested adding the phrase, "and may 
be found only during sleep."
Suggested terms for the combination of clinical spasms with hypsarrhyth­
mia (R2Q2a) are shown in table 5.4. The mode choice was the term West syn­
drome. Suggested terms for the combination of clinical spasms with epilepti­
form EEG abnormalities but absence of hypsarrhythmia (R2Q2b) are shown in 
table 5.5. Suggested terms for clinical spasms with no evidence of EEG abnor­
mality (R2Q2c) are shown in table 5.6, and terms for the scenario of hypsar­
rhythmia with clinical spasms that occur singly but never in clusters (R2Q2d) 
are shown in table 5.7. Tables 5.8 and 5.9 respectively show agreement with 
suggested terms for the scenario of hypsarrhythmia with no observed clini­
cal spasms (R2Q2e) and for cases with clinical spasms that have not yet had 
an EEG (R2Q2f). Suggested terms for the overall spectrum of conditions with 
clinical spasms (R2Q2g) are shown in table 5.10. These responses indicated 
substantial heterogeneity in the terms participants were prepared to use when 
faced with different clinical scenarios, and also suggested that terms might be 
used to indicate entirely different scenarios. This illustrated the breadth of the 
problem relating to definitional terms and acted as additional motivation for 
the project.
Table 5.3: Responses to multiple-choice questions in West Delphi round 2.
Question number
8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 26 27 28 29 30
Response (a) 9 8 12 1 1 6 4 3 3 1 1 3 5 8 9 0 0 0 5 6
Response (b) 7 14 5 5 5 5 14 17 5 3 14 13 14 16 12 2 1 0 0 12
Response (c) 2 1 4 4 4 6 6 3 5 5 7 6 4 2 4 1 1 4 4 2
Response (d) 6 0 1 11 11 6 3 2 10 16 4 2 2 0 2 7 2 13 9 4
Response (e) 2 2 4 5 5 3 0 1 4 2 0 1 2 1 0 2 1 4 6 1
Response (f) 5 12 4 1 -
Response (g) 0 0 1 - -
Response (h) 9 8 - - -
Total 26 25 26 25 26 26 27 26 27 27 26 25 27 27 27 26 25 26 25 25









CHAPTERS. WEST DELPHI 181
Table 5.4: Responses to round 2, question 2(a): suggested terms for the combi­
nation of clinical spasms with hypsarrhythmia.
Suggested term tt
West syndrome1 11
Classical West syndrome 2
Infantile spasms 2
Infantile spasms with hypsarrhythmia 2
Epileptic spasms with hypsarrhythmia 2
Classical infantile spasms 2
West syndrome/infantile spasms 1
Typical infantile spasms 1
Clinical spasms with hypsarrhythmia 1
1Including West's syndrome (n = 1)
Table 5.5: Responses to round 2, question 2(b): suggested terms for the combination of clinical spasms with epileptiform EEG abnor­




Epileptic spasms without hypsarrhythmia 2
Infantile spasms without hypsarrhythmia 2
Epilepsy with clinical spasms 1
West syndrome without hypsarrhythmia 1
West syndrome 1
Infantile spasms with modified hypsarrhythmia or abnormal EEG 1
Probable infantile spasms 1
Clinical spasms without hypsarrhythmia 1
Myoclonic seizures 1
Other infantile epileptic spasms 1
Clinical spasms with multifocal interictal discharges or burst-suppression 1
Possible infantile spasms 1
Generalized epilepsy with periodic spasms 1
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The term West syndrome was popular as a description for the combination 
of clinical spasms with hypsarrhythmia. The term epileptic spasms was the most 
popular suggestion for cases with clinical spasms and an epileptiform but 
non-hypsarrhythmic EEG. There was disagreement about whether apparent 
spasms in the context of a normal EEG should be called spasms or myoclonus. 
Some contributors were prepared to use the term West syndrome for cases with 
no observed clusters of spasms, but rather only single spasms. However, some 
contributors stated that they would regard absence of clustering as atypical. 
In the feedback to this round, it was commented that the label atypical alone 
is non-specific, and one might wish to use a term such as single-spasm variant. 
Spasms and IS were equally popular choices to describe the spectrum of condi­
tions with clinical spasms. Several contributors thought that it was not useful 
to designate a term for cases with clinical spasms but no EEG.
In response to R2Q3, several contributors were keen to retain the terms id­
iopathic and cryptogenic, even though there was disagreement about what these 
terms might refer to. Many contributors considered cases with tuberous scle­
rosis (TS) to constitute a separate aetiological subgroup. In aggregate, sugges­
tions for main diagnostic subgroups were: tuberous sclerosis, other neurocuta- 
neous conditions, familial and genetic conditions, inborn errors of metabolism, 
hypoxic-ischemic encephalopathy, cortical dysplasia or other malformations, 
intrauterine infections. One contributor suggested using a classification sys­
tem such as the pediatric version of the WHO ICD-10 in order to define a hier­
archy of classes.
R2Q4 and R2Q5 were apparently challenging. The most commonly stated 
necessary feature was high-amplitude slow waves, most often stated with a 
threshold of 200 pV, sometimes 150 pV. Some suggested that this background 
should be described as "arrhythmic", "disorganized" or "chaotic", though 
these descriptions are themselves subjective and require further specification
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Table 5.6: Responses to round 2, question 2(c): suggested terms for clinical 






Spasms, nature undefined 1
Benign spasms 1
Clinical spasms with normal EEG 1
West syndrome 1
WS or IS with hypersynchronous activity on EEG 1
Myoclonic seizures 1
Generalized epilepsy with periodic spasms 1
d e lu d in g  the variants non-epileptic clinical spasms 
and non-epileptic spasms of infancy.
2Including the variant term benign myoclonus of infancy.
Table 5.7: Responses to round 2, question 2(d): suggested terms for the sce­




West syndrome -  single spasms 4
Atypical IS (or IS variant) 3
Atypical WS (or WS variant) 2
Infantile spasms 1
Single spasms 1
Malignant myoclonic seizures 1
CHAPTER 5. WEST DELPHI 185
Table 5.8: Responses to round 2, question 2(e): suggested terms for the scenario 






Hypsarrhythmia with no observed seizures 1
Hypsarrhythmia without IS (or ES) 1
Patient showing hypsarrhythmia 1
Epilepsy syndrome depending upon semiology 1
No clinical diagnosis 1
Table 5.9: Responses to round 2, question 2(f): suggested terms for cases with 
clinical spasms that have not yet had an EEG.
Suggested term n
Spasms (or spasms without EEG diagnosis) 4
Still undefined clinical spasms 2
Suspected West syndrome 2
Suspected infantile spasms 1
Infantile spasms 1
Clinical infantile spasms 1
Generalized myoclonic seizures 1
Table 5.10: Responses to round 2, question 2(g): suggested terms for cases with 
clinical spasms that have not yet had an EEG.
Suggested term n
Spasms (or spasms in childhood) 3
Infantile spasms (or IS NOS) 3





Spectrum of conditions with IS 1
Entities with generalized myoclonic seizures 1
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Table 5.11: Responses to West Delphi round 2, question 25: features considered 
sufficient to constitute relapse.
Clinical feature Number
agreeing
Spasms occurring in clusters 25
Spasms that do NOT occur in clusters 20
Occurrence of single witnessed spasm 10
Epileptic movements that are not spasms 10
Hypsarrhythmia without clinical seizures 15
Epileptiform EEG but no hypsarrhythmia 2
Abnormal EEG with no epileptiform features 1
or qualification in order to facilitate clear categorisation. The following were 
regarded as potential necessary features: asynchrony, multifocal spikes and 
sharp waves occurring randomly from all areas of cerebral cortex (though 
feedback to this round suggested that this defined feature would exclude hemi- 
hypsarrhythmia and that the definition might adopt the phrase "randomly 
from all areas of affected cortex" [my emphasis added]); periodicity with al­
ternating low-amplitude periods (as an alternative to a chaotic appearance); 
greater synchrony, diffuseness, burst-suppression and pseudoperiodicity dur­
ing sleep; electrodecremental responses; and absence of a sustained posterior 
rhythm.
Since there was a mode preference in round 1 (12/31 responses, table 5.2) 
for 28 days as being a standardised duration of spasm freedom to define a pri­
mary clinical response cessation of spasms, further views were canvassed on this 
definition (R2Q6). Most contributors agreed that this would be a reliable and 
useful outcome definition, though further qualification and information were 
sought by some respondents, such as how this outcome should be backed up 
with EEG evidence of resolution of hypsarrhythmia and with empirical evi­
dence about relapse frequency after certain periods of spasm freedom. One 
contributor commented that, compared with studies of other seizures, partic­
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ularly in adults, this would be a short duration of seizure freedom.
With respect to R2Q7, suggested specific tests of neurodevelopment were: 
ADI (Autism Diagnostic Inventory); Bailey test; Beery visual motor integra­
tion test; Bender Visual-Motor Gestalt test; Binet test; Conners' questionnaire; 
Denver Developmental Screening Test version 2; DISCO (Diagnostic Interview 
for Social and Communication Disorders); Goodman; Griffiths; Kaufmann; 
Illinois test of psycholinguistic abilities; Leiter International Scales; Motor- 
free visual perception test; "period of linguistic play"; Rey Complex Figure 
test; Spreen-Benton Mendilaharsu battery; Vineland Adaptive Behavior Scales; 
Wechsler, WPPSI (Wechsler Preschool and Primary Scale of Intelligence), and 
WISC or WISC-R (Wechsler Intelligence Scale for Children (Revised)). One 
participant suggested that each country might follow its own standard for de­
velopmental testing.
5.4.2 Round 2 responses to multiple-choice questions
The second part of round 2 took MCQ format. The questions are shown in 
appendix C.3 and the responses are shown in tables 5.3 and 5.11.
R2Q10 responses were scored by ranking, with 4 points allocated to the first 
preference. Three contributors chose (e) and made comments that they did not 
think an age-related classification was important. In rank order, the choices 
were: (d) 55.5 points; (b) 51 points; (c) 42.5 points; and (a) 41 points. The scores 
suggest that no single response was considered substantially more important 
than the others.
The rank order for response preferences to R2Q24 were: a, f, g, d, c, h, b, e, 
and the distribution of summed rank scores was: (a) 183; (f) 140; (g) 138.5; (d) 
131; (c) 125; (h) 123; (b) 56; (e) 53.5. Eighteen contributors either ranked time 
to cessation of spasms first (12 responses) or joint first (6 responses). Devel­
opmental outcomes ranked higher than serious adverse events. Several par­
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ticipants actively disliked time to 50% reduction in ictal units: one participant 
described it as "inane", and several participants gave it zero stars rather than 
one.
Responses to R2Q25, which suggested features that might be considered to 
constitute relapse, are shown in table 5.11. Spasms occurring in clusters was 
clearly considered to constitute relapse, and more than half of respondents to 
this round thought that non-clustered spasms and hypsarrhythmia without 
clinical spasms ought also to be considered sufficient to define one form of 
relapse.
5.5 West Delphi round 3
In round 3, contributors were invited to respond to 32 statements that rep­
resented majority opinions from earlier rounds, and to state whether they 
agreed with the statement, were unsure about it, or would prefer it to be 
amended. They were also asked to state whether they thought the statements 
should be included in the final West Delphi proposal. The first two statements 
each included a diagram illustrating putative definitional relationships be­
tween epileptic spasms, infantile spasms, West syndrome, clustered and non­
clustered spasms, and hypsarrhythmia (figures 5.1 and 5.2).
Twenty contributors responded to this round. Round 3 questions were dis­
tributed on 13 May 2002 and the deadline for responses was 10 June 2002. Only 
8 responses were received by that date, and a further 4 responses were received 
in the following 4 days. It was decided that an extended time for response was 
required but that, since round 4 would address issues that were independent 
in many ways from issues addressed in round 3, further responses to round 3 
could be sought while round 4 was being processed.
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Figure 5.1: Flow diagram showing classification of children with infantile 
spasms from West Delphi round 3.
CHAPTER 5. WEST DELPHI 190
This flow diagram suggests a classification for children with hypsarrhythmia 
identified at age less than 2 years:
Hypsarrhythmia without 









Infantile spasms -  
single spasms variant
with hypsarrhvthmia
* I f  spasms or clusters are not observed clinically, we recommend performing video 
EEG for a period o f at least 24 hours should be performed to reliably rule out their 
occurrence.
Figure 5.2: Classification of children with hypsarrhythmia without infantile 
spasms as it appears in West Delphi round 3.
Table 5.12: Responses to West Delphi Round 3.
Question number
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Response (a) 13 16 14 13 16 15 18 17 17 13 14 16 15 18 15 16
Response (b) 3 5 5 5 2 2 1 0 3 4 5 2 2 1 2 1
Response (c) 4 1 1 2 2 3 1 3 0 3 0 2 3 1 3 3
Question number
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Response (a) 19 15 19 16 14 14 18 18 18 14 14 6 18 18 14 14
Response (b) 1 5 1 4 5 2 2 0 1 2 2 7 0 1 5 3
Response (c) 0 0 0 0 1 4 0 1 0 3 3 6 1 0 0 2
Response (a) = "I generally agree with this statement"
Response (b) = "I am not sure about this statement"
Response (c) = "I disagree with this statement, and my reasons are . . ."
Statements appear in appendix C.4.
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Questions for this round appear in appendix C.4 and responses are shown 
in table 5.12. Only three contributors suggested statements to be excluded 
from the consensus. These statements were round 3 questions 3, 4, 6,12, 18, 
19 (twice), 20 (twice), 21 (twice), 23,29, and 31. Several contributors suggested 
that some statements should definitely be included -  presumably in order to 
prevent their exclusion should other contributors suggest that -  but did not 
suggest any exclusions.
5.6 West Delphi round 4
Round 4 presented modified statements, requesting comments on their con­
tent and suitability for the proposal. There were 22 responses after extension 
of the deadline from 30 September to 30 October, 2002. Five contributors were 
prepared to accept Round 4 statements, without any alterations, as the con­
sensus proposal. The statements associated with round 4 related to the areas 
shown in table 5.13.
Several contributors wanted a primary outcome that depended in part upon 
the follow-up EEG findings, and they indicated that they would not be happy 
to be part of a consensus that did not include this as part of the primary out­
come. One contributor commented that, since discussion concerned an epilep­
tic encephalopathy, an EEG response should be a mandatory element of a pri­
mary outcome measure. However, some contributors explicitly stated that 
they prefer clinical outcomes without EEG adjuncts, and it was felt inappro­
priate to simply drop the clinical primary outcome. This led to the adoption, in 
round 5 and the final consensus statement, of two primary outcomes: (1) the 
clinical primary outcome of cessation of spasms as previously defined; and 
(2) an electroclinical primary outcome that requires cessation of spasms and 
resolution of hypsarrhythmia.
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Table 5.13: Areas covered by statements in West Delphi round 4.
Area covered by statement
1 Rationale and aim of West Delphi
2 Constitution of the West Delphi Group
3 Definition of infantile spasms
4 Definition of West syndrome
5 Developmental delay at onset of spasms
6 Definition of infantile spasms single-spasm variant (ISSV)
7 Hypsarrhythmia without clinical spasms (HWIS)
8 Relationship between IS, WS, ISSV and HWIS
9 Flow diagrams associated with statement 8
10 Definition of clinical spasms
11 Subtle clinical events
12 Seizure type
13 Clinical spasms, epileptic spasms, and infantile spasms
14 Syndrome classification of infantile spasms
15 Ictal unit of infantile spasms
16 Definition of hypsarrhythmia
17 Modified and atypical hypsarrhythmia
18 Use of Electroencephalograms
19 Aetiological subgroups of infantile spasms
20 Idiopathic infantile spasms
21 Cryptogenic infantile spasms
22 Symptomatic infantile spasms
23 Problems with the terms in statements 20-22
24 Predisposed and non-predisposed subgroups (new terms)
25 Developmental delay at onset of spasms and aetiology
26 Timing classification into aetiological subgroups
27 Classification and reporting of prognostic factors
28 Developmental delay as a prognostic factor
29 Categories of age at onset of spasms
30 Types of intervention (randomised vs non-randomised)
31 Duration of treatment
32 Cessation of spasms as primary outcome measure
33 Essential EEG outcome measures
34 Essential adverse event outcome measures
35 Other important outcome measures
36 Time to cessation of spasms
37 Relapse of spasms
38 Pyridoxine-dependent seizures
39 Pyridoxine-responsive seizures
40 Aggregation of data from different studies
41 Areas for future consensus development
42 Summary of the consensus statement
Statements appear in appendix C.5.
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Another area for debate was the status of subtle movements and whether 
they should they be classified as "spasms" for the purposes of enrolment and 
outcome. One contributor suggested using the terms infantile spasms to refer 
to the seizure type and West syndrome to refer to the epilepsy syndrome. Some 
contributors pointed out that clinical spasms is a pre-axis 1 classification, since 
the recent ILAE proposal does not formally consider non-epilepsy movement 
disorders. A central issue was whether the spasms alone can be considered a 
syndrome (that is, "A distinct group of symptoms or signs which, associated 
together, form a characteristic clinical picture or entity." [Butterworths Medical 
Dictionary, 2nd edition]).
There were many other suggestions during this round. Some contributors 
suggested that the classification infantile spasms single-spasm variant (ISSV) with 
hypsarrhythmia be included as a form of West syndrome rather than as the 
more generic class of infantile spasms. In contrast, some contributors recom­
mended not including cases with single spasms and without hypsarrhythmia 
as ISSV. One contributor suggested that the consensus should include a fuller 
description of the clinical features of infantile spasms that would include men­
tion of clinical features such as flexion, extension, and asymmetry. One con­
tributor requested a fuller description of the EEG features that one might find 
in modified (atypical) hypsarrhythmia. One suggestion, made by two contrib­
utors, was that asymmetric EEG findings predict poorer prognosis, and this 
might be included as a prognostic factor; and another contributor suggested 
expanding the description of hypsarrhythmia by discussing the chaotic nature 
of both frequency and amplitude.
One participant suggested emphasizing the unreliability of timing onset of 
the disorder by using the term age when symptom first noticed in place of the term 
age of onset. Most contributors agree that it is hard to assess developmental de­
lay at onset, but several suggested that unequivocally normal development is
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a useful prognostic feature. Since misclassification is a major issue, some par­
ticipants recommend that studies do not over-emphasize classification based 
on development at apparent onset of spasms.
One response suggested that, rather than reporting relapse in primary re­
sponders, we ought to report the proportion of study subjects with relapse-free 
response. It is also suggested that we report seizure-free response (distinguish­
ing this from relapse) and that it would be appropriate to standardize these to 
ages 2 years and 5 years. It was suggested that it is clearer to report time to 
relapse from the time of randomization or start of treatment than from the time 
of clinical response.
Several contributors were not convinced that response to pyridoxine is rare, 
citing personal experience and non-randomised studies. Pyridoxine has been 
used to treat pyridoxine-dependent seizures and, in its own right and at high 
doses, as a treatment for infantile spasms. This invited further consideration 
of the methodological and practical issues associated with using pyridoxine in 
studies of infantile spasms. At the suggestion of two participants, an opinion 
was sought from an external expert, Dr Peter Baxter of Sheffield Children's 
Hospital, Sheffield on the role that might be played by pyridoxine.
Several participants were keen to describe subtle movements associated 
with appropriate ictal and interictal EEG changes as subtle spasms, and several 
participants put forward a strong argument for accepting subtle spasms as 
sufficient to constitute a form of relapse.
There was further discussion of aetiological subgroups, with some partici­
pants being keen to focus more on specific underlying diagnoses and to move 
away from subgroup analyses of aetiological subgroups composed of hetero­
geneous disorders. However, the aetiological subgroups idiopathic, cryptogenic 
(or probably symptomatic) and symptomatic remained popular and it was con­
sidered necessary to incorporate these forms of classification in the consensus.
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In an attempt to clarify inconsistencies in the use of the terms cryptogenic, 
idiopathic, and symptomatic, round 4 proposed new terms, predisposed and 
non-predisposed. Although some contributors were enthusiastic about these 
new terms, others disliked the idea of introducing new terms and they were 
dropped.
One contributor questioned strongly the methodological rigor of using a 
retrospective etiologic classification, particularly if we wished to perform sta­
tistical analyses, suggesting that if we wish to use information about etiologic 
subgroups to inform future treatment decisions, we ought to use the classi­
fication at time of randomization since reclassification of cases will create an 
information bias. However, it was also considered useful to use information 
about cases when a final underlying diagnosis and presumed cause has been 
more specifically determined in order to provide prognostic information relat­
ing to specific underlying causes.
5.7 West Delphi rounds 5 and 6
Round 5 consisted of a draft paper for submission as a final proposal from the 
West Delphi Group. These statements were similar to the final consensus state­
ment apart from some details discussed below, and they are not reproduced 
independently in this thesis. Round 5 included 42 statements and a cover let­
ter outlining areas of incomplete agreement and contention. The areas covered 
by these statements and the number of comments in response to each of these 
statements are shown in table 5.14.
In response to these comments, which were made by 11 contributors, and 
after discussion with Professor Osborne that did not reveal the identity of the 
individual contributors, the author corresponded directly with those contrib­
utors to clarify the remaining points of incomplete agreement. Contributors
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Table 5.14: Areas covered by statements in West Delphi round 5.
Area covered by statement Number of 
comments
1 Rationale and aim of West Delphi 0
2 Definition of infantile spasms 2
3 Definition of West syndrome 0
4 Developmental delay at onset of spasms 1
5 Definition of infantile spasms single-spasm variant (ISSV) 5
6 Hypsarrhythmia without clinical spasms (HWIS) 0
7 Subtle spasms and relapse 5
8 Relationship between IS, WS, ISSV and HWIS 2
9 Flow diagrams associated with statement 8 3
10 Definition of clinical spasms 0
11 Subtle spasms 3
12 Epileptic spasms as seizure type 0
13 Clinical spasms, epileptic spasms, and infantile spasms 0
14 Syndrome classification of infantile spasms 1
15 Ictal unit of infantile spasms 2
16 Definition of hypsarrhythmia 3
17 Modified and atypical hypsarrhythmia 1
18 Use of Electroencephalograms 3
19 Aetiological subgroups of infantile spasms 3
20 Idiopathic infantile spasms 2
21 Cryptogenic infantile spasms 5
22 Symptomatic infantile spasms 4
23 Problems with the terms in statements 20-22 1
24 Timing of aetiological classification 2
25 Specific aetiological categories (referenced to appendix) 1
26 Reporting of baseline characteristics 1
27 Age categories for time at onset of spasms 1
28 Duration of a sufficient therapeutic trial 1
29 Primary clinical outcome 0
30 Timing of EEG investigations 1
31 Resolution of hypsarrhythmia vs normalisation of EEG 1
32 Role of sleep EEG and 24-hour video-EEG 4
33 Primary electroclinical outcome 2
34 Roles of primary clinical and electroclinical outcomes 0
35 Reporting of deaths occurring during study period 0
36 Suggested outcome measures 3
37 Multiple subgroup analyses 0
38 Reporting time to cessation of spasms 1
39 Clinical relapse of spasms 0
40 Pyridoxine-dependent seizures 3
41 Pyridoxine as an adjunct treatment 3
42 Areas for future consensus development 0
Statements discussed in section 5.7.
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who still wished to amend the consensus statements were were asked to re­
spond within two weeks if they felt that we had not given sufficient or ap­
propriate consideration to their suggestions, or if we had misunderstood what 
they were trying to suggest. The collected and anonymised responses, with 
some explanation and clarification by the author, were then sent to all contrib­
utors.
West Delphi round 6 consisted essentially of seeking written approval and 
any final comments from the contributors in order to submit the paper for 
publication. There were no major dissenting views, though it was appreciated 
by many contributors that, for the sake of consensus, several of the expressed 
proposals -  and particularly definitions that required some arbitrary limits -  
would not have been their individual first choices. The final consensus state­
ment was published in Epilepsia and is reproduced in appendix D. The final 
suggested system of aetiological classification is shown in table 5.15.
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Table 5.15: West Delphi classification of aetiology.
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Enzyme deficiencies (e.g. Krabbe, Leigh, biotinidase)




Cerebral palsy (unknown cause only) G80-83
Porencephaly G93
Other (if not classified elsewhere; e.g. leukomalacia)
Cerebrovascular disease (not perinatal)
Cerebral haemorrhage 160-62
Cerebral infarct or stroke 163-64
Perinatal
Maternal factors (e.g. drug abuse) P04
Birth trauma (including HIE if due to trauma) P10-11
Intrauterine asphyxia (HIE) P20-21
Infections (e.g. meningitis, toxoplasma, CMV, herpes) P35-36
Intracranial nontraumatic haemorrhage
Transient endocrine or metabolic neonatal disease P70-74
Other (e.g. PVH/PVL) secondary to preterm injury P91
Hypoxic-ischaemic injury of uncertain cause
Congenital (non-chromosomal)















HIE = Hypoxic-ischaemic encephalopathy.
PVH/PVL = Periventricular haemorrhage and /or leukomalacia.
Chapter 6
Discussion
6.1 Summary of main findings in this thesis
Analysis of the primary outcome of UKISS, cessation of spasms, showed a sta­
tistically significant difference between hormonal treatments (prednisolone or 
tetracosactide) and vigabatrin. The 95% confidence range for the difference in 
effects (1% to 36%) provides evidence against vigabatrin being a superior treat­
ment with respect to this outcome measure, but it does not provide unequiv­
ocal evidence that hormonal treatments are superior. The secondary analysis, 
comparing prednisolone against tetracosactide, showed no significant differ­
ences in treatment effect, and in fact there was very little difference in the effect 
estimates for these two treatments.
Vineland Adaptive Behavior Composite scores at age 14 months were not 
significantly different in the hormonal treatment and vigabatrin groups, but 
the scores were significantly higher in infants allocated hormonal treatments 
in the subgroup of infants who had no identified underlying aetiology. How­
ever, this finding was borderline rather than robust, and a sensitivity analysis 
that included two cases who were not reliably classified into aetiological cate­
gories because of absent neuroimaging information, resulted in the difference
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in Vineland ABC score being no longer significantly different between the two 
groups.
The West Delphi consensus process led to the development of a consen­
sus statement that was agreed by 31 participants from 15 countries. There 
was clear agreement on many aspects of study design that have potential to 
improve and standardise future studies of infantile spasms. There was incom­
plete consensus and a limited statement on some aspects of study design re­
lating to infantile spasms, and in particular on the issue of definitions for EEG 
criteria.
6.2 Discussion of UKISS
In the mid-1990s, the first-line treatment of infantile spasms in the United 
States was ACTH, the most popular regimen being 40 iu /day  for 1-2 months 
[212]. In Japan, ACTH was generally used in smaller doses and as second-line 
or third-line treatment of infantile spasms, the most popular first-line treat­
ment being pyridoxal phosphate [213]. Neither the United States nor Japan 
have licensed vigabatrin, but vigabatrin has found popular use in Europe. In­
deed, even during the course of enrolment in UKISS, several letters were pub­
lished in the BMJ relating to recommended use of vigabatrin as a first-line, 
and indeed first-choice, treatment of infantile spasms, with responses from the 
UKISS trial steering committee that aimed to justify continued enrolment of 
cases in a randomised trial.
Since the UKISS study started to enrol participants, there has been a pub­
lished Cochrane Review on treatment of infantile spasms [214, 215] and an­
other review using, to some degree, an evidence-based methodology [216]. In 
addition, the American Academy of Neurology (AAN) and the Child Neu­
rology Society (CNS) have published recommendations, termed a "practice
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parameter", on the treatment of infantile spasms. Its summary states that:
Adrenocorticotropic hormone (ACTH) is probably effective for the short­
term treatment of infantile spasms, but there is insufficient evidence to 
recommend the optimum dosage and duration of treatment. There is in­
sufficient evidence to determine whether oral corticosteroids are effective. 
Vigabatrin is possibly effective for the short-term treatment of infantile 
spasm and is possibly also effective for children with tuberous sclerosis. 
Concerns about retinal toxicity suggest that serial ophthalmologic screen­
ing is required in patients on vigabatrin; however, the data are insufficient 
to make recommendations regarding the frequency or type of screening.
There is insufficient evidence to recommend any other treatment of in­
fantile spasms. There is insufficient evidence to conclude that successful 
treatment of infantile spasms improves the long-term prognosis.
And its final conclusion seems very conservative indeed: "ACTH is prob­
ably an effective agent in the short-term treatment of infantile spasms. Vi­
gabatrin is possibly effective." This practice parameter was published before 
the results of UKISS, and it is possible that our findings will lead to changes 
when a similar practice parameter is next produced. For example, a new prac­
tice parameter might interpret UKISS findings as evidence that high-dose oral 
steroids have similar effect to intramuscular ACTH preparations; or it might 
suggest that there is now cumulative evidence that, in non-TSC cases of in­
fantile spasms, hormonal treatments have proven superiority over vigabatrin 
as first-line treatment with respect to early cessation of spasms, and possibly 
with respect to neurodevelopmental outcomes in cases with no identified un­
derlying aetiology. However, the generally conservative tone of the earlier 
recommendation would make such a strong interpretation unlikely.
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6.2.1 Comparison of UKISS findings with other studies of
hormonal treatments against vigabatrin
The difference in the proportions with cessation of spasms in hormonal treat­
ment and vigabatrin groups was similar to those found in the smaller study 
by Vigevano and Cilio, although that study was smaller and the difference 
was not statistically significant. As discussed in section 1.12.2 and in the trial 
steering committee's earlier letter to the BMJ, the proportions with cessation 
of spasms before 20 days were 14/19 (74%) in the ACTH-treated group and 
11/23 (48%) in the vigabatrin-treated group, a difference in treatment effect of 
26%, with a 95% confidence interval for that difference from -3% to 54% [188].
Cossette et al published a retrospective study of 42 children with infantile 
spasms with some excluded cases. They reported an initial response to ACTH 
in 18/21 (86%) infants, and to vigabatrin in 16/21 (76%), with relapse in 4/18 
and 0/21 infants in the respective treatment groups [217]. An erratum to this 
paper was published after the author of this thesis and Dr F.J.K. O'Callaghan, 
both members of the UKISS trial steering committee, sent a letter to the editor 
of Neurology. The editor of Neurology did not wish to publish the criticism 
that reassurance about absence of visual impairment in children of this age 
was invalid, though did not state a compelling reason for this. He did agree 
to publish an erratum relating to the repeated statistical testing without an 
appropriately more conservative P-value, but he suggested that associating 
oneself with an erratum, even as though the researcher bringing the error to 
light, was unwise, and we agreed not to be acknowledged in this respect.
In the erratum, Cossette et al acknowledged that the statistical method used 
to evaluate the differences between both groups should have been the Fisher 
exact test rather than the chi-square test (owing to the small number of indi­
viduals in certain groups). Hence, the differences in relapse rates were not
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statistically significant, with P values at 3, 6, and 12 months of 0.11, 0.10, and 
0.17, respectively. The erratum also stated that the authors of the paper by 
Cossette et al did not suggest that vigabatrin is superior to ACTH, but that it is 
"their drug of first choice because of its more favorable side-effect profile when 
used over a 12-month period for the control of infantile spasms."
6.2.2 Comparison of UKISS findings with other studies of 
vigabatrin
Early reports of add-on treatment suggested that vigabatrin is more effective 
in symptomatic infantile spasms. Aicardi et al retrospectively reviewed 250 
cases of infantile spasms, 196 of whom were considered to have "classic IS", 
and reported initial clinical response in 131/192 (68%) of cases with relapse in 
28/131 (21%) [167,168]. However, the primary clinical response used in these 
reports was not clearly defined.
Several later studies have reported vigabatrin to be generally more effective 
treatments of non-symptomatic than of symptomatic infantile spasms. Two 
larger non-randomised studies have reported response in 24/82 (29%) and 
15/39 (38%) of symptomatic cases, and 21/34 (62%) and 22/31 (71%) of non- 
symptomatic cases [78, 218]. Wohlrab et al reported initial response, defined 
as resolution of both spasms and hypsarrhythmia, to vigabatrin treatment in 
14/28 (50%) of infants [219]. There were reported to be no relapses in this 
treatment group. This same research group has reported four children with 
Angelman syndrome who showed worsening of seizures within several days 
of reaching maximal dose treatment with vigabatrin [220]. Granstrom et al re­
ported response in 11/42 (26%) of infants given vigabatrin, with one case later 
relapsing [221].
Symptomatic cases whose underlying cause is tuberous sclerosis seem to
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respond better to treatment with vigabatrin than symptomatic cases with other 
underlying causes. However, one group of investigators have reported a high 
rate of relapse in cases with tuberous sclerosis whose first-line treatment was 
vigabatrin alone, and they excluded children with tuberous sclerosis from a 
later study of vigabatrin monotherapy because of this relatively high risk of 
relapse of spasms [218].
Two randomised studies of vigabatrin for the treatment of infantile spasms 
were reported after UKISS started to enrol participants. Appleton et al re­
ported a placebo-controlled trial of vigabatrin, with the primary clinical out­
come being absence of reported spasms on study day 5 [95]. And Elterman et 
al reported outcomes on 142 infants treated with vigabatrin at either high-dose 
(100-148 m g/kg/day) or low-dose (18-36 m g/kg/day) [222].
Appleton et al reported a significant difference in the outcome reduction in 
spasms compared with baseline: 78% (95% Cl 55% to 89%) for vigabatrin com­
pared with 26% (-56% to 65%) for placebo, with a reported P-value of 0.02. 
However, cessation of spasms was reported in 7/20 (35%) of infants allocated 
vigabatrin compared with 2/20 (10%) of those allocated placebo, a difference 
that is not statistically significant. The P-value cited for this difference in pro­
portions with reported cessation of spasms is the value obtained from a one­
sided Fisher exact test, but a two-sided test would arguably be more appro­
priate -  and is conventional in clinical studies -  and this yields P = 0.13. The 
chi-square value is also insignificant: P = 0.06.
The infants in the study of Elterman et al were selected from 179 infants 
allocated randomised treatment with "high-dose" or "low-dose" vigabatrin. 
The high-dose regimen would be considered a standard regimen in Europe. Of 
these infants, 167 received vigabatrin, and outcomes were known 142. Six in­
fants were given an incorrect initial dose of vigabatrin, 3 infants in each of 
the high-dose and low-dose groups. Analysis was made by intention to treat,
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with the proportion responding to high-dose vigabatrin, 24/67 (36%), being 
lower than that in UKISS but similar to that in the study of Appleton et al; and 
with reported responses in the low-dose vigabatrin group in 8/75 (11%). This 
difference is statistically significant (x2(l) =  12.8, P < 0.001).
A published criticism of this paper was made by members of the UKISS 
steering committee [223]. This response credited the study as being a signifi­
cant advance in the study of infantile spasms, being substantial in size, clearly 
defining response and relapse both clinically and electrographically, and using 
survival analysis (actuarial) techniques. However, the trial steering committee 
criticised several aspects of the analysis performed by Elterman et al. Out­
comes were reported on only 142/179 (70%) of cases, with 16 missing obser­
vations from those allocated high-dose vigabatrin and 9 observations missing 
from those allocated the low-dose regimen. In a further 10 cases, it was not 
known which dose had been allocated, and 2 cases were known not to have re­
ceived the randomly allocated treatment. The number of missing observations 
(37) is substantial compared with the overall number of responders, which 
was 32, and certainly large enough to introduce substantial bias. A sensitivity 
analysis was not performed. Of those with an underlying diagnosis of tuber­
ous sclerosis, 13/25 (52%) had cessation of spasms, but it was not clear from 
the paper how many responders were in high-dose or low-dose groups. Only 
19/117 (16%) of cases with other underlying aetiologies, either identified or 
unidentified in the paper, responded to high-dose or low-dose regimens. The 
reported responses over the 3-month period of follow-up could be due to con­
comitant treatments other than vigabatrin, about which no information was 
included in the paper. The study claimed to confirm both safety and efficacy 
of treatment with vigabatrin, whereas the view of the UKISS steering commit­
tee was that there are no reliably validated methods for assessing visual field 
losses, which are probably the most likely serious adverse effect, and that the
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safety of vigabatrin cannot be confirmed in this respect.
6.2.3 Comparison of UKISS findings with other studies of 
prednisolone against tetracosactide
The comparison of prednisolone against tetracosactide in UKISS was substan­
tially underpowered. Even if 250 children had been recruited, as had been 
intended in the study protocol, the power to detect a significant difference be­
tween these two treatment arms would have been only 55%. However, the 
point estimates for the treatment effects measured as cessation of spasms, 70% 
and 76% for prednisolone and tetracosactide respectively, are very similar and 
it seems unlikely that, with these particular treatment regimens, a significant 
difference would have been found if the study had recruited the originally 
planned number of participants. In addition, the two cases that were randomly 
allocated tetracosactide but in fact received prednisolone both responded with 
cessation of spasms, such that an analysis by treatment actually received rather 
than by intention to treat gives an even smaller difference in effects of 23/32 
(72%) for prednisolone versus 17/23 (74%) for tetracosactide.
No previous studies have compared prednisolone against tetracosactide 
in the treatment of infantile spasms, but other studies have compared other 
ACTH and corticosteroid regimens, as discussed in section 1.12.1. The study 
of Baram et al showed a significantly higher response to treatment with ACTH 
at a dose of 150 m g/m 2/day  than with prednisolone at a dose of 2 m g/kg /day  
[182]. In the ACTH-treated group, 13/15 had cessation of spasms and resolu­
tion of hypsarrhythmia, and one of the two non-responders had cessation of 
spasms but unresolved hypsarrhythmia. In the prednisone-treated group, only 
4/14 infants had both cessation of seizures and resolution of hypsarrhythmia 
at 14 days. The differences in primary response are statistically significantly
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(X?1} = 10.1, P < 0  .002). Although there was a good response to treatment 
with ACTH in those participants who failed initial treatment with prednisone 
(8/9 had cessation of spasms and resolution of hypsarrhythmia within 14 days 
compared with one of two who had changed to treatment with prednisone) 
no clear conclusion can be drawn from these cases that had received a sec­
ondary treatment since the numbers are small, there was no washout period 
before starting the second treatment, and the effects of hormonal treatment 
may be delayed. However, the dose of prednisolone used in UKISS was sub­
stantially higher than that used for prednisone in the study of Baram et al, and 
one a priori hypothesis in UKISS was that this relatively higher dosage regimen 
would better mimic the effects of potent adrenocorticotropic activity and lead 
to a reduction in differences in effect. The study of Baram et al concluded that 
high-dose ACTH is a better treatment than "standard" doses of prednisone. It 
also discussed the potentially low value of assessing developmental outcome 
with this study design, in which non-responding participants were exposed to 
the alternative treatment, but this criticism of measuring neurodevelopmental 
outcomes is not fully justified (see section 6.2.4).
The study of Hrachovy et al used a smaller dosage regimen of ACTH and 
was relatively underpowered, but like UKISS it did not find any significant 
difference between ACTH and corticosteroid regimens [93]. The primary out­
come was cessation of spasms and resolution of the EEG pattern of hypsar­
rhythmia at 14 days. The numbers responding were lower than in the earlier 
studies: 5/12 in the ACTH group and 4/12 in the prednisone group. After 
a further 4 weeks of failed treatment and a one-week drug washout period, 
non-responders were treated with the alternative drug. At that time, 4 /8  re­
sponded to ACTH, and 3 /7  responded to prednisone. Relapse occurred in 
5 participants, 3 in the ACTH-treated group and 2 in the prednisone-treated 
group. All of these responded to a further two-week course of treatment with
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the original drug. Hypertension was not clearly defined, but was reported to 
occur in 4 participants treated with both trial drugs, and in 2 participants who 
had been treated with prednisolone only.
As discussed in section 1.12.1, the study of Snead et al did not have ran­
domly allocated treatments, blinding, or a clear definition for the primary clin­
ical outcome. Of the 116 children in the study, 52 (45%) had infantile spasms 
with hypsarrhythmia and 30 (26%) were described as having "infantile spasms 
-  myoclonic seizures [without] hypsarrhythmia/' In the former group (in­
fantile spasms with hypsarrhythmia) seizure control was reported in 30/30 
(100%) of infants treated with ACTH and 13/22 (59%) of those treated with 
prednisone (xf^ = 14.8; P  < 0.001). The proportions with seizure control 
in the latter group (infantile spasms or myoclonic seizures without hypsar­
rhythmia) were 13/16 (81%) with ACTH and 0/14 (0%) with prednisolone 
(X(i) = 20.1; P  < 0.001). These are substantial differences, despite the rel­
atively higher dosage regimen of prednisone compared with previous stud­
ies. Also, the response rates to ACTH (100% and 81% in the hypsarrhythmia 
present and absent groups respectively) are high compared with other stud­
ies. The findings are not consistent with those of UKISS. Any reasons for the 
different findings in this study are speculative, but it is possible that there was 
substantial selection bias, or simply that the differences and unusually high 
response rates to ACTH treatment are due to chance.
6.2.4 Neurodevelopmental outcomes
UKISS is the first randomised controlled trial of infantile spasms to systemati­
cally measure neurodevelopmental outcomes. One benefit of Vineland Adap­
tive Behavior Scales is that the interview can be performed by telephone by a 
trained researcher. Given that the final number of participants in UKISS was 
less than half the number intended in the study protocol, it is perhaps sur-
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prising that there was found to be a significant difference in developmental 
outcomes in those infants with no identified underlying aetiology, the group 
that a priori was thought to be most likely to show any effect of treatment upon 
neurodevelopment. However, the fact that the sensitivity analysis including 
only two further observations that were not reliably classified into aetiological 
groups removed the statistical significance of this finding illustrates that the 
finding is borderline rather than robust and might have been due to chance. 
However, the size of the difference in Vineland ABC score is potentially clin­
ically important, and the 95% confidence interval for this difference ranged 
from a minimal difference to one that was slightly greater than one population 
standard deviation.
In UKISS, we hypothesized that any difference in neurodevelopmental out­
come would be most readily identified in the subgroup of infants with no iden­
tified underlying aetiology for two reasons. First, there was no proven reason 
for these infants' development to be affected by any underlying neurological 
disorder. And second, because it would be more likely that this group would 
have had a normal potential for development prior to the onset of the spasms.
If cessation of spasms at day 14 and better neurodevelopmental outcome 
are causally related, then hormonal treatments may be the better first treat­
ment, despite their higher relapse rate and despite the fact that, in this study, 
overall hormonal treatments were not associated with better neurodevelop­
mental outcome. This hypothesised relationship between early cessation of 
spasms and better neurodevelopmental outcomes provide justification for mea­
suring later neurodevelopment and analysing the findings by intention to treat 
analyses, despite potential bias that might occur do to exposure to other med­
ications in those who do not have initial cessation of spasms or who later relapse. 
Any bias introduced by such later exposures is likely to act as a dilutional bias 
that reduces the magnitude of any true effect. It is likely that there are other
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underlying biasing or confounding factors relating to case-mix, such as dura­
tion of spasms before treatment and underlying aetiology.
A Cochrane review of studies has found equivocal evidence suggesting 
that the administration of steroids to neonates might have a deleterious effect 
upon later neurodevelopment [224]. In this respect, it is reassuring that UKISS 
showed no evidence of poorer neurodevelopmental outcomes in infants re­
ceiving hormonal treatments.
Fourteen months is an early age at which to assess neurodevelopment and 
may not reliably reflect cognitive function later in life. Any differences might 
become more marked as further development takes place. However, as in­
fants get older, social and environmental factors that are not so important at 
14 months, such as parental educational level, increasingly influence develop­
ment, and we did not stratify our groups to account for this. In addition, par­
ents and professionals do not want to wait too long before knowing if there is 
evidence to suggest that early control of spasms might influence development. 
Because of our findings relating to development at 14 months of age, it is im­
portant to know whether any difference between treatment groups persists. 
UKISS has since been extended with further neurodevelopmental assessments 
being made at the age of school entry on children whose parents consent to 
further assessment. This is technically a separate study and has required de 
novo consent from the parents.
6.2.5 Effects of delayed treatment upon neurodevelopmental 
outcome
Kivity et al reported findings from a non-randomised group of children with 
cryptogenic infantile spasms and assessed their cognitive outcomes using a 
Hebrew revised version of the Wechsler Intelligence Scale for Children (WISC-
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R) [225]. There was a standardised treatment regimen of tetracosactide depot 
in reducing doses over 10 to 12 weeks (1 mg IM alternate days for 2 weeks, then 
every 3 days for 2 weeks, then weekly for 4 to 6 weeks, then 0.5 mg weekly for 2 
weeks) followed by a second stage of oral prednisone (10 mg daily for 1 month, 
then 10 mg alternate days for 2 months, then 5 mg alternate days for 2 months, 
then 2.5 mg alternate days for 1 month or until aged 12 months, whichever is 
later). This is a larger tetracosactide dose and substantially longer treatment 
regimen than that of the UKISS study protocol.
They described normal cognition in all 22 infants who received treatment 
within one month of apparent onset of spasms but in only 6/15 infants who 
were not treated before the spasms had been present for over one month. Poor 
cognitive function at the time treatment started was also reported to be a pre­
dictor of subsequent poor cognitive function.
Eisermann et al reported a retrospective study of 18 children with infan­
tile spasms and Down syndrome, with a statistically significant correlation 
between lead-time to treatment (which they referred to as "treatment lag") 
and several outcomes: time to cessation of spasms (Pearson r = 0.55, P = 0.02); 
developmental quotient (r = -0.75, P = 0.003); and a score of autistic features 
(AF) (r=0.57, P = 0.04) [226]. They also reported a correlation between later 
response to treatment and lower developmental quotient (r = 0.86, P = 0.001) 
and with the higher score of autistic features (r = 0.5, P = 0.06). The strongest 
correlation was between longer duration of spasms and lower developmental 
quotient (r = -0.93, P < 0.0001).
Using a one-month reported duration of spasms prior to treatment inter­
vention as a threshold do define a dichotomous variable, lead-time to treatment, 
data from UKISS did not show a significant relationship between shorter lead- 
time to treatment and better neurodevelopmental outcome, either in an overall 
analysis or in an analysis stratified by presence or absence of an underlying
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aetiology 4.3.2. However, the direction of the differences in mean scores in 
these groups was the same as that in the studies of Eisermann et al and Kivity 
et al, and there is a strong biological plausibility to the argument that longer 
duration of spasms before effective treatment intervention is associated with 
poorer neurodevelopmental outcomes.
6.2.6 Value of pre-randomisation stratification variables
The pre-randomisation stratification variables are described in section 5 of the 
UKISS study protocol (appendix B.l, page 246). The sex and age category vari­
ables are explicit and relatively simple. The third pre-randomisation strati­
fication variable is a composite of factors that were thought to be likely to be 
associated with poorer prognosis for developmental outcomes. This third vari­
able was coded yes if there was any one or more of: several current diagnoses 
(syndromic, chromosomal, or cerebral palsy); a previous diagnosis (neonatal 
encephalopathy with seizures); or a diagnosis of developmental delay made 
before onset of spasms. In the context of discussions in West Delphi about the 
potential unreliability in assessing the time of onset of spasms, the last factor 
in this composite third variable might be misclassified in a high proportion of 
cases.
6.2.7 Administrative delays
There were substantial delays in the administration of the study relating to the 
need to obtain ethical approval from LRECs in addition to the approval given 
by the MREC; by the need for management approval; and by the reviews and 
changes to licensed indications for the trial treatments that occurred during 
the conduct of the study. It might be regarded as bad luck that one of the tried 
treatments, vigabatrin, underwent a substantial review of safety after the re­
CHAPTER 6. DISCUSSION 214
ports of its association with peripheral visual field defects, and such a major 
review might be anticipated not to occur during future studies. However, this 
series of events serves to emphasise the importance of systematically compar­
ing new drugs, no matter how popular and apparently effective they appear to 
be, against more established drugs. I believe that, during the time that UKISS 
was recruiting centres and enrolling participants, the recognition of potentially 
serious adverse effects associated with vigabatrin served to shift a balance of 
preference among many clinicians back to a position of equipoise of prefer­
ence between hormonal treatments and vigabatrin. However, there remained 
strong opinions on that matter, as is evident from correspondence appearing in 
the BMJ from an advisory group that had reassessed the indications for use of 
vigabatrin [227,228] and the UKISS trial steering committee [188,229]. There is 
no evidence that such administrative tasks have become easier since the time 
UKISS started to enrol participants, and indeed the procedure for obtaining 
ethical approval in member countries of the European Union has become stan­
dardised in a fashion that many investigators, including members of the UKISS 
trial steering committee, regard as more onerous than before.
6.2.8 Discussion of response times of local research ethics 
committees
The methods for obtaining informed consent for clinical trials, and particu­
larly for obtaining consent from parents or guardians of children participating 
in clinical trials, was a contentious issue at the time this study was conducted. 
It was becoming accepted that a single signed document is not adequate proof 
that consent has been obtained and maintained, and that clinical investigators 
ought to provide some method for ensuring that information is given to carers 
and permission to continue the research is granted continually. Since no for­
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mal method for ensuring continual consent had been developed, the United 
Kingdom Infantile Spasm Study provided regular newsletters for carers.
The two-tier system of ethical approval by MRECs and LRECs has left room 
for interpretation of their roles. Our experience was that the MREC and LRECs 
disagreed in several cases about whether the LREC was entitled to request 
changes to patient information sheets with respect to an issue that was not 
peculiarly local. In several cases, these different interpretations led to an im­
passe in which the MREC did not recommend an amendment suggested by 
an LREC, and the LREC refused to approve the study without the amendment 
being made [204]. There are obvious inefficiencies associated with a system of 
dual ethical approval, but there will always be a need for local input into eth­
ical decisions. Alberti wrote a BMJ editorial that accompanied the publication 
of the UKISS paper on times taken for ethical approval, revisiting questions 
he had asked in an editorial preceding the introduction of MRECs [230, 231]. 
Asking whether cure had been worse than the disease, he concluded that the 
two-tier system is better but that the main problems resided at the interface 
between MRECs and LRECs, and that simple methods, such as the standardis­
ation of application forms, would be effective in removing many of the definite 
obstructions to research.
6.2.9 Adverse events
Randomised controlled trials of treatment are not the best way to collect data 
about rare but serious adverse events because the numbers enrolled are rel­
atively small. The five deaths reported before the age of 12 months are con­
sistent with the natural history of infantile spasms. One death (study death 
1 described on page 163) was considered to have been in part attributable to 
treatment with prednisolone, but he had been allocated vigabatrin at the time 
of enrolment and had not responded with cessation of spasms. The certified
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cause of death was Staphylococcus aureus septicaemia, and it was considered 
that the recognition of clinical signs of septicaemia was delayed as a result of 
the corticosteroid treatment.
The findings of higher reported rates of irritability with hormonal treat­
ments and drowsiness with vigabatrin are not surprising, since these are recog­
nised adverse effects associated with these treatments. The P-vaiues cited in 
section 3.5.2 are not adjusted for multiple testing, but informally they provide 
evidence that there are differences in the frequency of these adverse effects be­
tween treatment groups. Other adverse events were less common and, because 
of the study size, statistically significant differences would not be expected 
even where true differences exist.
6.2.10 Potential roles of chance and bias in UKISS
As with any study, it is possible that the differences detected -  both in cessa­
tion of spasms at study day 14 and in neurodevelopment in the subgroup with 
no identified underlying aetiology -  were due to chance. However, in UKISS 
the proportion of infants allocated vigabatrin that had cessation of spasms was 
higher than that reported in the randomised studies of Appleton et al and El­
terman et al, making it unlikely that the vigabatrin effect estimate was lower 
than the true effect by chance. This is in the context of the UKISS randomised 
trial excluding cases with known or likely tuberous sclerosis, a condition that 
is generally considered to respond better to vigabatrin than other symptomatic 
cases of infantile spasms. If there were significant bias introduced by this ex­
clusion criterion, one would have expected the effect estimate for treatment 
with vigabatrin to have been lower, rather than higher, in UKISS than in these 
other two studies.
The proportions with cessation of spasms in hormonal treatment and vi­
gabatrin groups were similar in UKISS to those reported by Vigevano and
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Cilio, which is the only other published randomised controlled trial compar­
ing adrenocorticotropic hormones with vigabatrin. This repeatability suggests 
that the estimate of differences in effect is unlikely to have occurred by chance.
The potential absence of any role of chance and bias is less certain with 
the other main finding: that neurodevelopmental outcome is better in infants 
allocated hormonal treatment than vigabatrin in the subgroup with no iden­
tified underlying aetiology. Most notably, the significance of the difference 
was not sufficiently robust to withstand a sensitivity analysis that included 
only two observations that did not have reliable aetiological classifications. As 
described on page 147, one of these observations was an infant allocated vi­
gabatrin that had a Vineland ABC score of 93 and thus increased the average 
score for vigabatrin in this group. The other case was allocated tetracosac­
tide and had a a Vineland ABC score of 57, decreasing the score for hormonal 
treatments. Neither of these cases had had neuroimaging studies. The case 
allocated vigabatrin was considered by his parents to be too well to merit neu­
roimaging, which would involve exposure to ionising radiation (for CT scan) 
or, at his age, would probably require a general anaesthetic (for MRI scan). It 
is likely that he was a genuine idiopathic/cryptogenic case and that no under­
lying aetiology would have been found if neuroimaging had been performed. 
The case allocated tetracosactide died before any diagnosis was made and the 
parents did not give consent for a post-mortem pathological or radiological 
examination. It is likely that this case would have had an identifiable under­
lying cause if such investigations had been performed, and it could be argued 
that the sensitivity analysis was in this respect unfair to hormonal treatments. 
However, creating the most extreme case against the effect found is the pur­
pose of sensitivity analyses, and the effect found was at the margin of signif­
icance at the 5% level. The appropriate interpretation is that this finding is of 
scientific interest and invites further investigation, but is itself non-robust.
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The direction of the difference in neurodevelopment is different in the other 
subgroup of infants with an identified underlying aetiology, and there is no 
ready explanation for this. It is possible that infants with symptomatic aetiolo­
gies are more likely to progress to other seizure types and that treatment with 
an antiepileptic drug, such as vigabatrin, throughout this critical period is as­
sociated with better neurodevelopmental outcome because of an effect upon 
clinical or subclinical seizure control. However, this is speculative and the dif­
ference is not statistically significant. Approximately half of infants allocated 
hormonal treatments received vigabatrin before the end of the study, and vice 
versa. This means that there would be dilution of any true difference in treat­
ment effect because of the differential exposures to treatment.
The finding that cessation of spasms was significantly associated with bet­
ter neurodevelopmental outcome independently of randomised treatment is 
difficult to interpret. Any effect of randomised treatment would presumably 
be mediated by earlier cessation of spasms, or at least this would be the most 
likely mode of mediation. The finding cannot be interpreted as suggesting a 
chance selection bias in favour of the hormonal treatment since they are not 
independently predictors of better neurodevelopmental outcome in the over­
all study sample. The opinion of the UKISS steering committee is that these 
findings are not robust and merit replication or further testing in future stud­
ies; and later study of the current trial cohort is being undertaken to examine 
whether the apparent effects upon neurodevelopment are sustained. The rela­
tively small sample size precludes valid use of logistic regression methods to 
adjust more fully for the effects of potential prognostic factors upon the cessa­
tion of spasms outcome.
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6.2.11 Validity and generalisability of findings from UKISS
UKISS used an effectiveness study paradigm, as discussed in section 2.1.3. In 
this respect, generalisability to cases of infantile spasms diagnosed clinically 
in the United Kingdom is probably good, although there might be substantial 
differences in case definitions and required EEG features in specific centres. 
However, generalisability cannot be made to the group of infants whose un­
derlying aetiology was tuberous sclerosis, since these were excluded from the 
randomised controlled trial. It is interesting that, although vigabatrin is gener­
ally considered to be particularly effective in the treatment of infantile spasms 
when the underlying aetiology is tuberous sclerosis, the treatment effect ob­
tained in UKISS was better than that in other randomised studies that included 
cases with tuberous sclerosis [95,222].
6.2.12 Methodological and procedural insights from UKISS
There were substantial delays in the administration of the study that related 
to ethical approval and reappraisal in the light of new safety findings, and the 
administration of trust management approval for the study. Also, accrual of 
study participants was slower than predicted. It is possible that some cases 
were not reported because local investigators forgot, during the course of a 
relatively long study, to notify them. We were aware of several cases where 
the local investigators' colleagues were not immediately aware or mindful of 
the study when new cases presented, leading to later notification. However, 
the greatest procedural insight from UKISS was the realisation that there is 
substantial heterogeneity in case definitions and outcome measures between 
studies of infantile spasms, an insight that led to the development of the West 
Delphi consensus statement.
The study would have been methodologically sounder if neurodevelop-
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mental assessments had been made by an assessor who was more effectively 
blinded to the treatment intervention, but this could not be incorporated reli­
ably into the study design. In practice, it is unlikely that this interfered signifi­
cantly with the assessment because sufficient time had passed between allocat­
ing treatment and performing the assessment that the assessor's knowledge of 
the trial treatment in any particular case was poor. Further assessment of the 
reliability of these findings will be possible with later neurodevelopmental as­
sessments.
UKISS excluded cases with proven or likely tuberous sclerosis from the ran­
domised controlled trial. The rationale for this exclusion is discussed in section 
2.3.2. It was intended that cases with tuberous sclerosis would be enrolled in 
the non-randomised element of the study, but accrual of such cases was slow. 
The preamble to the UKISS study protocol, under the heading Epidemiology, 
clearly states that some patients excluded from the drug trial would be eligible 
for the non-randomised element of the study, but this did not make specific 
reference to tuberous sclerosis. The exclusion of tuberous sclerosis cases takes 
a prominent position in the UKISS study protocol, occurring at the head of 
section 2 (see page 245). These factors probably combined to lead some lo­
cal investigators to think that cases with tuberous sclerosis did not need to be 
notified to the UKISS trial centre.
There is no evidence that exclusion of cases with tuberous sclerosis led to 
significant bias in findings, as is discussed in section 6.2.10. However, it is in­
teresting to note from analysis of the data on non-randomised cases that, even 
though vigabatrin was prescribed more frequently than hormonal treatments 
overall in non-randomised cases, 4/15 infants with tuberous sclerosis were 
given treatments other than vigabatrin by their local investigator (section 3.3.4 
on page 119). This would suggest that, once the study was under way and 
new information about vigabatrin-associated visual field losses was available,
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there was more equipoise towards hormonal or vigabatrin treatment of tuber­
ous sclerosis than the UKISS trial steering committee had anticipated when the 
study protocol was being designed.
6.2.13 Impact of findings of UKISS
UKISS cannot claim to have definitively answered the question, "Which is the 
best first-line treatment for infantile spasms?" It is possible that aetiological 
subgroups will respond better to one or other of the established first-line treat­
ments, or possibly to other less established treatments.
There may be fears that finding vigabatrin to be less effective than ACTH or 
prednisolone would further compromise its position as a viable drug, perhaps 
leading to it being withdrawn from production or requiring special status as an 
orphan drug. Certainly, UKISS provides evidence that vigabatrin is not, overall, 
superior to hormonal treatments, but in isolation it does not definitively prove 
hormonal treatments to be superior; and it does not fully address the issues 
of differential effects in specific aetiological subgroups or the role of vigaba­
trin as rescue treatment in those who fail to respond to hormonal treatments. 
These are issues that are being considered by the UKISS steering committee for 
further investigation in new studies.
6.3 Discussion of West Delphi
Reaching consensus on case definitions is not easy. After the WHO and ILAE 
decided to develop an international classification of epilepsies to accompany 
the International Classification of Epileptic Seizures, Merlis reported the expe­
riences of the 15 contributors from 12 countries [232].
The initial period could be described as chaotic, with many divergent ap­
proaches being presented and with frequent interruptions of speakers by,
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sometimes, rather warm disagreement... I think I can say that, despite 
being hoarse and tired at the end of the day, many, if not all, of the par­
ticipants felt that it had been an instructive, productive and exhilarating 
experience.
The rationale behind West Delphi was to propose standard case definitions, 
outcomes, and outcome measures that would ease future study design; that 
would facilitate comparison of data from different studies; and that would 
encourage the design of studies answering questions that are important to 
clinicians and families seeking reliable and valid information about treatment 
choices. These aims are essential stages on the road to determining the best 
treatments for children with infantile spasms, and the West Delphi process dis­
sected many of the issues surrounding case definitions and outcomes. Though 
there were substantial areas of consensus, there were also several areas of in­
complete disagreement.
A Delphi process seemed to be a good way to elicit a consensus of opin­
ion in this setting. Although it is generally considered a way to elicit "ex­
pert" opinion, West Delphi aimed to recruit a variety of motivated contribu­
tors, not all of whom would necessarily be considered to be experts or from 
backgrounds in clinical research. Rather, the aim was to have a balance of con­
tributors, some of whom would have a proven record of published research 
in this area, but others of whom would represent clinicians who would be 
perhaps more likely to be interpreting and evaluating research than contribut­
ing to original research. However, there was also the implicit and secondary 
long-term aim of encouraging greater participation in future research projects. 
Although we did not formally classify the contributors to West Delphi as pri­
marily clinical researchers or service-orientated clinicians, I feel there was a 
balance of contributors that met the above aims, and I hope that many of these 
will be encouraged to contribute to future clinical research in the area of infan­
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tile spasms.
The anonymity associated with the consensus process has substantial ad­
vantages and helps to reduce the effects that might limit the contribution of 
frank and considered opinion. Such factors include fear of embarrassment at 
presenting views in public; fear of contradicting the views of established opin­
ion leaders in a particular field; fear of presenting novel ideas that might have 
substantial flaws; fear of being domineered by others; and fear of losing face 
when changing an opinion. However, there are also potential disadvantages 
associated with delphi processes. For example, with specific technical issues 
there might be a lack of insight within the group as a whole and the majority 
view might have technical flaws. There is the sense in West Delphi that the 
failure to progress further in EEG definitions was in part due to the group's 
lack of confidence that its members had insufficient technical skill to address 
specific technical issues of EEG description and interpretation.
6.3.1 West Delphi proposed case definitions
The West Delphi consensus statement is reproduced in appendix D (page 274). 
The process aimed, among other things, to propose definitions that are congru­
ent with previous usage and recent ILAE proposals. The proposed 5-axis diag­
nostic scheme for people with epileptic seizures and with epilepsy was felt to 
be potentially useful though several changes were suggested as modifications 
to the scheme [233]. Roger and Dulac used the terms infantile spasms and West 
syndrome to refer to syndrome diagnoses, and they suggested the term epilep­
tic spasms to refer to a seizure type [25]. The West Delphi consensus evolved 
to have strong congruence with these definitions. However, there were also 
examples where it was thought to be be valid and useful to make clear distinc­
tions and departures from previous practice. For example, the contributors 
found it valuable to use the term epileptic spasms to describe the seizure type,
CHAPTER 6. DISCUSSION 224
rather than as a phenomenological description as proposed in the ILAE Glos­
sary of Descriptive Terminology, 2001 [234]. And where the ILAE Proposed Di­
agnostic Scheme for People with Epileptic Seizures and with Epilepsy suggests 
the term spasms to describe the seizure type, the West Delphi Group proposed 
making a distinction between the terms clinical spasms to describe seizure phe­
nomenology and epileptic spasms to describe the seizure type. The West Delphi 
Group considered these terms to have strong intuitive appeal.
There was initial disagreement about the status of developmental delay as a 
defining feature of West syndrome. The consensus was that it is often difficult 
to determine when spasms started and whether development was normal at 
that time. Because these are unreliably determined and misclassification is 
likely, it was agreed that developmental delay at onset of spasms ought not to 
be a defining feature of infantile spasms.
Much debate focussed on the status of infantile spasms as a syndrome and 
the status of infantile spasms single-spasm variant with associated hypsarrhyth- 
mia. Some contributors considered there to be an argument for classifying 
these as seizure types, corresponding to Axis 2 of the proposed ILAE diag­
nostic scheme. However, overall the West Delphi Group did not find this ar­
gument compelling and thought that it is more appropriate to classify IS and 
ISSV  with hypsarrhythmia as epilepsy syndromes. Within the final consensus 
statement, the features that define West syndrome as a syndrome subgroup of 
infantile spasms are clustering of spasms and hypsarrhythmia.
Defining EEG features was evidently challenging, and several contributors 
found it difficult to distinguish necessary and sufficient features. In response 
to round 2, for example, the most popular feature suggested as sufficient was 
high voltage slow waves, but since slow waves are a non-specific feature of 
many encephalopathic processes, this is clearly not a sufficient feature of hyp­
sarrhythmia. Some participants suggested that high-voltage slow waves as­
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sociated with sharp waves or epileptiform spikes would be sufficient to de­
fine hypsarrhythmia, but these are clearly found in combination with other 
epilepsy conditions and are not sufficient [64]. The West Delphi Group agreed 
upon a description of hypsarrhythmia rather than a strict definition of limits, 
and it was agreed that there remains a strong element of Gestalt in recogniz­
ing this EEG pattern. There have been no studies of intra-rater and inter-rater 
agreement of classification of EEGs with hypsarrhythmia and its modifying 
features.
The consensus statement endorsed the proposal made by the 1991 ILAE 
Workshop that modifying features should be listed separately rather than be­
ing regarded in the aggregate as forming a distinct group of EEG types [28]. A 
list of individual modifying features was given in appendix A of the consen­
sus statement [209] and is reproduced on page 286 in appendix D of this thesis. 
Since modified EEGs may bear more or less resemblance to typical or classical 
hypsarrhythmia, it was felt to be irrational to dichotomise cases on the basis 
of presence of any one or more modifying features. Such modifying features 
might relate to a missed temporal window of opportunity for catching a more 
typical recording, since features such as increased synchrony and organisation 
in the EEG are related to brain development and sleep-wake behavioural state. 
Or they might relate to underlying causes or triggers of the spasms: for exam­
ple, increased focality where the trigger is a cortical malformation or tuber.
The consensus was that cases of infantile spasms might occur without hyp­
sarrhythmia, although some participants expressed reservations about this. It 
is well recognized that hypsarrhythmia is not found throughout the course of 
infantile spasms. It was noted that some studies, and notably the study of Ch­
iron et al, have reported hypsarrhythmia in fewer than half of cases classified 
as having infantile spasms at the time of randomized treatment [16].
With respect to ISSV without hypsarrhythmia, it was thought to be irra-
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tional to exclude these solely by definition if it were acceptable to admit cases 
with single spasms with hypsarrhythmia and cases with clustered spasms with­
out hypsarrhythmia. However, some contributors were certain that they would 
never diagnose infantile spasms in such cases, and the consensus was that in­
clusion of such cases should be explicitly justified with reasons for considering 
them valid cases of infantile spasms, since spasms that are never observed to 
cluster and that are not associated with hypsarrhythmia are likely to due to a 
cause other than infantile spasms. A related issue was that of how long a pe­
riod might elapse between spasms before they are considered not to be part of 
the same cluster. A pragmatic opinion was that spasms occurring with a fre­
quency of less than one per minute should be considered to be non-clustered, 
but there is again no biological plausibility in an absolute and rigid definition 
based upon elapsed time, and spasms occurring with a periodicity of less than 
one-per-minute might well be considered to be part of a cluster. This is another 
example of a case where a pragmatic and somewhat arbitrary definition might 
be necessary in order to facilitate the collection of standardised and reliable 
data.
Some contributors thought that unequivocally normal development at the 
time of onset of spasms was a good prognostic feature, and the consensus 
evolved to recommend that this should be recorded and used for prognos­
tic factor analysis in studies of infantile spasms. It was suggested that this 
reframing from apparently delayed development to unequivocally normal de­
velopment would be useful when counselling families about prognosis.
It was evident from the process of eliciting a consensus that clinicians and 
investigators have used the terms infantile spasms and West syndrome variably, 
and that there has been also great variation in the interpretation of the terms 
cryptogenic, idiopathic, and symptomatic. Previous ILAE commissions have used 
the terms idiopathic and cryptogenic as antonyms of symptomatic [34, 35].
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Contributors debated these terms a great deal. The eventual consensus was 
that information about prognosis and treatment response related to specific 
underlying diagnoses is probably more useful than classification into etiologic 
subgroups that are themselves heterogeneous.
Consideration was given to potential information bias due to reclassifica­
tion of cases between enrolment in a study and the time of study completion. 
It was felt important to clearly distinguish between an etiologic classification 
made at the time of study enrolment and a diagnostic classification made at the 
time of study completion. This allows those using information from studies to 
be clearer about what type of diagnostic information tends to be available at 
the time of treatment decision; and will also allow investigators to assess the 
value of specific investigations, such as MRI or CT scans, prior to initiation of 
treatment.
Some contributors wished to emphasise the limited value of aggregating 
cases into etiologic subgroups, preferring to look instead at outcomes in groups 
of children with the same specific underlying disorder. For example, tuberous 
sclerosis seems to have a better response to treatment with vigabatrin than 
other cases of symptomatic infantile spasms.
One area of strong controversy was subtle seizures associated with hyp­
sarrhythmia but without evidence of spasms. The consensus was that, while 
eye or subtle distal limb movements may be regarded as evidence of continual 
seizure activity, they do not provide a reliable outcome for the purposes of clin­
ical studies since they are likely to be missed without careful observation and 
are otherwise difficult to count. Even ictal events with more the more typical 
semiology of spasms have marked variation when ictal events are examined 
with EEG-video and EMG, but it is possible that such investigations will lead 
to recognisable and reliable patterns [235].
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6.3.2 West Delphi proposed outcome measures
The latter part of the consensus statement (sections 26 onwards) addresses the 
issue of standardised outcomes and outcome measures for studies of infantile 
spasms. Few published studies have provided information about even essen­
tial outcomes, such as how they defined clinical or electrodinical response. 
In the early rounds of West Delphi it was evident that most clinicians would 
not regard cases relapsing within a few weeks as primary clinical respon­
ders. However, they agreed that spasms recurring after 28 days of absence 
are described reasonably as relapse rather than failed primary response. This 
led to the definition of a primary clinical response, cessation of spasms, that is 
markedly more stringent in its requirement for duration of response than those 
of previous studies. For example, in UKISS, a case could potentially relapse 
after little more than 48 hours of freedom from spasms; and the studies of Ap­
pleton et al and Elterman et al respectively required 1 day and 7 days of spasm 
freedom [95,222].
In West Delphi, there was a consensus that a treatment has had sufficient 
opportunity to prove its effect by 14 days, and that it is necessary to give a 
treatment for this duration before concluding that it has failed to show any 
treatment effect. It was appreciated that this limit is arbitrary and that there 
might be good reasons for a new study to use a different duration of treatment. 
However, it was felt to be useful to suggest a standard, and the consensus 
suggested that, should investigators choose a different period, they ought to 
explain their reasons for that choice.
The consensus discussion emphasised the danger of adding an extra degree 
of subjectivity to study design and impeding aggregation of data by permitting 
study designs that might, for example, favour a drug that is reputed to act 
more quickly than another. Such factors would be better investigated by other
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means than altering the primary outcome, such as modelling time to cessation 
of spasms. Such an approach would preserve a reasonable degree of study 
standardisation and would facilitate comparison and aggregation of data from 
studies and, in the longer term, would provide better information for clinicians 
and families.
The consensus proposed three categories of age at onset of spasms (or more 
correctly, age at apparent onset of spasms, since timing can be unreliable) not 
with the aim of creating further subgroups for stratified randomisation, but 
rather to identify age at onset as a potential prognostic factor that should be 
considered in the analysis of trial data.
There was a good deal of negotiation about the most appropriate primary 
outcome. Most participants were keen on emphasising the clinical response, 
but others were sceptical at the idea of suggesting a response had occurred 
when the EEG still showed hypsarrhythmia. There are issues relating to the 
timing of EEG samples. Observation for seizures such as clinical spasms is a 
more-or-less continuous process, although this lacks sensitivity if one is inter­
ested in more subtle spasms or focal seizures. In contrast, EEGs performed at 
set times according to a study protocol are cross-sectional observations and, 
because of this form of sampling in time, are also insensitive. The final con­
sensus was that there should be reporting of two proper primary outcomes: 
the primary clinical outcome and the primary electroclinical outcome as de­
fined above. The finally approved approach of reporting both outcomes has 
many advantages, and the analysis of data from future studies reporting both 
outcomes should provide further information about their usefulness.
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6.3.3 Methodological and procedural problems with 
West Delphi
There were several procedural problems with West Delphi. Many rounds had 
to be extended to permit late responses to be sent, and not all contributors 
participated in all rounds (table 5.1, page 170). However, the final statement 
was agreed by all contributors. Also, there were occasionally responses that 
revisited questions that had been addressed in previous rounds. The last two 
rounds consisted to a large degree on discussion of the paper for publication, 
though specific issues of consensus were still being debated.
A strict interpretation of the guidelines for a Delphi process would not have 
permitted conferring by West Delphi contributors who were also members of 
the Konigsteiner Kreis, a group of German and Swiss doctors with an interest 
in pediatric epilepsy that deferred completion of an ongoing consensus state­
ment while several of its members contributed to West Delphi. The fact that 
the opinions of those members formed a single response rather than several re­
sponses for West Delphi prevented any significant bias being introduced from 
coordinated responses. However, it may have had the converse effect of re­
ducing the influence of their opinions where those opinions were in agreement 
before any consultation took place.
6.3.4 Summary of West Delphi
The West Delphi Group consisted of 31 clinicians and investigators, including 
the author (who acted as facilitator), who have an interest in infantile spasms. 
The process involved novel suggestions and lively debate. Relatively few cases 
of infantile spasms are enrolled into formal studies. To reliably and convinc­
ingly evaluate treatments, and to investigate potential variation in responses 
in different diagnostic groups, we should consider more collaborative and in-
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temational studies, and to aggregate data from disparate studies. West Delphi 
is a useful contribution to this process. The issue of underlying aetiology and 
its classification is likely to evolve and to remain controversial, and it is likely 
that future consensus statements will have to revisit this issue. The area that 
was least satisfactorily addressed was defining clearer limits on the classifica­
tion of EEG features, and this too will need to be addressed in the development 
of future consensus statements.
Although there is to date no published appraisal of the West Delphi Group's 
consensus statement and it has not attracted any published correspondence, 
informal feedback from sources has suggested that it is regarded as a sound 
basis for study design in this area and that studies designed according to its 
proposals are likely to gain wide acceptance. Along with the publication of 
UKISS, it is leading to renewed interest in larger studies of infantile spasms.
6.4 Considerations for future studies
The United Kingdom Infantile Spasms Study showed a clinically important 
difference in cessation of spasms at study day 14 and an association between 
this outcome variable and later neurodevelopmental scores in infants with no 
identified underlying cause for their infantile spasms. However, UKISS did 
not provide compelling evidence of a clear causal pathway that was free from 
bias and confounding, and that led directly from treatment intervention to ces­
sation of spasms, and thence to better neurodevelopment. The UKISS findings 
have prompted further questions, and an International Collaborative Infantile 
Spasms Study has been designed to investigate this further. The steering group 
for the international study includes members of the UKISS steering committee. 
This study will investigate, among other things, whether combined vigabatrin 
and hormonal treatment will result in better early spasm control and better
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neurodevelopment.
There remains a paucity of reliable population-based information on the 
incidence of infantile spasms and the relative prevalence of specific underly­
ing aetiologies. Providing such information was one of the motivations behind 
UKISS, but many factors conspired to make a reliable epidemiological study 
impossible. These factors included the volume of work associated with admin­
istering the randomised controlled trial, under-reporting of non-randomised 
cases, and delays associated with ethical and management approval that sub­
stantially staggered the times at which recruiting centres came on-line.
One way to improve notification and accrual of cases for a reliable popula­
tion-based epidemiological study would be to ensure that there is clear nesting 
of cases allocated random treatments within a larger group that are enrolled to 
provide epidemiological information. This might be possible in collaboration 
with established surveillance systems, such as the British Paediatric Surveil­
lance Unit. Potential underlying causes might be classified using the system 
suggested in the West Delphi consensus statement, and a study protocol might 
suggest an algorithmic approach to appropriate investigations to standardise 
such aetiological classification.
6.5 Conclusions of this thesis
The United Kingdom Infantile Spasms Study was large by comparison with 
most previous studies, and is the largest comparative head-to-head study of 
different treatments to date. It investigated the most popular treatments cur­
rently used in the United Kingdom and Europe and found that cessation of 
spasms in response to treatment, measured by using a variable that related to 
absence of observed spasms on days 13 and 14 after randomised treatment, 
was commoner in infants who were allocated hormonal treatments. However,
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relapse was less common in infants treated with vigabatrin, and overall the 
proportions with relapse-free cessation of spasms was similar in the groups 
allocated hormonal treatment and vigabatrin. There were no significant differ­
ences in neurodevelopmental outcome at the age of 14 months, but there was 
a non-robust finding that infants with no identified underlying aetiology had 
better scores if allocated hormonal treatments rather than vigabatrin.
Further investigation of issues identified in the process of conducting this 
study are already being addressed by the UKISS steering committee. Later 
developmental assessments are likely to be more discriminatory than assess­
ments performed at the age of 14 months, and these assessments are now be­
ing conducted. And there is the question of whether a combination of hor­
monal treatment and vigabatrin will be associated with better neurodevelop­
ment than hormonal treatments alone.
The conduct of the study highlighted several important aspects, such as the 
delays introduced by the need for ethical approval and management approval 
on many sites. However, it highlighted above all the lack of definition that 
has accompanied many previous studies. The pursuit of better definition and 
greater standardisation of outcome measures led to the development of the 
West Delphi consensus statement. Informed and unpublished reaction to this 
published statement suggest that it will be regarded as a reliable and valuable 
guide to study design in the area of infantile spasms for many years.
Appendix A
Study contributors
A.1 Members of the UKISS Trial Steering 
Committee
John P. Osborne, Professor of Paediatrics and Child Health,
School for Health, University of Bath; and 
Consultant Paediatrician, Department of Child Health,
Royal United Hospital, Bath, UK.
(Chair of Steering Committee)
Stuart W. Edwards, Research Fellow,
Bath Unit for Research in Paediatrics,
Royal United Hospital, Bath, UK.
(Study Administrator)
Eleanor Hancock, Clinical Research Fellow,
Bath Unit for Research in Paediatrics,
Royal United Hospital, Bath, UK.
Anthony L. Johnson, Statistician,
Medical Research Council Biostatistics Unit,
School of Public Health, University of Cambridge, Cambridge, UK. 
(Study Statistician)
234
APPENDIX A. STUDY CONTRIBUTORS 235
Colin R. Kennedy, Consultant Paediatric Neurologist,
Department of Paediatrics,
Southampton General Hospital, Southampton, UK.
Andrew L. Lux, Clinical Research Fellow,
Bath Unit for Research in Paediatrics,
Royal United Hospital, Bath; and 
Specialist Registrar in Paediatric Neurology,
Bristol Royal Hospital for Children and Frenchay Hospital, Bristol, UK. 
(Author of this thesis)
Richard W. Newton, Consultant Paediatric Neurologist,
Department of Paediatric Neurology,
Royal Manchester Children's Hospital, Manchester, UK.
Finbar J.K. O'Callaghan, Clinical Research Fellow,
Bath Unit for Research in Paediatrics,
Royal United Hospital, Bath; and 
Consultant Paediatric Neurologist,
Bristol Royal Hospital for Children and Frenchay Hospital, Bristol, UK.
Christopher M. Verity, Consultant Paediatric Neurologist,
Department of Paediatrics,
Addenbrooke's Hospital, Cambridge, UK.
APPENDIX A. STUDY CONTRIBUTORS 236
A.2 Members of the UKISS Data Monitoring and 
Ethics Committee
Philip J. Milner, Professor of Public Health,
Department of Medical Sciences,
University of Bath, Bath, UK 
(Chair of DMEC until April 2002).
Christopher N. Martyn, Clinical Scientist,
Medical Research Council Environmental Epidemiology Unit,
University of Southampton; and
Consultant Neurologist, Wessex Neurological Centre,
Southampton General Hospital, Southampton, UK 
(Chair of DMEC from April 2002).
R. Mark Gardiner, Professor of Paediatrics,
Department of Paediatrics and Child Health,
Royal Free and University Hospital Medical School, London, UK.
Christopher Jennison, Professor of Statistics,
Department of Mathematics,
University of Bath, Bath, UK.
Jane Schulte, Consultant Community Paediatrician,
North Bristol NHS Trust,
Westgate House, Southmead Hospital, Bristol, UK.
John Wilson, Retired Consultant Paediatric Neurologist,
Department of Paediatric Neurology,
Great Ormond Street Hospital for Children, London, UK.
APPENDIX A. STUDY CONTRIBUTORS 237
A.3 Centres and local investigators approved to en­
roll cases in UKISS
Addenbrooke's Hospital, Cambridge
Alexandra Hospital, Redditch
Altnagelvin Area Hospital, Londonderry
Antrim Hospital, Antrim
Barnet General Hospital, Barnet
Basildon Hospital, Basildon
Birmingham Children's Hospital, Birmingham
Birmingham Heartlands Hospital, Birmingham
Bishop Auckland General Hospital, Bishop Auckland
Blackpool Victoria Hospital, Blackpool
Booth Hall Children's Hospital, Blackley
Bristol Royal Hospital for Children, Bristol
Central Middlesex Hospital, London
Chase Farm Hospital, Enfield
Cheltenham General Hospital, Cheltenham
Child Development Unit, Watford
Children's Centre, Dorchester
City Hospital, Birmingham
Colchester General Hospital, Colchester
Coleraine Hospital, Coleraine
Conquest Hospital, St Leonards on Sea




Daisy Hill Hospital, Newry
Darlington Memorial Hospital, Darlington
Derbyshire Children's Hospital, Derby
Derriford Hospital, Plymouth
Diana Princess of Wales Hospital, Grimsby
Doncaster Royal Infirmary, Doncaster
Drybum Hospital, Durham
Eastbourne District General Hospital, Eastbourne
Epsom General Hospital, Epsom
Fairfield General Hospital, Bury
Famborough Hospital, Orpington
Frenchay Hospital, Bristol
Furness General Hospital, Barrow-in-Fumess
APPENDIX A. STUDY CONTRIBUTORS 238
Gian Clywd District General Hospital, Rhyl
Gloucestershire Royal Hospital, Gloucester
Great Ormond Street Hospital & Institute of Child Health, London
Guy's Hospital, London
Harrogate District Hospital, Harrogate
Hartlepool General Hospital, Hartlepool
Havering Hospital, Romford
Hemel Hempstead General Hospital, Hemel Hempstead
Hinchingbrooke Hospital, Huntingdon
Ipswich Hospital, Ipswich
James Paget Hospital, Great Yarmouth
John Radcliffe Hospital, Oxford
Joyce Green Hospital, Dartford
Kettering General Hospital, Kettering
King George Hospital, Goodmayes
King's College Hospital, London
King's Mill Hospital, Sutton-in-Ashfield
Kingston Hospital, Kingston-upon-Thames
Leighton Hospital, Crewe
Lincoln County Hospital, Lincoln
Lister Hospital, Stevenage
Macclesfield District General Hospital, Macclesfield 
Mayday University Hospital, Thornton Heath 
Medway Maritime Hospital, Gillingham 
Mid Ulster Hospital, Magherafelt 
Milton Keynes General Hospital, Milton Keynes 
New Cross Hospital, Wolverhampton 
Newcastle General Hospital, Newcastle-upon-Tyne 
Newham General Hospital, London 
Norfolk & Norwich Hospital, Norwich 
North Devon District Hospital, Barnstaple 
North Hampshire Hospital, Basingstoke 
North Middlesex University Hospital, London 
North Tees General Hospital, Stockton-on-Tees 
North Tyneside General Hospital, North Shields 
Northwick Park Hospital, Harrow.
Ormskirk & District General Hospital, Ormskirk 
Pembury Hospital, Tunbridge Wells 
Pilgrim Hospital, Boston 
Pontefract General Infirmary, Pontefract 
Poole General Hospital, Poole
APPENDIX A. STUDY CONTRIBUTORS 239
Royal Preston Hospital, Preston
Princess Margaret Hospital, Swindon
Princess Royal Hospital, Telford
Queen Elizabeth II Hospital, Welwyn Garden City
Queen Elizabeth Hospital, Gateshead
Queen Elizabeth Hospital, Greenwich
Queen Elizabeth Hospital, King's Lynn
Queen Elizabeth the Queen Mother Hospital, Margate
Queen Mary's Hospital for Children, Carshalton
Queen's Medical Centre, Nottingham
Queen's Park Hospital, Blackburn
Raeden Centre, Aberdeen
Royal Aberdeen Children's Hospital, Aberdeen
Royal Albert Edward Infirmary, Wigan
Royal Alexandra Hospital for Sick Children, Brighton
Royal Belfast Hospital for Sick Children, Belfast
Royal Berkshire Hospital, Reading
Royal Bolton Hospital, Bolton
Royal Cornwall Hospital, Truro
Royal Devon & Exeter Hospital, Exeter
Royal Free Hospital, London
Royal Glamorgan Hospital, Llantrisant
Royal Gwent Hospital, Newport
Royal Hampshire County Hospital, Winchester
Royal Lancaster Infirmary, Lancaster
Royal London Hospital, London
Royal Manchester Children's Hospital, Pendlebury
Royal Shrewsbury Hospital, Shrewsbury
Royal Surrey County Hospital, Guildford
Royal United Hospital, Bath
St Albans City Hospital, St Albans
St Ann's Hospital, London
St John's Hospital, Chelmsford
St Mary's Hospital, London
St Mary's Hospital, Newport (Isle of Wight)
St Mary's Hospital, Portsmouth 
St Peter's Hospital, Chertsey 
Salisbury District Hospital, Salisbury 
Sandwell General Hospital, West Bromwich 
Singleton Hospital, Swansea 
Stafford District General Hospital, Stafford
APPENDIX A. STUDY CONTRIBUTORS
Stepping Hill Hospital, Stockport
Stoke Mandeville Hospital, Aylesbury
South Cleveland Hospital, Middlesborough
Southend Hospital, Westcliff-on-Sea
Southampton General Hospital, Southampton
Southmead Hospital, Bristol
Southport District General Hospital, Southport
Sunderland Royal Hospital, Sunderland
Tameside General Hospital, Ashton-under-Lyne
Taunton & Somerset Hospital, Taunton
Thelma Golding Centre, London
Thorpe Coombe Hospital, London
Trafford General Hospital, Manchester
Ulster Hospital, Dundonald
University Hospital Lewisham, London
University Hospital of Wales, Cardiff
Walsall Manor Hospital, Walsall
Walsgrave Hospital, Coventry
West Cumberland Hospital, Whitehaven
West Middlesex University Hospital, Isleworth
West Suffolk Hospital, Bury St Edmunds
Weston General Hospital, Weston-Super-Mare
Whiston Hospital, Prescot
Whittington Hospital, London




Wycombe Hospital, High Wycombe
Wythenshawe Hospital, Manchester
Yeovil District Hospital, Yeovil
APPENDIX A. STUDY CONTRIBUTORS 241
Dr Simon Ackroyd (Cheltenham)
Dr M AS Ahmed (Goodmayes)
Dr Asya Al-Kharusi (Southport)
Dr Muna Alwaidh (Prescot)
Dr Patrida Atkinson, Dr Abdelhadi Abdelhadi (Crawley) 
Dr Thulasi Balakumar, Dr Alison Groves,
Dr Diab Haddad (Chertsey)
Dr Deborah Barff (Weston Super Mare)
Dr Richard Beach (Norwich)
Dr John Beesley (Gateshead)
Dr Angela Bell (Dundonald)
Dr Jeffrey Bissenden (Birmingham)
Dr Marilyn Black (Poole)
Dr Sandy Blewett, Dr Marian McGowan,
Dr David Ogilvie (Carshalton)
Dr Andrew Boon (Reading)
Dr Alan Bosley, Dr Mark Hughes (Barnstaple)
Dr Edward Broac&urst,
Dr Heather Mackinnon (London)
Dr Andrew Butterfill (Hereford)
Dr Duncan Cameron (Rhyl)
Dr Ruth Charlton (Epsom)
Dr Ravi Ch'mthapalfi (Swindon)
Dr Michael Clarke, Dr Keith Lacey (Stockport)
Dr Colin Close, Dr Rowena Sankey,
Dr Shahid Ghazi (Redditch)
Dr Nigel Coad, Dr Maybefle Tatman,
Dr Tariq Ahmad (Coventry)
Dr Gail Collins (Doncaster)
Dr David Cook, Dr Ese Ikhena (Margate)
Dr Christopher Corkey (Newry)
Dr Andrew Cottrell, Dr William Lamb (Bishop Auckland) 
Dr Selwyn D'Costa (Dartford)
Dr Peter Dale (Newport)
Dr Menaka De Silva (Orpington)
Dr Penny Dison, Dr Angela Moore (Wolverhampton)
Dr R M Downes, Dr Richard McGucken (Wigan)
Dr Nicholas Driver, Dr Helen Foley,
Dr Charles Godden (Guildford)
Dr Alison Earley, Dr Kamal Sawhney (High Wycombe) 
Dr Megan Eaton (Yeovil)
Dr Anthony Edeisten (Great Yarmouth)
Dr Hany El-Naggar (St Albans & Hemel Hempstead)
Dr Andrew Evans, Dr Helen Issler (Greenwich)
Dr Anthony Fan (Grimsby)
DrTheo Fenton, Dr Helen Underhill (Thornton Heath) 
Dr Amanda Freeman, Dr Richard Hallett (Portsmouth) 
Dr Jeffrey Freeman,
Dr Albert Massarano (Ashton-U-Lyne)
Dr Frances Gibbon, Dr Sandeep Jayawant (Cardiff)
Dr John Gibbs (Chester)
Dr Jim Gould, Dr Christopher Yale, Dr Kevin O'Neill,
Dr Michael Bamford (Ipswich)
Dr Donncha Hanrahan, Dr Elaine Hicks (Belfast)
Dr Gary HartnoH (London)
Dr Mohammed Hassoon (Pontefract)
Dr John Heck matt (Watford)
Dr Frank Hinde (Telford)
Dr Daniel Hindley (Bury)
Dr Wheldon Houkby (North Shields)
Dr Elaine Hughes, Dr Jean Pierre Lin, Dr Keith Pohl,
Dr Stephanie Robb (London)
Dr Adrian Hughes (Wirral)
Dr John Hyde (Stevenage)
Dr Philip Jardine, Dr Jayesh Patel,
Dr Peta Sharpies (Bristol)
Dr Rasieka Jayatunga (West Bromwich)
Dr Mary Johnson (Blackpool)
Dr Robert Jones, Dr Carolyn Adcock,
DrTony Cronin (Plymouth)
Dr Eman Jurges (Kingston Upon Thames)
Dr Colin Kennedy, Dr Fenella Kirkham,
Dr Neil Thomas (Southampton)
Dr David IGndley, Prof Josef Egger (Aberdeen)
Dr Pravin Lakhani, Dr Vanda Joss,
Dr Philip Latham (Milton Keynes)
Dr Su Laurent (Barnet)
Dr Geoffrey Lawson, Dr Sam Richmond (Sunderland) 
Dr Daniela Lessing, Dr Alex Habel (Isleworth)
Dr Helen Lewis (Manchester)
Prof Sam Lingam (London)
Dr Anthony Lipscomb, Dr Mahesh Babu (Chelmsford) 
Dr Maurice Little, Dr Bhavdeep Jani (Gillingham)
Dr Andrew Lloyd Evans (London)
Dr Calum MacLeod (Magherafelt)
Dr Adelaida Martinez (London)
Dr Sateesh Mathew (London)
Dr Anne McGeechan, Dr Jim Barnes,
Dr Robert Scott-Jupp (Salisbury)
Dr Colin Melville, Dr Shomik Ghosal (Stafford)
Dr Richard Miles (Huntingdon)
Dr Andrew Mitchell (Basingstoke)
Dr John Morgan (Llantrisant)
Dr Richard Morton, Dr Keith Dodd (Derby)
Dr Douglas Munio (Harrogate)
Dr Charith Nanayakkara (Kettering)
Prof Brian Neville, Dr Carlos de Sousa (London)
Dr Richard Newton, Dr Omar Ismayl,
Dr Tim Martland (Pendlebury)
Dr Stuart NichoRs (Worthing)
Dr John Nicholson (Antrim)
Dr Catherine Noone (Aylesbury)
Dr Heidi Northover (Bolton)
Dr Sue O'Halloran (Ormskirk)
Dr Corina O'Neill, Dr Gerald McEnery (London)
Dr Anas Olabi (Barrow-in-Fumess)
Prof John Osbome (Bath)
Dr John Owens (Macclesfield)
Dr Sunny Philip, Dr Wifliam Whitehouse,
Dr Caroline Ross (Birmingham)
Dr Mike Pike, DrTony Me Shane,
Figure A.l: Contributors to UKISS with lead local investigators in bold (part
1) as they appear on Lancet website.
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Figure A.2: Contributors to UKISS with lead local investigators in bold (part
2) as they appear on Lancet website.
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Appendix B
The UKISS Study Protocol
6.1 Protocol approved by Multicentre Research Ethics 
Committee
The following text is the Protocol of the United Kingdom Infantile Spasm 
Study as approved in September 1998 by the South and West Multicentre Re­
search Ethics Committee.
This is a pragmatic drug trial of the current, most common treatments using the clini­
cian's normal investigation plan.
EPIDEMIOLOGY
N o t i f y  ALL C a s e s  o f  I n f a n t i l e  S p a sm s .
Please notify all cases of infantile spasms to the trial centre even if you do not intend 
to recruit the individual patient, for whatever reason, into the trial. Any patient with a 
clinical diagnosis of infantile spasms should be included even if the EEG turns out to 
be normal. This would include patients younger than 2 months or older than 1 year. It 
would be very helpful if all cases can be notified so that we know how representative 
our trial population is compared to the whole UK population. Brief clinical details 
will be requested.
In order to carry out a capture-recapture analysis of the UK population with IS (thus 
allowing a more complete ascertainment of cases), we shall ask for information from 
pharmacists and EEG departments in collaborating hospitals. This information will 
be initials, date of birth and sex. The clinician will then be approached for pre-ran­
domisation stratification data.
DRUG TRIAL
1. In c l u s i o n  C r it e r ia  f o r  D r u g  T r ia l
All infants shall be included of either sex aged at seizure onset between 2 completed
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calendar months and 1 year of age (up to but not including their first birthday) who 
are resident in the UK and who have a clinical diagnosis of infantile spasms from any 
cause.
2. E x c l u s i o n  C r it e r ia  f o r  D r u g  T r ia l
1. Infants who are either known to suffer from tuberous sclerosis (TSC) or who are 
at high risk i.e. a presumptive diagnosis of tuberous sclerosis because of:
(a) known affected parent
(b) previously diagnosed cardiac rhabdomyoma
(c) hypomelanic macules, a forehead fibrous plaque or shagreen patch noted
(d) a retinal phakoma seen
(e) polycystic kidneys in the infant We recommend that first line therapy in 
these infants should be vigabatrin (see later for dosage). Please inform 
trial centre even though they will not be entered into the trial.
2. Infants previously treated with vigabatrin or steroids within 28 days of the first 
diagnosis of infantile spasms.
3. Infants with a contra-indication to vigabatrin or steroids.
4. Infants with a lethal or potentially lethal other condition.
5. Previous treatment for infantile spasms.
6. Inability of parents or guardians to give informed, signed consent.
7. Infants expected to leave the UK within one month of randomisation.
8. Inability of parents or guardians to know when spasms stop - to the nearest 
whole day.
9. Infants enrolled in a concurrent trial that either uses therapy that might affect 
the outcome measures of the UKISS trial or one that is time/ effort consuming 
for the patients/ guardians or the infants' medical practitioners.
All excluded infants should be reported to the trial centre.
3. C o n s e n t
The trial should then be discussed with the parents or guardians and their consent 
requested for participation in the trial. Please report any infants where consent is not 
obtained to the trial centre.
4. E l e c t r o e n c e p h a l o g r a m  (EEG)
An EEG (or video EEG) should be obtained as quickly as possible so that treatment can 
start within 72 hours of diagnosis. Only if this is not possible and only if your normal 
practice is to start treatment prior to an EEG (or video EEG) may you randomise before 
an EEG (or video EEG) is obtained. If the EEG (or video EEG) is normal, a sleep EEG
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will be required prior to randomisation, if this has not already occurred. If the sleep 
EEG is normal the child will be excluded from the drug trial (unless already enrolled) 
but please report the exclusion to the trial centre for further follow up. If there will be 
a delay of more than 72 hours before the EEG (or video EEG) can be performed and 
it is not your normal practice to start treatment prior to EEG (or video EEG), the child 
will be excluded from the drug trial (but please report the exclusion to the trial centre 
for further follow up).
5. P r e - r a n d o m i s a t i o n
Prior to entry into the study the children will be stratified for randomisation by three 
variables:
1. By gender: male, female
2. By age: 60 to 119 days; 120 to 179 days; 180 to 239 days; 240 days and over
3. By diagnosis known at time of randomisation (Yes /  No).
(a) a proven chromosomal abnormality
(b) a proven syndrome diagnosis
(c) a diagnosis of cerebral palsy made before the onset of the infantile spasms
(d) a diagnosis of neonatal encephalopathy with seizures
(e) a diagnosis of delayed development having already been made before the 
onset of the spasms. The diagnosis should have been made by either a 
medical practitioner or a health visitor, and must have been made before the 
onset of the spasms.
Stratification is being done not to provide definitive groups for subanalysis but to bal­
ance the treatment groups with respect to factors which are identifiable at randomisa­
tion and which might affect our outcome measures.
6. R a n d o m i s a t i o n
This will involve central randomisation by telephone call which will register the child 
into the trial, report base-line information and allocate initial treatment using the me­
thod of minimisation balancing over three factors.
7. T r e a t m e n t  G r o u p s
All children eligible for the trial will then be randomised into two treatment groups: 
Vigabatrin and "Steroids". All patients randomised to receive "steroids" will undergo 
a second randomisation, at that time, to either Synacthen Depot or prednisolone. The 
only pharmacological intervention for the infantile spasms in the first two weeks will 
be the use of the drug to which each patient has been randomised.
8. In i t i a l  T r e a t m e n t
This will be a period of two weeks during which the child will receive the drug to 
which they are allocated as monotherapy. It is the local doctor's responsibility to read 
the manufacturer's drug data sheet before prescribing the following drugs:
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Vigabatrin
Give 50 mg/kg/day orally in two divided doses for 24 hours (i.e. a total of 2 doses). 
Then increase to 100 m g//kg/day orally in two divided doses in all patients. If at 96 
hours seizure control has not been achieved then the dose should be further increased 
to 150 mg/kg/day orally in two divided doses. They then continue on this dose (100 
or 150 mg/kg/day) until the time of their final developmental assessment around 
12-14 months of age unless no response or relapse occurs (see below), or this is not 
your normal practice.
ACTH -  U s e  S y n a c t h e n  D e p o t  
As ACTH gel is not available in the UK, we have substituted Synacthen® Depot. Give
0.5 mg on alternate days (equivalent to 40 iu/day of ACTH) intramuscularly (regard­
less of age or weight) for two weeks. If at the end of the first week seizure control has 
not been achieved then the dose should be further increased to 0.75 mg on alternate 
days (equivalent to 60 iu/day of ACTH) intramuscularly. This group will then tail on 
oral prednisolone over 15 days. Those on 0.5 mg on alternate days of Synacthen Depot 
will receive 30 mg of oral prednisolone for 5 days, then 20 mg for 5 days then 10 mg 
for five days and stop. Those on 0.75 mg on alternate days of Synacthen Depot will 
receive 40mg of oral prednisolone for 5 days then 20 mg for 5 days then 10 mg for 5 
days then stop.
Prednisolone
Give 10 mg q.d.s. orally (regardless of age or weight) for two weeks. If at the end of 
the first week seizure control has not been achieved the dose should be increased to 
20 mg t.d.s. orally. This group will then tail on oral prednisolone over 15 days. Those 
on 40 mg (10 mg q.d.s.) will reduce to 30 mg for 5 days, then 20 mg for 5 days then 10 
mg for five days and stop. Those on 60 mg (20 mg t.d.s.) will reduce to 40 mg for 5 
days then 20 mg for 5 days then 10 mg for 5 days then stop.
9 . In v e s t i g a t i o n s
(a) An investigation of the child's development will be made by history. At enrolment 
the clinician will be asked to record the best development ever made on history by the 
child. It will not be necessary to record the age at which this performance was made. 
They will then be asked to record the current development achieved.
(b) As part of normal practice in the investigation of infants with infantile spasms, 
we assume the following investigations will be undertaken:
1. MRI or CT of the brain
2. Urine metabolic screen for amino acids
3. Ophthalmoscopy (either direct or indirect)
4. Ultraviolet light examination (Woods light) The results of these tests should be 
forwarded to the trial centre. If for any reason one or more of these tests is not 
completed the reason should be stated.
APPENDIX B. THE UKISS STUDY PROTOCOL 248
(c) The following tests may be considered appropriate in some cases and, if per­
formed, the results of these and any other tests should be forwarded to the trial centre.
1. Urea and electrolytes
2. Liver function tests
3. Chromosomes





9. Pyridoxine response - if pyridoxine is to be given we would recommend that 
pyridoxine is given one month after the start of the trial (after both the ran­
domised treatment and first alternate treatment have been given in a child who 
continues fitting).
(d) When venesection is performed for any clinical reason during the course of 
the infant's illness, please take a blood sample for DNA analysis (bottle, form and 
addressed sample box included in patient pack). A subgroup of those on steroids will 
have blood taken to measure cortisol levels.
10. In i t i a l  O b s e r v a t io n s
The patient will be admitted if necessary for clinical confirmation for the diagnosis of 
infantile spasms. If commencing treatment of steroids, the patient will preferably be 
detained in hospital for 48 hours in order to have their blood pressure checked twice a 
day for two days and to have a urine analysis for glucose performed before discharge.
11. A t  E n r o l m e n t
At enrolment the parents/ guardians will be given their copy of a 'fit diary'. Its use, 
and how to complete it, must be explained and fully understood. In addition the 
importance of this diary to interpreting the results of the trial should be explained. 
Details of the child's name, date of birth, address, NHS number, trial number, con­
sultant and general practitioner should be completed. In addition we will ask all par­
ents/guardians for a third party address (e.g. a grandparent) so that if they move and 
we lose contact with them we can try and track them through this third party. As a 
minimum, the parents/guardians will be expected to make a once daily entry for the 
first 4 weeks of the trial and a once weekly entry thereafter, until the time of the final 
developmental assessment (12 -14 months), with a final 7 day daily entry for those 
still having seizures. They should bring the diary with them to all clinic appointments 
and they may use the diary to record more detailed information if the lead clinician so 
wishes.
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12. B e f o r e  D is c h a r g e
Before discharge please arrange for a follow up EEG as close to 14 days after the start of 
treatment as possible. Please also see the child in out-patients as close to 14 days after 
the start of treatment as possible (but not less than 14 days after the start of treatment).
13. F o l l o w i n g  D i s c h a r g e , D u r i n g  t h e  In i t i a l  T w o - w e e k  P e r io d
Once the patient is discharged from hospital, if on steroids the blood pressure and 
urine analysis for glucose should be performed weekly whilst treatment continues, 
until the dose is reduced when this may be omitted if problems have not already been 
detected.
14. R e s p o n d e r s  a n d  P r o p o s e d  T r e a t m e n t  f o r  R e l a p s e
Responders: are those in whom there is total cessation of spasms for at least 48 hours 
up to and including the end of the 14th day of treatment.
Relapse: a single spasm in a responder constitutes a relapse.
If a child relapses within the initial 2-week period then the lead clinician would be 
expected to increase the dose of the initial therapy up to the maximum recommended 
dose as per protocol.
If for any reason the lead clinician felt that it was not in the child's best interest to in­
crease the dose of initial therapy (for example side effects experienced) then he should 
inform the trial centre as soon as possible, preferably but not necessarily before chang­
ing therapy.
15. R e v ie w  a t  2  W e e k s
Please review the patient as close to 14 days after the start of treatment as possible but 
not less than 14 days after the start of treatment. The patient should be seen in order 
to confirm their progress and to complete the brief standardised progress report form. 
If the infant has responded the patient will continue on the same therapy as above.
16. N o n - r e s p o n s e  a t  2  W e e k s
The trial will be analysed by intention to treat at randomisation. However, in order to 
minimise the effects of a multitude of different subsequent treatments, we will ask, but 
not require, clinicians to change to the alternative treatment (see below) if the primary 
treatment fails. If a response has not occurred after 2 weeks, we expect the lead clin­
ician to change to the alternative therapy i.e. either steroids after vigabatrin (the lead 
clinician to choose which steroid - Synacthen Depot or prednisolone) or vigabatrin af­
ter steroids. This alternative treatment will continue for the third and fourth weeks 
(a full 14 days) at the same dose as recommended for the first two weeks. If the lead 
clinician does not feel that this treatment is in the child's best interest they may change 
to a treatment of their own choice without violating the trial protocol, but they should 
notify the trial centre of this change in treatment plan using the 14 day standard report 
form. If both treatments fail, the clinician will be left to choose the most appropriate 
treatment.
17. R e l a p s e  A f t e r  t h e  I n i t i a l  T w o - w e e k  p e r io d
The lead clinician may choose his own treatment, but we suggest if the child relapses
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after the initial two week period either: If on vigabatrin increase the dose in parallel 
with the child's weight gain (if increase is more than 1 kg) or if on 100 mg/kg/day 
increase to 150 mg/kg/day; If on steroids repeat the course once even if tailing. If 
these measures fail after a full 14 days treatment change to the alternative therapy i.e. 
either steroids (Synacthen Depot or prednisolone) after vigabatrin, or vigabatrin after 
steroids.
18. S i d e  E f f e c t s
Should an infant suffer unacceptable side effects then the treatment should be discon­
tinued and the trial centre informed immediately. The lead clinician may choose his 
own alternative treatment, but we suggest the lead clinician change to the alterna­
tive therapy i.e. either steroids (Synacthen Depot or prednisolone) after vigabatrin, or 
vigabatrin after steroids.
19. S u b s e q u e n t  F o l l o w - u p
All enrolled infants should be seen at 3 monthly intervals as a minimum although we 
realise that many will be seen more often because of their clinical need. The lead clin­
ician will be asked to fill in a brief progress report form to send back to the trial centre 
in Bath at each 3 monthly visit until the 12 -14 month assessment. Psychomotor devel­
opment will also be assessed using a telephone questionnaire based on the "Vineland 
Adaptive Behaviour Scales" (see section 26). This will be done by a trained researcher 
who will be based in Bath when the infant is between 12 and 14 months of age.
20. R e c r u i t m e n t  R a t e
This is a national study and it is hoped to recruit all new cases of infantile spasm in the 
United Kingdom occurring within the study period. Papers dealing with the epidemi­
ology of infantile spasms put the incidence between 1 in 2380 and 1 in 6250 births. The 
average UK birth rate is approximately 800,000 per year. Therefore, it should be possi­
ble to recruit between 130 and 340 new cases per year. Taking into account exclusions, 
recruitment should be completed within 18 months. We intend to drive recruitment 
actively and have already sought to recruit one paediatric neurologist from each old 
health region to help promote the study. The trial centre will take responsibility for 
ethics committee approval for each district in the UK and will recruit one paediatri­
cian from each district to help promote the study. We will provide coasters and post-its 
printed with contact arrangements at the commencement of the trial. A newsletter will 
be sent to all recruiting clinicians and all promoters every 2 months. We will notify all 
EEG departments of the trial with coasters, post-its and newsletters and ask them to 
remind clinicians of the trial whenever a request is made for an EEG in a child with 
possible infantile spasms, or whenever hypsarrhythmia is found.
21. C o m p l i a n c e
This is a serious disorder with profound sequelae. The motivation for clinicians and 
parents of patients to participate in treatment is high. The clinical workload to be 
imposed on attending physicians is little more than constitutes good clinical practice. 
(The workload to be imposed on parents is small). The administrative work will be
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kept to a minimum - we will not collect unessential data and the trial centre will be 
responsible for documentation and for submissions to ethics committees.
22. L ik e l y  R a t e  o f  L o s s  t o  F o l l o w - u p
Loss to follow-up should be small. Patients known to be likely to move outside the 
country during the trial period will be excluded at entry. As this is a national study, 
movement within the UK should not lead to loss of contact. The patient's NHS num­
ber, general practitioner and a third party address (e.g. grandparents) will be recorded 
on entry to the trial thus making it easier to keep track of patients who move.
23. P o s t - r a n d o m i s a t i o n  S t r a t if ic a t io n
There will be post-randomisation stratification for potential confounding variables not 
accounted for in pre-randomisation. These include EEG appearance (i.e. hypsarrhyth- 
mia vs atypical vs normal awake, normal asleep) and diagnostic sub-groups (i.e. cere­
bral dysgenesis on cranial scanning, chromosomal abnormalities or other syndromes 
and other diagnosis such as metabolic disease). Social factors will include birth order 
and maternal age at school leaving.
24. POST-INVESTIGATION DIAGNOSTIC SUBGROUPS
It may be possible to see if any trends in outcome are repeated within subgroups of 
the trial population. The largest subgroup should be infants where development was 
delayed (as shown by pre-randomisation stratification data and as shown separately 
by the developmental history. Smaller subgroups, e.g. those diagnosed with cerebral 
palsy on clinical examination, cerebral dysgenesis on cranial imaging, normal awake 
and asleep EEGs, are unlikely to be large enough for separate analysis. However, the 
data will be examined in case there is a dramatic difference in outcome, or a consistent 
trend.
25. P r im a r y  O u t c o m e  M e a s u r e
The primary outcome measure will be the number of patients who achieve complete 
cessation of spasms for at least 48 hours up to and including the end of the 14th day 
of treatment.
26. S e c o n d a r y  O u t c o m e  M e a s u r e s
1. Time taken to complete cessation of all spasms for at least 48 hours.
2. Partial response i.e. those patients that have a reduction in the number of spasms 
during the two week period.
3. Relapse rates.
4. Other seizure types and frequency at 14 months, in those still having seizures.
5. Resolution of hypsarrhythmia at 14 days.
6. Developmental progress at 12-14 months of age. This will allow at least 2 
months of recovery following treatment and is an age at which some language 
development has occurred. It is believed that delaying the assessment to a
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greater age will give little advantage and would have the disadvantage of in­
creasing the impact of environmental factors.
The Vineland Adaptive Behaviour Scales have been developed and validated in the 
U.S.A. to measure "adaptive behaviour" defined as the performance of the daily ac­
tivities required for personal and social sufficiency. It concentrates on the usual re­
sponse, not the best response to any task. It has been validated in greater detail on 
larger numbers of children (3000) and has been used in the U.K. for other develop­
mental follow-up studies. It achieves construct validity, content validity and has been 
compared to other scales in both normal and handicapped children. It has been shown 
to have internal consistency, test-retest and interrater reliability. It has been designed 
to minimise the influence of physical handicap.
The Vineland has four domains (communication, daily living skills, socialization 
and motor skills) and these combine to give an Adaptive Behaviour Composite: each 
of these has a standard score of 100 with a standard deviation of 15 and each can be 
expressed as an age equivalent (developmental age).
The Vineland scales can easily be adapted to be performed as a parental question­
naire that can be administered over the phone.
27. A n a l y s is
Assuming recruitment of 250 children over the 18 month period, with approximately 
125 randomised to vigabatrin and 125 to "steroids", assuming approximately 50% will 
achieve cessation of seizures in the "steroid" group, the trial will have 90% power to 
detect an improvement in cessation of seizures to 70% in the vigabatrin group. We 
are aware that the pattern of developmental age in the two groups may be bimodal. 
A direct comparison of the developmental age (total score and subsets) of the two 
groups will be undertaken, but we will also determine the proportion of individuals 
in each group whose development is one, two and three standard deviations below 
the mean for the Vineland.
6.2 Study protocol amendment 11 May 2000
This information sheet for parents or guardians was a study protocol amend­
ment approved by the MREC on 11 May 2000.
U K I S S  -  E x t r a  i n f o r m a t i o n  f o r  p a r e n t s  o r  g u a r d i a n s :  1 1  M a y ,  2 0 0 0
T h e  U K I S S  s t u d y  w a s  a p p r o v e d  b y  a  M u l t i c e n t r e  R e s e a r c h  E t h i c s  C o m m i t t e e  i n  S e p t e m b e r  
1 9 9 8 .  S i n c e  t h e n ,  i t  h a s  b e e n  a p p r o v e d  b y  m o r e  t h a n  a  h u n d r e d  l o c a l  r e s e a r c h  e t h i c s  c o m m i t ­
t e e s .  S e v e r e d  o f  t h o s e  c o m m i t t e e s  s u g g e s t e d  h o w  w e  m i g h t  m a k e  t h e s e  i n f o r m a t i o n  s h e e t s  
c l e a r e r .  W e  h a v e  a l s o  h a d  u s e f u l  c o m m e n t s  f r o m  o t h e r  d o c t o r s ,  a n d  f r o m  s o m e  N H S  m a n ­
a g e r s .  W e  h a v e  w r i t t e n  t h i s  u p d a t e  t o  m a k e  y o u  a w a r e  o f  t h e s e  s u g g e s t i o n s .  W e  h o p e  t h a t  y o u  
w i l l  f i n d  i t  u s e f u l .
R e a s o n  f o r  d o i n g  t h e  s t u d y .  O n e  p a r t  o f  t h e  i n f o r m a t i o n  s h e e t  w a s  i n t e n d e d  t o  e x p l a i n  
t h e  r e a s o n  f o r  d o i n g  t h e  s t u d y .  T h i s  i s  t h e  p a r a g r a p h  t h a t  b e g i n s :  " I f  w e  d o  n o t  d o  t h i s  s t u d y
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w e  w i l l  n e v e r  l e a r n  w h i c h  t r e a t m e n t  i s  b e s t . "  S o m e  r e s e a r c h  e t h i c s  c o m m i t t e e s  t h o u g h t  t h a t  
t h i s  p a r a g r a p h  m i g h t  s e e m  c o e r c i v e .  I n  o t h e r  w o r d s ,  i t  m i g h t  s e e m  t o  p u t  p r e s s u r e  o n  y o u  t o  
a l l o w  y o u r  c h i l d  t o  j o i n  t h e  s t u d y .  W e  d o  n o t  w i s h  t o  p u t  p r e s s u r e  o n  y o u .  O u r  a i m  w a s  t o  
e x p l a i n  t h e  r e a s o n s  f o r  d o i n g  t h e  s t u d y .  W e  a p o l o g i s e  i f  t h i s  p a r t  o f  t h e  i n f o r m a t i o n  s h e e t  g a v e  
t h e  w r o n g  i m p r e s s i o n .
L e a v i n g  t h e  s t u d y  b e f o r e  i t  i s  f i n i s h e d .  Y o u  m a y  t a k e  y o u r  c h i l d  o u t  o f  t h i s  s t u d y  a t  a n y  
t i m e  a n d  f o r  a n y  r e a s o n .  Y o u  d o  n o t  h a v e  t o  e x p l a i n  y o u r  r e a s o n s  t o  y o u r  d o c t o r  o r  t o  a n y o n e  
e l s e ,  a n d  y o u r  d e c i s i o n  w i l l  n o t  a f f e c t  t h e  c a r e  y o u r  c h i l d  r e c e i v e s .  T h i s  f a c t  i s  w r i t t e n  o n  t h e  
c o n s e n t  f o r m .  H o w e v e r ,  i t  d o e s  n o t  a p p e a r  o n  t h e  i n f o r m a t i o n  s h e e t .  I t  i s  i m p o r t a n t  t h a t  y o u  
a r e  a w a r e  o f  t h i s  r i g h t .
G e t t i n g  m o r e  a d v i c e .  S o m e  L o c a l  R e s e a r c h  E t h i c s  C o m m i t t e e s  a s k e d  u s  t o  p r i n t  t h e i r  
a d d r e s s  a n d  p h o n e  n u m b e r ,  o r  t h a t  o f  t h e  l o c a l  C o m m u n i t y  H e a l t h  C o u n c i l .  P l e a s e  n o t e  t h a t  
y o u  c a n  o b t a i n  a d v i c e  f r o m  e i t h e r  o f  t h e s e  b o d i e s .  Y o u  m a y  a l s o  t e l l  t h e m  a n y  c o n c e r n s  o r  
w o r r i e s  y o u  h a v e  a b o u t  t h e  s t u d y .  Y o u  c a n  g e t  t h e  a d d r e s s e s  o r  p h o n e  n u m b e r s  f o r  t h e s e  
b o d i e s  f r o m  s e v e r a l  p l a c e s .  T r y  y o u r  l o c a l  t e l e p h o n e  d i r e c t o r y ;  y o u r  l o c a l  h o s p i t a l ;  o r  y o u r  
l o c a l  a r e a  h e a l t h  a u t h o r i t y .
W h a t  i f  s o m e t h i n g  g o e s  w r o n g ?  I f  y o u  a r e  h a r m e d  b y  t a k i n g  p a r t  i n  t h i s  r e s e a r c h  p r o j e c t ,  
t h e r e  a r e  n o  s p e c i a l  c o m p e n s a t i o n  a r r a n g e m e n t s .  I f  y o u  a r e  h a r m e d  d u e  t o  s o m e o n e 's  n e g l i ­
g e n c e ,  t h e n  y o u  m a y  h a v e  g r o u n d s  f o r  a  l e g a l  a c t i o n  b u t  y o u  m a y  h a v e  t o  p a y  f o r  i t .  R e g a r d ­
l e s s  o f  t h i s ,  i f  y o u  w i s h  t o  c o m p l a i n  a b o u t  a n y  a s p e c t  o f  t h e  w a y  y o u  h a v e  b e e n  a p p r o a c h e d  o r  
t r e a t e d  d u r i n g  t h e  c o u r s e  o f  t h i s  s t u d y ,  t h e  n o r m a l  N a t i o n a l  H e a l t h  S e r v i c e  c o m p l a i n t s  m e c h ­
a n i s m s  m a y  b e  a v a i l a b l e  t o  y o u .
E x t r a  i n f o r m a t i o n  a b o u t  v i g a b a t r i n .  S i n c e  t h e  s t u d y  w a s  f i r s t  a p p r o v e d ,  m o r e  s t u d i e s  
a b o u t  v i g a b a t r i n  h a v e  b e e n  c o m p l e t e d .  I n  1 9 9 7 ,  s o m e  a d u l t  p a t i e n t s  w h o  h a d  b e e n  t r e a t e d  w i t h  
v i g a b a t r i n  w e r e  f o u n d  t o  h a v e  p r o b l e m s  w i t h  v i s i o n .  T h i s  p r o b l e m  w a s  p o o r  v i s i o n  a r o u n d  t h e  
o u t s i d e  o f  t h e  v i s u a l  f i e l d .  I t  i s  c a l l e d  a  'v i s u a l  f i e l d  d e f e c t '  o r  ' v i s u a l  f i e l d  c o n s t r i c t i o n ' .  M a n y  
p e o p l e  a r e  n o t  a w a r e  t h a t  t h e y  h a v e  t h i s  t y p e  o f  v i s u a l  f i e l d  d e f e c t ,  a n d  i t  i s  o f t e n  o n l y  f o u n d  
w h e n  w e  d o  s p e c i a l  t e s t s  o f  v i s i o n .  S u c h  t e s t s  h a v e  n o w  b e e n  d o n e  o n  m a n y  p e o p l e  w h o  h a v e  
b e e n  t r e a t e d  w i t h  v i g a b a t r i n .  T h e s e  t e s t s  s u g g e s t  t h a t  t h e  p r o b l e m  o c c u r s  i n  a b o u t  o n e  i n  t h r e e  
p e o p l e  w h o  h a v e  b e e n  t r e a t e d  f o r  m o r e  t h a n  s i x  m o n t h s .  I t  h a s  b e e n  f o u n d  i n  a  s m a l l  n u m b e r  
o f  o l d e r  c h i l d r e n .  W e  a r e  n o t  a b l e  t o  d o  t h e s e  t e s t s  i n  b a b i e s  o r  c h i l d r e n  l e s s  t h a n  n i n e  y e a r s  
o l d ,  s o  w e  d o  n o t  k n o w  i f  t h e y  a r e  a t  r i s k  f r o m  t h i s  s i d e  e f f e c t .  V i g a b a t r i n  h a s  b e e n  r e v i e w e d  b y  
t h e  'E u r o p e a n  C o m m i t t e e  f o r  P r o p r i e t a r y  M e d i c i n a l  P r o d u c t s ' .  T h i s  c o m m i t t e e  h a s  m e m b e r s  
f r o m  a l l  c o u n t r i e s  i n  t h e  E u r o p e a n  C o m m u n i t y ,  a n d  i t  c o n s i d e r s  d r u g  l i c e n c e s  a n d  d r u g  s a f e t y .  
T h i s  r e v i e w  d e c i d e d  t h a t  v i g a b a t r i n  m a y  s t i l l  b e  u s e d  t o  t r e a t  i n f a n t i l e  s p a s m s .
D e s c r i p t i o n  o f  p r e d n i s o l o n e .  S o m e  o f  t h e  r e s e a r c h  e t h i c s  c o m m i t t e e s  c o m m e n t e d  o n  o u r  
d e s c r i p t i o n  o f  p r e d n i s o l o n e .  W e  s a i d  t h a t  i t  i s  a  ' t y p e  o f  s t e r o i d  t h a t  o u r  b o d i e s  p r o d u c e  n a t ­
u r a l l y ' .  W e  w o u l d  l i k e  t o  m a k e  i t  c l e a r  t h a t  p r e d n i s o l o n e  i t s e l f  i s  n o t  p r o d u c e d  i n  t h e  h u m a n  
b o d y .  I t  h a s  a  s t r u c t u r e  t h a t  i s  s l i g h t l y  d i f f e r e n t  f r o m  s t e r o i d s  t h a t  a r e  p r o d u c e d  i n  t h e  b o d y .  
H o w e v e r ,  i t s  a c t i o n s  a r e  l i k e  t h o s e  o f  s t e r o i d s  t h a t  t h e  b o d y  m a k e s  e v e r y  d a y ,  a n d  w h i c h  a r e  
m a d e  i n  h i g h e r  d o s e s  w h e n  t h e  b o d y  i s  s t r e s s e d  o r  i l l .  A  b e t t e r  d e s c r i p t i o n  i s  t h a t  p r e d n i s o l o n e  
i s  " s i m i l a r  t o  a  t y p e  o f  s t e r o i d  t h a t  o u r  b o d i e s  p r o d u c e  n a t u r a l l y " .  W e  h o p e  t h a t  t h i s  d e s c r i p ­
t i o n  i s  c l e a r e r .
D o s e  o f  p r e d n i s o l o n e .  S o m e  d o c t o r s  h a v e  c o m m e n t e d  t h a t  t h e  d o s e  o f  p r e d n i s o l o n e  i s  
h i g h e r  t h a n  t h e y  u s u a l l y  u s e .  W e  k n o w  t h a t  d r u g s  s u c h  a s  S y n a c t h e n  D e p o t  c a u s e  t h e  a d r e n a l  
g l a n d  o f  t h e  b o d y  t o  m a k e  v e r y  h i g h  d o s e s  o f  t h e  b o d y ' s  n a t u r a l  s t e r o i d s ,  a n d  w e  t h i n k  t h a t  
p r e d n i s o l o n e  m i g h t  b e  a  b e t t e r  t r e a t m e n t  i f  g i v e n  a t  a  h i g h e r  d o s e .  S o m e  d o c t o r s  u s e  s t e r o i d s
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f o r  s e v e r a l  m o n t h s .  H o w e v e r ,  o t h e r  d o c t o r s  h a v e  s u g g e s t e d  t h a t  s h o r t e r  c o u r s e s  o f  t r e a t m e n t  
a r e  s a f e r .  I t  i s  p o s s i b l e  t h a t  t h e  h i g h e r  d o s e  m a y  c a u s e  m o r e  s i d e  e f f e c t s .  H o w e v e r ,  w e  h o p e  
t h a t  t h e  h i g h e r  d o s e  a n d  s h o r t e r  l e n g t h  o f  t r e a t m e n t  w i l l  b e  b o t h  b e t t e r  a n d  s a f e r .
S t e r o i d s  a n d  i m m u n i s a t i o n s .  T h e  i n f o r m a t i o n  s h e e t s  f o r  p r e d n i s o l o n e  a n d  S y n a c t h e n ®  
D e p o t  s a y  t h a t  y o u r  c h i l d  s h o u l d  n o t  r e c e i v e  i m m u n i s a t i o n s  ( v a c c i n e s )  d u r i n g  t r e a t m e n t .  
P l e a s e  n o t e  t h a t  t h e  B r i t i s h  N a t i o n a l  F o r m u l a r y  -  t h e  g e n e r a l  g u i d e  t o  p r e s c r i b i n g  m e d i c i n e s  
i n  t h e  U K  -  r e c o m m e n d s  t h a t  s o m e  i m m u n i s a t i o n s  a r e  b e t t e r  a v o i d e d  f o r  t h r e e  m o n t h s  a f t e r  
t r e a t m e n t .  H o w e v e r ,  t h i s  n e e d s  t o  b e  c o n s i d e r e d  i n  t h e  l i g h t  o f  y o u r  c h i l d ' s  n e e d s .  I f  y o u r  
c h i l d  i s  g i v e n  p r e d n i s o l o n e  o r  S y n a c t h e n ®  D e p o t ,  p l e a s e  a s k  y o u r  d o c t o r  a b o u t  t h i s .
S u m m a r y .  W e  h o p e  t h a t  t h i s  e x t r a  i n f o r m a t i o n  i s  u s e f u l .  P l e a s e  a s k  y o u r  d o c t o r  i f  y o u  
w o u l d  l i k e  m o r e  e x p l a n a t i o n  a b o u t  a n y  o f  t h e s e  i s s u e s .  T h a n k  y o u  f o r  t a k i n g  t h e  t i m e  t o  
c o n s i d e r  j o i n i n g  t h e  s t u d y .
B.3 Study protocol amendment 30 April 2001
This information sheet for parents or guardians was a study protocol amend­
ment approved by the MREC on 30 April 2001. It is identical to the earlier pro­
tocol amendment shown in Section B.2 with the exception of the paragraph on 
Dose of prednisolone, which was broadened into the paragraph shown below on 
Safety of prednisolone and Synacthen® Depot.
U K I S S  -  E x t r a  i n f o r m a t i o n  f o r  p a r e n t s  o r  g u a r d i a n s :  3 0  A p r i l  2 0 0 1  ( i n c o r p o r a t e s  a n d  r e ­
p l a c e s  e x t r a  i n f o r m a t i o n  s h e e t  1 1  M a y ,  2 0 0 0 )
S a f e t y  o f  p r e d n i s o l o n e  a n d  S y n a c t h e n ®  D e p o t  S o m e  d o c t o r s  h a v e  c o m m e n t e d  t h a t  t h e  
d o s e  o f  p r e d n i s o l o n e  i s  h i g h e r  t h a n  t h e y  u s u a l l y  u s e .  W e  k n o w  t h a t  d r u g s  s u c h  a s  S y n a c t h e n ®  
D e p o t  c a u s e  t h e  a d r e n a l  g l a n d  o f  t h e  b o d y  t o  m a k e  v e r y  h i g h  d o s e s  o f  t h e  b o d y ' s  n a t u r a l  
s t e r o i d s ,  a n d  w e  t h i n k  t h a t  p r e d n i s o l o n e  m i g h t  b e  a  b e t t e r  t r e a t m e n t  i f  g i v e n  a t  a  h i g h e r  d o s e .  
S o m e  d o c t o r s  u s e  s t e r o i d s  f o r  s e v e r a l  m o n t h s .  H o w e v e r ,  o t h e r  d o c t o r s  h a v e  s u g g e s t e d  t h a t  
s h o r t e r  c o u r s e s  o f  t r e a t m e n t  a r e  s a f e r .  T r e a t m e n t  w i t h  p r e d n i s o l o n e  o r  S y n a c t h e n ®  D e p o t  
m a y  m a s k  t h e  s i g n s  a n d  s y m p t o m s  o f  i n f e c t i o n .  I t  m a y  a l s o  m a k e  y o u r  c h i l d  l e s s  a b l e  t o  
f i g h t  i n f e c t i o n s .  I f  y o u r  c h i l d  b e c o m e s  u n w e l l  o r  d e v e l o p s  f e v e r  w h i l e  t a k i n g  e i t h e r  o f  t h e s e  
t r e a t m e n t s ,  p l e a s e  p h o n e  y o u r  d o c t o r  f o r  a d v i c e .  Y o u r  c h i l d  m a y  n e e d  u r g e n t  t r e a t m e n t  w i t h  
a n t i b i o t i c s .  C h i c k e n  p o x  i s  m o r e  d a n g e r o u s  t o  c h i l d r e n  o n  s t e r o i d s  a n d  i f  y o u r  c h i l d  c o m e s  
i n t o  c o n t a c t  w i t h  c h i c k e n  p o x  w h i l e  o n  s t e r o i d s ,  o r  s h o r t l y  a f t e r w a r d s ,  y o u  m u s t  i m m e d i a t e l y  
i n f o r m  y o u r  c o n s u l t a n t .  T r e a t m e n t  f o r  c h i c k e n  p o x  i s  a v a i l a b l e .  I t  i s  p o s s i b l e  t h a t  t h e  h i g h e r  
d o s e  m a y  c a u s e  m o r e  s i d e  e f f e c t s .  H o w e v e r ,  w e  h o p e  t h a t  t h e  h i g h e r  d o s e  a n d  s h o r t e r  l e n g t h  
o f  t r e a t m e n t  w i l l  b e  b o t h  b e t t e r  a n d  s a f e r .
Appendix C
Questions and Statements from 
West Delphi
In this thesis, references to questions and statements from West Delphi rounds 
are referred to by abbreviations of the form R1Q5, for example, to refer to West 
Delph round 1 question 5; and R4S1 to refer to round 4 statement 1.
C.l Round 1 invitation 
C.2 West Delphi round 1 questions
R 1 Q 1 .  T h e  c l i n i c a l  f e a t u r e s  o f  i n f a n t i l e  s p a s m s  a r e  w e l l  e s t a b l i s h e d ,  a n d  I  h a v e  n o  p r o b l e m  i n  
d e c i d i n g  w h e n  a  c h i l d  h a s  t h i s  c o n d i t i o n :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  
a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 1 Q 2 .  I  t h i n k  t h a t  w e  s h o u l d  d i a g n o s e  i n f a n t i l e  s p a s m s  o n l y  i f  o n s e t  o f  s y m p t o m s  o c c u r s :  ( a )  
b e f o r e  1 y e a r  o f  a g e ;  ( b )  b e f o r e  2  y e a r s  o f  a g e ;  ( c )  b e f o r e  5  y e a r s  o f  a g e ;  ( d )  I  a m  n o t  s u r e  i f  w e  
s h o u l d  h a v e  a n  u p p e r  a g e  l i m i t ;  ( e )  I  t h i n k  t h a t  w e  s h o u l d  N O T  h a v e  a n y  u p p e r  a g e  l i m i t .
R 1 Q 3 .  I t  i s  e a s y  t o  d e c i d e ,  a t  t h e  t i m e  o f  d i a g n o s i s  o f  i n f a n t i l e  s p a s m s ,  w h e t h e r  a  c h i l d  h a d  
d e v e l o p m e n t a l  d e l a y  t h a t  p r e c e d e d  t h e  o n s e t  o f  s p a s m s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  
a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 1 Q 4 .  T h e  t r a d i t i o n a l  c a t e g o r i s a t i o n  o f  i n f a n t i l e  s p a s m s  i n t o  s y m p t o m a t i c  a n d  c r y p t o g e n i c / i d ­
i o p a t h i c  g r o u p s  i s  a  u s e f u l  w a y  o f  p r e d i c t i n g  d e v e l o p m e n t a l  p r o g n o s i s :  ( a )  I  a g r e e  s t r o n g l y ;
( b )  I  a g r e e ;  (c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 1 Q 5 .  I t  i s  c l e a r  w h e n  a  c h i l d  h a s  i d i o p a t h i c  r a t h e r  t h a n  c r y p t o g e n i c  i n f a n t i l e  s p a s m s :  ( a )  I  
a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  
s t r o n g l y .
R 1 Q 6 .  I d e n t i f y i n g  E E G  f e a t u r e s  t h a t  a r e  n e c e s s a r y  a n d  s u f f i c i e n t  t o  d e f i n e  h y p s a r r h y t h m i a  
f o r  s t u d i e s  o f  i n f a n t i l e  s p a s m s  i s  t o o  c o m p l i c a t e d  a n d  a m b i t i o u s  f o r  t h i s  D e l p h i  p r o c e s s :  ( a )  I  
a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e
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s t r o n g l y .
R 1 Q 7 .  A g g r e g a t e d  d a t a  f r o m  s t u d i e s  s u c h  a s  m e t a - a n a l y s e s  a r e  l i k e l y  t o  h e l p  m e  m a k e  t r e a t ­
m e n t  d e c i s i o n s  f o r  m y  o w n  p a t i e n t s  w i t h  i n f a n t i l e  s p a s m s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  (c )  
I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 1 Q 8 .  W e  n e e d  t o  s t a n d a r d i s e  t h e  i d e a  o f  " c e s s a t i o n  o f  s p a s m s "  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s  
b y  r e q u i r i n g  t h a t  n o  s p a s m s  a r e  w i t n e s s e d  f o r  a  m i n i m a l  p e r i o d  o f :  ( a )  2 4  h o u r s ;  ( b )  4 8  h o u r s ;
(c )  1 w e e k ;  ( d )  2  w e e k s ;  ( e )  1 m o n t h ;  ( f )  a  m i n i m a l  p e r i o d  d i f f e r e n t  f r o m  t h o s e  a b o v e ;  ( g )  i t  
m a k e s  n o  s e n s e  t o  h a v e  s u c h  a  m i n i m a l  p e r i o d .
R 1 Q 9 .  I f  a  s t u d y  r e p o r t s  t h a t  s o m e  c h i l d r e n  d e v e l o p e d  h y p e r t e n s i o n ,  i t  i s  c l e a r  t o  m e  t h a t  t h e s e  
h a v e  b e e n  s e r i o u s  a d v e r s e  e v e n t s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  
d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 1 Q 1 0 .  W e  s h o u l d  m a k e  a  s t r o n g  r e c o m m e n d a t i o n  t h a t  s t u d i e s  o f  i n f a n t i l e  s p a s m s  i n c l u d e  a n  
a s s e s s m e n t  o f  d e v e l o p m e n t  a t  l e a s t  a s  l a t e  a s :  ( a )  1 2  m o n t h s ;  ( b )  2 4  m o n t h s ;  ( c )  3 6  m o n t h s ;  ( d )  5  
y e a r s ;  ( e )  1 2  y e a r s ;  ( f )  I  d o  n o t  t h i n k  t h a t  s u c h  d e v e l o p m e n t a l  a s s e s s m e n t s  s h o u l d  b e  r e q u i r e d .
C.3 West Delphi round 2 questions
S E C T I O N  1
R 2 Q 1 .  P l e a s e  i n d i c a t e  a m e n d m e n t s ,  a d d i t i o n s  o r  d e l e t i o n s  y o u  w o u l d  m a k e  t o  t h i s  g e n e r a l  
o v e r v i e w  s t a t e m e n t  a b o u t  i n f a n t i l e  s p a s m s .  T r y  t o  k e e p  t h e  s t a t e m e n t  s h o r t ,  s o  t h a t  i t  p r o v i d e s  
a  s u c c i n c t  d e s c r i p t i o n  o f  i n f a n t i l e  s p a s m s .
S T A T E M E N T :  " I n f a n t i l e  s p a s m s  i s  a  f o r m  o f  e p i l e p s y  t h a t  u s u a l l y  h a s  a n  o n s e t  
i n  c h i l d r e n  l e s s  t h a n  t w o  y e a r s  o l d .  I t s  m a i n  c l i n i c a l  m a n i f e s t a t i o n  i s  e p i l e p t i c  
s p a s m s ,  w h i c h  u s u a l l y  o c c u r  i n  c l u s t e r s .  T h e r e  a r e  m a n y  p o t e n t i a l  e t i o l o g i e s  
s i n c e  i t  i s  a s s o c i a t e d  w i t h  m a n y  c o n d i t i o n s .  T h e  m o s t  c h a r a c t e r i s t i c  E E G  f i n d i n g  
i s  h y p s a r r h y t h m i a .  T h i s  i s  f o u n d  i n  m o s t  c a s e s ,  b u t  n o t  t h r o u g h o u t  t h e  c l i n i c a l  
c o u r s e  o f  t h e  c o n d i t i o n .  H y p s a r r h y t h m i a  i s  u s u a l l y  s u p p r e s s e d  d u r i n g  a  c l i n i c a l  
a t t a c k  o f  e p i l e p t i c  s p a s m s .  T h i s  s u g g e s t s  t h a t ,  a l t h o u g h  t h e r e  i s  E E G  e v i d e n c e  o f  
w i d e s p r e a d  d y s f u n c t i o n  o f  t h e  c e r e b r a l  c o r t e x ,  t h e  a c t u a l  e p i l e p t i c  s p a s m s  o r i g i ­
n a t e  f r o m  t h e  c e r e b r a l  s u b c o r t e x . "
R 2 Q 2 .  W e  m i g h t  w i s h  t o  u s e  d i s t i n c t  t e r m s  t o  d e f i n e  t h e  f o l l o w i n g  c l i n i c a l  s c e n a r i o s :  ( a )  t h e  
s y n d r o m e  o f  c l i n i c a l  s p a s m s  w i t h  h y p s a r r h y t h m i a ;  ( b )  c l i n i c a l  s p a s m s  w i t h  e p i l e p t i f o r m  E E G  
f e a t u r e s  b u t  n o  e v i d e n c e  o f  h y p s a r r h y t h m i a ;  ( c )  c l i n i c a l  s p a s m s  w i t h  n o  e v i d e n c e  o f  E E G  a b ­
n o r m a l i t y ;  ( d )  h y p s a r r h y t h m i a  w i t h  c l i n i c a l  s p a s m s  t h a t  o c c u r  s i n g l y  b u t  n e v e r  i n  c l u s t e r s ;  ( e )  
h y p s a r r h y t h m i a  w i t h  n o  o b s e r v e d  c l i n i c a l  s p a s m s  f )  c a s e s  w i t h  c l i n i c a l  s p a s m s  t h a t  h a v e  n o t  
y e t  h a d  a n  E E G ;  ( g )  t h e  s p e c t r u m  o f  c o n d i t i o n s  w i t h  c l i n i c a l  s p a s m s .
P l e a s e  s u g g e s t  s u c c i n c t  a n d  d i s t i n c t  t e r m s  o r  p h r a s e s  f o r  t h e s e  e n t i t i e s  ( t h o u g h  y o u  m a y  
p r e f e r  a  s i n g l e  t e r m  f o r  ( f )  a n d  ( g ) ) .
R 2 Q 3 .  C a s e s  o f  i n f a n t i l e  s p a s m s  w i t h  t u b e r o u s  s c l e r o s i s  ( T S )  s e e m  t o  s h o w  s u b s t a n t i a l l y  b e t t e r  
t r e a t m e n t  r e s p o n s e s  t o  v i g a b a t r i n  t h a n  o t h e r  s y m p t o m a t i c  c a s e s .  T h i s  s u g g e s t s  t h a t  i t  w o u l d  b e  
u s e f u l  t o  h a v e  a  d i a g n o s t i c  o r  p r o g n o s t i c  c l a s s i f i c a t i o n  o f  i n f a n t i l e  s p a s m s  b a s e d  o n  d i f f e r e n t
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e t i o l o g i e s .  T h e r e  i s  a  b a l a n c e  b e t w e e n  h a v i n g  t o o  f e w  g r o u p s  a n d  f a i l i n g  t o  i n v e s t i g a t e  i m ­
p o r t a n t  d i f f e r e n c e s ,  a n d  h a v i n g  t o o  m a n y  g r o u p s  a n d  l e a v i n g  s t u d i e s  p r o n e  t o  s m a l l  n u m b e r  
b i a s e s .  E t i o l o g i c  c l a s s e s  w o u l d  i d e a l l y  r e f l e c t  s i m i l a r i t i e s  i n :  u n d e r l y i n g  m e c h a n i s m s  ( a b o u t  
w h i c h  l i t t l e  i s  k n o w n ) ;  p r o g n o s i s ;  a n d  t r e a t m e n t  r e s p o n s e s .
P l e a s e  s u g g e s t  a  s y s t e m  o f  e t i o l o g i c  c l a s s e s  t h a t  m i g h t  m e e t  t h e s e  n e e d s .  F o r  e x a m p l e ,  y o u  
m i g h t  s u g g e s t  3  c l a s s e s :  ( 1 )  n o n - s y m p t o m a t i c  c a s e s ;  ( 2 )  c a s e s  w i t h  T S ;  ( 3 )  s y m p t o m a t i c  c a s e s  
o t h e r  t h a n  T S .  O r  y o u  m i g h t  s u g g e s t  7  o r  8  c l a s s e s .
R 2 Q 4 .  P l e a s e  s t a t e  y o u r  o p i n i o n  o n  w h a t  a r e  n e c e s s a r y  E E G  f e a t u r e s  o f  h y p s a r r h y t h m i a .  N e c ­
e s s a r y  f e a t u r e s  a r e  t h o s e  w h i c h ,  i f  n o t  p r e s e n t ,  w o u l d  m a k e  y o u  d e c i d e  t h a t  t h e  E E G  i s  N O T  
h y p s a r r h y t h m i c .  T h e s e  s h o u l d  b e  s i n g l e  f e a t u r e s :  f o r  e x a m p l e ,  " h i g h  a m p l i t u d e  s l o w  w a v e s "  
( o r  p r e f e r a b l y  s o m e t h i n g  m o r e  s p e c i f i c ,  s u c h  a s ,  " s l o w  w a v e s  w i t h  a m p l i t u d e  g r e a t e r  t h a n  2 0 0  
m i c r o v o l t s " ) .  I f  y o u  c a n  i m a g i n e  c a l l i n g  a n  E E G  h y p s a r r h y t h m i c  i n  t h e  a b s e n c e  o f  t h i s  f e a t u r e ,  
i t  i s  n o t  a  n e c e s s a r y  f e a t u r e .
R 2 Q 5 .  P l e a s e  s t a t e  y o u r  o p i n i o n  o n  w h a t  a r e  s u f f i c i e n t  E E G  f e a t u r e s  o f  h y p s a r r h y t h m i a .  S u f ­
f i c i e n t  f e a t u r e s  a r e  l i k e l y  t o  b e  c l u s t e r s ,  s u c h  a s  " h i g h - a m p l i t u d e ,  m u l t i f o c a l ,  e p i l e p t i f o r m  
s p i k e s ,  w i t h  t e m p o r a l  v a r i a t i o n  i n  s p i k e  l o c a t i o n  a n d  d u r a t i o n . "  T h e r e  m a y  b e  s e v e r a l  d i f ­
f e r e n t  c l u s t e r s  o r  p a t t e r n s  t h a t  y o u  w o u l d  c o n s i d e r  s u f f i c i e n t  t o  c o n s t i t u t e  h y p s a r r h y t h m i a .  
N o t e  t h a t ,  i f  y o u  h a v e  d e f i n e d  a  n e c e s s a r y  f e a t u r e ,  t h i s  w o u l d  n e e d  t o  o c c u r  i n  e a c h  c l u s t e r  o f  
s u f f i c i e n t  f e a t u r e s .  F o r  e x a m p l e ,  i f  y o u  h a d  s t a t e d  " h i g h - a m p l i t u d e  s l o w  w a v e s "  a s  a  n e c e s ­
s a r y  f e a t u r e ,  t h i s  f e a t u r e  s h o u l d  a p p e a r  i n  e a c h  c l u s t e r  o f  s u f f i c i e n t  f e a t u r e s .  I f  y o u  c a n  i m a g i n e  
c a l l i n g  a n  E E G  w i t h  a l l  t h e s e  f e a t u r e s  s o m e t h i n g  o t h e r  t h a n  h y p s a r r h y t h m i a ,  i t  i s  n o t  a  c l u s t e r  
o f  s u f f i c i e n t  f e a t u r e s .
R 2 Q 6 .  S t a t e  a n y  a r g u m e n t s  y o u  m a y  h a v e  i n  f a v o r  o f  o r  a g a i n s t  t h e  c h o i c e  o f  a  2 8 - d a y  s p a s m -  
f r e e  p e r i o d  t o  d e t e r m i n e  t h e  o u t c o m e  cessation of spasms. T h e s e  a r g u m e n t s  w i l l  i n f o r m  a  v o t e  
i n  R o u n d  3  o f  W e s t  D e l p h i .
R 2 Q 7 .  P l e a s e  s t a t e  w h i c h  t e s t ( s )  o f  d e v e l o p m e n t  o r  f u n c t i o n  y o u  w o u l d  w i s h  t o  p e r f o r m  o n  a  
c h i l d  w h o  h a d  h a d  i n f a n t i l e  s p a s m s  a n d  w a s  n o w  a g e d  5  y e a r s .  I f  y o u  k n o w  o f  a n  a n a l o g o u s  
t e s t  i n  E n g l i s h ,  p l e a s e  s t a t e  t h a t  a l s o .
R O U N D  2  S E C T I O N  2
P l e a s e  i n d i c a t e  y o u r  p r e f e r r e d  r e s p o n s e s  t o  t h e s e  q u e s t i o n s  a s  i n  R O U N D  1 .
R 2 Q 8 .  A  c l i n i c a l  d i a g n o s i s  o f  i n f a n t i l e  s p a s m s  s h o u l d  o n l y  b e  m a d e  w h e n  s o m e  o f  t h e  s p a s m s  
o c c u r  i n  c l u s t e r s ,  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  
d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 9 .  T h e  m o s t  a p p r o p r i a t e  i c t a l  u n i t  ( o r  s e i z u r e  u n i t )  i s :  ( a )  T h e  s p a s m ;  ( b )  T h e  c l u s t e r  o f  
s p a s m s ;  (c )  I  a m  n o t  s u r e  w h i c h  o f  t h e s e  o u g h t  t o  b e  t h e  i c t a l  u n i t ;  ( d )  I  t h i n k  a n o t h e r  m e a s u r e  
s h o u l d  c o n s t i t u t e  t h e  i c t a l  u n i t ;  ( e )  I  d o  N O T  t h i n k  t h e  c o n c e p t  o f  a n  i c t a l  u n i t  i s  u s e f u l .
I n  t h e  f o l l o w i n g  q u e s t i o n ,  p l e a s e  r a n k  y o u r  r e s p o n s e s  a c c o r d i n g  t o  w h i c h  y o u  b e l i e v e  t o  b e  
m o s t  i m p o r t a n t .
R 2 Q 1 0 .  I t  i s  i m p o r t a n t  t o  h a v e  a n  a g e - r e l a t e d  c l a s s i f i c a t i o n  o f  i n f a n t i l e  s p a s m s  b e c a u s e :  ( a )  
o l d e r  a n d  y o u n g e r  c a s e s  a r e  m o r e  l i k e l y  t o  b e  m i s c l a s s i f i e d  c a s e s  o f  o t h e r  c o n d i t i o n s ;  ( b )  t h e r e  
i s  a  s u b s t a n t i a l l y  d i f f e r e n t  e t i o l o g i c  c a s e - m i x ;  ( c )  a g e  a t  o n s e t  i s  a n  i n d e p e n d e n t  p r e d i c t o r  o f  
p r o g n o s i s ;  ( d )  a g e - r e l a t e d  p a t h o p h y s i o l o g i c a l  m e c h a n i s m s  a r e  l i k e l y  t o  r e s u l t  i n  d i f f e r e n t  r e ­
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s p o n s e s  t o  t r e a t m e n t ;  ( e )  o t h e r  [ p l e a s e  s t a t e ] .
R 2 Q 1 1 .  W e  s h o u l d  c l a s s i f y  c a s e s  o f  i n f a n t i l e  s p a s m s  b y  a g e  a t  o n s e t :  ( a )  i n t o  3  c l a s s e s :  ( i)  
a g e  l e s s  t h a n  3  m o n t h s  ( e a r l y ) ;  ( i i )  a g e  3  t o  1 2  m o n t h s  ( c l a s s i c ) ;  a n d  ( i i i )  a g e  o v e r  1 2  m o n t h s  
( l a t e ) ;  ( b )  i n t o  4  c l a s s e s :  ( i )  a g e  l e s s  t h a n  3  m o n t h s  ( e a r l y ) ;  ( i i )  a g e  3  t o  1 2  m o n t h s  ( c l a s s i c ) ;  
( i i i )  a g e  1 2  m o n t h s  t o  2 4  m o n t h s  ( l a t e ) ;  ( i v )  a g e  o v e r  2 4  m o n t h s  ( v e r y  l a t e ) ;  ( c )  i n t o  c l a s s e s  
d i f f e r e n t  f r o m  t h e  a b o v e  [ p l e a s e  s t a t e ] ;  ( d )  i n t o  o n e  o f  t h e  a b o v e  c l a s s i f i c a t i o n s  b u t  r e f e r r i n g  t o  
t h e m  b y  d i f f e r e n t  t e r m s  [ p l e a s e  s t a t e ] ;  ( e )  I  d o  N O T  t h i n k  t h a t  a n  a g e - r e l a t e d  c l a s s i f i c a t i o n  i s  
w o r t h w h i l e .
R 2 Q 1 2 .  W i t h  r e s p e c t  t o  a n  a g e - r e l a t e d  c l a s s i f i c a t i o n  o f  i n f a n t i l e  s p a s m s ,  a g e  a t  o n s e t  i s  l i k e l y  t o  
b e  a s s e s s e d  u n r e l i a b l y ,  a n d  a g e  a t  d i a g n o s i s  i s  a  b e t t e r  a g e - r e l a t e d  v a r i a b l e :  ( a )  I  a g r e e  s t r o n g l y ;
( b )  I  a g r e e ;  (c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 3 .  W i t h  r e s p e c t  t o  a n  a g e - r e l a t e d  c l a s s i f i c a t i o n  o f  i n f a n t i l e  s p a s m s ,  w e  s h o u l d  a d j u s t  f o r  
t h e  e f f e c t  o f  g e s t a t i o n a l  a g e  a t  b i r t h  ( p r e t e r m  d e l i v e r y ) :  ( a )  a t  a l l  a g e s ;  ( b )  f o r  c h i l d r e n  u p  t o  
t h e  a g e  o f  2  y e a r s ;  ( c )  f o r  c h i l d r e n  u p  t o  t h e  a g e  o f  1 y e a r ;  ( d )  f o r  c h i l d r e n  u p  t o  t h e  a g e  o f  3  
m o n t h s ;  ( e )  I  a m  n o t  s u r e  i f  w e  o u g h t  t o  u s e  a g e  a d j u s t m e n t ;  ( f )  w e  d o  N O T  n e e d  t o  u s e  a g e s  
a d j u s t e d  f o r  g e s t a t i o n a l  a g e  a t  b i r t h .
R 2 Q 1 4 .  S i n c e  d e v e l o p m e n t a l  d e l a y  a t  t h e  t i m e  o f  o n s e t  o f  i n f a n t i l e  s p a s m s  i s  h a r d  t o  a s s e s s ,  
m a n y  c a s e s  a r e  l i k e l y  t o  b e  m i s d a s s i f i e d  a n d  w e  o u g h t  N O T  t o  u s e  t h i s  a s  a  c r i t e r i o n  f o r  
d e f i n i n g  W e s t  s y n d r o m e :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;
( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 5 .  D e v e l o p m e n t a l  d e l a y  a t  t h e  t i m e  o f  d i a g n o s i s  i s  l i k e l y  t o  b e  a n  i n d e p e n d e n t  p r e d i c t o r  
o f  p r o g n o s i s  a f t e r  a d j u s t m e n t  f o r  t h e  e f f e c t  o f  u n d e r l y i n g  c a u s e :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;
(c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 6 .  W e  s h o u l d  d i s t i n g u i s h  p r o s p e c t i v e  c l a s s i f i c a t i o n  o f  i n f a n t i l e  s p a s m s  ( i e ,  c l a s s i f i c a t i o n  
s o o n  a f t e r  d i a g n o s i s  a n d  b e f o r e  a  t r e a t m e n t  d e c i s i o n  i s  m a d e )  f r o m  r e t r o s p e c t i v e  c l a s s i f i c a t i o n  
( i e ,  c l a s s i f i c a t i o n  a f t e r  w e  h a v e  p e r f o r m e d  a  f u l l  s e t  o f  i n v e s t i g a t i o n s ) :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  
I  a g r e e ;  (c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 7 .  T h e  t e r m  cryptogenic infantile spasms s h o u l d  n o  l o n g e r  b e  u s e d :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  
I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 8 .  I t  i s  e a s y  t o  c l i n i c a l l y  d i s t i n g u i s h  m y o c l o n u s  f r o m  s p a s m s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  
a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 1 9 .  S p a s m s  c a n  b e  r e l i a b l y  d i s t i n g u i s h e d  f r o m  m y o c l o n u s  a n d  t o n i c  s e i z u r e s  b y  t h e  d u r a ­
t i o n  o f  E M G  p o t e n t i a l s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;
( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 2 0 .  I t  s e e m s  l i k e l y  t h a t  t h e  i c t a l  e p i s o d e s  a s s o c i a t e d  w i t h  i n f a n t i l e  s p a s m s  h a v e  a  s u b c o r t i -  
c a l  o r i g i n :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;
( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 2 1 .  W e s t  D e l p h i  s h o u l d  c o n s i d e r  t h e  d i a g n o s t i c  a n d  t h e r a p e u t i c  r o l e  o f  p y r i d o x i n e  i n  
i n f a n t i l e  s p a s m s :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  (c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  
d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
T h e  n e x t  q u e s t i o n  r e f e r s  t o :  E n g e l  J ,  J r .  A  P r o p o s e d  D i a g n o s t i c  S c h e m e  f o r  P e o p l e  w i t h  E p i l e p ­
t i c  S e i z u r e s  a n d  w i t h  E p i l e p s y :  R e p o r t  o f  t h e  I L A E  T a s k  F o r c e  o n  C l a s s i f i c a t i o n  a n d  T e r m i n o l ­
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o g y .  Epilepsia 2 0 0 1 ; 4 2 :1 - 8 .  T h i s  s u g g e s t s  f i v e  d i a g n o s t i c  a x e s :  A x i s  1 -  I c t a l  p h e n o m e n o l o g y ;  
A x i s  2  -  S e i z u r e  t y p e ;  A x i s  3  -  S y n d r o m e ;  A x i s  4  -  E t i o l o g y ;  A x i s  5  -  I m p a i r m e n t .
R 2 Q 2 2 .  W e s t  D e l p h i  s h o u l d  a t t e m p t  t o  d e v e l o p  a  c l a s s i f i c a t i o n  s c h e m e  f o r  i n f a n t i l e  s p a s m s  
t h a t  i s  c o n s i s t e n t  w i t h  t h e  5 - a x i s  d i a g n o s t i c  s y s t e m  p r o p o s e d  b y  t h e  I L A E  T a s k  F o r c e  o n  C l a s ­
s i f i c a t i o n  a n d  T e r m i n o l o g y :  ( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  ( c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  
d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  d i s a g r e e  s t r o n g l y .
R 2 Q 2 3 .  I n  f u t u r e  s t u d i e s  o f  i n f a n t i l e  s p a s m s ,  t h e  p r i m a r y  o u t c o m e  s h o u l d  b e  cessation of spasms: 
( a )  I  a g r e e  s t r o n g l y ;  ( b )  I  a g r e e ;  (c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  
d i s a g r e e  s t r o n g l y .
R 2 Q 2 4 .  P l e a s e  r a n k  t h e  f o l l o w i n g  o u t c o m e s :  ( a )  t i m e  t o  c e s s a t i o n  o f  s p a s m s ;  ( b )  t i m e  t o  5 0 %  r e ­
d u c t i o n  i n  n u m b e r  o f  i c t a l  u n i t s ;  ( c )  r e l a p s e ;  ( d )  s e r i o u s  a d v e r s e  e v e n t s ;  ( e )  n o n - s e r i o u s  a d v e r s e  
e v e n t s ;  ( f )  d e v e l o p m e n t  a t  2  y e a r s  o f  a g e ;  ( g )  d e v e l o p m e n t  a t  5  y e a r s  o f  a g e ;  ( h )  p r o g r e s s i o n  t o  
o t h e r  s e i z u r e  t y p e s .
I n  t h e  f o l l o w i n g  q u e s t i o n ,  p l e a s e  i n d i c a t e  a s  m a n y  r e s p o n s e s  a s  y o u  t h i n k  a p p r o p r i a t e .  Y o u  
m a y  w i s h  t o  c o m m e n t  o n  w h i c h  t e r m s  w e  m i g h t  u s e  f o r  s u c h  r e l a p s e s .
R 2 Q 2 5 .  I n  a  c h i l d  t h a t  h a s  h a d  c e s s a t i o n  o f  s p a s m s  b y  a n  a g r e e d  d e f i n i t i o n ,  t h e  o c c u r r e n c e  
o f  t h e  f o l l o w i n g  f e a t u r e s  s h o u l d  b e  c o n s i d e r e d  a  f o r m  o f  relapse: ( a )  s p a s m s  o c c u r r i n g  i n  c l u s ­
t e r s ;  ( b )  s p a s m s  t h a t  d o  N O T  o c c u r  i n  c l u s t e r s ;  ( c )  a  s i n g l e  w i t n e s s e d  s p a s m ;  ( d )  e p i l e p t i c  
m o v e m e n t s  t h a t  a r e  n o t  s p a s m s ;  ( e )  h y p s a r r h y t h m i a  o n  a n  E E G  w i t h o u t  a n y  c l i n i c a l  s e i z u r e  
a c t i v i t y ;  ( f )  a n  e p i l e p t i f o r m  E E G  t h a t  d o e s  n o t  s h o w  h y p s a r r h y t h m i a ;  ( g )  a n  a b n o r m a l  E E G  
w i t h  n o  e p i l e p t i f o r m  f e a t u r e s .
I n  t h e  n e x t  q u e s t i o n  w e  c o n s i d e r  t h e  period of sufficient therapeutic trial. T h i s  i s  t h e  p e r i o d  w i t h i n  
w h i c h  y o u  w o u l d  r e a s o n a b l y  e x p e c t  a  t r e a t m e n t  r e s p o n s e  ( f o r  e x a m p l e ,  n o  f u r t h e r  o b s e r v e d  
s p a s m s ) .  Y o u  w o u l d  e x p e c t  m o s t  c a s e s  t o  h a v e  r e s p o n d e d  w i t h i n  t h i s  p e r i o d .  I f  t h e  t r e a t m e n t  
h a s  n o t  b e e n  e f f e c t i v e  w i t h i n  t h i s  p e r i o d ,  y o u  w o u l d  c o n s i d e r  i t  u n l i k e l y  t h a t  t h e  c h i l d  w i l l  
r e s p o n d  t o  t h i s  t r e a t m e n t  a n d  y o u  w o u l d  c h a n g e  t o  a n o t h e r  t r e a t m e n t  r e g i m e n .
R 2 Q 2 6 .  T h e  m o s t  a p p r o p r i a t e  p e r i o d  o f  s u f f i c i e n t  t h e r a p e u t i c  t r i a l  f o r  t r e a t m e n t s  o f  i n f a n t i l e  
s p a s m s  i s :  ( a )  5  d a y s ;  ( b )  7  d a y s ;  ( c )  1 0  d a y s ;  ( d )  1 4  d a y s ;  ( e )  2 1  d a y s ;  ( f )  2 8  d a y s ;  ( g )  o t h e r  
[ p l e a s e  s t a t e ] ;  ( h )  t h i s  w o u l d  v a r y  f r o m  t r e a t m e n t  t o  t r e a t m e n t  a n d  w e  o u g h t  n o t  t o  a t t e m p t  t o  
r e c o m m e n d  a  s t a n d a r d .
I n  t h e  n e x t  q u e s t i o n  w e  w i l l  c o n s i d e r  t h e  period of necessary therapeutic trial. T h i s  i s  t h e  p e r i o d  
w i t h i n  w h i c h  y o u  w o u l d  n o t  e x p e c t  a  t r e a t m e n t  r e s p o n s e  ( f o r  e x a m p l e ,  n o  f u r t h e r  o b s e r v e d  
s p a s m s ) .  F e w  c a s e s  w o u l d  h a v e  r e s p o n d e d  t o  t r e a t m e n t  b y  t h e  e n d  o f  t h i s  p e r i o d .  I f  t h e  
t r e a t m e n t  h a s  n o t  b e e n  g i v e n  f o r  t h i s  p e r i o d ,  y o u  w o u l d  c o n s i d e r  t h a t  t h e  t r e a t m e n t  h a d  n o t  
h a d  a  fair therapeutic trial. ( O f  c o u r s e ,  i f  t h e r e  w e r e  a n  a d v e r s e  e v e n t ,  i t  m i g h t  b e  n e c e s s a r y  t o  
s t o p  t h e  t r e a t m e n t  b e f o r e  t h e  e n d  o f  t h i s  p e r i o d . )
R 2 Q 2 7 .  T h e  m o s t  a p p r o p r i a t e  p e r i o d  o f  n e c e s s a r y  t h e r a p e u t i c  t r i a l  f o r  t r e a t m e n t s  o f  i n f a n t i l e  
s p a s m s  i s :  ( a )  2  d a y s ;  ( b )  3  d a y s ;  ( c )  5  d a y s ;  ( d )  7  d a y s ;  ( e )  1 0  d a y s ;  ( f )  1 4  d a y s ;  ( g )  o t h e r  
[ p l e a s e  s t a t e ] ;  ( h )  t h i s  w o u l d  v a r y  f r o m  t r e a t m e n t  t o  t r e a t m e n t  a n d  w e  o u g h t  n o t  t o  a t t e m p t  t o  
r e c o m m e n d  a  s t a n d a r d .
R 2 Q 2 8 .  W i t h  r e s p e c t  t o  d e v e l o p m e n t a l  a s s e s s m e n t  o f  c h i l d r e n  w i t h  i n f a n t i l e  s p a s m s ,  w e  
s h o u l d  a d j u s t  f o r  t h e  e f f e c t  o f  g e s t a t i o n a l  a g e  a t  b i r t h  ( p r e t e r m  d e l i v e r y ) :  ( a )  a t  a l l  a g e s ;  ( b )  
f o r  c h i l d r e n  a s s e s s e d  a t  t h e  a g e  o f  5  y e a r s ;  (c )  f o r  c h i l d r e n  a s s e s s e d  a t  t h e  a g e  o f  2  y e a r s ;  ( d )
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f o r  c h i l d r e n  a s s e s s e d  a t  t h e  a g e  o f  1 y e a r ;  ( e )  f o r  c h i l d r e n  a s s e s s e d  a t  t h e  a g e  o f  3  m o n t h s ;  ( f )  I  
a m  n o t  s u r e  i f  w e  o u g h t  t o  u s e  a g e  a d j u s t m e n t ;  ( g )  w e  d o  N O T  n e e d  t o  u s e  a g e s  a d j u s t e d  f o r  
g e s t a t i o n a l  a g e  a t  b i r t h .
R 2 Q 2 9 .  T h e  m o s t  a p p r o p r i a t e  s i n g l e  a g e  f o r  e a r l y  d e v e l o p m e n t a l  o r  f u n c t i o n a l  a s s e s s m e n t  o f  
c h i l d r e n  w h o  h a v e  h a d  i n f a n t i l e  s p a s m s  i s :  ( a )  1 2  m o n t h s ;  ( b )  1 4  m o n t h s ;  ( c )  1 8  m o n t h s ;  ( d )  2 4  
m o n t h s ;  ( e )  3 6  m o n t h s ;  ( f )  o t h e r .
R 2 Q 3 0 .  P O T E N T I A L  C O N S E N S U S  S T A T E M E N T :  W e  r e c o m m e n d  t h a t  d e v e l o p m e n t a l  a s s e s s ­
m e n t s  o f  c h i l d r e n  w h o  h a v e  h a d  i n f a n t i l e  s p a s m s  a r e  m a d e  a t  l e a s t  a s  l a t e  a s  t h e  a g e  o f  5  y e a r s ,  
a n d  w e  e n c o u r a g e  f u r t h e r  a s s e s s m e n t s  a t  t h e  a g e  o f  1 2  y e a r s ,  ( a )  I  s t r o n g l y  a g r e e ;  9 b )  I  a g r e e ;
(c )  I  a m  n o t  s u r e  i f  I  a g r e e  o r  d i s a g r e e ;  ( d )  I  d i s a g r e e ;  ( e )  I  s t r o n g l y  d i s a g r e e .
S E C T I O N  3 : G E N E R A L  C O M M E N T S  O N  T H I S  R O U N D
S E C T I O N  4 : C O M M E N T S  A B O U T  F U T U R E  R O U N D S
C.4 West Delphi round 3 questions
R o u n d  3  w i l l  c o n s i s t  m a i n l y  o f  p o t e n t i a l  c o n s e n s u s  s t a t e m e n t s  t h a t  y o u  a r e  i n v i t e d  t o  c r i t i c i s e  
a n d  c o m m e n t  u p o n .  R e s p o n s e s  t o  t h e s e  p o t e n t i a l  c o n s e n s u s  s t a t e m e n t s  w i l l  g e n e r a l l y  b e  o f  
t h e  f o r m :  " ( a )  I  g e n e r a l l y  a g r e e  w i t h  t h i s  s t a t e m e n t ;  ( b )  I  a m  n o t  s u r e  a b o u t  t h i s  s t a t e m e n t ;  ( c )  I  
d i s a g r e e  w i t h  t h i s  s t a t e m e n t ,  a n d  m y  r e a s o n s  a r e . . .  c o m m e n t s ,  i n c l u d i n g  w h e t h e r  y o u  t h i n k  a  
s t a t e m e n t  a b o u t  t h i s  a r e a  o f  s t u d y  d e s i g n  s h o u l d  b e  i n c l u d e d  i n  t h e  W e s t  D e l p h i  c o n s e n s u s . "  I t  
i s  n o t  n e c e s s a r y  t o  s t a t e  a n y  r e a s o n s  f o r  d i s a g r e e i n g  w i t h  t h e  s t a t e m e n t ,  b u t  i t  h e l p s  t h e  p r o c e s s  
i f  o t h e r  p a r t i c i p a n t s  k n o w  w h y  t h e r e  i s  d i s a g r e e m e n t .  A l s o ,  w e  n e e d  a s  a  g r o u p  t o  a d d r e s s  t h e  
u n d e r l y i n g  r e a s o n  f o r  t h e  d i s a g r e e m e n t  w h e n  w e  f o r m u l a t e  q u e s t i o n s  f o r  t h e  n e x t  r o u n d .
I n  o r d e r  t o  a s s e s s  t h e  v a l u e  o f  a  p o t e n t i a l  c o n s e n s u s  s t a t e m e n t ,  i t  m i g h t  b e  u s e f u l  t o  a s k  t h e  
q u e s t i o n s  s u c h  a s :
•  I f  I  w e r e  d e s i g n i n g  a  s t u d y  o f  t r e a t m e n t s  f o r  i n f a n t i l e  s p a s m s ,  w o u l d  t h i s  r e c o m m e n d a ­
t i o n  o r  s t a t e m e n t  m a k e  m y  t a s k  e a s i e r ?
•  I f  I  w e r e  t r y i n g  t o  c l a s s i f y  a  c h i l d  w h o  p r e s e n t s  t o  m e  w i t h  w h a t  l o o k  l i k e  i n f a n t i l e  
s p a s m s ,  w o u l d  t h i s  s c h e m e  b e  u s e f u l  a n d  v a l i d ?
•  I s  t h i s  s t a t e m e n t  c o n s i s t e n t  w i t h  o t h e r  s t a t e m e n t s  w i t h  w h i c h  I  a g r e e ?
•  I f  I  w e r e  r e a d i n g  s e v e r a l  p a p e r s  o n  i n f a n t i l e  s p a s m s ,  w o u l d  m y  t a s k  b e  e a s i e r  i f  I  k n e w  
t h a t  t h e  a u t h o r s  h a d  u s e d  d e f i n i t i o n s  f r o m  t h i s  c o n s e n s u s ?
I n  t h i s  r o u n d ,  w e  w i l l  s t a r t  t o  a d d r e s s  p r o p o s a l s  f o r  h o w  o u t c o m e  m e a s u r e s  m i g h t  b e s t  b e  
r e p o r t e d .  T h e s e  h a v e  b e e n  i n c o r p o r a t e d  i n t o  t h e  s t a t e m e n t s  a n d  a r e  o p e n  t o  d e b a t e  a n d  c r i t i ­
c i s m .
N o t e s  o n  f l o w  c h a r t  s h o w n  i n  f i g u r e  5 .1  o n  p a g e  1 8 9  a n d  t o  a c c o m p a n y  R 3 Q 1 .
" * E E G :  s t a n d a r d ,  s l e e p  a n d  v i d e o  E E G s  a r e  a l l  p e r f o r m e d ,  a s  n e c e s s a r y ,  b e f o r e  e x c l u d i n g  a  
p o s i t i v e  f i n d i n g .
"* * 2  y e a r s :  2  y e a r s  i s  n o t  a n  a b s o l u t e  u p p e r  l i m i t ,  b u t  s u b s t a n t i a l l y  o l d e r  c a s e s  w o u l d  b e  c l a s ­
s i f i e d  a s  a n o t h e r  s y n d r o m e ,  s u c h  a s  t h a t  o f  p e r i o d i c  s p a s m s .
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" S u g g e s t e d  c r o s s - r e f e r e n c e  t o  I L A E  m u l t i a x i a l  c l a s s i f i c a t i o n :  A x i s  1 ( i c t a l  p h e n o m e n o l ­
o g y )  =  s p a s m s ;  A x i s  2  ( s e i z u r e  t y p e )  =  e p i l e p t i c  s p a s m s ;  A x i s  3  ( s y n d r o m e )  =  W e s t  s y n d r o m e ,  
i n f a n t i l e  s p a s m s  a n d  IS - S S  v a r i a n t .
" S u g g e s t e d  u s e  f o r  s y n d r o m e  t e r m s :  1 )  S t u d i e s  o f  i n f a n t i l e  s p a s m s  w o u l d  i n c l u d e  c a s e s  o f  
I S -S S  v a r i a n t  a n d  c a s e s  o f  W e s t  s y n d r o m e  u n l e s s  e x c l u s i o n s  o r  r e s t r i c t i o n s  a r e  e x p l i c i t l y  s t a t e d ;  
2 )  S t u d i e s  o f  W e s t  s y n d r o m e  w o u l d  e x c l u d e  c a s e s  w i t h o u t  c l u s t e r e d  s p a s m s  a n d  c a s e s  w i t h o u t  
h y p s a r r h y t h m i a .
" N o t e  t h a t  t h i s  c l a s s i f i c a t i o n  r e q u i r e s  c l u s t e r s  o f  s p a s m s  f o r  a  d i a g n o s i s  o f  W e s t  s y n d r o m e .  
C a s e s  w i t h  s p a s m s  o c c u r r i n g  s i n g l y  a n d  w i t h o u t  a n y  w i t n e s s e d  c l u s t e r s ,  e v e n  w h e n  a s s o c i a t e d  
w i t h  h y p s a r r h y t h m i a ,  a r e  n o t  c l a s s i f i e d  a s  W e s t  s y n d r o m e .  T h u s ,  u s i n g  t h i s  c l a s s i f i c a t i o n ,  W e s t  
s y n d r o m e  b e c o m e s  e f f e c t i v e l y  a  t r i a d :  s p a s m s ;  o c c u r r e n c e  o f  t h o s e  s p a s m s  i n  c l u s t e r s ;  a n d  
h y p s a r r h y t h m i a . "
R 3 Q 1 :  a )  I  g e n e r a l l y  a g r e e  w i t h  t h e  c o n t e n t  o f  t h e  a b o v e  f l o w  d i a g r a m ;  b )  I  a m  n o t  s u r e  a b o u t  
t h e  c o n t e n t  o f  t h i s  f l o w  d i a g r a m ;  c )  I  t h i n k  t h i s  f l o w  d i a g r a m  w o u l d  b e  b e t t e r  i f . . ..
N o t e s  o n  f l o w  c h a r t  s h o w n  i n  f i g u r e  5 .2  o n  p a g e  1 9 0  a n d  d i s c u s s e d  i n  R 3 Q 2 .
" I t  i s  w e l l  k n o w n  t h a t  h y p s a r r h y t h m i a  c a n  o c c u r  i n  t h e  a b s e n c e  o f  s p a s m s ,  a n d  s o m e t i m e s  
w i t h o u t  a n y  e v i d e n t  c l i n i c a l  s e i z u r e  [ 2 3 6 ] .  S i n c e  h y p s a r r h y t h m i a  i s  e f f e c t i v e l y  t h e  p r e s e n t i n g  
f e a t u r e  i n  s u c h  c a s e s  ( a t  l e a s t ,  w i t h  r e s p e c t  t o  c o n s i d e r i n g  a  d i a g n o s i s  o f  i n f a n t i l e  s p a s m s )  i t  i s  
u s e f u l  t o  h a v e  a  s c h e m e  f o r  c l a s s i f i c a t i o n  c o n d i t i o n a l  u p o n  t h e  p r e s e n c e  o f  h y p s a r r h y t h m i a . "
R 3 Q 2 :  a )  I  g e n e r a l l y  a g r e e  w i t h  t h e  c o n t e n t  o f  t h e  a b o v e  f l o w  d i a g r a m ;  b )  I  a m  n o t  s u r e  a b o u t  
t h e  c o n t e n t  o f  t h i s  f l o w  d i a g r a m ;  c )  I  t h i n k  t h i s  f l o w  d i a g r a m  w o u l d  b e  b e t t e r  i f  .. ..
T h e  f o l l o w i n g  q u e s t i o n s  r e l a t e  t o  t h e  r e p o r t s  o f  t h e  I L A E  T a s k  F o r c e  o n  C l a s s i f i c a t i o n  a n d  
T e r m i n o l o g y  Proposed Diagnostic Scheme for People with Epileptic Seizures and Epilepsy a n d  t h e  
Glossary of Descriptive Terminology for Ictal Semiology [ 2 3 3 , 2 3 4 ] .
R 3 Q 3 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  s t u d i e s  o f  i n f a n t i l e  s p a s m s  u s e  t h e  m e t h o d  o f  c l a s s i f i c a t i o n  
a n d  d e s c r i p t i o n  p r o p o s e d  b y  t h e  I L A E  T a s k  F o r c e  o n  C l a s s i f i c a t i o n  a n d  T e r m i n o l o g y ,  2 0 0 1 ,  
w h i c h  u s e s  a  5 - a x i s  s y s t e m  o f  c l a s s i f i c a t i o n  [ 2 3 3 ] . "
R 3 Q 4 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  t h e  Glossary of Descriptive Terminology for Ictal Semiology, 
2001, w e  p r e f e r  t o  d r o p  t h e  a d j e c t i v a l  c o m p o n e n t  o f  t h e  t e r m  e p i l e p t i c  s p a s m s  s i n c e ,  f r o m  t h e  
d e s c r i p t i o n  o f  t h e  i c t a l  p h e n o m e n a  a l o n e ,  i t  i s  i m p o s s i b l e  t o  i n f e r  t h a t  t h e  s p a s m s  a r e  e p i l e p t i c  
i n  n a t u r e .  T h u s ,  w e  p r e f e r  t o  r e f e r  t o  t h e  i c t a l  p h e n o m e n a  a s  spasms [ 2 3 4 ] . "
R 3 Q 5 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  A x i s  1 ( i c t a l  p h e n o m e n o l o g y ) ,  w e  p r o p o s e  t h e  t e r m  spasms 
f o r  t h e  i c t a l  p h e n o m e n a  o f  i n f a n t i l e  s p a s m s  o r  W e s t  s y n d r o m e .  T h e  s p a s m s  n o r m a l l y  i n v o l v e  
t h e  t r u n k  a n d  p r o x i m a l  l i m b s .  T h e y  m a y  i n v o l v e  o n l y  t h e  t r u n k  a n d  m a y  m a n i f e s t  a s  m e r e l y  a  
h e a d  n o d .  T h e  s u b t l e s t  m a n i f e s t a t i o n  w o u l d  b e  a  f a c i a l  g r i m a c e  [ 2 3 7 ] .  S p a s m s  w o u l d  n o t  u s u ­
a l l y  i n v o l v e  o n l y  t h e  l i m b s ,  a n d  t h i s  f e a t u r e  w o u l d  s u g g e s t  m y o c l o n u s  o r  a n o t h e r  s e i z u r e  t y p e .  
A s y m m e t r i c  s p a s m s  a r e  c o n s i s t e n t  w i t h  a  d i a g n o s i s  o f  i n f a n t i l e  s p a s m s  o r  W e s t  s y n d r o m e ,  a n d  
t h e  p r e s e n c e  o f  f e a t u r e s  s u c h  a s  t h i s  s h o u l d  b e  i n c l u d e d  i n  t h e  A x i s  1 d e s c r i p t i o n . "
R 3 Q 6 .  S t a t e m e n t :  " T h e r e  h a v e  b e e n  d e s c r i p t i o n s  o f  m o r e  s u b t l e  f o r m s  o f  b e h a v i o u r a l  a c ­
c o m p a n i m e n t  t o  w h a t  a p p e a r s  t o  b e  t h e  a t t a c k  a s s o c i a t e d  w i t h  a  h y p s a r r h y t h m i c  E E G .  T h e s e  
i n c l u d e  e p i s o d e s  o f  g a s p i n g  a n d  i s o l a t e d  e y e  m o v e m e n t s  [ 2 3 7 ] .  W e  r e c o m m e n d  t h a t ,  t h o u g h  
t h e y  m a y  b e  t h e  i c t u s  i n  s o m e  c h i l d r e n  w i t h  h y p s a r r h y t h m i a ,  s u c h  s u b t l e  f o r m s  a r e  n o t  c l a s s i ­
f i e d  a s  s p a s m s .  S u c h  m o v e m e n t s  a r e  n o t  s u g g e s t e d  b y  t h e  t e r m  s p a s m s ,  a r e  d i f f i c u l t  t o  d e t e c t
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c l i n i c a l l y  a n d ,  b e c a u s e  o f  t h e i r  s u b t l e t y ,  w o u l d  n o t  b e  r e l i a b l e  o u t c o m e s  i n  c l i n i c a l  s t u d i e s . "
R 3 Q 7 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  A x i s  2  ( s e i z u r e  t y p e )  o f  t h e  I L A E  p r o p o s e d  d i a g n o s t i c  
s c h e m e ,  w e  p r o p o s e  t h a t  t h e  t e r m  epileptic spasms i s  u s e d  t o  d e s c r i b e  t h e  e p i s o d e s  o f  b r i e f  
m u s c u l a r  c o n t r a c t i o n ,  g e n e r a l l y  w i t h  a  d u r a t i o n  o f  a p p r o x i m a t e l y  1 s e c o n d :  t h a t  i s ,  l o n g e r  
t h a n  a n  e p i s o d e  o f  m y o c l o n u s ,  a n d  s h o r t e r  t h a n  a  t o n i c  s e i z u r e .  T h i s  t e r m  w o u l d  i n c l u d e  t h e  
period spasms o f  G o b b i  a n d  infantile spasms [ 2 5 ,  2 9 ] .  T h e  t e r m  epileptic spasms i m p l i e s  t h a t  t h e  
E E G  i s  c o n s i s t e n t  w i t h  t h e  d i a g n o s i s  o f  a n  e p i l e p s y ,  b u t  d o e s  n o t  i m p l y  a n y  m o r e  s p e c i f i c  E E G  
p a t t e r n . "
R 3 Q 8 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  A x i s  3  ( s y n d r o m e )  o f  t h e  I L A E  p r o p o s e d  d i a g n o s t i c  s c h e m e ,  
w e  p r o p o s e  t h a t  infantile spasms i s  t h e  s y n d r o m e  o f  e p i l e p t i c  s p a s m s  w i t h  o n s e t  g e n e r a l l y  d u r ­
i n g  t h e  f i r s t  t w o  y e a r s  o f  l i f e  i n  a s s o c i a t i o n  w i t h  f o c a l  o r  d i f f u s e  i n t e r i c t a l  E E G  a b n o r m a l i t i e s  
[2 5 ] .  W e  p r o p o s e  t h a t  West syndrome i s  d e f i n e d  b y  t h e  a s s o c i a t i o n  o f  i n f a n t i l e  s p a s m s ,  a t  l e a s t  
s o m e  o f  w h i c h  o c c u r  i n  c l u s t e r s ,  w i t h  a n  i n t e r i c t a l  E E G  s h o w i n g  h y p s a r r h y t h m i a .  T h i s  m a y  
b e  e i t h e r  t y p i c a l  h y p s a r r h y t h m i a ,  o r  h y p s a r r h y t h m i a  w i t h  a t y p i c a l  f e a t u r e s . "  [ P l e a s e  n o t e  t h a t  
w e  w o u l d  t h e r e f o r e  b e  p r o p o s i n g  t w o  t e r m s  f o r  i n c l u s i o n  i n  t h i s  a x i s :  i n f a n t i l e  s p a s m s  a n d  
W e s t  s y n d r o m e . ]
R 3 Q 9 .  S t a t e m e n t :  " W e  s e e  n o  r e a s o n  f o r  i n c l u d i n g  d e v e l o p m e n t a l  d e l a y  a t  t h e  t i m e  o f  o n s e t  a s  
a  d e f i n i n g  f e a t u r e  o f  W e s t  s y n d r o m e .  I n d e e d ,  d e v e l o p m e n t a l  d e l a y  a t  o n s e t  o f  s p a s m s  i s  l i k e l y  
t o  b e  a s s e s s e d  u n r e l i a b l y  b e c a u s e  s p a s m s  a r e  o f t e n  s u b t l e  a n d  u n r e c o g n i s e d  a t  t h e i r  t r u e  t i m e  
o f  o n s e t ,  a n d  b e c a u s e  d e v e l o p m e n t  i s  h a r d  t o  a s s e s s  i n  e a r l y  i n f a n c y .  T h i s  w o u l d  b e  l i k e l y  t o  
l e a d  t o  m i s c l a s s i f i c a t i o n  o f  c a s e s . "
R 3 Q 1 0 .  T h i s  q u e s t i o n  r e l a t e s  t o  t h e  a b s t r a c t  f r o m  t h e  I C D - 1 0  p a e d i a t r i c  a d a p t a t i o n  [ s i m i l a r  t o  
t h e  v e r s i o n  i n c l u d e d  i n  t h e  f i n a l  c o n s e n s u s  s t a t e m e n t  t h a t  i s  s h o w n  i n  t a b l e  5 .1 5  o n  p a g e  1 9 9 ] .  
S t a t e m e n t :  " W e  p r o p o s e  t h a t  A x i s  4  ( e t i o l o g y )  o f  t h e  m u l t i a x i a l  c l a s s i f i c a t i o n  s y s t e m ,  w h e n  
u s e d  f o r  s t u d i e s  o f  i n f a n t i l e  s p a s m s ,  s h o u l d  u s e  a  c l a s s i f i c a t i o n  t h a t  c o n c o r d s  w i t h  t h e  W H O  
I C D - 1 0  p a e d i a t r i c  a d a p t a t i o n .  C a s e s  t h a t  c a n n o t  b e  c l a s s i f i e d  i n t o  a n y  o f  t h e s e  g r o u p s  w o u l d  
b e  c l a s s i f i e d  a s  idiopathic. S t u d i e s  m i g h t  u n d e r t a k e  s e p a r a t e  a n a l y s e s  o f  e t i o l o g i c  s u b g r o u p s ,  
o r  a g g r e g a t i o n s  o f  t h e s e  s u b g r o u p s ,  w h e n  t h e r e  e x i s t  a priori r e a s o n s  f o r  s u s p e c t i n g  d i f f e r e n t  
r e s p o n s e  f r o m  s u c h  g r o u p s .  S t a n d a r d i s e d  c l a s s i f i c a t i o n  b y  t h i s  m e t h o d  w o u l d  f a c i l i t a t e  a pos­
teriori a n a l y s e s  o f  e t i o l o g i c  g r o u p s  u s i n g  d a t a  a g g r e g a t e d  f r o m  m a n y  e a r l i e r  s t u d i e s . "
R 3 Q 1 1 .  " W i t h  r e s p e c t  t o  A x i s  5  ( i m p a i r m e n t ) ,  w e  s h o u l d  e x p l o r e  t h e  u s e  o f  c l a s s e s  o b t a i n e d  
f r o m  t h e  W H O  I D I D H - 2  c l a s s i f i c a t i o n . "
R 3 Q 1 2 .  S t a t e m e n t :  " I n f a n t i l e  s p a s m s  t y p i c a l l y  h a v e  a n  o n s e t  b e t w e e n  3  a n d  1 2  m o n t h s  o f  a g e .  
Y o u n g e r  a n d  o l d e r  c h i l d r e n  a r e  m o r e  l i k e l y  t o  h a v e  o t h e r  c o n d i t i o n s ,  a n d  t h e r e  i s  a  g r e a t e r  r i s k  
o f  m i s c l a s s i f i c a t i o n .  A l s o ,  a g e  a t  o n s e t  o f  s p a s m s  m a y  i n f l u e n c e  o u t c o m e s .  W e  p r o p o s e  t h a t  
s t u d i e s  o f  W e s t  s y n d r o m e  a n d  i n f a n t i l e  s p a s m s  r e p o r t  o u t c o m e s  f o r  c h i l d r e n  i n  t h e  a g e  g r o u p s :  
1 )  l e s s  t h a n  t h r e e  m o n t h s  o f  a g e  ( c o r r e c t e d  f o r  p r e t e r m  d e l i v e r y ) ;  2 )  3  m o n t h s  ( c o r r e c t e d  a g e )  
a n d  u p  t o  1 2  m o n t h s  o f  a g e ;  3 )  1 2  m o n t h s  o f  a g e  a n d  o l d e r .  W e  p r o p o s e  t h a t  t h e s e  b e  r e f e r r e d  
t o  r e s p e c t i v e l y  b y  t h e  t e r m s :  early onset, classic onset, a n d  late onset. O n s e t  w o u l d  r a r e l y  o c c u r  
a f t e r  t w o  y e a r s  o f  a g e ,  b u t  i t  i s  b i o l o g i c a l l y  i m p l a u s i b l e  t o  s e t  a n  a b s o l u t e  u p p e r  a g e  l i m i t . "
R 3 Q 1 3 .  S t a t e m e n t :  " I n  s t u d i e s  o f  i n f a n t i l e  s p a s m s ,  t h e  t e r m s  symptomatic, cryptogenic, a n d  id­
iopathic h a v e  b e e n  u s e d  v a r i a b l y  a n d  o f t e n  w i t h o u t  e x p l i c i t  d e f i n i t i o n .  T h e  r e c e n t  t a s k  f o r c e  
d i a g n o s t i c  s c h e m e  p r o p o s e s  t h a t  t h e  t e r m  probably symptomatic epilepsy syndrome i s  u s e d ,  i n  
p l a c e  o f  t h e  f o r m e r  t e r m  cryptogenic, t o  d e s c r i b e  s y n d r o m e s  i n  w h i c h  t h e r e  i s  n o  i d e n t i f i e d
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e t i o l o g y  b u t  w h e r e  t h e r e  i s  t h o u g h t  t o  b e  a n  u n d e r l y i n g  s t r u c t u r a l  b r a i n  l e s i o n  ( i e ,  a  s y m p ­
t o m a t i c  e p i l e p s y  s y n d r o m e )  [ 2 3 3 ] .  I t  p r o p o s e s  t h e  t e r m  idiopathic epilepsy syndrome t o  d e s c r i b e  
s y n d r o m e s  w i t h  e p i l e p s y  a n d  n o  u n d e r l y i n g  b r a i n  l e s i o n ;  n o  o t h e r  n e u r o l o g i c  s y m p t o m s  o r  
s i g n s ;  a n  a g e - d e p e n d e n t  c o u r s e ;  a n d  a  p r e s u m a b l y  g e n e t i c  e t i o l o g y . "
R 3 Q 1 4 .  S t a t e m e n t  " W i t h  r e s p e c t  t o  e t i o l o g i c  c l a s s i f i c a t i o n ,  w e  p r o p o s e  t h a t  s t u d i e s  s t a t e  
c l e a r l y  t h e  e t i o l o g i c  s t a t u s  o f  p a r t i c i p a n t s  a t  t h e  t i m e  o f  t h e  t r e a t m e n t  d e c i s i o n  a n d  a t  t h e  e n d  
o f  t h e  s t u d y .  W e  s u g g e s t  t h e  q u a l i f y i n g  t e r m  prospectively t o  i n d i c a t e  t h e  e t i o l o g i c  c l a s s  s t a t u s  
o f  p a r t i c i p a n t s  a t  t h e  t i m e  o f  t r e a t m e n t  d e c i s i o n  ( a n d  t o  r e f e r  t o  t h i s  a s  t h e  prospective etiologic 
classification), a n d  t h e  u n q u a l i f i e d  t e r m s  symptomatic, probably symptomatic, a n d  idiopathic t o  i n ­
d i c a t e  t h e  e t i o l o g i c  s t a t u s  o f  p a r t i c i p a n t s  a t  t h e  e n d  o f  t h e  s t u d y  o r  a t  t h e  t i m e  o f  t h e  m o s t  
r e c e n t  a s s e s s m e n t  ( a n d  t o  r e f e r  t o  t h i s  a s  t h e  final etiologic classification). O n e  m i g h t  e x p e c t  a  
l a r g e  p r o p o r t i o n  o f  p r o s p e c t i v e l y  p r o b a b l y  s y m p t o m a t i c  s t u d y  p a r t i c i p a n t s  t o  l a t e r  b e c o m e  
s y m p t o m a t i c ,  a n d  t h e  s a m e  f o r  a  s m a l l e r  p r o p o r t i o n  o f  p r o s p e c t i v e l y  i d i o p a t h i c  p a r t i c i p a n t s .  
P r o s p e c t i v e l y  s y m p t o m a t i c  p a r t i c i p a n t s  o u g h t  a l l  t o  e n d  t h e  s t u d y  a s  s y m p t o m a t i c . "
R 3 Q 1 5 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  e t i o l o g i c  c l a s s i f i c a t i o n ,  w e  p r o p o s e  t h a t  t h e  f i n a l  e t i o l o g i c  
c l a s s i f i c a t i o n  i s  u s e d  f o r  a n a l y s e s  w h e n  t h e  p r i m a r y  s t u d y  q u e s t i o n  i s  r e l a t e d  t o  e f f i c a c y  a n d  b i ­
o l o g i c a l  m e c h a n i s m s ;  a n d  t h a t  t h e  p r o s p e c t i v e  e t i o l o g i c  c l a s s i f i c a t i o n  i s  u s e d  f o r  a n a l y s e s  w h e n  
t h e  p r i m a r y  s t u d y  q u e s t i o n  r e l a t e s  t o  e f f e c t i v e n e s s  a n d  t r e a t m e n t  d e c i s i o n s .  T h e  p r o s p e c t i v e  
e t i o l o g i c  c l a s s i f i c a t i o n ,  w h i c h  p r o v i d e s  i n f o r m a t i o n  a b o u t  p r o g n o s i s  a n d  t h a t  i n f o r m s  f u t u r e  
t r e a t m e n t  d e c i s i o n s ,  s h o u l d  n o t  b e  r e g a r d e d  a s  i n f e r i o r  t o  t h e  f i n a l  e t i o l o g i c  c l a s s i f i c a t i o n ,  b u t  
m e r e l y  s e r v e s  d i f f e r e n t  p u r p o s e s .  W e  r e c o m m e n d  t h a t  s t u d i e s  c l e a r l y  r e p o r t  r e c l a s s i f i c a t i o n  o f  
c a s e s  b e t w e e n  p r o s p e c t i v e  a n d  f i n a l  e t i o l o g i c  c l a s s e s . "
R 3 Q 1 6 .  S t a t e m e n t  " W e  p r o p o s e  t h a t ,  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s  a n d  W e s t  s y n d r o m e ,  t h e  
c l a s s i f i c a t i o n  o f  c a s e s  a s  symptomatic o r  probably symptomatic s h o u l d  b e  e x t e n d e d  b e y o n d  s t r u c ­
t u r a l  b r a i n  a b n o r m a l i t i e s  t o  i n c l u d e  c a s e s  w i t h  u n d e r l y i n g  c h r o m o s o m a l  a n d  m e t a b o l i c  e t i o l o ­
g i e s  t h a t  d o  n o t  h a v e  e v i d e n t  s t r u c t u r a l  b r a i n  a b n o r m a l i t i e s . "
R 3 Q 1 7 .  S t a t e m e n t  " W i t h  r e s p e c t  t o  t h e  t e r m  hypsarrhythmia, w e  p r o p o s e  t h a t  t h i s  t e r m  i s  u s e d  
t o  d e s c r i b e  a n  E E G  p a t t e r n  t h a t  i s  c h a r a c t e r i s e d  b y  r a n d o m ,  h i g h - v o l t a g e  s p i k e s  a n d  s l o w  
w a v e s .  T h e  m o s t  s t r i k i n g  f e a t u r e s  o f  h y p s a r r h y t h m i a  a r e :  h i g h - v o l t a g e  ( g e n e r a l l y  >  2 0 0  fiV) 
s l o w  w a v e s ;  s p i k e s  a n d  w a v e s  f r o m  m a n y  f o c i  a n d  v a r y i n g  w i t h  t i m e ;  a  l a c k  o f  s y n c h r o n y  a n d  
" c h a o t i c "  a p p e a r a n c e .  T h e  t y p i c a l  a p p e a r a n c e  i s  m o r e  l i k e l y  t o  b e  f o u n d  i n  e a r l i e r  s t a g e s  o f  t h e  
d i s o r d e r  a n d  w h e n  o n s e t  o c c u r s  a t  a  y o u n g e r  a g e .  T h e  h y p s a r r h y t h m i c  p a t t e r n  m a y  d i s a p p e a r  
d u r i n g  R E M  s l e e p ,  b u t  i t  m a y  b e  f o u n d  w i t h  g r e a t e r  s e n s i t i v i t y  i n  s o m e  o t h e r  s t a g e s  o f  s l e e p  
[66]."
R 3 Q 1 8 .  S t a t e m e n t :  " W i t h  r e s p e c t  t o  t h e  u s e  o f  t h e  t e r m s  m o d i f i e d  h y p s a r r h y t h m i a  [ 6 7 ]  a n d  
a t y p i c a l  h y p s a r r h y t h m i a  [ 3 2 ] ,  w e  e n d o r s e  t h e  r e c o m m e n d a t i o n  o f  t h e  1 9 9 1  w o r k s h o p  o n  i n f a n ­
t i l e  s p a s m s  ( C o m m i s s i o n  o n  P e d i a t r i c  E p i l e p s y  o f  t h e  I n t e r n a t i o n a l  L e a g u e  A g a i n s t  E p i l e p s y  
1 9 9 2  [ 2 8 ] )  t h a t  s t u d y  p a r t i c i p a n t s  w i t h  t y p i c a l  a n d  m o d i f i e d  h y p s a r r h y t h m i a  a r e  n o t  r e p o r t e d  
i n  d i c h o t o m i s e d  g r o u p s  b u t  t h a t ,  w h e r e  a p p r o p r i a t e ,  i n d i v i d u a l  a t y p i c a l  f e a t u r e s  a r e  d e s c r i b e d .  
T h e  p r e s e n c e  o f  a t y p i c a l  f e a t u r e s  m a y  d e p e n d  u p o n  t h e  s t a g e  o f  i n f a n t i l e  s p a s m s  a t  w h i c h  t h e  
E E G  i s  p e r f o r m e d ;  i t  m a y  d e p e n d  u p o n  t r e a t m e n t ;  a n d  i t  p r o b a b l y  h a s  l i t t l e  p r a c t i c a l  s i g n i f i ­
c a n c e  i n  r a n d o m i s e d  s t u d i e s . "
R 3 Q 1 9 .  S t a t e m e n t :  " W e  e n d o r s e  t h e  s t a t e m e n t  b y  t h e  I L A E  C o m m i s s i o n  o n  O u t c o m e  M e a ­
s u r e m e n t  i n  E p i l e p s y ,  1 9 9 4 - 9 7  f i n a l  r e p o r t  t h a t  ' t h e r e  i s  a  g r e a t  n e e d  f o r  s t a n d a r d i z a t i o n  o f
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r e p o r t i n g  r e s e a r c h  r e s u l t s  [ 2 3 8 ] /  W e  c o m m e n d  t h e s e  a i m s  a n d  r e c o m m e n d  t h e m  t o  t h o s e  w h o  
e m b a r k  o n  s t u d i e s  o f  i n f a n t i l e  s p a s m s . "
R 3 Q 2 0 .  S t a t e m e n t :  " W e  r e c o m m e n d  t o  t h o s e  d e s i g n i n g ,  a n a l y s i n g ,  i n t e r p r e t i n g ,  a n d  u t i l i z i n g  
s t u d i e s  o f  i n f a n t i l e  s p a s m s  t h a t  c o n s i d e r a t i o n  i s  g i v e n  t o  t h e  d i s t i n c t i o n  b e t w e e n  efficacy a n d  ef­
fectiveness. A n  e f f i c a c y  s t u d y  l o o k s  a t  a n  i n t e r v e n t i o n  i n  i d e a l  c i r c u m s t a n c e s  a n d  w i t h  s e l e c t e d  
p a t i e n t s .  A n  e f f e c t i v e n e s s  s t u d y  l o o k s  a t  i n t e r v e n t i o n s  i n v o l v i n g  t y p i c a l  o r  u n s e l e c t e d  p a t i e n t s  
i n  e v e r y d a y  c i r c u m s t a n c e s  a n d  i n c l u d e s  t h e  e f f e c t s  o f  o t h e r  b i a s e s ,  s u c h  a s  n o n - c o m p l i a n c e  a n d  
d r u g  i n t e r a c t i o n s  [ 2 3 8 , 1 9 0 ] .  W e  c a n  t h i n k  o f  n o  g e n e r a l  a priori r e a s o n  f o r  e f f i c a c y  a n d  e f f e c ­
t i v e n e s s  s t u d i e s  t o  r e p o r t  r a d i c a l l y  d i f f e r e n t  o u t c o m e s  a n d  o u t c o m e  m e a s u r e s .  W e  p r o p o s e  a  
c o m m o n  s t a n d a r d  o f  o u t c o m e s  f o r  a l l  s t u d i e s  o f  i n f a n t i l e  s p a s m s ;  t h a t  r e s e a r c h e r s  s t a t e  c l e a r  
r e a s o n s  f o r  p r e f e r r i n g  o t h e r  p r i m a r y  o u t c o m e s ;  a n d  t h a t ,  i f  o t h e r  p r i m a r y  o u t c o m e s  a r e  p r e ­
f e r r e d ,  t h e  c o n s e n s u s  s t a n d a r d  o u t c o m e s  a r e  i n s t e a d  r e p o r t e d  a s  s e c o n d a r y  o u t c o m e  m e a s u r e s  
i n  o r d e r  t o  f a c i l i t a t e  f u t u r e  s y n t h e s i s  o f  d a t a . "
R 3 Q 2 1 .  S t a t e m e n t :  " T h e r e  i s  d i s a g r e e m e n t  a b o u t  w h e t h e r  t h e  a p p r o p r i a t e  i c t a l  u n i t  i n  s t u d i e s  
o f  i n f a n t i l e  s p a s m s  s h o u l d  b e  t h e  spasm o r  t h e  cluster of spasms. M o s t  m e m b e r s  o f  W e s t  D e l p h i  
t h o u g h t  t h a t  i t  w a s  m o r e  a p p r o p r i a t e  t o  u s e  t h e  c l u s t e r  o f  s p a s m s  a s  t h e  i c t a l  u n i t .  H o w e v e r ,  
w e  f e l t  t h a t  t h e r e  w a s  l i m i t e d  v a l u e  i n  o u t c o m e s  t h a t  r e l y  o n  m e a s u r e m e n t  o f  i c t a l  u n i t s ,  s u c h  
a s  t i m e  t o  5 0 %  r e d u c t i o n  o f  s p a s m s ,  o r  p r o p o r t i o n  o f  p a r t i c i p a n t s  h a v i n g  a  5 0 %  o r  g r e a t e r  
r e d u c t i o n  i n  s p a s m s . "
R 3 Q 2 2 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  t h e  p r i m a r y  o u t c o m e  i n  s t u d i e s  o f  W e s t  s y n d r o m e  a n d  
i n f a n t i l e  s p a s m s  b e  c e s s a t i o n  o f  s p a s m s  f o r  a  p e r i o d  o f  2 8  d a y s .  T h e  p r i m a r y  r e s p o n s e  n e e d  
n o t  r e q u i r e  c e s s a t i o n  o f  h y p s a r r h y t h m i a  o r  n o r m a l i s a t i o n  o f  t h e  E E G ,  b u t  p e r s i s t e n c e  o r  r e ­
c u r r e n c e  o f  h y p s a r r h y t h m i a  i n  p r i m a r y  r e s p o n d e r s  s h o u l d  b e  r e p o r t e d .  W e  p r o p o s e  t h a t  t h e  
m a i n  o u t c o m e  m e a s u r e  i s  t h e  p r o p o r t i o n  i n  e a c h  t r e a t m e n t  g r o u p  t h a t  h a s  b e e n  s p a s m - f r e e  f o r  
a  p e r i o d  o f  2 8  d a y s  b y  t h e  e n d  o f  s t u d y  d a y  4 2  ( t h a t  i s ,  t h e  p r o p o r t i o n  o f  s t u d y  p a r t i c i p a n t s  
t h a t  a r e  s p a s m - f r e e  a t  t h e  e n d  o f  s t u d y  d a y  1 4  a n d  r e m a i n  s p a s m - f r e e  2 8  d a y s  l a t e r ) .  A  u s e f u l  
a n d  r e l a t e d  v a r i a b l e  i s  ' t i m e  t o  2 8 - d a y  f r e e d o m  f r o m  s p a s m s ' ,  w h i c h  i s  b e s t  p r e s e n t e d  i n  t h e  
f o r m  o f  a n  a c t u a r i a l  ( ' s u r v i v a l ' )  c u r v e . "
R 3 Q 2 3 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  a  v i d e o  E E G  ( o r ,  l e s s  p r e f e r a b l y ,  a n o t h e r  f o r m  o f  E E G  
t h a t  i n c l u d e s  a  p e r i o d  o f  s l e e p )  i s  p e r f o r m e d  w i t h i n  s e v e n  d a y s  o f  s t u d y  d a y  4 2  o n  s t u d y  
p a r t i c i p a n t s  w h o  a p p e a r  t o  h a v e  r e s p o n d e d  t o  t r e a t m e n t :  t h a t  i s ,  i t  i s  p e r f o r m e d  b e t w e e n  
s t u d y  d a y s  3 5  a n d  4 9 .  T h i s  w i l l  p e r m i t  d e t e c t i o n  o f  p e r s i s t e n t  h y p s a r r h y t h m i a  i n  t h e  a b s e n c e  
o f  s p a s m s ,  a n d  d e t e r m i n a t i o n  o f  t h e  g r o u p  w i t h  t h e  s e c o n d a r y  o u t c o m e  f r e e d o m  f r o m  s p a s m s  
w i t h  a s s o c i a t e d  r e s o l u t i o n  o f  h y p s a r r h y t h m i a .  I d e a l l y ,  a n  E E G  w o u l d  a l s o  b e  p e r f o r m e d ,  o n  
p a r t i c i p a n t s  w h o  a p p e a r  t o  h a v e  r e s p o n d e d  t o  t r e a t m e n t ,  s o o n  a f t e r  s t u d y  d a y  1 4 ."
R 3 Q 2 4 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  s t u d i e s  o f  i n f a n t i l e  s p a s m s  a n d  W e s t  s y n d r o m e  r e p o r t  
d e v e l o p m e n t  a t  2  y e a r s  o f  a g e  a s  a  p r i m a r y  o u t c o m e  m e a s u r e  t h a t  c o m p l e m e n t s  c e s s a t i o n  o f  
s p a s m s .  W e  r e c o m m e n d  r e p o r t i n g  o f  a  f u r t h e r  d e v e l o p m e n t a l  a s s e s s m e n t  a t  5  y e a r s  o f  a g e ,  
a n d  w e  e n c o u r a g e  r e p o r t i n g  o f  d e v e l o p m e n t  a t  t h e  a g e  o f  1 2  y e a r s .  S t u d i e s  s h o u l d  c o n s i d e r  
r e p o r t i n g  b o t h  a n  a s s e s s m e n t  o f  b e h a v i o u r  a n d  a n  a s s e s s m e n t  o f  i n t e l l i g e n c e . "
R 3 Q 2 5 .  " S t u d i e s  o f  W e s t  s y n d r o m e  a n d  i n f a n t i l e  s p a s m s  s h o u l d  r e p o r t ,  a s  a  b a s e l i n e  c h a r a c t e r ­
i s t i c ,  t h e  p r o p o r t i o n  o f  c h i l d r e n  i n  e a c h  t r e a t m e n t  g r o u p  w h o  a p p e a r e d  t o  h a v e  d e v e l o p m e n t a l  
d e l a y  a t  t h e  t i m e  o f  o n s e t  o f  s p a s m s .  H o w e v e r ,  i t  s h o u l d  b e  a p p r e c i a t e d  t h a t  t h e  e x a c t  t i m i n g  
o f  o n s e t  o f  s p a s m s  a n d  o f  a n y  a p p a r e n t  d e v e l o p m e n t a l  d e l a y  m a y  b e  d i f f i c u l t  t o  a s s e s s ,  a n d
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t h a t  t h e r e  i s  a  h i g h  r i s k  o f  m i s c l a s s i f i c a t i o n  o f  t h i s  c h a r a c t e r i s t i c . "
R 3 Q 2 6 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  b a s e l i n e  c h a r a c t e r i s t i c s  s h o u l d  b e  r e p o r t e d  f o r  e a c h  t r e a t ­
m e n t  o r  i n t e r v e n t i o n  g r o u p ,  a n d  t h a t  t h e  v a r i a b l e s  r e p o r t e d  s h o u l d  i n c l u d e  f a c t o r s  t h a t  m a y  
b e  p r o g n o s t i c  i n d i c a t o r s .  W e  p r o p o s e :  ( 1 )  e t i o l o g i c  c l a s s ;  ( 2 )  s e x ;  ( 3 )  a g e  a t  o n s e t  ( m e d i a n  a n d  
r a n g e ,  a n d  p r o p o r t i o n s  i n  a g e  c a t e g o r i e s ) ;  ( 4 )  g e s t a t i o n  ( p r o p o r t i o n  b o m  p r e t e r m ,  a n d  m e d i a n  
g e s t a t i o n ) ;  ( 5 )  b i r t h w e i g h t  ( m e d i a n  b i r t h w e i g h t  a n d  p r o p o r t i o n  u n d e r  1 5 0 0  g r a m s ) ;  (6 )  p r e c e d ­
i n g  s e i z u r e s ;  ( 7 )  c o n c u r r e n t  a n d  p r e v i o u s  t r e a t m e n t  w i t h  A E D s  o r  s t e r o i d s ;  (8 )  l e a d  t i m e  f r o m  
a p p a r e n t  o n s e t  o f  s p a s m s  t o  t r e a t m e n t  ( m e d i a n  a n d  r a n g e ) ;  ( 9 )  p r e s e n c e  o f  h y p s a r r h y t h m i a .  
A t t e n t i o n  s h o u l d  b e  d r a w n  t o  l a r g e  d i f f e r e n c e s  t h a t  m i g h t  b i a s  t h e  r e s u l t s .  H o w e v e r ,  w e  d o  
n o t  r e c o m m e n d  r o u t i n e  r e p o r t i n g  o f  P  v a l u e s  f o r  b a s e l i n e  c h a r a c t e r i s t i c s  i n  a  r a n d o m i s e d  t r i a l :  
i t  i s  i l l o g i c a l  t o  s t a t e  s i g n i f i c a n c e  o r  t o  r e j e c t  a  n u l l  h y p o t h e s i s  t h a t  t h e  d i f f e r e n c e  o c c u r r e d  b y  
c h a n c e  w h e n  i t  i s  k n o w n  t h a t  t h e  d a t a  w e r e  g e n e r a t e d  r a n d o m l y  a n d  t h e  d i f f e r e n c e  m u s t  h a v e  
o c c u r r e d  b y  c h a n c e . "
R 3 Q 2 7 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  t r e a t m e n t s  f o r  i n f a n t i l e  s p a s m s  a n d  W e s t  s y n d r o m e  
s h o u l d  b e  c o n s i d e r e d  t o  h a v e  h a d  a  s u f f i c i e n t  t h e r a p e u t i c  t r i a l  a f t e r  1 4  d a y s .  I n  g e n e r a l ,  i t  
i s  n e c e s s a r y  t o  g i v e  a  t r e a t m e n t  f o r  1 4  d a y s  b e f o r e  d e c i d i n g  t h a t  i t  h a s  n o  t r e a t m e n t  e f f e c t ,  b u t  
w i t h d r a w a l  s h o u l d  b e  c o n s i d e r e d  s o o n e r  i f  t h e r e  i s  a n  a d v e r s e  e f f e c t  o f  t h a t  t r e a t m e n t .  W e  
p r o p o s e  t h a t  a n y  s t u d y  t h a t  u s e s  a  d i f f e r e n t  p e r i o d  o f  n e c e s s a r y  a n d  s u f f i c i e n t  t h e r a p e u t i c  t r i a l  
s h o u l d  s t a t e  a  r a t i o n a l e  o r  e m p i r i c a l  e v i d e n c e  f o r  t h a t  d e c i s i o n . "
R 3 Q 2 8 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  p y r i d o x i n e  s h o u l d  b e  g i v e n  i n t r a v e n o u s l y  u n d e r  s i ­
m u l t a n e o u s  E E G  m o n i t o r i n g  a s  a  t h e r a p e u t i c  a n d  d i a g n o s t i c  t e s t  f o r  p y r i d o x i n e - d e p e n d e n t  
s e i z u r e s .  C l i n i c a l  r e s p o n s e  s h o u l d  o c c u r  w i t h i n  m i n u t e s ,  a n d  c e s s a t i o n  o f  p a r o x y s m a l  d i s ­
c h a r g e s  s h o u l d  o c c u r  w i t h i n  h o u r s  [1 2 1 ] .  T h e  t h e r a p e u t i c  t r i a l  n e e d  t a k e  n o  l o n g e r  t h a n  s i x  
h o u r s ,  a n d  r a n d o m i s e d  t r i a l  t r e a t m e n t s  m a y  t h e n  b e  g i v e n . "
R 3 Q 2 9 .  S t a t e m e n t :  " W e  p r o p o s e  t h a t  a t  l e a s t  t h e  f o l l o w i n g  o u t c o m e s  a n d  m e a s u r e s  b e  r e ­
p o r t e d ,  b y  i n t e r v e n t i o n  g r o u p ,  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s  a n d  W e s t  s y n d r o m e :  ( 1 )  c e s s a t i o n  
o f  s p a s m s  [ n u m b e r  a n d  p r o p o r t i o n  w i t h  l a s t  w i t n e s s e d  s p a s m  b e f o r e  t h e  e n d  o f  d a y  1 4  o f  t r e a t ­
m e n t  a n d  w i t h  n o  s p a s m s  f o r  2 8  c o n s e c u t i v e  d a y s  t h e r e a f t e r ] ;  ( 2 )  d e v e l o p m e n t  a t  2  y e a r s  o f  
a g e  [ m e d i a n  a n d  r a n g e s  f o r  t e s t s  c h o s e n ] ;  ( 3 )  d e a t h s  a n d  o t h e r  s e r i o u s  a d v e r s e  e v e n t s  [ n u m ­
b e r s  a n d  d e s c r i p t i o n s  o f  e v e n t s ] ;  ( 4 )  r e l a p s e  [ n u m b e r s  a n d  p r o p o r t i o n  o f  p r i m a r y  r e s p o n d e r s  
r e l a p s i n g ;  p r o p o r t i o n  o f  w h o l e  i n t e r v e n t i o n  g r o u p  ( t h a t  i s ,  i n c l u d i n g  n o n - r e s p o n d e r s ) ;  a n d  
d i s t r i b u t i o n s  o f  t i m e  t o  r e l a p s e  ( f r o m  t i m e  o f  r e s p o n s e ) ] ;  ( 5 )  p r e s e n c e  o f  a n d  p r o g r e s s i o n  t o  
o t h e r  s e i z u r e  t y p e s  [ n u m b e r s ,  p r o p o r t i o n s ,  a n d  s e i z u r e  t y p e s ] ;  (6 )  n o n - s e r i o u s  a d v e r s e  e v e n t s  
[ n u m b e r s ,  p r o p o r t i o n s ,  a n d  d e s c r i p t i o n  o f  e v e n t s ] ;  ( 7 )  r e s o l u t i o n  o f  h y p s a r r h y t h m i a  a t  d a y s  
1 4  a n d  4 2  o f  t h e  s t u d y  [ n u m b e r s  w i t h  h y p s a r r h y t h m i a  a t  s t a r t  o f  s t u d y ,  a t  s t u d y  d a y  1 4  a n d  a t  
s t u d y  d a y  4 2 ;  p r o p o r t i o n s ,  a n d  t y p e s  o f  E E G  p e r f o r m e d ] . "
R 3 Q 3 0 .  S t a t e m e n t :  'T i m e  t o  c e s s a t i o n  o f  s p a s m s  c a n  b e  r e p r e s e n t e d  b y  a c t u a r i a l  c u r v e s  a n d  i s  
a  c l i n i c a l l y  u s e f u l  o u t c o m e  t h a t  m i g h t  i n f o r m  f u t u r e  s t u d y  d e s i g n s .  W e  p r o p o s e  t h a t  i t  i s  p e r ­
m i s s i b l e  f o r  s t u d i e s  t o  r e p o r t ,  i n  a d d i t i o n  t o  ' t i m e  t o  2 8 - d a y s  o f  s p a s m - f r e e d o m /  ' t i m e  t o  l a s t  
w i t n e s s e d  s p a s m  i n  p r i m a r y  r e s p o n d e r s . '  T h i s  g i v e s  a  u s e f u l  a n d  i n t u i t i v e  c l i n i c a l  m e a s u r e . "
R 3 Q 3 1 .  S t a t e m e n t :  " I n  g e n e r a l ,  i n  d i s c u s s i n g  r e s u l t s  w e  w o u l d  d e p r e c a t e  t h e  u s e  o f  r e p o r t i n g  
o u t c o m e s  i n  c o n d i t i o n a l  s t a t e m e n t s  s u c h  a s :  'O f  t h o s e  r e s p o n d i n g  t o  t r e a t m e n t  X , x /(n  — / )  
d i d  s o  w i t h i n  y  d a y s . '  T h i s  i n v o l v e s  a  s i l e n t  r i g h t - c e n s o r i n g  o f  d a t a ,  a n d  c a n  g i v e  a  m i s l e a d i n g  
i m p r e s s i o n  o f  g r e a t e r  o r  q u i c k e r  t r e a t m e n t  e f f e c t .  W e  w o u l d  e n c o u r a g e  s i m p l e r ,  u n c o n d i t i o n a l
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s t a t e m e n t s  s u c h  a s :  'F o r  t r e a t m e n t  X , x /n  r e s p o n d e d  b y  d a y  y.' "
R 3 Q 3 2 .  S t a t e m e n t :  " T h e  f o l l o w i n g  s h o u l d  b e  c o n s i d e r e d  t o  c o n s t i t u t e  a  r e l a p s e  o f  i n f a n t i l e  
s p a s m s  a t  a n y  s t a g e  a f t e r  a  p r i m a r y  r e s p o n s e  h a s  b e e n  o b t a i n e d :  1 )  s p a s m s  o c c u r r i n g  i n  c l u s ­
t e r s ;  a n d  2 )  s p a s m s  o c c u r r i n g  s i n g l y  b u t  n o t  i n  c l u s t e r s .  A  s i n g l e  w i t n e s s e d  s p a s m  w o u l d  n o t  
b e  r e l i a b l e  a n d  s h o u l d  n o t  b e  c l a s s i f i e d  a s  a  r e l a p s e .  B e c a u s e  p r i m a r y  r e s p o n s e  i s  d e f i n e d  b y  
c e s s a t i o n  o f  s p a s m s ,  p e r s i s t e n t  o r  r e c u r r e n t  h y p s a r r h y t h m i a  s h o u l d  n o t  b e  c o n s i d e r e d  t o  b e  a  
r e l a p s e  u n l e s s  i t  i s  a c c o m p a n i e d  b y  w i t n e s s e d  s p a s m s .  H o w e v e r ,  t h e  p e r s i s t e n c e  o r  r e c u r r e n c e  
o f  h y p s a r r h y t h m i a  i s  r e p o r t e d  a s  p a r t  o f  a  s e c o n d a r y  o u t c o m e  m e a s u r e . "
C.5 West Delphi Round 4 questions
I n  r o u n d  4 ,  w e  w i l l  p r o v i d e  a n  e x t e n d e d  s t a t e m e n t  t h a t  m a y  b e  r e g a r d e d  a s  a  p u t a t i v e  c o n ­
s e n s u s  s t a t e m e n t .  T h e  s t a t e m e n t s  a r e  p r e s e n t e d  i n  n u m b e r e d  p a r a g r a p h s ,  a n d  w e  i n v i t e  y o u  
t o  m a k e  c o m m e n t s  b y  r e f e r r i n g  t o  t h e s e  p a r a g r a p h s .  P l e a s e  s t a t e :  ( 1 )  I f  y o u  d o  n o t  a g r e e  c o m ­
p l e t e l y  w i t h  t h e  c o n t e n t  o f  t h e  s t a t e m e n t ,  a n d  (2 )  I f  y o u  t h i n k  t h a t  t h e  s t a t e m e n t  o u g h t  n o t  t o  
b e  i n c l u d e d .  P l e a s e  m a k e  a s  f u l l  a n  e x p l a n a t i o n  a s  p o s s i b l e  f o r  y o u r  o p i n i o n s .  W e  b e l i e v e  t h a t  
w e  a r e  n e a r i n g  a  f i n a l  c o n s e n s u s ,  b u t  i t  w i l l  b e  n e c e s s a r y  t o  p u t  f u r t h e r  a m e n d m e n t s  t o  t h e  
w h o l e  g r o u p  i n  r o u n d  5 .
D r a f t  W e s t  D e l p h i  G r o u p  C o n s e n s u s  S t a t e m e n t  ( W e s t  D e l p h i  R o u n d  4 )
R 4 S 1 :  Rationale and aims of West Delphi. W e s t  D e l p h i  i s  a  c o n s e n s u s  e l i c i t a t i o n  p r o c e s s  t h a t  
a i m e d  t o  p r o p o s e  a  s e r i e s  o f  d e f i n i t i o n s  a n d  s t a n d a r d s  f o r  u s e  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s .  
I n  p a r t i c u l a r ,  i t s  a i m  w a s  t o  p r o v i d e  c l e a r e r  d e f i n i t i o n s  o f  c a s e s  a n d  e t i o l o g i c  s u b g r o u p s ,  a n d  
t o  p r o v i d e  i n f o r m a t i o n  a b o u t  w h a t  a r e  c o n s i d e r e d  t o  b e  t h e  m o s t  i m p o r t a n t  o u t c o m e s  a n d  
o u t c o m e  m e a s u r e s .  W e  h o p e  t h a t  t h e s e  s t a n d a r d s  w i l l  h e l p  t h o s e  w h o  w i s h  t o  d e s i g n  f u t u r e  
s t u d i e s  o f  i n f a n t i l e  s p a s m s ,  a n d  t h a t  t h e y  w i l l  r e s u l t  i n  b e t t e r  i n f o r m a t i o n  f o r  d o c t o r s  w h o  w i s h  
t o  c h o o s e  t h e  b e s t  a p p r o a c h  t o  t r e a t i n g  i n f a n t i l e  s p a s m s .
R 4 S 2 :  Constitution of the West Delphi Group. T h e  W e s t  D e l p h i  G r o u p  c o n s i s t s  o f  d o c t o r s  w i t h  
a n  i n t e r e s t  i n  i n f a n t i l e  s p a s m s  a n d  w h o  a g r e e d  t o  p a r t i c i p a t e  i n  t h e  e m a i l  c o n s e n s u s  e l i c i t a t i o n  
p r o c e s s .  S o m e  o f  t h e m  h a v e  b e e n  i n v o l v e d  i n  p r e v i o u s  s t u d i e s  o f  i n f a n t i l e  s p a s m s ,  a n d  o t h e r s  
a r e  i n t e r e s t e d  i n  t h e  c l i n i c a l  u s e f u l n e s s  o f  i n f o r m a t i o n  f r o m  s t u d i e s .  M a n y  w e r e  r e c r u i t e d  f r o m  
t h o s e  a t t e n d i n g  t h e  i n t e r n a t i o n a l  s y m p o s i u m  o n  W e s t  s y n d r o m e  a n d  o t h e r  i n f a n t i l e  e p i l e p t i c  
e n c e p h a l o p a t h i e s ,  T o k y o ,  F e b r u a r y  2 0 0 1 .  T h e  f i n a l  c o n s e n s u s  s t a t e m e n t  h a s  b e e n  a g r e e d  b y  X  
d o c t o r s  f r o m  Y  c o u n t r i e s ,  a n d  t h e  n a m e s  o f  p a r t i c i p a n t s  a r e  l i s t e d  a t  t h e  e n d  o f  t h i s  p a p e r .
R 4 S 3 :  Definition of infantile spasms (IS). T h e  W e s t  D e l p h i  G r o u p  p r o p o s e s  t h a t  t h e  t e r m  infantile 
spasms (IS) i s  u s e d  t o  d e s c r i b e  a  p a r t i c u l a r  f o r m  o f  e p i l e p s y  t h a t  r a r e l y  h a s  a n  o n s e t  i n  c h i l d r e n  
o v e r  t w o  y e a r s  o l d  a n d  u s u a l l y  h a s  o n s e t  i n  c h i l d r e n  u n d e r  o n e  y e a r  o l d .  I t s  m a i n  c l i n i c a l  
m a n i f e s t a t i o n  i s  c l i n i c a l  s p a s m s  t h a t  u s u a l l y  o c c u r  i n  c l u s t e r s .  T h e r e  a r e  m a n y  p o t e n t i a l  e t i o l o ­
g i e s  a n d  i n f a n t i l e  s p a s m s  a r e  a s s o c i a t e d  w i t h  m a n y  c o n d i t i o n s .  T h e  m o s t  c h a r a c t e r i s t i c  E E G  
f i n d i n g  i s  h y p s a r r h y t h m i a .  H o w e v e r ,  h y p s a r r h y t h m i a  i s  n o t  f o u n d  i n  a l l  c a s e s ,  n o r  i s  i t  f o u n d  
t h r o u g h o u t  t h e  c l i n i c a l  c o u r s e  o f  t h e  c o n d i t i o n .  H y p s a r r h y t h m i a  i s  u s u a l l y  s u p p r e s s e d  d u r i n g  
a  c l i n i c a l  a t t a c k  o f  e p i l e p t i c  s p a s m s .  T h e  s p a s m s  a r e  o f t e n  a s s o c i a t e d  w i t h  d e v e l o p m e n t a l  a r ­
r e s t  o r  r e g r e s s i o n .
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R 4 S 4 :  Definition of West syndrome (IS). W e  p r o p o s e  u s e  o f  t h e  t e r m  West syndrome ( W S )  t o  m e a n  
t h e  c o m b i n a t i o n  o f  s p a s m s  t h a t  o c c u r  i n  c l u s t e r s  a n d  h y p s a r r h y t h m i a  o n  a n  E E G .  W e  d o  n o t  
r e q u i r e ,  a s  h a v e  s o m e  p r e v i o u s  d e f i n i t i o n s  o f  W e s t  s y n d r o m e ,  t h a t  t h e r e  i s  e v i d e n c e  o f  d e ­
l a y e d  d e v e l o p m e n t  b e f o r e  t h e  o n s e t  o f  s p a s m s .  T h e  i n c l u s i o n  o f  t h e  r e q u i r e m e n t  f o r  s p a s m s  
o c c u r r i n g  i n  c l u s t e r s  f o r m s  a  n e w  t r i a d .  W e s t  s y n d r o m e  i s  t h e  t r i a d  o f :  ( 1 )  c l i n i c a l  s p a s m s ;  (2 )  
s p a s m s  t h a t  o c c u r  i n  c l u s t e r s ;  a n d  (3 )  t h e  p r e s e n c e  o f  h y p s a r r h y t h m i a  o n  a n  E E G .
R 4 S 5 :  Developmental delay at onset of clinical spasms. W e  s e e  n o  r e a s o n  f o r  i n c l u d i n g  d e v e l o p ­
m e n t a l  d e l a y  a t  t h e  t i m e  o f  o n s e t  a s  a  d e f i n i n g  f e a t u r e  o f  W e s t  s y n d r o m e .  I n d e e d ,  d e v e l o p m e n ­
t a l  d e l a y  a t  o n s e t  o f  s p a s m s  i s  l i k e l y  t o  b e  a s s e s s e d  u n r e l i a b l y  b e c a u s e  s p a s m s  a r e  o f t e n  s u b t l e  
a n d  t h e i r  t r u e  t i m e  o f  o n s e t  i s  o f t e n  u n r e c o g n i s e d ,  a n d  a l s o  b e c a u s e  d e v e l o p m e n t  i s  h a r d  t o  
a s s e s s  i n  e a r l y  i n f a n c y .
R 4 S 6 :  Definition of infantile spasms single-spasm variant (ISSV). I t  i s  l e s s  u s u a l  f o r  i n f a n t i l e  s p a s m s  
t o  a l w a y s  o c c u r  s i n g l y  r a t h e r  t h a n  i n  c l u s t e r s ,  y e t  w e  a g r e e  t h a t  s u c h  c a s e s  d o  o c c u r .  W e  p r o ­
p o s e  t h a t  t h e s e  c a s e s  a r e  d i s t i n g u i s h e d  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s  b y  b e i n g  c a l l e d  infantile 
spasms single-spasm variant (ISSV). A  c h i l d  w i t h  s i n g l e  s p a s m s  a n d  h y p s a r r h y t h m i a  s h o u l d  b e  
c l a s s i f i e d  a s  ISSV  r a t h e r  t h a n  W S . W e  d o  n o t  p r o p o s e  a  s t r i c t  d e f i n i t i o n  o f  c l u s t e r i n g  b u t ,  a s  a  
g e n e r a l  g u i d e ,  a  s p a s m  c a n  b e  r e g a r d e d  a s  a  s i n g l e  s p a s m  i f  t h e r e  a r e  n o  o t h e r  s p a s m s  f o r  o n e  
m i n u t e  b e f o r e h a n d  a n d  o n e  m i n u t e  a f t e r w a r d s .
R 4 S 7 :  Classification of children with hypsarrhythmia but no evidence of clinical spasms. S o m e  c h i l ­
d r e n  a r e  i n v e s t i g a t e d  f o r  s y m p t o m s  o t h e r  t h a n  c l i n i c a l  s p a s m s  a n d  a r e  f o u n d  t o  h a v e  h y p s a r ­
r h y t h m i a .  I f  t h e s e  c h i l d r e n ,  e v e n  a f t e r  v i d e o  E E G  i n v e s t i g a t i o n ,  a r e  f o u n d  n o t  t o  h a v e  a n y  
e v i d e n c e  o f  c l i n i c a l  s p a s m s ,  w e  p r o p o s e  t h a t  t h e y  a r e  c l a s s i f i e d  a s  h a v i n g  hypsarrhythmia with­
out infantile spasms (HWIS).
R 4 S 8 :  Relationship between IS, WS, ISSV and HWIS. W e  p r o p o s e  u s i n g  t h e  t e r m  infantile spasms 
a s  a n  i n c l u s i v e  t e r m  f o r  a l l  c h i l d r e n  w i t h  c l i n i c a l  s p a s m s  w h o  h a v e  e v i d e n c e  o f  E E G  a b n o r ­
m a l i t i e s  c o n s i s t e n t  w i t h  t h e  c l i n i c a l  s y n d r o m e  o f  i n f a n t i l e  s p a s m s  t h a t  h a s  b e e n  d e s c r i b e d  i n  
p r e v i o u s  s t u d i e s .  T h e  t e r m s  West syndrome a n d  infantile spasms single-spasm variant d e s c r i b e  
m o r e  s p e c i f i c  s u b g r o u p s  o f  i n f a n t i l e  s p a s m s .  I n v e s t i g a t o r s  m i g h t  w i s h  t o  r e p o r t  s t u d i e s  o f  
c h i l d r e n  w i t h  a l l  f o r m s  o f  i n f a n t i l e  s p a s m s  a n d  r e p o r t  t h e  p r o p o r t i o n s  i n  t h e i r  s t u d y  w i t h  W S  
a n d  IS S V . O r  t h e y  m i g h t  w i s h  t o  p e r f o r m  a  s t u d y  t h a t  i n c l u d e d ,  s a y ,  o n l y  c h i l d r e n  w i t h  W S  
a n d  I S S V  w i t h  h y p s a r r h y t h m i a .  S t u d i e s  u s i n g  d e v e l o p m e n t a l  a n d  E E G  o u t c o m e s  m i g h t  w i s h  
t o  i n c l u d e  c h i l d r e n  w i t h  H W I S .  C o n s i s t e n t  u s e  o f  t h e s e  d e f i n i t i o n a l  t e r m s  a n d  a  c l e a r  s t a t e m e n t  
o f  h o w  m a n y  c h i l d r e n  c a m e  f r o m  e a c h  g r o u p  w i l l  a s s i s t  t h o s e  w h o  w i s h  t o  u s e  a n d  i n t e r p r e t  
s t u d y  d a t a .  W e  b e l i e v e  t h a t  t h e s e  d e f i n i t i o n s  c l e a r l y  d i s t i n g u i s h  c l i n i c a l  s u b g r o u p s ,  e n c o u r a g ­
i n g  b o t h  c l a r i t y  a n d  f l e x i b i l i t y  i n  s t u d y  d e s i g n .
R 4 S 9 :  Flow diagrams illustrating the relationships between IS, W S , ISSV and HWIS. F i g u r e s  1 a n d  2  
[ n o t  r e p r o d u c e d  i n  t h i s  t h e s i s  b u t  s i m i l a r  t o  f i g u r e s  5 .1  a n d  5 .2  o n  p a g e s  1 8 9  a n d  1 9 0 ]  i l l u s t r a t e  
t h e s e  r e l a t i o n s h i p s .  T h e y  a l s o  i l l u s t r a t e  t h e  r e l a t i o n s h i p s  o f  t h e s e  t e r m s  t o  t h e  5 - a x i s  s y s t e m  
p r o p o s e d  b y  t h e  I L A E  T a s k  F o r c e  o n  C l a s s i f i c a t i o n  a n d  T e r m i n o l o g y ,  2 0 0 1  [2 3 3 ] .
R 4 S 1 0 :  Definition of clinical spasms. W e  p r o p o s e  t h a t  t h e  t e r m  clinical spasms i s  u s e d  t o  d e s c r i b e  
b r i e f  a n d  s y n c h r o n o u s  m o v e m e n t s  o f  t h e  h e a d ,  t r u n k  a n d  l i m b s ,  o r  s o m e t i m e s  o f  t h e  h e a d ,  
t r u n k  o r  l i m b s  a l o n e .  T h e s e  m o v e m e n t s  h a v e  a  l o n g e r  d u r a t i o n  t h a n  t h e  m o v e m e n t  o f  m y ­
o c l o n u s ,  a n d  t h e y  a r e  s h o r t e r  t h a n  t h e  m o v e m e n t  a s s o c i a t e d  w i t h  a  t o n i c  s e i z u r e .  T h u s ,  t h e i r  
d u r a t i o n  i s  a p p r o x i m a t e l y  o n e  s e c o n d .  T h e  s u b t l e s t  m o v e m e n t  t h a t  m i g h t  b e  c l a s s i f i a b l e  a s  a
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c l i n i c a l  s p a s m  i s  a  h e a d  n o d .  W e  p r e f e r  t h e  t e r m  clinical spasms t o  t h e  t e r m  epileptic spasms t o  
d e s c r i b e  t h e  i c t a l  p h e n o m e n o l o g y  ( A x i s  1 o f  t h e  p r o p o s e d  I L A E  5 - a x i s  s c h e m e ) .
R 4 S 1 1 :  Subtle ictal events. M o r e  s u b t l e  m o v e m e n t s  m a y  c o n s t i t u t e  t h e  c l i n i c a l  a t t a c k  a s s o c i a t e d  
w i t h  h y p s a r r h y t h m i a .  S u c h  m o v e m e n t s  i n c l u d e  e p i s o d e s  o f  g a s p i n g  a n d  i s o l a t e d  e y e  m o v e ­
m e n t s .  W e  p r o p o s e  t h a t  c h i l d r e n  w i t h  t h e s e  s u b t l e  i c t a l  e v e n t s  a r e  c l a s s i f i e d  a s  h a v i n g  H W I S  
b e c a u s e  s u c h  e v e n t s  a r e  m o r e  d i f f i c u l t  t o  c o u n t  a n d  a r e  n o t  s u g g e s t e d  b y  t h e  t e r m  s p a s m s .  
I d e a l l y ,  a  v i d e o  E E G  w o u l d  b e  p e r f o r m e d  t o  c o n f i r m  t h a t  s p a s m s  a r e  i n d e e d  n o t  o c c u r r i n g .
R 4 S 1 2 :  Seizure type. W e  p r o p o s e  u s i n g  t h e  t e r m  epileptic spasms t o  d e s c r i b e  c l i n i c a l  s p a s m s  
a s s o c i a t e d  w i t h  a n  e p i l e p t i f o r m  E E G .  T h i s  c o r r e s p o n d s  t o  A x i s  2  o f  t h e  I L A E  s c h e m e .  T h i s  
t e r m  w o u l d  i n c l u d e  c o n d i t i o n s  s u c h  a s  t h e  p e r i o d i c  s p a s m s  o f  G o b b i  a n d  i n f a n t i l e  s p a s m s  
[ 2 5 , 2 9 ] .  T h e  t e r m  epileptic spasms i m p l i e s  t h a t  t h e  E E G  i s  c o n s i s t e n t  w i t h  t h e  d i a g n o s i s  o f  a n  
e p i l e p s y ,  b u t  d o e s  n o t  b y  i t s e l f  i m p l y  h y p s a r r h y t h m i a  o r  a n y  m o r e  s p e c i f i c  E E G  p a t t e r n .
R 4 S 1 3 :  Relationship between clinical spasms, epileptic spasms, and infantile spasms. U s i n g  t h e s e  d e ­
f i n i t i o n s  a n d  c l a s s i f i c a t i o n ,  c l i n i c a l  s p a s m s ,  e p i l e p t i c  s p a s m s ,  a n d  i n f a n t i l e  s p a s m s  c o r r e s p o n d  
w i t h  a x e s  1 ( i c t a l  p h e n o m e n o l o g y ) ,  2  ( s e i z u r e  t y p e ) ,  a n d  3  ( s y n d r o m e )  r e s p e c t i v e l y  o f  t h e  I L A E  
5 - a x i s  s c h e m e .
R 4 S 1 4 :  Syndrome classification of IS. W i t h  r e s p e c t  t o  A x i s  3  ( s y n d r o m e )  o f  t h e  I L A E  p r o p o s e d  
d i a g n o s t i c  s c h e m e ,  w e  p r o p o s e  t h a t  infantile spasms i s  t h e  s y n d r o m e  o f  e p i l e p t i c  s p a s m s  w i t h  
o n s e t  g e n e r a l l y  d u r i n g  t h e  f i r s t  t w o  y e a r s  o f  l i f e  i n  a s s o c i a t i o n  w i t h  f o c a l  o r  d i f f u s e  i n t e r i c t a l  
E E G  a b n o r m a l i t i e s  [ 2 5 ] .  W e  p r o p o s e  t h a t  West syndrome i s  d e f i n e d  b y  t h e  a s s o c i a t i o n  o f  i n f a n ­
t i l e  s p a s m s ,  a t  l e a s t  s o m e  o f  w h i c h  o c c u r  i n  c l u s t e r s ,  w i t h  a n  i n t e r i c t a l  E E G  s h o w i n g  h y p s a r ­
r h y t h m i a .  T h i s  m a y  b e  e i t h e r  " c l a s s i c a l "  h y p s a r r h y t h m i a ,  o r  h y p s a r r h y t h m i a  w i t h  m o d i f i e d  
f e a t u r e s .  Infantile spasms single-spasm variant i s  a n o t h e r  f o r m  o f  i n f a n t i l e  s p a s m s .
R 4 S 1 5 :  Ictal unit of infantile spasms. T h e r e  i s  d i s a g r e e m e n t  a b o u t  w h e t h e r  t h e  a p p r o p r i a t e  i c t a l  
u n i t  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s  s h o u l d  b e  t h e  s p a s m  o r  t h e  c l u s t e r  o f  s p a s m s .  M o s t  p a r t i c ­
i p a n t s  o f  W e s t  D e l p h i  t h o u g h t  t h a t  t h e  m o r e  a p p r o p r i a t e  i c t a l  u n i t  w a s  t h e  c l u s t e r  o f  s p a s m s .  
H o w e v e r ,  w e  f e l t  t h a t  t h e r e  w a s  l i m i t e d  v a l u e  i n  o u t c o m e s  t h a t  r e l y  o n  m e a s u r e m e n t  o f  i c t a l  
u n i t s ,  s u c h  a s  t i m e  t o  5 0 %  r e d u c t i o n  o f  s p a s m s  o r  t h e  p r o p o r t i o n  o f  s t u d y  p a r t i c i p a n t s  h a v i n g  
a  5 0 %  o r  g r e a t e r  r e d u c t i o n  i n  s p a s m s .
R 4 S 1 6 :  Definition of hypsarrhythmia. W e  p r o p o s e  t h a t  t h e  t e r m  hypsarrhythmia i s  u s e d  t o  d e s c r i b e  
a n  E E G  p a t t e r n  t h a t  i s  c h a r a c t e r i s e d  b y  r a n d o m ,  h i g h - v o l t a g e  s p i k e s  a n d  s l o w  w a v e s .  T h e  
m o s t  s t r i k i n g  f e a t u r e s  o f  h y p s a r r h y t h m i a  a r e :  h i g h - v o l t a g e  ( g e n e r a l l y  >  2 0 0  pV) s l o w  w a v e s ;  
s p i k e s  a n d  w a v e s  f r o m  m a n y  f o c i  a n d  v a r y i n g  w i t h  t i m e ;  a  l a c k  o f  s y n c h r o n y  a n d  a  " c h a o t i c "  
a p p e a r a n c e .  T h e  t y p i c a l  a p p e a r a n c e  i s  m o r e  l i k e l y  t o  b e  f o u n d  i n  e a r l i e r  s t a g e s  o f  t h e  d i s o r d e r  
a n d  w h e n  o n s e t  o c c u r s  a t  a  y o u n g e r  a g e .  T h e  h y p s a r r h y t h m i c  p a t t e r n  m a y  d i s a p p e a r  d u r i n g  
R E M  s l e e p ,  b u t  i t  m a y  b e  f o u n d  w i t h  g r e a t e r  s e n s i t i v i t y  i n  s o m e  o t h e r  s t a g e s  o f  s l e e p  [6 6 ] .
R 4 S 1 7 :  Modified and atypical hypsarrhythmia. W i t h  r e s p e c t  t o  t h e  u s e  o f  t h e  t e r m  modified hyp­
sarrhythmia [ 8 ]  [6 7 ]  a n d  i t s  s y n o n y m  a t y p i c a l  h y p s a r r h y t h m i a  [ 3 2 ] ,  w e  e n d o r s e  t h e  r e c o m m e n ­
d a t i o n  o f  t h e  1 9 9 1  w o r k s h o p  o n  i n f a n t i l e  s p a s m s  ( C o m m i s s i o n  o n  P e d i a t r i c  E p i l e p s y  o f  t h e  
I n t e r n a t i o n a l  L e a g u e  A g a i n s t  E p i l e p s y  1 9 9 2  [ 2 8 ] )  t h a t  s t u d y  p a r t i c i p a n t s  w i t h  m o d i f i e d  h y p ­
s a r r h y t h m i a  a r e  n o t  r e p o r t e d  i n  d i c h o t o m i s e d  g r o u p s  b u t  t h a t ,  w h e r e  a p p r o p r i a t e ,  a  d e s c r i p ­
t i o n  i s  g i v e n  o f  t h e  i n d i v i d u a l  m o d i f y i n g  f e a t u r e s .  T h e  p r e s e n c e  o f  m o d i f i e d  f e a t u r e s  m a y  
d e p e n d  u p o n  t h e  s t a g e  o f  i n f a n t i l e  s p a s m s  a t  w h i c h  t h e  E E G  i s  p e r f o r m e d ;  i t  m a y  d e p e n d  
u p o n  t r e a t m e n t ;  a n d  a s  a n  a g g r e g a t e  v a r i a b l e ,  i t  p r o b a b l y  h a s  l i t t l e  p r a c t i c a l  p r o g n o s t i c  s i g n i f ­
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i c a n c e  i n  r a n d o m i s e d  s t u d i e s .
R 4 S 1 8 :  Use of electroencephalograms (EEGs) in studies of IS. W e  s u g g e s t  t h a t  E E G  f i n d i n g s  p r o v i d e  
e s s e n t i a l  i n f o r m a t i o n  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s .  W e  r e c o m m e n d  a  d e g r e e  o f  s t a n d a r d i s ­
a t i o n  i n  t h e  t i m i n g  o f  E E G  i n v e s t i g a t i o n s ,  a n d  t h a t  i n v e s t i g a t o r s  l i m i t  p o t e n t i a l  i n f o r m a t i o n  
b i a s  i n  s t u d i e s  b y  m a k i n g  a l l o w a n c e  f o r  d i f f e r e n c e s  i n  s e n s i t i v i t y  o f  d i f f e r e n t  i n v e s t i g a t i o n s .  
I n c r e a s e d  s e n s i t i v i t y  i s  l i k e l y  i n  t h e  c a s e  o f  v i d e o  E E G s ,  f o r  l o n g e r  p e r i o d s  o f  r e c o r d i n g ,  a n d  
f o r  r e c o r d i n g s  t h a t  i n c l u d e  p e r i o d s  o f  n o n - R E M  s l e e p .  W h i l e  l e s s  s e n s i t i v e  i n v e s t i g a t i o n s  a r e  
p e r m i t t e d ,  i t  i s  p r u d e n t  t o  d e s i g n  s t u d i e s  t h a t  u s e  i n c r e a s i n g l y  m o r e  s e n s i t i v e  i n v e s t i g a t i o n s  
b e f o r e  i n f e r r i n g  t h a t  E E G  a b n o r m a l i t i e s  a r e  g e n u i n e l y  n o t  p r e s e n t .
R 4 S 1 9 :  Etiologic subgroups of IS. S e v e r a l  t e r m s  h a v e  b e e n  u s e d  t o  d e s c r i b e  e t i o l o g i c  s u b g r o u p s  o f  
IS ,  b u t  t h e s e  t e r m s  h a v e  n o t  b e e n  u s e d  c o n s i s t e n t l y  b e t w e e n  s t u d i e s .  T h e r e  r e m a i n s  i n c o m p l e t e  
a g r e e m e n t  a b o u t  t h e  u s e  o f  t h e  t e r m s  symptomatic, idiopathic, a n d  cryptogenic e v e n  t h o u g h  t h e y  
a r e  u s e d  i n  t h e  c l a s s i f i c a t i o n  o f  s e v e r a l  e p i l e p s i e s .
R 4 S 2 0 :  Idiopathic IS. T h e  t e r m  idiopathic infantile spasms i s  u s e d  t o  d e s c r i b e  c a s e s  i n  w h i c h  t h e r e  
a r e  i n f a n t i l e  s p a s m s  w i t h o u t  a n y  i d e n t i f i a b l e  u n d e r l y i n g  c a u s e ,  n o r  o t h e r  n e u r o l o g i c  s i g n s  o r  
s y m p t o m s .  S u c h  c a s e s  a r e  s o m e t i m e s  p r e s u m e d  t o  b e  g e n e t i c  i n  o r i g i n  -  b u t  n o  p r o o f  c u r r e n t l y  
e x i s t s  t o  s u p p o r t  t h i s  s t a t e m e n t  [2 3 3 ] .  A  m o r e  r e s t r i c t e d  c l a s s i f i c a t i o n  o f  i d i o p a t h i c  I S  h a s  b e e n  
s u g g e s t e d  i n  w h i c h  c a s e s  a r e  l i k e l y  t o  s h o w  d i s a p p e a r a n c e  o f  s p i k e s  a f t e r  t h e  a d m i n i s t r a t i o n  
o f  i n t r a v e n o u s  d i a z e p a m ,  a n d  t o  h a v e  h y p s a r r h y t h m i a  b e t w e e n  s p a s m s  w i t h i n  a  s i n g l e  c l u s t e r  
o f  s p a s m s  [2 3 3 ]  [3 6 ]  [5 1  ].
R 4 S 2 1 :  Cryptogenic IS. T h e  t e r m  cryptogenic infantile spasms h a s  b e e n  u s e d  t o  d e s c r i b e  c a s e s  
s u s p e c t e d  o f  b e i n g  s y m p t o m a t i c  b u t  f o r  w h o m  a n  u n d e r l y i n g  s t r u c t u r a l  o r  b i o c h e m i c a l  c a u s e  
c o u l d  n o t  b e  i d e n t i f i e d .  I t  h a s  b e e n  s u g g e s t e d  t h a t  t h e  t e r m  probably symptomatic i s  p r e f e r r e d  
t o  cryptogenic [ 2 3 3 ] .
R 4 S 2 2 :  Symptomatic IS. T h e  t e r m  symptomatic infantile spasms h a s  b e e n  u s e d  t o  r e f e r  t o  c a s e s  i n  
w h i c h  t h e  s e i z u r e s  r e s u l t  f r o m  o n e  o r  m o r e  i d e n t i f i a b l e  s t r u c t u r a l  l e s i o n s  o f  t h e  b r a i n ,  b u t  h a s  
a l s o  b e e n  a p p l i e d  i n  s o m e  s t u d i e s  t o  c h i l d r e n  w h o  h a v e  d e v e l o p m e n t a l  a r r e s t  o r  r e g r e s s i o n  
t h a t  s e e m e d  t o  p r e c e d e  t h e  o n s e t  o f  s p a s m s .
R 4 S 2 3 :  Problems with the terms idiopathic, cryptogenic and symptomatic. T h e s e  t e r m s  a r e  c o n s i d ­
e r e d  b y  s o m e  i n v e s t i g a t o r s  t o  b e  u n s a t i s f a c t o r y .  F o r  e x a m p l e ,  m a n y  b i o c h e m i c a l  d e f e c t s  a r e  
g e n e t i c ,  y e t  c a s e s  w i t h  p r o v e n  b i o c h e m i c a l  d e f e c t s  a r e  l i k e l y  t o  b e  c l a s s i f i e d  a s  s y m p t o m a t i c  
c a s e s .  A l s o ,  t h e  c l a s s i f i c a t i o n  o f  c a s e s  a s  c r y p t o g e n i c  c l a s s i f i c a t i o n  i s  l i k e l y  t o  b e  p r o n e  t o  p o o r  
i n t e r - r a t e r  r e l i a b i l i t y .  F u r t h e r m o r e ,  a s s e s s i n g  d e v e l o p m e n t a l  d e l a y  a t  o n s e t  a n d  t h e  t i m i n g  o f  
o n s e t  o f  s p a s m s  i s  d i f f i c u l t .
R 4 S 2 4 :  Predisposed and non-predisposed subgroups. S i n c e  t h e r e  r e m a i n s  d i s a g r e e m e n t  a b o u t  u s e  
o f  t h e  t e r m s  symptomatic, idiopathic, a n d  cryptogenic, w e  r e c o m m e n d  t h e  i n t r o d u c t i o n  o f  t w o  
n e w  t e r m s .  C a s e s  t h a t  a r e  s h o w n  t o  h a v e  u n d e r l y i n g  c o n d i t i o n s  s h o u l d  b e  r e f e r r e d  t o  a s  b e ­
l o n g i n g  t o  a  predisposed subgroup. T h o s e  w i t h o u t  a n y  i d e n t i f i e d  u n d e r l y i n g  c o n d i t i o n  s h o u l d  
b e  r e f e r r e d  t o  a s  non-predisposed, e v e n  w h e r e  i t  i s  s u s p e c t e d  t h a t  t h e r e  i s  a n  u n i d e n t i f i e d  u n d e r ­
l y i n g  c a u s e .  W e  f e e l  t h a t  t h e s e  n e w  t e r m s  a r e  o b j e c t i v e  a n d  h a v e  s e v e r a l  a d v a n t a g e s .  F i r s t ,  t h e  
t e r m  symptomatic i s  l e s s  t h a n  i d e a l  s i n c e  t h e  s p a s m s  t h e m s e l v e s  a r e  a  s y m p t o m  a n d  a  s i g n  a n d ,  
i n  t h i s  s e n s e  a t  l e a s t ,  a l l  c a s e s  o f  i n f a n t i l e  s p a s m s  a r e  s y m p t o m a t i c .  S e c o n d ,  t h e  t e r m  predis­
posed d o e s  n o t  i m p l y  a  c a u s a l  r e l a t i o n s h i p  b e t w e e n  t h e  u n d e r l y i n g  c o n d i t i o n  a n d  t h e  i n f a n t i l e  
s p a s m s ,  b u t  r a t h e r  t h a t  t h e  r i s k  o f  i n f a n t i l e  s p a s m s  i s  m o d i f i e d  b y  t h e  a s s o c i a t e d  u n d e r l y i n g
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c o n d i t i o n .  T h i r d ,  t h i s  c l a s s i f i c a t i o n  m a k e s  n o  g l o b a l  d i s t i n c t i o n s  b e t w e e n  s t r u c t u r a l ,  b i o c h e m ­
i c a l ,  g e n e t i c  o r  o t h e r  c o n d i t i o n s ,  t h o u g h  p e r m i t s  a l l  p r e d i s p o s e d  c a s e s  t o  b e  f u r t h e r  c l a s s i f i e d  
i n t o  s u b g r o u p s  a c c o r d i n g  t o  t h e i r  k n o w n  u n d e r l y i n g  c o n d i t i o n s .  F o u r t h ,  i n v e s t i g a t o r s  r e m a i n  
f r e e  t o  u s e  a n d  d e f i n e  t h e  t e r m s  idiopathic, cryptogenic a n d  symptomatic i n  f u r t h e r  s t u d i e s .
R 4 S 2 5 :  Developmental delay at onset of spasms and etiologic subgroups. T h o u g h  d e v e l o p m e n t a l  
d e l a y  a t  t h e  t i m e  o f  o n s e t  o f  i n f a n t i l e  s p a s m s  h a s  i n  m a n y  p r e v i o u s  s t u d i e s  b e e n  r e g a r d e d  
a s  i n d i c a t i n g  a  s y m p t o m a t i c  u n d e r l y i n g  c o n d i t i o n ,  i t  i s  n o t  p o s s i b l e  t o  k n o w  i f  t h e  e p i l e p t i c  
p r o c e s s  t h a t  c a u s e s  h y p s a r r h y t h m i a  h a s  p r e c e d e d  t h e  o n s e t  o f  c l i n i c a l  s p a s m s  a n d  h a s  a l o n e  
b e e n  r e s p o n s i b l e  f o r  t h e  d e v e l o p m e n t a l  d e l a y .  I n  o t h e r  w o r d s ,  d e v e l o p m e n t a l  d e l a y  b e f o r e  
o n s e t  o f  s p a s m s  d o e s  n o t  r e l i a b l y  i n d i c a t e  a  p r e d i s p o s i n g  c o n d i t i o n .  F o r  t h i s  r e a s o n ,  w e  r e c ­
o m m e n d  t h a t  d e v e l o p m e n t a l  d e l a y  a t  t h e  t i m e  o f  o n s e t  o f  s p a s m s  i s  r e p o r t e d  i n d e p e n d e n t l y  
o f  e t i o l o g i c  s u b g r o u p s .
R 4 S 2 6 :  Timing the classification of cases into etiologic subgroups. W e  p r o p o s e  t h a t  s t u d i e s  o f  i n f a n ­
t i l e  s p a s m s  d i s t i n g u i s h  t w o  e t i o l o g i c  c l a s s i f i c a t i o n s :  t h e  f i r s t  a t  t h e  t i m e  o f  t r e a t m e n t  d e c i s i o n ,  
a n d  t h e  s e c o n d  a t  t h e  t i m e  o f  s t u d y  c o m p l e t i o n .  A  c a s e  m a y  e n t e r  a  r a n d o m i s e d  s t u d y  w i t h o u t  
a  d i a g n o s e d  p r e d i s p o s i n g  c o n d i t i o n ,  b u t  a  p r e d i s p o s i n g  c o n d i t i o n  m a y  b e  d i a g n o s e d  l a t e r  i n  
t h e  s t u d y .  I t  i s  u s e f u l  t o  r e c o r d  t h e  f r e q u e n c y  o f  s u c h  c h a n g e s  i n  c l a s s i f i c a t i o n .  W e  r e c o m m e n d  
t h a t  t h e  l a t e r  c l a s s i f i c a t i o n  b e  u s e d  a s  t h e  " g o l d  s t a n d a r d "  f o r  s u b g r o u p  a n a l y s e s .  H o w e v e r ,  i t  
i s  u s e f u l  t o  r e p o r t  w h i c h  c o n d i t i o n s  a r e  a s s o c i a t e d  w i t h  d e l a y s  i n  d i a g n o s i s ,  s i n c e  t h i s  i n f o r ­
m a t i o n  m a y  m o d i f y  t r e a t m e n t  c h o i c e s .
R 4 S 2 7 :  Classification and reporting of prognostic factors. W e  p r o p o s e  t h a t  t h e  f o l l o w i n g  b a s e l i n e  
c h a r a c t e r i s t i c s  s h o u l d  b e  r e p o r t e d  f o r  e a c h  t r e a t m e n t  o r  i n t e r v e n t i o n  g r o u p :  ( 1 )  e t i o l o g i c  s u b ­
g r o u p ;  ( 2 )  s e x ;  ( 3 )  a g e  a t  o n s e t  ( m e d i a n  a n d  r a n g e ,  a n d  p r o p o r t i o n s  i n  e a c h  a g e  c a t e g o r y ) ;  
( 4 )  g e s t a t i o n  ( p r o p o r t i o n  b o m  p r e t e r m ,  a n d  m e d i a n  g e s t a t i o n ) ;  (5 )  b i r t h w e i g h t  ( m e d i a n  b i r t h ­
w e i g h t  a n d  p r o p o r t i o n  u n d e r  1 5 0 0  g r a m s ) ;  ( 6 )  p r e c e d i n g  s e i z u r e s ;  ( 7 )  c o n c u r r e n t  a n d  p r e v i o u s  
t r e a t m e n t  w i t h  A E D s  o r  s t e r o i d s ;  ( 8 )  l e a d  t i m e  f r o m  a p p a r e n t  o n s e t  o f  s p a s m s  t o  t r e a t m e n t  
( m e d i a n  a n d  r a n g e ) ;  (9 )  p r e s e n c e  o f  h y p s a r r h y t h m i a .  A t t e n t i o n  s h o u l d  b e  d r a w n  t o  l a r g e  d i f ­
f e r e n c e s  t h a t  m i g h t  b i a s  t h e  r e s u l t s ,  e v e n  w h e r e  t h e s e  h a v e  o c c u r r e d  b y  c h a n c e .
R 4 S 2 8 :  Developmental delay at onset of spasms as a prognostic factor. S t u d i e s  o f  i n f a n t i l e  s p a s m s  
s h o u l d  r e p o r t ,  a s  a  b a s e l i n e  c h a r a c t e r i s t i c ,  t h e  p r o p o r t i o n  o f  c h i l d r e n  i n  e a c h  t r e a t m e n t  g r o u p  
w h o  a p p e a r e d  t o  h a v e  d e v e l o p m e n t a l  d e l a y  a t  t h e  t i m e  o f  o n s e t  o f  s p a s m s .  H o w e v e r ,  i t  s h o u l d  
b e  a p p r e c i a t e d  t h a t  t h e  e x a c t  t i m i n g  o f  o n s e t  o f  s p a s m s  a n d  o f  a n y  a p p a r e n t  d e v e l o p m e n t a l  
d e l a y  m a y  b e  d i f f i c u l t  t o  a s s e s s ,  a n d  t h a t  t h e r e  i s  a  h i g h  r i s k  o f  m i s c l a s s i f i c a t i o n  o f  t h i s  c h a r a c ­
t e r i s t i c .
R 4 S 2 9 :  Categories of age at onset of spasms. I n f a n t i l e  s p a s m s  t y p i c a l l y  h a v e  a n  o n s e t  b e t w e e n  3  
a n d  1 2  m o n t h s  o f  a g e .  Y o u n g e r  a n d  o l d e r  c h i l d r e n  a r e  m o r e  l i k e l y  t o  h a v e  o t h e r  c o n d i t i o n s ,  
a n d  t h e r e  i s  a  g r e a t e r  r i s k  o f  m i s c l a s s i f i c a t i o n .  A l s o ,  a g e  a t  o n s e t  o f  s p a s m s  m a y  i n f l u e n c e  o u t ­
c o m e s .  W e  p r o p o s e  t h a t  s t u d i e s  o f  W e s t  s y n d r o m e  a n d  i n f a n t i l e  s p a s m s  r e p o r t  o u t c o m e s  f o r  
c h i l d r e n  i n  t h e  a g e  g r o u p s :  (1 )  l e s s  t h a n  t h r e e  m o n t h s  o f  a g e  ( c o r r e c t e d  f o r  p r e t e r m  d e l i v e r y ) ;
( 2 )  3  m o n t h s  ( c o r r e c t e d  a g e )  a n d  u p  t o  1 2  m o n t h s  o f  a g e ;  ( 3 )  1 2  m o n t h s  o f  a g e  a n d  o l d e r .  W e  
p r o p o s e  t h a t  t h e s e  b e  r e f e r r e d  t o  r e s p e c t i v e l y  b y  t h e  t e r m s :  early onset, classic onset, a n d  late 
onset. O n s e t  w o u l d  r a r e l y  o c c u r  a f t e r  t w o  y e a r s  o f  a g e ,  b u t  i t  i s  b i o l o g i c a l l y  i m p l a u s i b l e  t o  s e t  
a n  a b s o l u t e  u p p e r  a g e  l i m i t .
R 4 S 3 0 :  Types of intervention. W e  e n c o u r a g e  s t u d y  d e s i g n s  t h a t  u s e  r a n d o m i z e d  i n t e r v e n t i o n s ,
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s i n c e  t h e s e  a r e  l e s s  p r o n e  t o  s e l e c t i o n  a n d  c l a s s i f i c a t i o n  b i a s e s .  H o w e v e r ,  w e  w o u l d  a l s o  e n ­
c o u r a g e  t h e  c o l l e c t i o n  o f  d a t a  f r o m  n o n - r a n d o m i s e d  s t u d i e s ,  s i n c e  t h e s e  p e r m i t  s e n s i t i v i t y  
a n a l y s e s  a n d  m a y  i n v o l v e  l a r g e r  n u m b e r s .  F u r t h e r m o r e ,  b e c a u s e  o f  l a r g e r  n u m b e r s ,  t h e y  m a y  
i m p r o v e  e s t i m a t e s  o f  r i s k s  f r o m  a d v e r s e  e v e n t s .
R 4 S 3 1 :  Duration of treatment. W e  p r o p o s e  t h a t  t r e a t m e n t s  f o r  i n f a n t i l e  s p a s m s  s h o u l d  b e  c o n ­
s i d e r e d  t o  h a v e  h a d  a  s u f f i c i e n t  t h e r a p e u t i c  tried a f t e r  1 4  d a y s .  I n  g e n e r a l ,  i t  i s  n e c e s s a r y  t o  g i v e  
a  t r e a t m e n t  f o r  1 4  d a y s  b e f o r e  d e c i d i n g  t h a t  i t  h a s  n o  t r e a t m e n t  e f f e c t ,  b u t  w i t h d r a w a l  s h o u l d  
b e  c o n s i d e r e d  s o o n e r  i f  t h e r e  i s  a n  a d v e r s e  e f f e c t  o f  t h a t  t r e a t m e n t .  W e  p r o p o s e  t h a t  a n y  s t u d y  
t h a t  u s e s  a  d i f f e r e n t  p e r i o d  o f  n e c e s s a r y  a n d  s u f f i c i e n t  t h e r a p e u t i c  t r i a l  s h o u l d  s t a t e  a  r a t i o n a l e  
o r  e m p i r i c a l  e v i d e n c e  f o r  t h a t  d e c i s i o n .
R 4 S 3 2 :  Cessation of spasms as primary outcome measure for studies of IS. W e  p r o p o s e  t h a t  t h e  
p r i m a r y  o u t c o m e  o f  s t u d i e s  o f  i n f a n t i l e  s p a s m s  i s  cessation of spasms, a n d  w e  s u g g e s t  a  s t a n d a r d  
d e f i n i t i o n  f o r  t h i s  o u t c o m e .  W i t h o u t  q u a l i f i c a t i o n ,  t h e  t e r m  cessation of spasms s h o u l d  d e n o t e  
t h a t  n o  c l i n i c a l  s p a s m s  h a v e  b e e n  w i t n e s s e d  f r o m  a  t i m e  w i t h i n  1 4  d a y s  o f  t r e a t m e n t ,  a n d  f o r  
a  p e r i o d  o f  a t  l e a s t  2 8  c o n s e c u t i v e  d a y s  f r o m  t h e  t i m e  o f  t h e  l a s t  w i t n e s s e d  s p a s m .  S t u d i e s  o f  
i n f a n t i l e  s p a s m s  s h o u l d  r e p o r t  t h e  n u m b e r  a n d  p r o p o r t i o n  o f  c h i l d r e n  i n  e a c h  t r e a t m e n t  g r o u p  
w h o  m e e t  t h e s e  c r i t e r i a .
R 4 S 3 3 :  Essential EEG outcome measures. A l t h o u g h  w e  h a v e  n o t  d e t e r m i n e d ,  i n  t e r m s  o f  p r o g n o ­
s i s  f o r  d e v e l o p m e n t  a n d  f u n c t i o n ,  t h e  c l i n i c a l  i m p o r t a n c e  o f  c e s s a t i o n  o f  s p a s m s  a n d  r e s o l u ­
t i o n  o f  a b n o r m a l  E E G  f i n d i n g s ,  w e  f e e l  t h a t  i t  i s  e s s e n t i a l  t o  r e p o r t  t h e  E E G  s t a t u s  o f  c h i l d r e n  a t  
b a s e l i n e  a n d  a t  f o l l o w - u p .  W e  s u g g e s t  t h a t  a n  E E G  i s  p e r f o r m e d  a t  l e a s t :  ( 1 )  b e f o r e  t r e a t m e n t  
i s  a l l o c a t e d ;  ( 2 )  b e t w e e n  s t u d y  d a y s  1 4  a n d  2 1  ( t h a t  i s ,  w i t h i n  7  d a y s  o f  t h e  e n d  o f  t h e  p e r i o d  
o f  s u f f i c i e n t  t h e r a p e u t i c  t r i a l ) ;  a n d  ( 3 )  b e t w e e n  s t u d y  d a y s  4 2  a n d  4 9  ( t h a t  i s ,  a f t e r  t h e  p e r i o d  
d u r i n g  w h i c h  t h e r e  s h o u l d  h a v e  b e e n  2 8  d a y s  o f  f r e e d o m  f r o m  s p a s m s ) .  I f  l e s s  s e n s i t i v e  i n ­
v e s t i g a t i o n s  d o  n o t  s h o w  h y p s a r r h y t h m i a ,  w e  r e c o m m e n d  t h a t  a  v i d e o  E E G  i s  p e r f o r m e d  t o  
s t r e n g t h e n  t h e  i n f e r e n c e  t h a t  t h e  h y p s a r r h y t h m i a  h a s  r e s o l v e d .  A l t h o u g h  i t  m i g h t  b e  i n f e r r e d  
t h a t  t h e  E E G  r e m a i n s  a b n o r m a l  i n  c a s e s  w h e r e  t h e r e  a r e  c o n t i n u i n g  s p a s m s ,  i t  i s  u s e f u l  t o  h a v e  
i n f o r m a t i o n  f r o m  E E G s  e v e n  i n  c h i l d r e n  w i t h  c o n t i n u i n g  s p a s m s .  W e  r e g a r d  t h i s  i n f o r m a t i o n  
a s  e s s e n t i a l  b e c a u s e  i t  w i l l  h e l p  t o  i n f o r m  u s  a b o u t  t h e  p r o g n o s t i c  i m p o r t a n c e  o f  E E G  f i n d i n g s ,  
a n d  a b o u t  t r e a t m e n t  e f f e c t s  o n  t h e  E E G .
R 4 S 3 4 :  Essential adverse effect outcome measures. S t u d i e s  s h o u l d  r e p o r t  a l l  d e a t h s  o c c u r r i n g  
d u r i n g  t h e  s t u d y  p e r i o d ,  e v e n  w h e n  t h e y  a r e  n o t  r e g a r d e d  a s  a t t r i b u t a b l e  t o  t r e a t m e n t .  S t u d y  
r e p o r t s  s h o u l d  s t a t e  w h i c h  a d v e r s e  e v e n t s  w e r e  i n v e s t i g a t e d ,  h o w  t h e y  w e r e  s o u g h t ,  a n d  h o w  
t h e y  w e r e  c l a s s i f i e d .
R 4 S 3 5 :  Other important outcome measures. W e  p r o p o s e  t h a t  a t  l e a s t  t h e  f o l l o w i n g  o u t c o m e s  a n d  
m e a s u r e s  b e  r e p o r t e d ,  b y  i n t e r v e n t i o n  g r o u p ,  i n  s t u d i e s  o f  i n f a n t i l e  s p a s m s :  ( a )  C e s s a t i o n  o f  
s p a s m s  [ n u m b e r  a n d  p r o p o r t i o n  w i t h  l a s t  w i t n e s s e d  s p a s m  b e f o r e  t h e  e n d  o f  d a y  1 4  o f  t r e a t ­
m e n t  a n d  w i t h  n o  s p a s m s  f o r  2 8  c o n s e c u t i v e  d a y s  t h e r e a f t e r ] ;  ( b )  D e v e l o p m e n t  a t  2  y e a r s  o f  a g e  
[ m e d i a n  a n d  r a n g e s  f o r  t e s t s  c h o s e n ] ;  ( c )  D e a t h s  a n d  o t h e r  s e r i o u s  a d v e r s e  e v e n t s  [ n u m b e r s  
a n d  d e s c r i p t i o n s  o f  e v e n t s ] ;  ( d )  R e l a p s e  [ n u m b e r s  a n d  p r o p o r t i o n  o f  p r i m a r y  r e s p o n d e r s  r e ­
l a p s i n g ;  p r o p o r t i o n  o f  w h o l e  i n t e r v e n t i o n  g r o u p  r e l a p s i n g  ( t h a t  i s ,  i n c l u d i n g  n o n - r e s p o n d e r s ) ;  
a n d  d i s t r i b u t i o n s  o f  t i m e  t o  r e l a p s e  ( f r o m  t i m e  o f  r e s p o n s e ) ] ;  ( e )  P r e s e n c e  o f  a n d  p r o g r e s s i o n  t o  
o t h e r  s e i z u r e  t y p e s  [ n u m b e r s ,  p r o p o r t i o n s ,  a n d  s e i z u r e  t y p e s ] ;  ( f )  N o n - s e r i o u s  a d v e r s e  e v e n t s  
[ n u m b e r s ,  p r o p o r t i o n s ,  a n d  d e s c r i p t i o n  o f  e v e n t s ] ;  ( g )  R e s o l u t i o n  o f  h y p s a r r h y t h m i a  a t  a  t i m e  
b e t w e e n  d a y s  1 4  a n d  2 1 ,  a n d  b e t w e e n  d a y s  4 2  a n d  4 9  o f  t h e  s t u d y  [ n u m b e r s  w i t h  h y p s a r -
APPENDIX C. DATA FROM WEST DELPHI 272
r h y t h m i a  a t  s t a r t  o f  s t u d y ,  a t  s t u d y  d a y  1 4  a n d  a t  s t u d y  d a y  4 2 ;  p r o p o r t i o n s ,  a n d  t y p e s  o f  E E G  
p e r f o r m e d ] .
R 4 S 3 6 :  Time to cessation of spasms. T i m e  t o  c e s s a t i o n  o f  s p a s m s  c a n  b e  r e p r e s e n t e d  b y  a c t u a r i a l  
c u r v e s  a n d  i s  a  c l i n i c a l l y  u s e f u l  o u t c o m e  t h a t  m i g h t  i n f o r m  f u t u r e  s t u d y  d e s i g n s .  W e  p r o p o s e  
t h a t  i t  i s  p e r m i s s i b l e  f o r  s t u d i e s  t o  r e p o r t ,  i n  a d d i t i o n  t o  " t i m e  t o  2 8 - d a y s  o f  s p a s m - f r e e d o m " ,  
" t i m e  t o  l a s t  w i t n e s s e d  s p a s m  i n  c a s e s  t h a t  w e r e  p r i m a r y  r e s p o n d e r s . "  T h i s  g i v e s  a  u s e f u l  
a n d  i n t u i t i v e  c l i n i c a l  m e a s u r e  t h a t  c a n  b e  e x a m i n e d  u s i n g  t h e  s t a t i s t i c a l  t e c h n i q u e s  o f  s u r v i v a l  
a n a l y s i s .  M e a s u r e s  o f  t i m e  t o  c e s s a t i o n  o f  s p a s m s  a r e  m o r e  r e l i a b l e  a n d  i n f o r m a t i v e  t h a n  
m e a s u r e s  o f  t i m e  t o  5 0 %  r e d u c t i o n  i n  i c t a l  u n i t s .
R 4 S 3 7 :  Relapse. T h e  f o l l o w i n g  s h o u l d  b e  c o n s i d e r e d  t o  c o n s t i t u t e  a  r e l a p s e  o f  i n f a n t i l e  s p a s m s  
a t  a n y  s t a g e  a f t e r  a  p r i m a r y  r e s p o n s e  h a s  b e e n  o b t a i n e d :  1 )  a n y  e p i s o d e  o f  s p a s m s  o c c u r r i n g  
i n  c l u s t e r s ;  a n d  2 )  t w o  o r  m o r e  e p i s o d e s  o f  s p a s m s  t h a t  o c c u r  s i n g l y  b u t  n o t  i n  c l u s t e r s .  A  s i n ­
g l e  w i t n e s s e d  s p a s m  w o u l d  n o t  b e  r e l i a b l e  a n d  s h o u l d  n o t  b e  c l a s s i f i e d  a s  a  r e l a p s e .  B e c a u s e  
p r i m a r y  r e s p o n s e  i s  d e f i n e d  b y  c e s s a t i o n  o f  s p a s m s ,  p e r s i s t e n t  o r  r e c u r r e n t  h y p s a r r h y t h m i a  
s h o u l d  n o t  b e  c o n s i d e r e d  t o  b e  a  r e l a p s e  u n l e s s  i t  i s  a c c o m p a n i e d  b y  w i t n e s s e d  s p a s m s .  H o w ­
e v e r ,  t h e  p e r s i s t e n c e  o r  r e c u r r e n c e  o f  h y p s a r r h y t h m i a  s h o u l d  b e  r e p o r t e d  a s  p a r t  o f  a  s e c ­
o n d a r y  a n d  e s s e n t i a l  o u t c o m e  m e a s u r e .
R 4 S 3 8 :  Pyridoxine-dependent seizures. P y r i d o x i n e  d e p e n d e n t  s e i z u r e s  a r e  r a r e .  T h e y  e v e n  m o r e  
r a r e l y  h a v e  t h e  c l i n i c a l  m a n i f e s t a t i o n  o f  i n f a n t i l e  s p a s m s ,  t h o u g h  t h i s  i s  t h o u g h t  t o  b e  m o s t  
l i k e l y  w h e n  o t h e r  s e i z u r e  t y p e s  h a v e  o c c u r r e d  b e f o r e  t h e  o n s e t  o f  s p a s m s .  G i v i n g  i n t r a v e n o u s  
p y r i d o x i n e  i s  a s s o c i a t e d  w i t h  a  r i s k  o f  a p n e a .  I t  r e q u i r e s  c l o s e  m o n i t o r i n g ,  a n d  i s  n o t  k n o w n  
t o  b e  a s s o c i a t e d  w i t h  r a p i d  r e s o l u t i o n  o f  h y p s a r r h y t h m i a .  O r a l  p y r i d o x i n e  s e e m s  t o  b e  a s s o ­
c i a t e d  w i t h  a  m e d i a n  t i m e  t o  r e s p o n s e  o f  s e v e r a l  d a y s .  T h u s ,  i n c o r p o r a t i n g  a  d i a g n o s t i c  a n d  
t h e r a p e u t i c  t e s t  o f  p y r i d o x i n e  i n t o  s t u d y  d e s i g n s  i s  c h a l l e n g i n g .
R 4 S 3 9 :  Pyridoxine-responsive seizures. T h e  C o c h r a n e  r e v i e w  d i d  n o t  i d e n t i f y  a n y  R C T  e v i d e n c e  
o f  t r e a t m e n t  e f f e c t  f o r  p y r i d o x i n e  i n  i n f a n t i l e  s p a s m s ,  b u t  s o m e  i n v e s t i g a t o r s  u s e  p y r i d o x i n e  
a s  a n  i n i t i a l  o r  a d j u n c t  t r e a t m e n t  o f  i n f a n t i l e  s p a s m s .  I f  p y r i d o x i n e  i s  u s e d ,  t h e  r e p o r t  s h o u l d  
c l e a r l y  s t a t e  i t s  t i m i n g ,  d o s e ,  a n d  d u r a t i o n .
R 4 S 4 0 :  Aggregation of data from several or many studies. I n c o r p o r a t i n g  d a t a  f r o m  m a n y  a n d  
l a r g e r  s t u d i e s  i s  a  l o n g e r - t e r m  g o a l  o f  d o c t o r s  w h o  a r e  i n t e r e s t e d  i n  m a k i n g  t h e  b e s t  t r e a t ­
m e n t  d e c i s i o n s  f o r  c h i l d r e n  w i t h  i n f a n t i l e  s p a s m s .  F o r  r a n d o m i s e d  c o n t r o l l e d  t r i a l s ,  t h e r e  i s  
a  C o c h r a n e  r e v i e w  o f  t r e a t m e n t s  f o r  i n f a n t i l e  s p a s m s .  T h i s  w i l l  c o n t i n u e  t o  p r o v i d e  m e t a ­
a n a l y s e s  o f  r a n d o m i s e d  s t u d i e s  o f  i n f a n t i l e  s p a s m s .  F o r  s t u d i e s  w i t h  r a n d o m i s e d  a n d  o t h e r  
d e s i g n s ,  w e  r e c o m m e n d  t h e  u s e  o f  u n i f o r m  d e f i n i t i o n s  a n d  c l a s s i f i c a t i o n  t h a t  w i l l  f a c i l i t a t e  
a g g r e g a t i o n  o f  d a t a  t h a t  a v o i d s  a m b i g u i t y ,  c o n f u s i o n  o r  m i s c l a s s i f i c a t i o n .
R 4 S 4 1 :  Areas for future consensus. T h e r e  r e m a i n  a r e a s  o f  i n c o m p l e t e  c o n s e n s u s ,  s u c h  a s  h o w  
w e  m i g h t  a g g r e g a t e  d a t a  f r o m  s t u d i e s  t h a t  d o  n o t  m e e t  t h e  i n c l u s i o n  c r i t e r i a  o f  t h e  C o c h r a n e  
r e v i e w  o f  t r e a t m e n t s  f o r  i n f a n t i l e  s p a s m s .  I n  t h e  f u t u r e ,  w e  m i g h t  w i s h  t o  d e v e l o p  a  m o r e  
d e t a i l e d  s t r u c t u r e  f o r  r e p o r t i n g  o f  a d v e r s e  e v e n t s ,  a n d  r e c o m m e n d a t i o n s  o n  w h i c h  t o o l s  t o  
u s e  t o  a s s e s s  d e v e l o p m e n t a l  o u t c o m e s  a n d  t o  c l a s s i f y  d i s a b i l i t y .  F i n a l l y ,  w e  f o u n d  i t  d i f f i c u l t  
t o  p r o v i d e  a  d e t a i l e d  d e s c r i p t i o n  o f  t h e  l i m i t s  o f  d e f i n i t i o n  o f  h y p s a r r h y t h m i a ,  a n d  a  f u t u r e  
c o n s e n s u s  m i g h t  w i s h  t o  r e v i s i t  t h i s  i s s u e .
R 4 S 4 2 :  Summary cfW est Delphi consensus statement. T h i s  c o n s e n s u s  i s  t h e  r e s u l t  o f  m a n y  h o u r s  
o f  c o n s i d e r a t i o n  b y  t h e  X  p a r t i c i p a n t s .  W e  a i m e d  t o  p r o d u c e  p r o p o s a l s  t h a t  w i l l  a s s i s t  i n v e s t i ­
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g a t o r s  i n  d e s i g n i n g  s t u d i e s  b u t  w h i c h  a r e  n o t  u n n e c e s s a r i l y  c o n s t r a i n i n g .  W e  h a v e  a t t e m p t e d  
t o  c l a r i f y  o l d  t e r m s  a n d  h a v e  g e n e r a l l y  a v o i d e d  n e w  t e r m s .  T h e  m a i n  p r o p o s a l s  t h a t  m i g h t  
b e  c o n s i d e r e d  t o  b e  n e w  c o n c e p t s  a r e :  (1 )  d e f i n i t i o n s  o f  t h e  t e r m s  c l i n i c a l  s p a s m s ,  e p i l e p t i c  
s p a s m s ,  a n d  i n f a n t i l e  s p a s m s  t h a t  c o n f o r m  t o  t h e  5 - a x i s  I L A E  p r o p o s a l ;  (2 )  s y n d r o m e  c l a s s i f i ­
c a t i o n  f o r  I S ,  W S ,  IS S V , a n d  H W I S ;  ( 3 )  c l a s s i f i c a t i o n  b y  a g e  a t  o n s e t  i n t o  e a r l y  o n s e t ,  c l a s s i c  o n ­
s e t  a n d  l a t e  o n s e t  g r o u p s ;  ( 4 )  t h e  p r o p o s a l  f o r  a n  e t i o l o g i c  c l a s s i f i c a t i o n  i n t o  g r o u p s  d e s c r i b e d  
a s  predisposed a n d  non-predisposed; a n d  (5 )  s t a n d a r d i s e d  d e f i n i t i o n s  o f  r e s p o n s e  a n d  r e l a p s e .
Appendix D 
West Delphi Consensus Statement
This appendix contains the West Delphi consensus statement as published in 
Epilepsia 2004;45:1416-28 [209]. The contributing authors, members of the West 
Delphi Group, are listed in appendix A.4 on page 243.
West Delphi Proposal
1. Introduction to W est Delphi. The West Delphi Proposal is a consensus statement that 
proposes a series of definitions and standards for use in studies of infantile spasms. In 
particular, it aims to provide clearer definitions of cases and etiologic subgroups, and a 
standard for outcomes and outcome measures. We hope that this will help those who 
wish to design future studies of infantile spasms, and that such studies will provide 
optimal information for those who wish to learn from these studies and to choose the 
best approach to treating infantile spasms.
Case definitions
2. Infantile spasms. We propose using the term infantile spasms (ISs) to describe an 
epilepsy syndrome that rarely has onset in children over two years old and usually 
has onset in children aged less than one year. Its main clinical manifestation is clinical 
spasms  that usually occur in clusters. There are many potential etiologies or associated 
conditions. The most characteristic EEG finding is hypsarrhythmia. However, hypsar­
rhythmia is not found in all cases, nor is it found throughout the clinical course of the 
condition. Hypsarrhythmia is usually interrupted during a clinical attack of epileptic 
spasms. The spasms are often associated with developmental arrest or regression.
3. W est syndrome. We propose using the term W est syndrom e (W S)  to describe the 
combination of spasms that occur in clusters and hypsarrhythmia on an EEG. We do 
not require, as have some previous definitions of West syndrome, that there is evi­
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dence of delayed development before the onset of spasms. Some participants wished 
to classify children with single spasms (that is, without spasms in clusters) and with 
hypsarrhythmia as having W est syndrome, but most preferred to reserve the term West 
syndrome for cases with clustered spasms.
4. Significance o f developmental delay. We see no reason for including developmental 
delay at the time of onset as a defining feature of West syndrome. Indeed, develop­
mental delay at onset of spasms is likely to be assessed unreliably because spasms are 
often subtle and their true time of onset is often unrecognised, and also because de­
velopment is hard to assess in early infancy. However, we feel that information about 
unequivocally normal development at the time of onset of spasms is worth recording, 
since this may be associated with better developmental outcome. Apparently abnor­
mal development may be confounded by the effect of unrecognised spasms at onset 
or the epileptic encephalopathy.
5. Infantile spasms -  single-spasm variant. It is less usual for infantile spasms to always 
occur singly rather than in clusters, yet we agree that such cases do occur. We propose 
that these cases are distinguished in studies of infantile spasms by being called infan­
tile spasms single-spasm variant (ISSV). A  child with single spasms and hypsarrhythmia 
should be classified as ISSV rather than WS. We do not propose a strict definition 
of clustering  but, as a general guide and until further evidence is available, we sug­
gest that a spasm can be regarded as a single spasm if there are no other spasms for 
one minute beforehand and for one minute afterwards. Any definition of clustering 
should be clearly stated. We wish to emphasise that a child with single spasms and 
without hypsarrhythmia is rare and such cases are likely to have a diagnosis other 
than ISSV. Some participants felt that they would never diagnose infantile spasms in 
such a case. We would suggest that authors state clearly, in cases with neither cluster­
ing of spasms nor hypsarrhythmia, why they are accepting the diagnosis of ISSV.
6. H ypsarrhythm ia w ithout infantile spasms. Some children are investigated for symp­
toms other than clinical spasms and are found to have hypsarrhythmia. If these chil­
dren, even after video EEG investigation, are found not to have any evidence of clinical 
spasms, we propose that they are classified as having hypsarrhythmia w ithout infantile 
spasms (HW IS). Future studies will inform us whether these children have a high risk 
of developing infantile spasms at a later date, and about their developmental outcome.
7. Relationship between definitional terms. We propose using infantile spasms as an inclu­
sive term for all children with clinical spasms who have evidence of EEG abnormal­
ities consistent with the clinical syndrome of infantile spasms - typically, though not 
necessarily, hypsarrhythmia or modified hypsarrhythmia (see statements 16 and 17) - 
provided that the EEG findings do not suggest another specific diagnosis. The terms 
W est syndrom e  and infantile spasms single-spasm variant describe specific subgroups of 
infantile spasms. Investigators might wish to report studies of children with all forms
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of infantile spasms and report the proportions in their study with WS and ISSV. Or 
they might wish to perform a study that included, say, only children with W S  and 
ISSV  w ith  hypsarrhythmia. Studies that focus on developmental and EEG outcomes 
might wish to include children with H W IS  (though HW IS  is not a subgroup of ISs). 
Consistent use of these definitional terms and a clear statement of how many children 
came from each group will assist those who wish to use and interpret study data. We 
believe that these definitions clearly distinguish clinical subgroups, encourage clarity, 
and permit flexibility in study design.
8. Our proposed relationships between IS, WS, ISSV and HWIS are illustrated in [fig­
ures D.l and D.2]. These figures also illustrate the relationships between these terms 
and the 5-axis system proposed by the ILAE Task Force on Classification and Termi­
nology, 2001 [233].
9. Features o f clinical spasms. We propose that the term clinical spasms  is used to describe 
brief and synchronous movements of the head, trunk and limbs, or sometimes of the 
head, trunk or limbs alone. The movements may be flexor or extensor, or a mixture 
of extensor and flexor movements, and they may be asymmetric. These movements 
have a longer duration than the movement of myoclonus, and they are shorter than 
the movement associated with a tonic seizure. Thus, their duration is approximately 
one second. The subtlest movement that might be classifiable as a clinical spasm is a 
head nod. Though it has been suggested that the term describing this seizure semi­
ology should be epileptic spasm  (ILAE Glossary of Descriptive Terminology for Ictal 
Semiology, 2001: paragraph I I 1.1.1.1), we propose using the term clinical spasms  to 
describe the ictal phenomenology, and reserving the term epileptic spasms to describe 
the seizure type [234].
10. Subtle spasms. More subtle movements, often described as subtle spasms, may con­
stitute the clinical attack associated with hypsarrhythmia. Such movements include 
episodes of yawning, gasping, facial grimacing, isolated eye movements, and tran­
sient focal motor activity. These cases may be having focal seizures, and the episodes 
are difficult to count and record. Ideally, a video EEG would be performed to confirm 
that clinical spasms are not occurring.
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leptiform ■ No ♦
Nonepilepsy condition, such as 
benign myoclonus o f infancy
Epileptic spasms
Age at onset <2 years* No Other syndrome of spasms, such as Gobbi syndrome
Yes
EEG*: interictal EEG consistent with infantile 
spasms and not suggesting other syndrome Other epilepsy condition




EEG*: hypsarrhythmia (with 




ISSV  with 
hypsarrhythmia
EEG**: hypsarrhythmia (with 
or without atypical features) - No




FIG. 1. Classification of infantile spasm s lor study tndusion
'Excludes subtle spasms
"EEG, standard, sleep and video EEGs are performed, as necessary, before excludmg a positive finding.
•"2  years is not an absolute upper limit, but substantially older cases would be likely to be classified as another syndrome, such as that 
of periodic spasms. If thought to be infantile spasms, they would be dearly identified as unusual, and the numbers of such patients should 
be dearly stated.
Suggested cross-reference to ILAE muMaxial classification:
Axis 1 (idal phenomenology): cMnicai spasm s 
Axis 2 (seizure type): epileptic spasm s
Axis 3 (syndrome): Infantile spasm s (ISs), West syndrome (WS), and Infantile spasm s slngte-spasm variant (ISSV) ore syndrome 
subgroups o f ISs.
Suggested use lor terms:
• Studies of infantile spasms would include cases of ISSV and cases of West syndrome, unless axdusions or restridions are explicitly 
stated
• Studies of West syndrome would exdude cases without clustered spasms and cases without hypsarrhythmia
Note that this classification requires dusters of spasms lor a diagnosis of West syndrome. Cases with spasms occurring singly and without
any witnessed dusters, even when associated with hypsarrhythmia, are not classified as West syndrome.
Figure D.l: Classification of infantile spasms for study inclusion as it appears 
in the West Delphi consensus statement.
FIG. 2. Classification of children with hypsarrhythmia 
without clinical spasms but who may have subtle spasms. 
It is well known that hypsarrhythmia can occur in the ab­
sence of spasms and sometimes without any evident clin­
ical seizure (26). Because hypsarrhythmia is effectively 
the presenting feature in such cases (at least, with re­
spect to considering a diagnosis of infantile spasms), it is 
useful to have a scheme for classification, conditional on 
the presence of hypsarrhythmia.
This flow diagram suggests a classification for children 
with hypsarrhythmia identified at younger than 2 years.
H ypsarrhythm ic e e g]
S p asm s*  —  N o
Hypsarrhythmia without infantile 
spasms (HWIS) (m a y  b e  su b c la ss ifie d  
acco rd in g  to  c l in ic a l fea tu res)
Y e s




* l f  sp asm s or  c lu ster s  are n ot o b se rv ed  c l in ic a l ly , w e  re co m m en d  p erform in g  
v id eo -E E G  for a p eriod  o f  > 2 4  h  to  ru le ou t th eir  o cc u r ren ce  re liab ly .
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11. Subtle spasms at onset or at follow up. We propose that children with these subtle ictal 
events are classified at onset as having hypsarrhythmia without infantile spasms (HWIS) 
because the events are different from clinical spasms, they are difficult to recognise and 
count, and they are not reliably measured as a primary clinical outcome. However, we 
suggest that investigators should, during follow up of a case of infantile spasms, re­
port subtle movements associated with typical electrodecremental EEG changes or in­
terruption in the interictal background, and that this combination of clinical and neu- 
rophysiological findings would be sufficient to constitute electroclinical non-response 
or relapse.
12. Epileptic spasms. We propose using the term epileptic spasms to describe the epileptic 
seizure type of clinical spasms associated with an epileptiform EEG. This corresponds 
to Axis 2 of the proposed ILAE scheme. This term would include conditions such as 
the periodic spasms of Gobbi and infantile spasms [25,29]. The term epileptic spasms 
implies that the EEG is consistent with the diagnosis of an epilepsy, but does not by 
itself imply hypsarrhythmia or any more specific EEG pattern.
13. Relationship to proposed ILAE 5-axis system. Using these definitions and classifi­
cation, clinical spasms, epileptic spasms, and infantile spasms correspond with axes 
1 (ictal phenomenology), 2 (seizure type), and 3 (syndrome) respectively of the pro­
posed ILAE 5-axis scheme. West syndrome is a syndrome in its own right and a sub­
group of infantile spasms, as is ISSV.
14. With respect to Axis 3 (syndrome) of the proposed ILAE diagnostic scheme, we 
propose that infantile spasms is the syndrome of epileptic spasms with onset generally 
during the first two years of life, in association with high voltage, multifocal or diffuse 
interictal EEG abnormalities [25]. We propose that West syndrome is defined by the 
association of clinical spasms, at least some of which occur in clusters, with an inter­
ictal EEG showing hypsarrhythmia. This may be either "classic" hypsarrhythmia, or 
hypsarrhythmia with modified features. Infantile spasms single-spasm variant is another 
form of infantile spasms and is also regarded as an epilepsy syndrome.
15. Ictal unit of infantile spasms. There is disagreement about whether the appropriate 
ictal unit in studies of infantile spasms should be the spasm or the cluster of spasms. 
Most West Delphi participants thought that the more appropriate ictal unit was the 
cluster of spasms. However, we felt there was limited value in outcomes that rely on 
measurement of ictal units, such as time to 50% reduction of spasms or the proportion 
of study participants having a 50% or greater reduction in spasms.
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Electrographic features
16. Hypsarrhythmia. We propose that the term hypsarrhythmia is used to describe an 
EEG pattern that is characterised by random, high-voltage spikes and slow waves. 
The most striking features of hypsarrhythmia are: high-voltage (generally > 200 mi­
crovolts) slow waves with variable amplitude; spikes and waves from many foci and 
varying with time; and a lack of synchrony with a generally "chaotic" appearance. 
The typical appearance is more likely to be found in earlier stages of infantile spasms 
and when onset occurs at a younger age. The hypsarrhythmic pattern may disappear 
during REM sleep, but it may be found with greater sensitivity in some other stages 
of sleep [66].
17. Modified and atypical hypsarrhythmia. With respect to the use of the term modi­
fied hypsarrhythmia [8, 67] and its synonym (or at least near-synonym) atypical hyp­
sarrhythmia [32], we endorse the recommendation of the 1991 workshop on infantile 
spasms [28] that study participants with modified hypsarrhythmia are not reported 
in dichotomised groups but that, where appropriate, a description is given of the in­
dividual modifying features. The presence of modified features may depend upon 
the stage of infantile spasms at which the EEG is performed; it may depend upon 
treatment; and as an aggregate variable, it probably has little practical prognostic sig­
nificance in randomized studies.
18. Forms of EEG recording. EEG findings provide essential information in studies of 
infantile spasms. We recommend a degree of standardisation in the timing of EEG in­
vestigations, and that investigators limit potential information bias in studies by mak­
ing allowance for differences in the sensitivity of different investigations. Increased 
sensitivity is likely in the case of video EEGs, with longer periods of recording, and 
with recordings that include periods of non-REM sleep. While performing less sensi­
tive investigations is reasonable, it is prudent to design studies that use more sensitive 
investigations before inferring that EEG abnormalities are genuinely not present.
Etiology of infantile spasms
19. Etiologic subgroups of infantile spasms. Several terms have been used to describe 
etiologic subgroups of ISs, but these terms have not been used consistently between 
studies. There remains incomplete agreement about the use of the terms symptomatic, 
idiopathic, and cryptogenic even though such terms are also used in the classification 
of other epilepsies. The terms idiopathic and cryptogenic have been used in some 
studies as synonyms of each other and as antonyms of symptomatic.
20. Idiopathic infantile spasms. The term idiopathic infantile spasms is used to describe 
cases in which there are infantile spasms without any identifiable underlying cause, 
nor other neurologic signs or symptoms. Such cases may be associated with a family 
history. While we agree that cases in this group may have good developmental out­
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comes, we do not approve making eventual normal development part of its definition, 
since we are reserving its use as part of an etiologic classification for use at the time of 
study enrolment.
21. Cryptogenic infantile spasms. The term cryptogenic infantile spasms has been used to 
describe cases suspected of being symptomatic but for whom an underlying structural 
or biochemical cause could not be identified. Features suggesting an unidentified un­
derlying cause include preceding developmental delay, or other neurologic features, 
such as seizures. It has been suggested that the term probably symptomatic is preferred 
to cryptogenic [233], though West Delphi participants had a range of views on this. 
Some prefer to retain the term cryptogenic; some prefer probably symptomatic; and some 
suggest that, if we cannot identify the underlying cause, we ought to use the term 
non-symptomatic rather than subjectively classify cases further.
22. Symptomatic infantile spasms. The term symptomatic infantile spasms has been used to 
refer to cases in which the seizures result from an identifiable cause, and often to refer 
also to cases in which neurological features or an unequivocal developmental delay 
precede the onset of spasms. We suggest reserving the term symptomatic for cases with 
an identified underlying disorder, and classifying cases with neurological symptoms, 
signs or developmental delay, but no proven cause or etiology, as cryptogenic.
23. Specific etiologies. However constituted, the etiologic subgroups discussed above 
will include children with different underlying causes, which may or may not be iden­
tified, and such aggregation into etiologic subgroups is of limited value. However, 
within any one study, it is only possible to obtain precise estimates of effect, and to 
perform formal statistical tests for heterogeneity of effect, on groups with specific di­
agnoses if they are relatively commonly associated with infantile spasms. An example 
of such commonly associated diagnoses is tuberous sclerosis. Greater homogeneity of 
study design will help in aggregating data about rare causes of infantile spasms.
24. Timing of etiologic classification. It is often unclear in study reports whether the 
classification into etiologic subgroups is based on diagnostic information known at 
the time of treatment decision or randomization, or information available at the time 
of study completion. If the data are to be used to inform future treatment choice, it is 
rational for the study to report outcomes according the classification made at the time 
of treatment decision. This avoids the information bias introduced by reclassification 
of cases between time of treatment decision and study completion. Initial classification 
is the natural choice for stratified analyses by intention-to-treat.
25. We ought also to use the more complete and specific diagnostic information that 
is available at the time of study completion. This informs us about outcomes and 
treatment choice for children with specific diagnoses, though we should be aware of 
the bias that might be introduced by incomplete diagnostic information at the time
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of treatment decision. We propose that, in order to make this clear, studies reserve 
the terms cryptogenic, idiopathic, and symptomatic to refer to an etiologic classification 
made at the time of randomisation or treatment choice, and that they report the final 
diagnostic classification in more specific diagnostic groups. We suggest a list of specific 
diagnostic groups in Appendix B. Of course, study inclusion criteria or stratified ran­
domisation might include more specific diagnostic groups, such as tuberous sclerosis, 
but the study report should make clear if there has been diagnostic reclassification of 
cases by the time of study completion.
Reporting baseline characteristics in studies of infantile spasms
26. Baseline characteristics in interventional studies. We propose that the following base­
line characteristics should be reported for each treatment or intervention group: (a) 
etiologic group, if used for pre-randomisation stratification; (b) sex; (c) age at onset 
(median and range, and proportions in each age category -  see statement 27); (d) 
gestation (proportion bom preterm, and median gestation); (e) birthweight (median 
birthweight and proportion under 1500 grams); (f) preceding seizures; (g) concurrent 
and previous treatment with AEDs or steroids; (h) lead time from apparent onset of 
spasms to treatment (median and range); (i) presence of hypsarrhythmia; and (j) un­
equivocally normal development at apparent onset of spasms. Attention should be 
drawn to large differences that might bias the results, even where treatments have 
been allocated randomly and these differences must have occurred by chance.
27. Classification by age at onset of spasms. Infantile spasms typically have an onset be­
tween 3 and 12 months of age. Younger and older children are more likely to have 
other conditions, and there is a greater risk of misclassification. Also, age at onset of 
spasms may influence outcomes. We propose that studies of infantile spasms report 
outcomes for children in age of onset groups: (1) less than three months of age (cor­
rected for preterm delivery); (2) 3 months (corrected age) and up to 12 months of age;
(3) 12 months of age and older. We propose that these be referred to respectively by 
the terms: early onset, classic onset, and late onset. Onset would rarely occur after two 
years of age, but it is biologically implausible to set an absolute upper age limit.
Duration of treatment
28. Duration of treatment in interventional studies. We propose that treatments for in­
fantile spasms should be considered to have had a sufficient therapeutic trial after 14 
days. In general, it is necessary to give a treatment for 14 days before deciding that 
it has no treatment effect, but withdrawal should be considered sooner if there is an 
adverse effect of that treatment. We suggest that any study that uses a different pe­
riod of necessary and sufficient therapeutic trial should state a rationale or empirical 
evidence for that decision. If adjunct treatments are used, the study protocol should 
state clearly how these might affect outcome.
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Outcomes
29. Primary clinical outcome. We propose that the primary clinical outcome of studies of 
infantile spasms is cessation of spasms, and we suggest a standard definition for this 
outcome. Without qualification, the term cessation of spasms should denote that no 
clinical spasms have been witnessed from a time commencing within 14 days of treat­
ment, and for a period of > 28 consecutive days from the time of the last witnessed 
spasm. Studies of infantile spasms should report the number and proportion of chil­
dren in each treatment group who meet these criteria.
30. Timing of EEG investigations. Although we do not have evidence for the clinical 
importance of cessation of spasms and resolution of abnormal EEG findings, in terms 
of prognosis for development and function, we propose that it is essential to report 
the EEG status of children at baseline and at follow-up. We suggest that an EEG is 
performed at least:
• before treatment is allocated;
• between study days 14 and 21 (that is, within 7 days of the end of the period of 
sufficient therapeutic trial); and
• between study days 42 and 49 (that is, after the period during which there 
should have been 28 days of freedom from spasms).
31. EEG classification. Resolution of hypsarrhythmia is a more appropriate EEG out­
come than normalization of EEG, since with many underlying etiologies we cannot 
expect the background EEG to normalize even if epileptiform changes resolve. Also, 
there may be progression to other seizure types without any evidence of infantile 
spasms or hypsarrhythmia.
Electroclinical outcomes
32. If less sensitive investigations do not show hypsarrhythmia, we recommend that 
a sleep EEG is performed to provide stronger evidence that the hypsarrhythmia has 
resolved. Ideally, there would be a video EEG recording that includes sleep. There 
is no evidence for recommending a specific duration for video EEG recording, but a 
24-hour period is typical and some participants thought 6 hours would be as sensitive 
as 24 hours. Although it might be inferred that the EEG remains abnormal in cases 
where there are continuing spasms, it is also useful to have information from EEGs 
in children with continuing spasms. We regard this information as essential because 
it will help to inform us that the seizure type has not changed, about the prognostic 
importance of EEG findings, and also about treatment effects on the EEG.
33. Primary electroclinical response. Some West Delphi participants are uneasy with the 
idea that children with no witnessed spasms but continuing hypsarrhythmia should
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be classified as primary responders. They suggest that a primary responder should 
have both cessation of spasms and resolution of hypsarrhythmia. We propose the 
term primary electroclinical outcome to describe this combination of outcomes, and we 
propose that it be regarded as an essential outcome [182].
34. Studies that report both primary clinical outcome and primary electroclinical outcome 
provide important information about how often the clinical response is associated 
with resolution of hypsarrhythmia. Such studies would permit a degree of extrap­
olation of data from studies performed in places where access to neurophysiological 
equipment is more restricted and where the primary electroclinical outcome cannot 
be reliably determined.
Adverse events
35. Deaths during study period. Studies should report all deaths occurring during the 
study period, even when they are not regarded as attributable to treatment. Study 
reports should state which adverse events were investigated, how they were sought, 
and how they were classified.
Outcome measures and analysis of data
36. Outcome measures. We propose that at least the following outcomes and measures, 
stratified by intervention group, are reported in studies of infantile spasms:
• primary clinical response
• primary electroclinical response
• relapse-free primary responses (clinical and electroclinical, numbers and pro­
portions)
• continuing subtle spasms where clinical spasms have ceased
• distribution of time to relapse (from time of randomisation, perhaps best rep­
resented graphically as a variable proportion with relapse-free remission over 
time)
• development at 2 years of age (medians and ranges for tests chosen)
• deaths and other serious adverse events (numbers and descriptions of events)
• presence of and progression to other seizure types (numbers, proportions, and 
seizure types)
• non-serious adverse events (numbers, proportions, and description of events)
37. Analyzing different etiologic subgroups. We suggest that most outcomes are influ­
enced more strongly by underlying disorders than by treatment. We recommend that
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investigators exercise caution in performing multiple tests on such outcomes and at­
tributing significant differences to treatments since, in addition to there being biases 
introduced by multiple testing, the conclusions may lack biological plausibility. How­
ever, one aim of treatment is to improve development and function by limiting any 
damage that might be caused by repeated spasms.
38. Analyzing time to cessatwn of spasms. Time to cessation of spasms can be represented 
by actuarial curves and is a clinically useful outcome that might inform future study 
designs. We suggest the convention of reporting time to 28-days of spasm-freedom for 
the primary clinical response. This is a useful and intuitive clinical measure that can 
be examined using the statistical techniques of survival analysis. Measures of time 
to cessation of spasms are more reliable and informative than measures of time to 
50% reduction in ictal units. The primary electroclinical response does not lend itself 
so readily to such analyses because EEGs are performed in a cross-sectional fashion, 
whereas clinical observation is a more continuous measure.
39. Relapse. The following should be considered to constitute a clinical relapse of in­
fantile spasms at any stage after a primary clinical response has been obtained: (1) any 
episode of spasms occurring in clusters; (2) two or more episodes of spasms that occur 
singly but not in clusters; and (3) subtle spasms (if accompanied by an EEG showing 
appropriate changes). A single witnessed spasm would not be reliable and should 
not be classified as a relapse of clinical spasms, but investigators might wish to report 
their occurrence.
Role of pyridoxine (vitamin 66)
40. Diagnostic role of pyridoxine. Pyridoxine-dependent seizures are rare [122]. They 
even more rarely have the clinical manifestation of infantile spasms, though this is 
thought to be most likely when other seizure types have occurred before the onset of 
spasms. Giving intravenous pyridoxine is associated with a risk of apnea. It requires 
close monitoring, and is not known to be associated with rapid resolution of hypsar­
rhythmia. Oral pyridoxine seems to be associated with a median time to response of 
several days. Thus, incorporating a diagnostic and therapeutic test of pyridoxine into 
study designs is challenging.
41. Treatment role of pyridoxine. In addition to use in diagnosing potential pyridoxine- 
dependent seizures, pyridoxine has been used more broadly as a treatment or adjunct 
treatment for infantile spasms. The Cochrane Review of treatment of infantile spasms 
did not identify any evidence of treatment effect in trials meeting its inclusion crite­
ria [214, 215]. If pyridoxine is used, the report should clearly state its timing, dose, 
and duration; and also whether it is being used to exclude a diagnosis of pyridoxine- 
dependent seizures or as a treatment intervention for infantile spasms in its own right.
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Areas of incomplete consensus
42. There remain areas of incomplete consensus. In the future, we might wish to de­
velop a more detailed structure for reporting adverse events, and recommendations 
on which tools to use to assess developmental outcomes and to classify disability. Fi­
nally, we found it difficult to provide a detailed description of the limits of definition 
of hypsarrhythmia: those designing studies will need to consider the advantages of 
using several EEG assessors, and how to assess intra-rater and inter-rater agreement 
in classification of EEGs.
Appendix A of West Delphi consensus statement: List of EEG features that 
are regarded as modifying features of hypsarrhythmia
Asymmetry
Consistent focal discharge




Increased interhemispheric synchronization 
Increased periodicity
Predominant high-voltage, bilaterally asynchronous slow activity
Appendix E
Abbreviations used in this thesis
AAN American Academy of Neurology
ABC (Vineland) Adaptive Behavior Composite (score)
ABPI Association of British Pharmaceutical Industries
ACTH Adrenocorticotropic hormone (adrenocorticotropin)
ADI Autism Diagnostic Inventory
ADR Adverse drug reaction
ADROIT Adverse Drug Reaction On-line Information Tracking
AE Adverse event
AED Anti-epileptic drug
ANOVA Analysis of variance
BACCH British Association of Community Child Health
BAN British Approved Name
BMEI Benign Myoclonus of Early Infancy
BURP Bath Unit for Research in Paediatrics
Cl Confidence interval
CNS Child Neurology Society
CPMP Committee for Proprietary Medicinal Products
CTX Clinical Trial Certificate
DDX Doctors' and Dentists' Exemption Certificate
DISCO Diagnostic Interview for Social and Communication Disorders
DMEC Data monitoring and ethics committee
EEG Electroencephalogram
EIEE Early infantile epileptic encephalopathy
EME Early myoclonic encephalopathy
EMG Electromyogram
HIE Hypoxic-ischaemic encephalopathy
ICH International Conference on Harmonisation
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ILAE International League Against Epilepsy
IM Intramuscular or intramuscularly
ISs or IS Infantile spasms
ISSV Infantile spasms, single spasm variant
IU International Units
LREC Local research ethics committee
MCA Medicines Control Agency (Now MHRA)
MedDRA Medical Dictionary for Regulatory Activities
MEDDRA Medical Dictionary for Drug Regulatory Affairs
MeSH Medical Subject Headings
MHRA Medicines and Healthcare products Regulatory Agency
MRI Magnetic resonance imaging
MRC Medical Research Council
MREC Multicentre research ethics committee
NHS National Health Service
NHSLA National Health Service Litigation Authority
nv-CJD New variant Creutzfeld-Jakob Disease
PSUR Periodic Safety Update Report
PVH Periventricular haemorrhage
PVL Periventricular leukomalacia
REM Rapid eye movement (sleep stage)
rINN Recommended International Non-proprietary Name
SAE Serious adverse event
SAR Serious adverse reaction
SmPC Summary of Product Characteristics
TRH Thyrotropin-releasing hormone
TSC Tuberous sclerosis (+/- complex)
UKISS The United Kingdom Infantile Spasms Study
V-AVFL Vigabatrin-associated visual field loss
VFL Visual field loss
WHO World Health Organisation
wise Wechsler Intelligence Scale for Children
WISC-R Revised Wechsler Intelligence Scale for Children
WPPSI Wechsler Preschool and Primary Scale of Intelligence
WS West syndrome
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